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Abstract 
Genome-wide association studies (GWAS) have identified germline single nucleotide 
polymorphisms (SNPs) that are associated with colorectal cancer (CRC) susceptibility. 
This thesis applies the same approach to the identification of germline determinants of 
prognosis in CRC, attempts to verify potential susceptibility loci, and examines the 
relationship between SNPs and some forms of non-SNP based germline variation. 
The GWAS for prognosis used 931 patients enrolled in the VICTOR trial in the 
discovery phase, screening 309,200 autosomal SNPs for an association with disease-free 
survival (DFS). Following the application of selection filters based on statistical 
significance levels and performance of the genotyping, 40 SNPs were identified to be 
examined in further cohorts. The verification phase consisted of 1338 patients in the 
PETACC 3 trial and three population based cohorts: 899 patients from Scotland, 599 
patients from Denmark, and 962 patients from Finland. 
The SNPs that came closest to genome-wide significance in stage 2 and 3 CRC was 
rs7556894, 15kb from Actin-related protein 2 (ARP2) on chromosome 2, part of the 
ARP2/3 complex essential for cell shape and motility, with p=8.96e-07. The impact on 
prognosis of rs7556894 was estimated as HR=1.52 (95% CI 1.17-1.96). 
Because of the failure to reach genome-wide significance (p<1e-07), two further 
approaches to the discovery phase are presented: the meta-analysis of two discovery 
cohorts to increase event rate and subject numbers and a GWAS for predictive markers 
for the benefit of adjuvant 5-FU chemotherapy. Formal verification of either approach 
was not undertaken as part of this thesis. 
Further loci were subjected to specific analyses of association with prognosis or CRC 
susceptibility: rs6983267 and the previously identified CRC susceptibility loci to a survival 
analysis, and not found to be associated; rs6687758, previously identified as a potential 
CRC risk locus to a susceptibility verification, confirming a significant association with 
HR=1.15, 95% CI 1.10-1.21, p=5.04e-08; and a variety of hypothesis driven potential 
risk loci to a screen for an association with CRC susceptibility, none was found but the 
LD relationship between tagSNPs and insertion/deletion polymorphisms appears to be 
the same as for ‘normal’ SNPs. 
Overall, the data presented in this thesis quantify further the contribution of germline 
variation to CRC susceptibility, exclude a major effect of such variation on prognosis, and 
verify rs6687758 as a further low-penetrance CRC susceptibility locus. 
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Definitions and Conventions 
BeadChip Duo 
The Illumina SNP array, so-called because hundreds of thousands of Beadtypes are 
hybridised to the array, and because each array can be used to analyse two samples. 
BeadStudio 
The Illumina genotype analysis software. 
Beadtype 
A bead with several multimer DNA sequences attached. Each multimer consists of 50 
bases for target sequence recognition (the SNP), and 22 bases for determining positional 
information on the array (the IllumiCode). Each bead carries tags for only one SNP, and 
each Beadtype is replicated approximately 15-17 times per Duo array 
Call frequency 
A SNP score giving the percentage of samples called for that SNP.  
Call rate 
A sample score giving the percentage of SNPs called for that sample. 
Cases and controls 
Throughout this thesis, cases are those patients with the phenotype of interest, whereas 
controls are those without the phenotype.  
GenCall 
A sample (genotype) and SNP specific quality score that measures the distance of an 
individual genotype position from the centre of the cluster for that genotype and SNP. 
GenCall scores are calculated for each genotype, and give an estimate of how reliable that 
genotype is (for a specific sample and SNP). It ranges from 0 to 1, with a lower score 
indicating increasing distance from the centre of a cluster, implicating worse clustering. 
Genetic models 
All models were coded to determine the impact of the minor allele. 
Genotypic - each genotype forms a separate group. 
Allelic - the allelic odds ratio, derived from the counts of major and minor alleles in the 
case and control group. 
Dominant - major allele homozygotes versus the remaining genotypes grouped together. 
Recessive - minor allele homozygotes versus the remaining genotypes grouped together.  
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GenTrain 
A SNP specific statistical score, defining how well an individual SNP has assayed, taking 
into account the shapes of the clusters and their relative distance to each other. The 
GenTrain scores can range from 0 to 1, with 0 representing poorly performing/failed 
SNPs. 
Germline 
Normally the DNA content of germ cells, in this thesis taken to mean the DNA content of 
non-tumour cells (cf. somatic), but also the unaltered DNA content of tumour cells. 
Illumina naming convention 
The alleles for each SNP are coded A and B, the A allele of any SNP is always the 
adenosine (A) or thymine (T), the B allele always cytosine (C) or guanine (G) . All SNPs on 
the BeadChip are either A or T substituted by either C or G, there are no A/T or C/G 
SNPs present on the BeadChips (Table 2-3). 
Infinium II 
The Illumina proprietary chemistry used for genotyping in the Hap300 and Hap370 
arrays in this thesis. 
Manhattan plot 
A plot of the -log10(p-value) of a series of SNPs against the position on the chromosome. 
Quotes 
Quotes are indicated in italics. 
References 
References adjacent to numbers are indicated by (ref), unless when next to a genetic locus 
or gene, when they are indicated in numerical superscript as usual. 
Survival endpoints 
Disease-free survival (DFS) - interval from start of therapy to relapse or new CRC 
diagnosis (stage 1-3 only). 
Progression-free survival (PFS) - interval from start of therapy to progression (stage 4). 
Where a term refers to relapse or progression in a cohort of all stages, DFS is used to 
describe the time from therapy to either endpoint.  
Overall survival (OS) - interval from start of therapy to death from any cause. 
CRC specific overall survival - interval from start of therapy to death from CRC 
Somatic 
Normally the DNA content of somatic cells, in this thesis taken to mean the DNA content 
of tumour cells when used in the term somatic changes or markers.  









Colorectal cancer (CRC) is an epithelial malignancy of the large bowel. It represents a 
global health burden, with an estimated 1 million new cases per year, with over half a 
million deaths, resulting in an estimated mortality rate of 52%. The majority of these 
cancers occur in the developed world, 64% for men and 66% for women, suggesting 
environmental and possibly genetic factors that influence CRC incidence2. While 
treatments have improved, the disease-specific mortality, even in modern Western 
healthcare settings, remains at 33%, accounting for about 10% of all cancer deaths3. A 
better understanding of why some patients with CRC have different outcome from others, 
and why they develop CRC in the first place, will be of major benefit in dealing with this 
deadly disease. 
1.1  Anatomy of the large bowel 
The large bowel is the terminal part of the alimentary tract, extending from the ileo-
caecal valve to the anal verge. It consists of several parts: caecum, ascending colon, 
transverse colon, descending colon, sigmoid colon, rectum, with a largely uniform 
structure (Figure 1-1). Apart from the distal sigmoid colon and rectum, the whole of the 
large bowel lies intraperitoneally. The wall of the large bowel is made up of several layers: 
the innermost layer is the mucosal surface with a monolayer of columnar epithelium and 
mucus secreting goblet cells, supported by a basement membrane. The epithelial surface 
invaginates, forming colonic crypts (of Lieberkühn). Next is the lamina propria made up of 
connective tissue, the mucosal neurovasculature and lymphoid tissue, followed by the 
muscularis mucosae, a thin layer of smooth-muscle cells. These layers form the mucosa. Next 
comes the submucosa with larger vessels and loose connective tissue, supported by the 
thicker of the two muscular layers, the muscularis externa. The surface of the large bowel 
‘facing’ the abdominal cavity, the peritoneal surface, is covered by a monolayer of non-
keratinising squamous epithelium, the serosa. Between serosa and muscularis externa lies a  
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further thin layer of loose connective tissue4. The overwhelming majority of CRC arise 
from the columnar epithelium to form adenocarcinomas, and in this thesis, colon cancer, 
rectal cancer and CRC are taken to mean such malignancies. 
Figure 1­1  Anatomy of the large bowel 
 
The major parts of the large bowel from the proximal colon at the ileo-ceacal valve to the anus, which as it 
has a different epithelial layer is not part of the large bowel (left). Cross-section of the colon depicting the 
anatomical layers from mucosa to serosa (right). (Images reproduced with permission: left by Kathy Mak5 
(modified); right obtained from http://oreilly.com/medical/colon/news/equivalents.html). 
 
1.2  Demographics and survival of CRC 
Colorectal cancer is a disease of the older population with an average age of onset of 66 
years3, and although the incidence has been falling, it still is between 45 and 50 per 
100,000 persons per year in the Western world. It affects men slightly more than women 
56.0/100,000 compared to 35.7/100,000, giving a total of 36,500 new cases per year in 
the UK. It contributes roughly equal proportions to the overall cancer burden of the 
sexes, about 10% each. The overall mortality from CRC irrespective of stage (Table 1-3) 
is 43.4% in the UK, compared with 33.6% the US, although the gender picture here is 
reversed compared to incidence, with a mortality of 42.2% for men compared to 44.8% 
for women in the UK, and 31.4%, and 35.9% in the US, respectively. Due to the lower 
incidence rate, the actual mortality rate per 100,000 women is lower than that for men: 
15 compared to 23 (UK figures: CRUK Cancer Stats6, US figures: 2008 Cancer 
Statistics3). 
Over the past ten years, the improvements in CRC diagnosis and therapy have led to a 
steady fall in mortality, from a peak of 30 per 100,000 persons in the early 1970s to 18 per 
100,000 in 2005, with the benefit driven equally by falls in male (35 to 23 per 100,000) 
and female (26 to 15 per 100,000) mortality. This improvement in survival has been  
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particularly marked in the younger age groups, but even the over 80s have experienced a 
10% drop in mortality over the last 10 years6. 
1.3  Risk factors for CRC 
1.3.1  Lifestyle factors 
In most cases, a clear aetiological association with either a particular risk factor or genetic 
pre-disposition is not apparent, making CRC largely a sporadic disease. Nonetheless, in 
addition to the inherited predisposition (section 1.3.2), there is a clear evidence that some 
environmental or life-style factors increase the risk of CRC.  
Immigrants from low risk areas moving to high risk areas assume the risk of the ‘recipient’ 
area within the first offspring generation: in Chinese migrants to the US, CRC risk 
increased with number of years lived in the US7, while the CRC rates increase the more 
the diet resembles a Western diet rich in red meat, animal fat and low in fibre8. The 
protective properties of a high fibre diet, postulated because of the low CRC incidence in 
countries with a traditionally high fibre diet9 have been challenged by large, prospective 
trials where it was not independent of the increased risk attributable to red meat 
intake10,11. Ultimately, fibre intake may merely reflect fruit and vegetable intake, which 
may be inversely related to red meat consumption. 
Several large case-control studies have found that total calorie intake, sedentary lifestyle 
and being overweight also combine to increase CRC risk, in men more than women7,12, 
while in women, the waist-to-hip ratio may also be important, with body fat carried 
predominantly around the waist conferring a higher risk13.  
Lastly, tobacco smoke has been linked to CRC risk, with increasing cigarette 
consumption conferring a higher risk initially of adenoma, but later also carcinoma, both 
in men14 and women15. 
1.3.2  Genetic predisposition 
At least one third of all CRC is thought to have a heritable component16, but only about 
5% are explained by the high-penetrance familial syndromes17. These syndromes, 
however, give an insight into some of the genes important in colorectal carcinogenesis. 
1.3.2.1  HIGH-PENETRANCE SYNDROMES 
1.3.2.1.1  Familial Adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant disease caused by 
mutations in the Adenomatous polyposis coli gene (APC) located on chromosome 5. 
Originally described in 1934 as a hereditary disease causing multiple adenomata in the 
large bowel, it is not the most common of the CRC predisposition syndromes, but 
perhaps the best known18. The locus for FAP was mapped to chromosome 5q21 by  
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linkage analysis19 and cloned a few years later by two groups independently20,21. APC is a 
large protein (316KDa, 2,843 amino acids) with many different mutations, although 
clustered around two mutational hotpots (codons 1061 and 1307). The vast majority of 
mutations are truncating, leading to non-functioning gene product, with a small number 
of missense mutations22. The incidence is about 1 in 8000, accounting for 0.5%-1.0% of 
all CRC, and making it one the most common dominantly inherited diseases23. Affected 
individuals have a large bowel carpeted with hundreds or thousands of colorectal polyps 
by the second or third decade, and by the age of 40, almost invariably develop frank 
carcinoma24. In addition, extra-colonic features include small bowel adenomata and 
(occasionally) carcinoma, Congenital Hypertrophy of the Retinal Pigment Epithelium 
(CHRPE), and desmoids tumours25. A recessive form of colonic polyposis is associated 
with germline mutations in MYH26. 
1.3.2.1.2  Hereditary Non-polyposis Colon Cancer (HNPCC) 
Hereditary Non-polyposis Colon Cancer is an autosomal dominant disorder due to 
mutations in the mismatch repair (MMR) genes MLH1, MSH2, and less commonly in 
MSH3, MSH6, and PMS227,28. These genes function in the mismatch repair of 
spontaneous errors during DNA replication in DNA (as well as in response to exogenous 
DNA toxins), most commonly seen in short mono- or dinucleotide repeats 
(microsatellites), thus maintaining the fidelity of DNA replication29. HNPCC should be 
suspected if a set of clinical criteria are met, e.g. the modified Amsterdam criteria30, and 
diagnosed by subsequent demonstration of a mutation in an MMR gene. The penetrance 
of HNPCC is about 80%, and extra-colonic cancers occur in a subsets (particularly 
endometrial cancer), and in the case of skin tumours, is termed Muir-Torre syndrome. 
HNPCC accounts for about 1-3% of all CRC, depending on the population studied31,32. 
Table 1­1  Diagnosis of HNPCC 
Modified Amsterdam criteria for genetic testing for HNPCC 
At least three relatives with HNPCC-associated cancer (colorectal, endometrial, small bowel, 
ureter or renal pelvis) 
One should be a first-degree relative of the other 2 
At least two successive generations should be affected 
At least one case before age 50 
FAP should be excluded 
Tumours should be verified histopathologically 
Adapted from Vasen et al.30 
1.3.2.1.3  Hamartomatous Polyposis Syndromes 
Mutations in LKB1, a serine threonine kinase on chromosome 19, cause Peutz-Jeghers 
Syndrome (PJS), an autosomal dominant disorder33. LKB1 has an essential role in the G1 
cell cycle arrest. The classical clinical lesion in PJS are pigmented macules of the lips and 
mucous membranes of patients who also are prone to multiple gastrointestinal  
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hamartomatous polyps with an increased risk of gastrointestinal as well as other cancers. 
Juvenile Polyposis (JP), also autosomal dominant, has a similar clinical presentation to 
PJS, although polyps are more commonly colonic. The classical causal mutation is in 
PTEN34, although mutations in SMAD4 and BMPR1 have also been described35,36. The 
polyps in the hamartomatous polyposis syndromes have malignant potential, although 
they account only for a minority of CRC. 
1.3.2.2  COMMON VARIANTS 
If, as stated above, only a proportion of the inherited predisposition to CRC can be 
explained by the high-penetrance syndromes described in section 1.3.2.1, other loci must 
play a part. It is unlikely that further high penetrance syndromes exist that contribute 
appreciably to the overall familial CRC burden, even if this does not exclude the 
existence of further rare high penetrance loci. The common variant - common disease 
hypothesis suggests that there are many common variants that individually increase the 
risk of the individual only by a small fraction, in other words have a low penetrance. Due 
to their common nature, minor allele frequencies (MAF) of 5-49%, they have the 
potential to contribute substantially to familial CRC. With increasing knowledge of the 
structural variants in the human genome, in particular the abundance of single nucleotide 
polymorphisms (SNPs), and the ability to perform highly multiplexed assays to interrogate 
these loci, genome-wide association studies (GWAS) have become feasible, and have led 
to a marked increase in the understanding of the genetic architecture of many complex 
disease traits37. GWAS using high-density SNP arrays have been successful in the 
identification of susceptibility loci for colorectal and other cancers38,39, as well as non-
malignant disease40,41.  
In CRC, 10 loci (13 SNPs) have been described (see Table 1-2), derived from two GWAS 
with more than 13,000 cases and controls and over 27,000 verification subjects42-46. None 
of these SNPs had previously been linked to CRC development, and only three SNPs in 
SMAD7 on chromosome 18q lie within a known CRC predisposition gene45, although the 
locus on chromosome 15 with two SNPs had been linked to increased CRC risk in 
Ashkenazi Jews43. 
Only one of the CRC susceptibility SNPs has been linked to cancer susceptibility in a 
different tissue type: rs6983267 on chromosome 8q24 is also associated with an increased 
risk of prostate cancer38, and while variants on 8q24 also confer a higher risk of breast, 
ovarian and bladder cancer, rs6983267 was shown not to be the associated variant in 
those instances47-49. The initial hypothesis was that the transcription factor POU5F1P1 was 
the gene tagged by rs6983267, but the proto-oncogene MYC, implicated in pathways 
important to the development of colon50, breast51 and other cancers lies 337Kb telomeric  
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and could harbour the true causal variant(s) detected by long-range LD. It is possible that 
the region harbours several tissue specific enhancers of MYC, defined by the five LD 
blocks in this region: one associated with CRC and prostate cancer, containing 
rs6983267, one associated with breast cancer, and three associated with prostate cancer 
alone49. Thus, as expected from studies that directly type only a tiny fraction of the 
sequence variation in the human genome, the causal variants within 8q24 have yet to be 
elucidated. 
The ten regions identified so far, based on the assumption of an additive model, 
collectively probably account for approximately 6% of the excess familial risk in CRC46. 
Table 1­2  Known CRC low­penetrance risk loci 
SNP  Alleles  Region  OR (95% CI)  p-value  Gene  Distance  
rs6983267
44  T/G  8q24  1.21 (1.15-1.27)  1.3E-14  MYC  337Kb 
rs16892766
42  A/C  8q23  1.25 (1.19-1.32)  3.3E-18  EIF3H  27Kb 
rs10795668
42  A/G  10p14  0.89 (0.86–0.91)  2.5E-13  none  within 500Kb 
rs3802842
52  A/C  11q23  1.17 (1.12-1.22)  1.08E-12  POU2AF1  51Kb 
rs4444235
46  T/C  14q22  1.11 (1.08–1.15)  8.1E-10  BMP4  9.4Kb 
rs4779584
43  T/C  15q13  1.26 (1.19-1.34)  4.4E-14  GREM1  15Kb 
rs9929218
46  A/G  16q22  0.90 (0.87–0.94)  1.2e-08  CDH1  intronic 
rs4939827
45  T/C  18q21  0.85 (0.81–0.89)  1.0E-12  SMAD7  intronic 
rs10411210
46  T/C  19q13  0.83 (0.78–0.88)  4.6e-09   RHPN2  intronic 
rs961253
46  A/C  20p12  1.12 (1.08–1.16)  2.0E-10  BMP2  342Kb 
MYC – MYC proto oncogene; EIF3H - eukaryotic translation initiation factor 3; POU2AF1 - POU class 2 
associating factor 1; BMP - bone morphogenic protein; Grem1 - gremlin-1; CDH1 - E-cadherin; RHPN2 - Rho 
GTPase  binding  protein  2.  Where  more  than  one  SNP  has  been  described  per  locus,  only  the  most 
significant SNP is listed. 
 
1.4  Colorectal tumorigenesis 
Colorectal cancers are characterised by genomic instability, either chromosomal 
instability (CIN) with many cytogenetic abnormalities, occurring in the majority of CRC, 
or microsatellite instability (MSI), with mutations in simple nucleotide repeats 
(microsatellites) throughout the genome53. CIN is present in about 65-70% of CRC, and 
in practice, often inferred from finding aneuploidy and/or polyploidy on flow 
cytometry54. About 15% of CRC have a near-diploid chromosome set and MSI, defined 
as a tumour having instability in at least two of five standard microsatellite markers55. 
While about one third of CRC do not display either form of instability56, direct 
measurement of aneuploidy utilising flow cytometry is relatively crude and it is likely that 
the ‘double-negative’ group harbours some cytogenetic abnormalities not detected by 
cytometry57. 
CRC also harbour epigenomic instability, either as global hypomethylation or as the CpG 
Island Methylator Phenotype (CIMP), defined as methylation at 3 or more specific  
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marker loci58. The latter has considerable overlap with MSI, and CIMP appears to be 
associated with MSI in patients who do not harbour germline mutations in mismatch 
repair (MMR) genes, which are characteristic of Hereditary Non-Polyposis Colon Cancer 
(HNPCC or Lynch syndrome)58. In addition, this group is strongly associated with BRAF 
V600E mutations (previously named V599E59), and has been variably termed CIMP-
high60,61 (CIMP-H) or CIMP 1 (ref 62). A third group of the CIMP+ve phenotype is 
associated with KRAS mutations and has been termed CIMP-low63 (CIMP-L) in response 
to the not universally reported60 lower levels of methylation, or CIMP 2 (ref 62); see also 
section 1.6.1.5 and Figure 1-6. 
Figure 1­2  Adenoma­carcinoma sequence 
 
The adenoma-carcinoma sequence, first described by Vogelstein et al.64, see text for more information. 
Picture modified with permission from Walther et al.1 
 
Tumorigenesis leading to CRC with chromosomal instability is said to occur in a series of 
steps involving specific mutations in key genes along the way, the Adenoma-Carcinoma 
model initially proposed by Vogelstein et al. in 1988 (ref 64). This model is likely to be an 
oversimplification, but aligns observed clinico-pathological changes with genetic 
abnormalities in the progression of chromosomally unstable CRC (the “gatekeeper 
pathway” involving genes that regulate cell growth65). The initial step in tumorigenesis is 
that of adenoma formation, associated with loss or somatic mutation of APC. Larger 
adenomas and early carcinomas acquire mutations in the small GTPase, KRAS, followed 
by loss of chromosome 18q with SMAD4, downstream of TGFβ, and mutations in TP53 
in frank carcinoma (Figure 1-2).  
1.4.1  Genetic changes leading to CRC with chromosomal instability 
1.4.1.1  APC 
Mutations of APC are present in at least 60 – 70% of CRC66,67, and APC appears to be 
involved in at least two independent pathways important to colorectal tumorigenesis.  
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Firstly, APC acts in the degradation of β-catenin, a molecule involved in cell-cell adhesion 
by anchoring E-cadherin to the intracellular cytoskeleton. Free β-catenin is 
phosphorylated by a complex consisting of APC, axin and glycogen synthase kinase-3β 
(GSK), which marks it for ubiquitination and subsequent degradation in the proteasome. 
In the presence of extracellular WNT bound to its receptor, Frizzled, the latter 
phosphorylates the cytosolic protein Dishevelled which in turn leads to the dissociation of 
the APC/axin/GSK complex and the accumulation and translocation to the nucleus of 
free β-catenin. Here β-catenin interacts with T-cell factor (TCF) leading to the 
transcription of genes involved in cell cycling, including cyclin D1. More than 90% of 
patients with CRC have alterations affecting this pathway68. 
More recently, a role for APC in the mitotic spindle checkpoint has been suggested: APC 
mutations cause defects in microtubule plus-end attachments leading to CIN in cell 
lines69. Introduction of mutant APC into diploid cell lines leads to CIN70, and resistance 
to pharmacological spindle disruption71. Mouse embryonic stem cells with homozygous 
APC mutant genotype show extensive chromosome and spindle aberrations72,73. Lastly, 
APC mutations are less common in diploid, MSI+ tumours74 than in CIN+ tumours75,76, 
although some diploid cell-lines and CRC have mutant APC (Figure 1-3).  
1.4.1.2  KRAS 
The KRAS (Kirsten-ras) gene is located on chromosome 12 and its product plays a central 
role in the signal transduction of several pathways (e.g. epidermal growth factor (EGF)77, 
vascular endothelial growth factor (VEGF)78, platelet-derived growth factor (PDGF)79, 
fibroblast growth factor (FGF)80) by converging these onto the mitogen-activated protein 
kinase (MAPK) signalling pathway. Following the binding of the extra-cellular signalling 
molecule to its respective receptor, the associated receptor-tyrosine kinase becomes 
activated and recruits adaptor proteins (Grb2 and SOS) to activate KRAS. In a 
phosphorylation cascade, this activates RAF, then MAPK-kinase (MEK), and then the 
MAP kinases ERK1 and ERK2 in successive steps. The ultimate outcome of this cascade 
is an anti-apoptotic signal81 and, via cyclin D1, regulation of the cell cycle82, although the 
precise effect on the cell cycle depends on the duration of the signal83. Consequently, 
activating mutations of KRAS generally drive cellular proliferation and they are found in 
between 30% and 50% of CRC84,85. 
1.4.1.3  TP53 
Germline mutations in TP53 are the underlying abnormality of the Li-Fraumeni 
syndrome, a hereditary cancer susceptibility syndrome predisposing individuals to many 
cancers, in particular sarcoma86. Somatic mutations are also found in about half of 
sporadic solid tumours and up to 60% of human CRC87. TP53 codes for a transcription  
  19 
factor that in resting cells is switched off through the interaction with MDM2, mediating 
ubiquitin-dependant degradation by the proteasome. The best known function of TP53 is 
its involvement in DNA damage checkpoints during the cell cycle, with the ability to 
arrest mitotic division to allow repair or induce apoptosis, acting predominantly during 
the G1 and G2 DNA checkpoints88. It appears, however, that it can affect a much wider 
range of cellular functions: invasion and motility, angiogenesis, cell survival and 
regulation of oxidative stress, repair of genotoxic damage, and autophagy89. 
1.4.1.4  LOSS OF CHROMOSOME 18Q 
The long arm of chromosome 18 is fully or partially lost in 50–70% of CRC90, and 
appears to drive tumorigenesis as re-introduction of lost 18q reverses the malignant 
phenotype in cell-lines91. The likely gene is SMAD4 (also known as DPC4): Mutations in 
SMAD4 occur in only 6 – 35% of CRC92-94, but loss or reduction of SMAD4 function 
through loss of 18q occurs in 60 – 70% of CRC95,96. While many CRC exhibit bi-allelic 
loss97, even loss of heterozygosity (LOH) may play a role in colonic tumorigenesis98. 
SMAD4 functions in the signal transduction of the transforming growth factor β (TGFβ) 
pathway: after binding of TGFβ to the heterodimeric TGFβ-receptor (TGFβR1 and 
TGFβR2), SMAD2 (also located on 18q21) and SMAD3, so-called receptor-activated or 
R-SMADs, are phosphorylated and form a complex with SMAD4 (a common mediator 
or Co-SMAD), before translocating to the nucleus and interacting with a variety of 
transcription factors and modulators99,100. The interaction with other proteins at the 
p15INK4B promoter leads to upregulation of p15INK4B and subsequent cell cycle arrest101. 
Together, these mechanisms form a potent tumour suppressor pathway97,102. TGFβ 
signalling can be repressed by the “inhibitory” SMADs 6 and 7, which are part of a 
TGFβ induced negative feedback loop. Thus, loss of function mutations in either 
TGFβR2 or SMAD4 will decrease the inhibitory signal and can lead to tumorigenesis. 
However, signalling through the TGFβ pathway is more complicated than this linear 
model suggests, and 29 members of the TGFβ ligand superfamily as well as five isoforms 
of receptors 1 and 2 have been described. The receptors can form homo- and 
heterodimers which themselves can combine with a variety of R-SMADs and Co-SMADs 
to mediate the different effects of the various ligands103. Further, some of the downstream 
outcomes actually facilitate tumour progression and invasion through a transition from 
epithelial to mesenchymal morphology of the tumour cells104,105. Lastly, TGFβR signalling 
can effect changes in SMAD independent pathways, such as MAPK, Erk and JNK, which 
may be growth promoting.  
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1.4.2  Genetic changes leading to CRC with microsatellite instability 
Microsatellite instability is found in about 15-17% of CRC, of which only a minority are 
HNPCC tumours. MSI+ve CRC, characterised by deficiency of the mismatch repair 
system, leading to ‘slippage’ in microsatellites (the “caretaker pathway” involving genes 
maintaining genomic stability65), only carry the changes described for CIN+ve CRC in 
section 1.4.1 infrequently, thus development of CRC must involve different but analogous 
genetic changes (Figure 1-2). 
The predominant impairment of MMR genes in sporadic MSI+ve CRC is the down-
regulation of MLH1 expression through promotor methylation106, although the MSI 
status is increased through positive selection of tumour cells with mutated microsatellites 
in MSH3 and MSH6107. 
Figure 1­3  Frequency of mutations seen in MSI+ve and MSI­ve CRC 
 
Data for each marker are derived from the several sources (where available). All studies have at least 200 
patients  unless  only  one  study  citing  incidence  of  genetic  change  across  MSI  spectrum.  Aneuploidy108; 
APC68,75,109;  KRAS61,87,110,111;  loss  of  18q56,112,113;  TP5387,111,114;  SMAD495;  BRAF60,61,115,116;  TGFβR256,117; 
BAX118; CIMP60,61,115,119,120 
 
However, MSI is uncommon in adenomata121, and the initial step is thought to involve 
alteration in WNT signalling28, possibly involving AXIN122. BRAF mutations, common in 
MSI+ve CRC, are likely to occur in the place of KRAS mutations123, although the latter 
do occur in a minority. Further positive selection occurs for mutations affecting 
microsatellites in transforming growth factor receptor 2 (TGFβR2)124, caspase-5 (ref 125), 
and insulin like growth factor 2 receptor (IGF2R)126. These genes appear to have 
mutations in both alleles without cancer cells displaying a similar rate of mutation in other 
microsatellite tracts of similar length107,124. Mutations in TGFβR2 induced by MSI lead to 
the disappearance of the TGFβR2 from the cell surface and an escape from TGF-beta- 
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mediated growth control127, with analogous consequences to loss of SMAD4 function in 
CIN+ve CRC. While TP53 mutations are rare in MSI+ve CRC, mutations in the pro-
apoptotic gene BAX are common, providing a TP53 independent mechanism for the 
transition from late adenoma to carcinoma128. 
CDC4 inactivation may precede TP53 mutation129, leading to increasing CIN130, although 
it is not always associated with CIN and may also play a role in the MSI pathway131. 
1.5  Treatment of CRC 
Treatment recommendations for CRC are based on pathological stage. While several 
staging systems are in clinical use, the oldest being Dukes’ system described in 1932 for 
rectal cancer132 and subsequently modified to include the colon and distant metastatic 
disease133, the recommended staging system is the TNM system134-136.  
The TNM system is shown in Table 1-3 assesses the tumour itself (T) for its depth of 
invasion into the bowel wall, the lymphnode status (N) according to the number of 
lymphnodes involved, and the presence of distant metastasis (M). CRC staged by the 
TNM system are then often grouped into categories with similar prognosis, the AJCC 
stages (Figure 1-4 and Table 1-4). 
Table 1­3  Description of the components of the TNM system 
Stage  Code  Description 
Tx  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ: intraepithelial or invasion of the lamina propria 
T1  Tumour invades submucosa 
T2  Tumour invades muscularis propria 
T3 
Tumour invades through the muscularis propria into the subserosa or into non-








T4  Tumour directly invades other organs or structures and/or perforates visceral 
peritoneum 
Nx  Regional nodes cannot be assessed 
N0  No regional lymph node metastasis 











N2  Metastasis in 4 or more regional lymph nodes 
Mx  Distant metastasis cannot be assessed 












M1  Distant metastasis 
The TNM staging system assesses the depth of tumour invasion, the number of involved lymphnodes, and 
the presence of distant metastasis 134. 
  
  22 
For stage 1 CRC, the only treatment required is surgical resection, and appropriate 
follow-up with regular colonoscopy. There is no evidence for any benefit from adjuvant 
therapy and 5-year survival rates are in excess of 93% for correctly classified stage 1 
CRC135. The picture is similar for stage 2 CRC, for which the role of adjuvant systemic 
therapy after curative resection remains controversial, and the added survival benefit at 5 
years is 3-4 %137 with 5-fluorourcail (5-FU) alone, and a further 2% with the addition of 
oxaliplatin138.  
For stage 3 CRC, the role of systemic adjuvant combination chemotherapy is well 
established: the relative reduction in risk of death from CRC with 5-FU alone estimated 
at 26%139, and the addition of oxaliplatin reduces the risk of death from CRC at 5 years 
by a further 10%138. Despite good activity of irinotecan in the metastatic setting, there is 
no role for it in the adjuvant setting after three trials failed to demonstrate survival 
benefit140-142. There is currently no role either for the use of targeted agents in the 
management of AJCC stage 3 CRC following the negative results of the NSABP C-08 
study143, with further trials still underway testing this hypothesis144,145.  
Within the early stage groups, in particular stage 2 and 3, where adjuvant therapy must 
be considered, histopathological examination of tumour material can help to define 
prognosis further146, using lympho-vascular invasion147; resection margins (as part of the 
TNM staging); and tumour grade148. In addition, some clinical parameters independently 
appear to influence outcome: obstruction/perforation at presentation149; performance 
status150; and pre-operative carcinoembryonic antigen (CEA) levels151, which probably 
reflect tumour burden at the time of surgery. Patients with stage 2 CRC and adverse 
histological factors are deemed high-risk and treated along the same lines as stage 3 
patients. 
Table 1­4  Stage groupings based on TNM system 
TNM  AJCC 5
th ed  AJCC 6
th ed  Dukes  Astler-Coller 
T1 or T2, N0, M0  I  I  A  A, B1 
T3, N0, M0  II  IIA  B  B2 
T4, N0, M0  II  IIB  B  B3 
T1-2, N1, M0  III  IIIA  C  C1 
T3-4, N1, M0  III  IIIB  C  C2, C3 
Any T, N2, M0  III  IIIC  C  C1, C2, C3 
Any T, Any N, M1  IV  IV    D 
Stage groupings according to the AJCC. The latest edition (6th) subclassifies stage 2 and 3 CRC to take 
account of differing prognoses in these subgroups 134. 
 
In stage 4 CRC, 5-FU in combination with either oxaliplatin or irinotecan is the mainstay 
of therapy, with potentially curative surgery considered for those who have limited sites of 
metastatic disease and a good response to chemotherapy152. Increasingly, targeted agents  
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are finding their way into the management of stage 4 disease, with in particular 
monoclonal antibodies directed against the EGF receptor (EGFR) and VEGF being 
utilised153,154. 
1.6  Genetic markers of outcome in CRC 
Despite the overall improvements in CRC therapy, our understanding of why individual 
patients do or do not respond to therapy or relapse remains poor. Consequently, there is a 
large, unknown subset of patients who receive treatment from which they do not benefit. 
In the metastatic setting, this failure to benefit is relatively easy to judge by demonstrating 
tumour progression using clinical and radiological assessment. In the adjuvant setting, 
many patients must be treated with significant attendant toxicity155 so that relatively few 
will benefit as there are clearly patients who would not have relapsed even without 
adjuvant therapy156. Understanding the reasons for treatment failure, and developing an 
ability to predict those who would benefit the most (and least) remain important aims in 
the management of CRC. 
Figure 1­4  CRC survival by stage 
 
Kaplan Meier curves for survival in CRC by stage (from O’Connell et al.135). It is clear from this graph that on 
a population basis, clinico-pathological staging does sub-divide patients into groups with similar prognosis. It 
is also clear that the current staging systems are imperfect, with stage IIB having a worse prognosis than 
stage IIIA. 
 
To date, the gold standard for prognostication remains clinico-pathological staging as 
described in section 1.5. While clinico-pathological staging separates patients into groups 
with distinct outcomes, importantly, it offers little information about response to 
treatment in individual patients, or about the risk of relapse in early stage CRC.  
A number of protein and genetic markers have been described in an attempt to refine 
prognostic information and predict benefit from systemic treatment in an attempt to spare  
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those who will not benefit from the toxicities associated with systemic therapy. None of 
these are in routine clinical use157, but much excitement has been generated by the 
progress made in other tumour types towards such goals. In breast cancer, for example, 
hormone receptor status is associated with prognosis158 and response to hormonal 
therapies159, there is a clearer understanding of who benefits from trastuzumab therapy160, 
and a gene expression signature conveying worse prognosis161 has been approved by the 
FDA to support clinical decision making162. While the CRC community has lagged 
behind somewhat, there is now a growing knowledge base of analogous determinants. 
1.6.1  Hypothesis driven markers 
To date, the most studied markers are somatic (acquired) changes for which some 
biological rationale exists for a potential impact on cancer outcome. These are often 
changes associated with tumour progression in the adenoma-carcinoma sequence model 
(Figure 1-2) or the observed type of genomic instability (chromosomal or microsatellite). 
Where germline (inherited) changes have been studied, they have been in 
pharmacological pathways involved in the metabolism and mechanism of action of 5-FU, 
the therapeutic mainstay for CRC. They are all hypothesis driven, with often limited a 
priori evidence to suggest a link to prognosis. 
1.6.1.1  KRAS 
Many studies have evaluated KRAS mutations in exon 2 (codons 12 and 13) and to a lesser 
extent in exon 3 (codon 61), for their association with outcome in CRC in general. KRAS 
mutations are an early event in the adenoma-carcinoma sequence, although they are 
demonstrable only in about a third of CRC, with a large majority located in codon 12163. 
Mutations in all three codons compromise the ability of GTPase activating proteins to 
effect the inactivating hydrolysis of KRAS bound GTP to GDP164. Other mutations are 
uncommon as they result in lower constitutive KRAS signalling than mutations in codons 
12, 13, and 61 and are selected against in the tumour165. 
While the largest international effort to combine data from different groups, the RASCAL 
collaborative, found that mutations generally confer a worse prognosis163, the subsequent 
analysis including a further 700 patients found only the glycine to valine substitution at 
codon 12 to be associated, and only in AJCC stage 3 patients84. Other studies have found 
no association, and to date, there is no convincing evidence to suggest that KRAS 
mutations are independent prognostic factors in CRC. 
More recently, however, KRAS mutation status has been established as a predictive 
marker for treatment with EGFR inhibitors. This interaction was initially observed with 
small molecule inhibitors of EGFR in non-small cell lung cancer (NSCLC)166, but several 
studies in CRC have now shown that due to the convergence of the EGFR and KRAS  
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pathways (Figure 1-5), patients with stage 4 KRAS mutant CRC receiving treatment with 
anti-EGFR antibodies, cetuximab167-171 and panitumumab172 derive significantly less 
benefit than patients whose tumours are KRAS wildtype. Further, in 80 KRAS wildtype 
patients treated with cetuximab, 11 patients with the BRAF V600E mutation did not 
respond173. BRAF acts downstream from KRAS and mutations in the two appear 
mutually exclusive123; BRAF could therefore be a locus for a second hit affecting the same 
pathway, and both are important determinants of resistance to anti-EGFR therapies.  
Figure 1­5  KRAS and its interactions with other signalling pathways 
 
Upon ligand binding, the EGFR type 1 homo-dimerises leading to the activation of the intracellular kinase 
domain.  Via  small  adaptor  proteins,  the  KRAS  signalling  cascade  is  activated  leading  to  increased 
proliferation. Downstream of KRAS is BRAF, explaining why non-constitutively activated KRAS and BRAF 
are necessary for EGFR blockade to work. The initial assumption that the common EGFR overexpression in 
CRC174 is also required, making this model very elegant, is challenged by a lack of correlation between 
EGFR expression and anti-EGFR antibody response153 and the observation that patients with irinotecan 
refractory,  EGFR  negative  CRC  can  still  respond  to  irinotecan  and  cetuximab175.  Picture  modified  with 
permission from Walther et al.1 
 
KRAS is close to the ideal predictive biomarker: most mutations are limited to a small part 
of the gene and relatively easily detected, the negative predictive value is high (99% of 
patients with mutated KRAS do not respond to EGFR inhibition167, even if the positive 
predictive value remains poor), and the effects are based on a plausible biological 
rationale. The example of KRAS further demonstrates how our evolving knowledge of 
cancer biology can refine treatment strategies and interventions, but also highlights the 
difficulties that the regulatory agencies will face when evaluating anti-EGFR or other 
targeted agents in response to retrospective clinical studies.  
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1.6.1.2  APC AND β-CATENIN 
The APC gene acts to promote the degradation of β-catenin and so limits the transcription 
of WNT target genes involved in regulating the cell cycle. This pathway is integral to 
colorectal tumorigenesis and more than 90% of patients have alterations affecting it68. 
Given the frequency of changes, it is not surprising that neither APC nor β-catenin is a 
prognostic marker able to differentiate between patients. While the type of APC mutation 
could hold prognostic information – for example mutations that abolish β-catenin binding 
sites of the APC protein may be associated with poorer prognosis75 – addressing specific 
mutations in clinical practice could be technically difficult due to the large number of APC 
mutations already described. Testing for general over-expression of β-catenin does not 
appear useful, but determining the cellular location of over-expressed β-catenin may hold 
prognostic information176,177, even if it is likely to be a surrogate marker for a genetic 
change elsewhere in its degradation pathway. Changes in APC and β-catenin are thus 
insufficiently validated in patients and have no role in clinical practice at present.  
1.6.1.3  TP53 
Loss of heterozygosity at chromosome 17p is a frequent event in CIN+ve CRC and many 
studies have focused on the 17p region containing the TP53 tumour suppressor gene. 
TP53 has been frequently investigated as both a prognostic factor and a predictor of 
response to therapy with conflicting results. The methods used to assess the mutation of 
TP53 vary greatly between studies, as do study designs in terms of clinico-pathological 
data reported and patient selection, making firm conclusions about the prognostic value 
of TP53 difficult178,179.  
1.6.1.4  LOSS OF 18Q 
Deletion of the long arm of chromosome 18 is the most common cytogenetic abnormality 
in CRC and has been associated with a poorer prognosis180, but again, this is not a 
uniform finding181,182. Many studies have investigated the genes found in this region as 
prognostic markers, in particular Deleted in Colon Cancer (DCC) without demonstrating 
a clear link to prognosis183, and the known CRC predisposition gene, SMAD4. The latter 
is a member of the TGF-β signalling pathway, and decreased SMAD4 mRNA levels 
appear to be associated with a worse prognosis184 and poorer response to 5-FU185, but not 
all studies find a relationship between loss of 18q and SMAD4 expression92, thus failing to 
definitively link any gene on 18q to prognosis. Further, it appears likely that loss of 18q is 
a marker of CIN57 and therefore not an independent prognostic marker (section 1.6.5.1), 
while the other common alteration in TGF-β pathway in patients with CRC – mutations 
in TGFβR2 – are almost exclusively linked to MSI186.  
  27 
Overall, to date, somatic markers have proved to be of limited prognostic utility in 
patients with CRC. Some of this might reflect the fact that many changes are associated 
with molecular phenotype, most (mutations in KRAS, APC, and TP53, and loss of 18q) are 
much less common in patients with MSI+ve CRC113,186. Thus, any somatic marker 
studied must be evaluated in the light of possible confounding by genomic instability. 
1.6.1.5  (EPI) GENOMIC INSTABILITY AND PROGNOSIS 
The prognostic value of CIN and MSI is no longer in question: both have been subject to 
large meta-analyses187,188, which unequivocally established that patients with CIN+ve 
disease have a poorer prognosis (Hazard ratio for death (HR)=1.45, 95% CI 1.35-1.55, 
p<0.001) and patients with MSI+ve CRC have a better prognosis (HR=0.65, 95% CI 
0.59-0.71, p<0.001) than patients with CIN-ve and MSI-ve CRC, respectively. Less clear 
is the prognostic relationship between CIN and MSI. The traditional view that they are 
mutually exclusive and all CRC are either one or the other is probably not correct (see 
Figure 1-6). While CIN and MSI may carry separate prognostic information, the only 
published study to date to assess the impact of both MSI and CIN in multivariate analysis 
did not find that the impact on survival of MSI was independent of that of CIN108. 
Figure 1­6  Overlap of CIN, MSI and CIMP 
 
Venn diagram of CIN measured by cytometry, MSI and CIMP (all figures are percentages of the overall 
number of patients). About 17% of patients display MSI188, about 60% CIN187, and about 20% CIMP58,60,61,115. 
About a quarter of MSI+ve CRC are CIN+ve108. Only one study has addressed the intersection of all three 
forms of instability189. The best estimate of the distribution of the CIMP phenotype relative to CIN and MSI is 
that it accounts for the majority of MSI+ve, CIN-ve CRC (the sporadic MSI+ve CRC)58, about 12% of all CRC; 
that CIN is independent of CIMP, and CIMP is therefore relatively evenly spread over the CIN+ve and CIN-ve 
groups; and that the CIN+ve MSI+ve CRC may also be CIMP+ve, but there is no evidence in the literature for 
this, likely to reflect the small size of this group189. Picture reproduced with permission from Walther et al.1 
 
The CIMP-H phenotype has also been associated with a better prognosis compared to 
CIMP-ve61, while in contrast, in MSI-ve CRC which are CIMP+ve and harbour BRAF 
V600E mutations, this phenotype is associated with a worse prognosis190 and increasing  
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levels of CIMP (-ve to low to high) confer worsening prognosis in MSI-ve CRC60. Despite 
the finding in one study that MSI associated prognostic information was not independent 
of CIMP status61, the relative contributions of CIN, MSI and CIMP to outcome need to 
be further investigated to understand the impact and interaction of these variables. 
Decreased methylation in the form of global genomic hypomethylation is also involved in 
colorectal carcinogenesis191 and associated with CIN192,193, representing the opposite end 
of the methylation spectrum to CIMP+ve MSI+ve CRC. It has been found to be 
associated with worse prognosis, but this analysis did not include CIN status192, and again, 
the interplay of the various types of (epi)genomic instability is not clear.  
1.6.1.6  MSI, CIN AND RESPONSE TO THERAPY 
Since the initial publication of a detrimental effect of adjuvant 5-FU in loco-regional 
MSI+ve CRC194, further data have been published by the same group confirming their 
earlier findings195. The clinical data are supported by in vitro evidence showing that a 
functioning MMR system is required for cytotoxicity in response to 5-FU incorporation 
into DNA196, in addition to its effects mediated by inhibition of thymidylate synthetase 
(Figure 1-7). In contrast, other retrospective data suggest that patients with MSI+ve CRC 
do benefit from adjuvant 5-FU197. This is supported by the observation that in stage 4 
CRC, 5-FU is effective in MSI+ve CRC198. The conflicting views demonstrate the 
difficulty in looking at uncommon subgroups, but the evidence for a detrimental effect is 
sufficiently strong for a clinical trial (E5202), now underway, to compare MSI+ve CRC 
without adjuvant chemotherapy to MSI-ve CRC with adjuvant chemotherapy 
prospectively to resolve these conflicting data. 
In addition, there are data to suggest that MSI+ve CRC are more sensitive to irinotecan 
based regimes in some clinical series199,200 and cell line studies201. The increased survival 
following irinotecan was also observed in the adjuvant setting199, where irinotecan had 
failed to be of benefit in the unselected patients140, making it an attractive proposition for 
prospective study in this setting. 
CIN could also be a negative predictive marker for the response to taxanes, a class of drug 
that showed limited activity in CRC during initial drug development. An intact spindle 
assembly check-point is required for taxane sensitivity, in other words, only diploid cells 
segregate chromosomes normally and are sensitive to paclitaxel202,203, a hypothesis 
currently being tested in a phase 2 clinical trial (CINATRA) using a novel taxane, 
patupilone. 
1.6.2  Pharmacogenetic markers 
Inherited polymorphisms have the potential to impact greatly on treatment; for 
conventional chemotherapy agents with a narrow therapeutic window, subtle genomic  
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changes can modulate drug-specific pharmacokinetics or pharmacodynamics and 
substantially affect individual response and toxicity after chemotherapy. Almost all 
chemotherapy regimes for CRC incorporate 5-FU or its oral prodrug, capecitabine, often 
in combination with oxaliplatin or irinotecan, and the ability to tailor therapy to take 
account of variation in their metabolism has the potential to translate into benefit for a 
large patient population. 
1.6.2.1  5-FU AND CAPECITABINE 
The anti-tumour effect of 5-FU mediated by TS inhibition as well as its effect on RNA is 
well established204, but incorporation of 5-FU derivatives into DNA can also lead to 




5′DFCR, 5′deoxy-5-fluorocytidine; 5′DFUR, 3′deoxy-5-fluorouridine; 5-FUR, 5-fluorouridine; CDD, cytosine 
deaminase;  CES,  carboxylesterase;  DHP,  dihydropyrimidinase;  DPD,  dihydropyrimidine  dehydrogenase; 
FBAL, fluoro-b-alanine; FUH2, dihydro-5-fluorouracil; MTHFR, methylenetetrahydrofolate reductase; OPRT, 
uridine monophosphate synthetase; RNR, ribonucleotide reductase; TK, thymidine kinase; TP, thymidine 
phosphorylase; UK, uridine-cytidine kinase 2; UP, uridine phosphorylase 1. Picture modified with permission 
from Walther et al.1 
 
Variation in the enzymes mediating the incorporation into RNA and DNA, the 
conversion of the oral pro-drug capecitabine to 5-FU, or metabolism to inactive 
breakdown products can alter the intracellular 5-FU concentrations and cytotoxicity, 
leading to altered anti-tumour activity or systemic toxicity. For example, expression levels 
of TS are associated with drug efficacy: CRC with high levels of TS appear to have a 
poorer overall survival than tumours with low TS expression205. In many instances, it is  
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not clear what drives the changes in expression levels, although it is likely that underlying 
germline genetic variation or change is responsible in a proportion of the observed 
variation. 
1.6.2.1.1  Thymidylate synthetase 
Thymidylate synthetase (TS) is thought to be the dominant target for the active principle 
of 5-FU, fluorodeoxyuridine monophospate (5-FdUMP). A meta-analysis of TS 
expression suggested that higher expression of TS is associated with poorer overall 
survival (OS)205. Two main genetic determinants of TS expression have been described: a 
variable number tandem repeat (VNTR) polymorphism in the TS promoter-enhancer 
region (TSE) and a 6bp insertion/deletion polymorphism in the 3’-UTR of TS. The 
tandem repeat sequence is 28bp long, and usually present as either 2 or 3 repeats (TSER), 
although four and more repeats have been described206. An increase in the number of 
repeats leads to increased efficiency of mRNA translation and expression207. In addition, 
the G allele of a G/C SNP in the second repeat of the TSER3 correlates with even higher 
mRNA expression via conservation of an upstream stimulatory factor (USF) binding site 
in which the SNP lies208. The 6bp deletion polymorphism in the 3’-UTR region alters 
mRNA stability209 and is associated with low mRNA expression210. The ‘high expressing’ 
variants have been associated with decreased survival in patients treated with 5-FU206,211, 
and these three markers in combination may predict those with increased risk of 
recurrence in stage 2 and stage 3 colon cancer212. 
1.6.2.1.2  Dehydropyrimidine dehydrogenase  
More than 80% of 5-FU is catabolised by dehydropyrimidine dehydrogenase (DPD), but 
levels of activity can vary widely between individuals: 3-5% of the population are partially 
DPD deficient, but complete deficiency is rare213. The bulk of DPD deficiency can be 
explained by more than 30 polymorphisms214, which can lead to severe, sometimes life 
threatening toxicity after 5-FU treatment215, although pre-treatment levels of DPD 
activity do not correlate well with toxicity216. It is impractical to screen all cancer patients 
for 30 polymorphisms a priori, and the lower toxicity associated with modern infusional or 
oral 5-FU based regimens make this less important. Despite extensive investigation, the 
pharmacogenetic basis of varied DPD activity remains to be fully elucidated, although 
advances in high throughput sequencing techniques may make the pre-treatment 
prediction of 5-FU toxicity achievable217.  
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1.6.2.1.3  Methylenetetrahydrofolate reductase  
Reduced methylenetetrahydrofolate reductase (MTHFR) activity creates variation in 
folate pools, indirectly increasing sensitivity to 5-FU. Two common polymorphisms in 
MTHFR lower enzyme activity218: the C677T polymorphism leads to a change of alanine 
to valine at position 222 and A1298C results in a glutamine to alanine change at position 
429. Increased response to 5-FU treatment has been associated with the 677T allele219,220 
and to a lesser extent the 1298C allele. Recent studies suggest these polymorphisms affect 
capecitabine toxicity221, as well as efficacy of 5-FU222. However, clinical data do not 
unequivocally support the influence of MTHFR genotype on 5-FU responsiveness, toxicity 
and patient outcome223. 
1.6.2.2  OXALIPLATIN 
There is some evidence to suggest that genetic polymorphisms in detoxifying enzymes and 
DNA repair genes play an important role in treatment response to the DNA binding 
agent oxaliplatin. Decreased sensitivity to platinum agents has been attributed to 
diminished cellular drug accumulation; increased intracellular drug detoxification and 
enhanced DNA repair224. 
Glutathione-S-transferases (GSTs) are a class of phase II detoxification enzymes that 
target a wide variety of drugs for excretion by conjugation with glutathione. A number of 
isoenzymes and polymorphisms within these exist, with varying specificity, activity and 
tissue localisation225. The isoenzyme GSTP1 is the primary enzyme for the detoxification 
of platinum derivatives. Two missense polymorphisms in GSTP1, I105V and A114V lead 
to decreased GSTP1 activity and predict neuropathy after oxaliplatin treatment226. There 
is no evidence for other isoenzymes or alleles (including null alleles) being associated with 
prognosis. 
The primary anti-tumour mechanism of platinum derivatives is formation of DNA 
adducts, which interfere with DNA replication and require the activity of DNA repair 
enzymes to avoid cell death. Several polymorphisms in different DNA repair enzymes 
have been shown to correlate with function227, however, association studies with outcome 
appear to be regimen and cancer-type specific. Out of six commonly studied functional 
polymorphisms in four repair genes (ERCC1, ERCC2, XRCC1, XRCC3) only ERCC1 
N118N and ERCC2 K751Q were associated with overall survival in colorectal cancer228, 
but not in all reports229. 
1.6.2.3  IRINOTECAN 
The active metabolite of the topoisomerase I inhibitor irinotecan, SN-38, is conjugated 
and detoxified primarily by UDP-glucuronosyltransferase (UGT1A1). The number of TA 
repeats in the TATA element in UGT1A1 correlates with reduced enzyme expression and  
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activity230. Individuals who are homozygous for the 7-repeat, also known as the 
UGT1A1*28 allele, have decreased degradation and clearance of SN-38, commonly 
leading to dose-limiting neutropaenia231. Initially, several groups reported this association 
but findings were heterogeneous in significance and effect size. A recent meta-analysis 
established that the incidence of toxicity in UGT1A1*28 patients was positively correlated 
with dose used232. A commercial genetic test was approved by the FDA in 2005 to make 
dosing recommendations based on UGT1A1 genotypic results and avoid life-threatening 
neutropaenia, a first for any chemotherapy agent. The routine use of this test by 
oncologists has been limited in clinical practice because with the lower irinotecan doses 
used in combination regimens with 5-FU, haematological toxicity has decreased. The 
prognostic impact of UGT1A1*28 has not been established233. 
At present, there are no pharmacogenetic markers which are useful in clinical practice, 
and those with a published positive association still require further validation. 
1.6.3  Unbiased high‐throughput screening 
High-throughput arrays for evaluating mRNA expression levels or SNPs have opened 
new avenues of marker discovery by moving from hypothesis driven, targeted research to 
unbiased screening of the whole genetic spectrum. The former is aimed at quantitative 
markers, while DNA based techniques analyse discrete markers. The bulk of biomarker 
research has focussed on somatic changes, but germline variation equally can have an 
impact on prognosis and response to therapy, although to date only the few 
pharmacogenetic markers in the previous section have been described. For prognostic 
purposes, gene expression analysis is classically performed on tumour tissue, although 
comparative analyses with normal surrounding mucosa have been published, while 
genome-wide DNA screens have focussed on the germline, particularly in the search for 
disease susceptibility loci. 
1.6.3.1  GENE EXPRESSION SIGNATURES  
Gene expression analysis holds great promise for the understanding of functional 
differences between tumour and normal tissue, and with it the hope of developing 
meaningful signatures that stratify patients further beyond pathological staging. In CRC, 
much effort has been expended to repeat the perceived success in breast cancer, both by 
analysing tumour tissue234-242 or the surrounding mucosa243-246. Similar analysis has also 
been applied to the study of miRNA arrays in tumour tissue247-249. 
The first published signature in CRC by Wang et al., identified a 23-gene prognostic 
signature based on 31 relapses in 74 stage 2 patients250. This was subsequently subjected 
to validation both independently and by the same group. Based on 25 relapses in 50 stage 
2 patients, the former found a positive predictive value of 67%, only marginally better  
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than the toss of a coin and therefore proposed a separate set of 30 genes238, while the 
latter found that using only 7 genes of the original set performed better in their validation 
set241, this time based on 123 patients and further validated in 104 patients. In common 
with other studies describing signatures based on differentially expressed genes (range 7 to 
72), the overlap between the 30 and 7-gene signatures, even when in the same 
pathological stage, has been poor. One of the more convincing studies concerned miRNA 
expression, with 74 patients of all stages in the testing set, and 110 patients in the 
validation set, which suggested a single miRNA (miR21) as a prognostic marker. Again, 
this has not yet been validated further. 
The reasons for this include that studies were underpowered, looking at sample sets as 
small as 20 patients while analysing the expression of tens of thousands of genes; 
validation was not always performed; and correction for other prognostic variables was 
omitted from the main analysis, leading to over-fitting of the prognostic model with poor 
reproducibility and a high false discovery rate251. This problem is not unique to CRC, nor 
has the quality of studies improved with increased familiarity with the technology252-254 
and even for the first signature, described in breast cancer, concerns have been raised 
over the inclusion of the training set in the initial validation set255, and the insufficient 
patient numbers required to derive a robust signature. Many different signatures could be 
derived from the same data depending on the clustering parameters256, and a sample set 
of at least 3000 patients may be necessary to identify a unique, robust signature257. Efforts 
are underway to generate a gene expression signature from fixed paraffin embedded 
tumour tissue using quantitative Real-Time PCR258. The initial signature was generated 
in a set of over 500 samples and will be validated in a large (n=2,000) cohort of colon 
cancer patients enrolled in the QUASAR trial137. 
Meta-analysis is commonly performed for other markers combining small datasets to 
boost numbers, but this is difficult and unreliable for expression signatures due to the 
differing methodologies applied in each study259, leading to a high false positive and 
negative discovery rate260. Given the undoubted potential — and it is important to state 
that even a signature which does separate relapse from non-relapse only imperfectly may 
add to the clinical decision making process — there must nonetheless be a concerted 
effort to find sample sets of sufficient size to allow the definition of a robust, reproducible 
signature in CRC as “small sample sizes might actually hinder the identification of truly important 
genes”261, and the emphasis on the detection of bias and chance and the validation of the 
findings remain as important as ever262.  
  34 
1.6.3.2  GENOME-WIDE ASSOCIATION STUDIES (GWAS) 
Genome-wide association studies using high-density SNP arrays have been successful in 
the identification of susceptibility loci for colorectal42,43, prostate38 and breast cancer39, 
non-malignant disease40,41, and physiological variation263,264. They have relied on the 
premise that many diseases have a heritable component, and that traditional linkage 
analysis using a collection of affected families will only identify rare, high-penetrance 
susceptibility alleles. GWAS attempts to define common alleles that confer only a 
moderate risk for the disease in question (see section 1.3.2.2).  
Figure 1­8  Basic structure of a GWAS 
 
Initially all genotyped SNPs are analysed for an association with the complex trait in question. SNPs that 
have failed, are non-informative and those that appear to be unreliable are excluded before a selection is 
made to take a subset forward into verification in other cohorts. Further fine-mapping is (usually) required to 
determine the causative variant. Picture reproduced with permission from Hardy et al.265 (modified). 
 
It is likely that ‘host’ factors — the genetic make-up of normal tissue — can have an 
influence on outcome, either as prognostic or predictive marker. Genetic variation 
associated with genes involved in cell adhesion and motility may make early metastasis 
more likely, and cell cycle checkpoint associated variation may make the cell more 
tolerant of genomic abnormality and thus more resistant to chemotherapy.   
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Pharmacogenomic variation is likely to play a role both in host response (toxicity) and 
tumour response to chemotherapy. This is discussed above, but GWAS has the potential 
to uncover new variants affecting the metabolism and efficacy of anti-cancer agents.  
Until all genetic variation has been described and can be tested for simultaneously, 
GWAS necessarily relies on the association of a tested marker with the true or ‘causal’ 
variant affecting outcome, although there is no inherent reason why the tested marker 
could not be the true variant. This means that all identified markers meeting a specified 
significance threshold need to be followed up irrespective of biological rationale, although 
if the marker identified is not in complete linkage disequilibrium with the true variant, 
replication would be more difficult. Once identified, however, routine clinical use would 
be easy as the necessary DNA could easily be extracted from a standard blood sample and 
genotyping is robust (Figure 1-8).  
It is conceptually possible to apply the same techniques to tumour DNA, although 
prognostic markers may be due to mutations within the malignant tissue and not be 
captured by the SNPs analysed if these do not predispose to the mutation in the first 
place, nor would this capture epigenetic events which undoubtedly play a role in 
tumorigenesis and could also affect outcome. In malignant tissue, however, SNP typing 
platforms would give information about copy number changes (deletions, insertions, loss 
of homozygosity) that can affect gene expression (functional aneuploidy266). 
To date, no GWAS looking at outcome, either in untreated or treated patients has been 
published for any cancer. The main obstacle is that for the analysis of several hundred 
thousand SNPs, in order to retain a degree of statistical power, sample sets need to be 
large37. While it is relatively easy to collect these sets for the analysis of risk, outcome, if 
nothing else, requires follow-up for at least three years to assess progression-free survival 
(DFS) with top quality data, in a clinical trial setting if at all possible. 
1.7  The germline as the driving factor in CRC? 
The encouraging improvement in patient outcome over the last 20 years has been 
followed by a plethora of markers of prognosis and response to anti-cancer therapy, the 
majority of which fail to demonstrate clinical utility. Many more DNA and RNA-based 
markers of prognosis than those described in section 1.6 have already been described, 
often only once and in small series. They are all based on somatic abnormalities detected 
in CRC cells, and fall into the category of hypothesis driven markers. Given that to date 
the only (predictive) marker to have been described this way with sufficient evidence to 
justify routine clinical assessment is KRAS mutational analysis for the selection of anti-
EGFR strategies, new approaches to marker discovery are required. It is reasonable to 
assume that unbiased screening of either DNA or RNA based markers will significantly  
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advance our understanding of cancer biology, and allow for quasi individualised 
treatment to be given, exploiting inter-individual CRC differences to maximise treatment 
benefit. 
The success of GWAS in defining novel CRC susceptibility loci shows that germline DNA 
variability confers CRC risk. Given that tumour cells arise from normal colonic mucosa, 
they start off with the same germline DNA, but acquire somatic mutations in a few key 
regulators and checkpoints. Anything that makes these mutations more likely to occur will 
increase CRC risk, and at the same time, any variation at the cellular level hardwired into 
the blueprint of the cell, namely DNA, will be present in tumour as well as normal cells. 
At present, up to 35% of CRC is thought to have a familial component16, but this may 
only be a lower limit estimate267, with many more CRC attributable to genetic causes 
through gene-environment interaction, genetic variation modifying the impact of the 
environmental factor in the individual. Even the well-described hyper-methylation of the 
MLH1 promoter in sporadic MSI+ve CRC106 could be determined by variation in genes 
governing levels of DNA methylation. 
By analogous logic, outcome in CRC as a complex trait may also be influenced by 
germline genetic variation in a large proportion of cases, predisposing to somatic changes 
associated with prognosis, as well as altering the interaction between tumour and its 
environment, and the overall host response to tumour and treatment. It is difficult to 
predict the functional consequences of any novel marker that may be identified by such 
an approach - hypothesis driven research has not yielded any validated candidates - but 
conceptually they should fall into one of three categories: markers that alter the likelihood 
of early and frequent metastasis, thus determining whether surgery could be curative; 
markers that make cancer cells more tolerant of its sub-optimal environment (hypoxia, 
damage induced by chemotherapy, host response to the tumour) thus conferring a growth 
advantage; and markers that allow the cancerous cell to develop resistance to any 
chemotherapy given. The last category could include changes that alter the host response 
to treatment, meaning that it may not be the malignant cells that are more tolerant to 
chemotherapeutic agents but that, for example, the more efficient degradation of these 
agents leads to the delivery of a sub-lethal dose to the cancer. 
In the absence of validated prognostic factors outside pathological staging, however, the 
genetic factors governing the ‘prognostic process’ are unknown, and an unbiased, high-
throughput approach is most likely to provide insights into the effect of the germline on 
CRC prognosis. This thesis describes a search for novel markers of prognosis and risk 
using GWAS, and the attempted validation of several hypothesis driven markers.  









2.1  Samples used 
The genotype data used in this thesis was derived from 13 cohorts, this was generated by 
collaborators for multiple loci for the following cohorts: 1958 Birth Cohort, PETACC, 
London Phase 2, Scotland Phase 1, and Scotland Phase 2. rs6983267 was typed by 
collaborators for these cohorts: Quasar 1, Australia, and Epicolon. For Corgi 2 (London 
Phase 1), Denmark, and Finland, some genotypes were generated by collaborators, others 
by Axel Walther. (Almost) all genotypes for VICTOR and all for Quasar 2 were 
generated by Axel Walther (Table 2-1).  
All cases had pathologically proven adenocarcinoma of the colon or rectum. All 
participants gave informed consent for the collection of blood and tumour samples, and 
clinical and pathological information. All studies had local ethical review board approval 
in accordance with the Declaration of Helsinki. DNA was extracted from samples using 
conventional methodologies and quantified using PicoGreen (Invitrogen, Paisley, UK) or 
Nanodrop 1000 (Thermo Scientific, Waltham, MA). 
2.1.1  VICTOR 
Germline DNA was available for 947 patients enrolled in the VICTOR trial (612 males, 
335 females). All patients had stage 2 (480 patients) or 3 (467 patients) CRC treated with 
surgery, and received adjuvant 5-FU based chemo- and/or (neo-)adjuvant radiotherapy 
as appropriate for stage and site of disease. This was at the discretion of the treating 
physician. Patients were subsequently randomised to receive rofecoxib or placebo for 2 or 
5 years. The trial was stopped because of concerns over the cardiac side-effects of 
rofecoxib. Because of early closure, only 30 patients received trial medication for more 
than 24 months (median 8 months, range 0 - 28 months).  
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Table 2­1  Responsibility for genotyping in the cohorts utilised 
Cohort  Genotypes  Performed by 
1958 Birth Cohort  all  Collaborators 
Australia  rs6983267  Collaborators 




London Phase 2  all   Collaborators 
Denmark  all   Axel Walther 
Epicolon  rs6983267  Collaborators 




PETACC 3  all  Collaborators 
Quasar 1  rs6983267  Collaborators 
Quasar 2  all  Axel Walther 
Scotland Phase 1  all  Collaborators 
Scotland Phase 2  all  Collaborators 
VICTOR  all except 







Collaborators  ultimately  provided  all  genotypes,  either  directly,  or  by  providing  DNA  for  typing  in  the 
laboratory of Prof Ian Tomlinson. I am grateful to Dr Enric Domingo for helping with the genotyping of a 
subset of the VICTOR cohort. 
 
Germline DNA was extracted using from blood using standard methods by the 
Department of Pharmacology at Oxford University. The data cut-off for the initial 
analysis presented in chapter 3 was 17 November 2007, and the latest available follow-up 
was 29 April 2009. Genotyping was performed on HumanHap300 and HumanHap370 
arrays, and those who had relapsed were typed first to enrich for cases should the funding 
for the arrays become an issue at a later stage, therefore there was an excess of stage 2 
patients among those typed on the Hap370 arrays (p=2.12e-05). 526 patients were typed 
using Hap300 arrays , the remainder on Hap370 arrays. Individual SNPs were typed 
using KASPar allele specific PCR.  
184 additional patients were typed for rs6983267 from FFPE tissue, of these, 10 patients 
were censored at date of death from other causes, and five were excluded as follow-up 
data were missing. 
2.1.2  PETACC  
Germline DNA from FFPE tissue of patients enrolled in the PETACC 3 trial was 
available at the University Hospital Gasthuisberg, Leuven, Belgium. Patients had stage 2 
(375 patients) or 3 (841 patients) colon cancer, and were randomised to receive either 5-
FU alone or in combination with irinotecan following curative resection. Individual SNPs 
were typed using a fluorogenic 5' nuclease assay (TaqMan, Applied Biosystems, CA),  
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multiple SNPs were typed using MassARRAY® iPLEX Gold single-base extension 
technology (Sequenom, CA). 4-year DFS data was mature in March 2008. 
2.1.3  GWAS for CRC risk loci 
The London phase 1 GWAS was conducted using the Illumina HumanHap550 
BeadChips, and the Scottish phase 1 GWAS was conducted using various Illumina SNPs 
arrays. In London and Edinburgh phase 2, genotyping was conducted using Illumina 
Infinium custom arrays. The 1958 Birth Cohort was typed on HumanHap550 
BeadChips. All genotyping was performed in accordance with Illumina’s protocols. No 
survival data was available except for Scotland Phase 1. 
2.1.3.1  LONDON PHASE 1 (COLORECTAL TUMOUR GENE IDENTIFICATION 2, CORGI 2) 
Phase 1 comprised 940 cases with colorectal neoplasia (443 males, 497 females) 
ascertained through the Corgi consortium. All had at least one first-degree relative 
affected by CRC and one or more of the following phenotypes: CRC at age 75 or less; 
any colorectal adenoma at age 45 or less; three or more colorectal adenomas at age 75 or 
less; or a large (>1 cm diameter) or aggressive (villous and/or severely dysplastic) 
adenoma at age 75 or less. Controls (n=965; 439 males, 526 females) were spouses or 
partners unaffected by cancer and without a personal family history (to second-degree 
relative level) of colorectal neoplasia. All cases and controls were of European ancestry 
and from the UK46.  
2.1.3.2  LONDON PHASE 2 (PHASE 2) 
Phase 2 consisted of 2,873 CRC cases (1,199 males, 1,674 females, mean age at diagnosis 
59.3 years; SD ± 8.7) ascertained through two ongoing initiatives at the Institute of 
Cancer Research/Royal Marsden Hospital NHS Trust (from 1999 onwards: the 
NSCCG27 and the Royal Marsden Hospital NHS Trust/Institute of Cancer Research 
Family History and DNA Registry. A total of 2,871 healthy individuals were recruited as 
part of ongoing National Cancer Research Network genetic epidemiological studies, 
NSCCG (n=1,235), the Genetic Lung Cancer Predisposition Study (1999–2004; n=917) 
and the Royal Marsden Hospital NHS Trust/Institute of Cancer Research Family 
History and DNA Registry (1999–2004; n=719). These controls (1,164 males, 1,707 
females; mean age 59.8 years; SD ± 10.8) were the spouses or unrelated friends of 
individuals with malignancies. None had a personal history of malignancy at time of 
ascertainment. All cases and controls were British of recent European ancestry, and there 
were no obvious differences in the demography of cases and controls in terms of place of 
residence within the UK46.  
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2.1.3.3  SCOTLAND PHASE 1 
Phase 1 included 1,012 CRC cases (518 males, 494 females; mean age at diagnosis 49.6 
years; SD ± 6.1) and 1,012 age- and gender-matched cancer-free population controls (518 
males, 494 females; mean age 51.0 years; SD ± 5.9). Cases were enriched for genetic 
aetiology by early age at onset (age less than or equal to 55 years). Known dominant 
polyposis syndromes, hereditary non-polyposis colorectal carcinoma/Lynch syndrome or 
bi-allelic MYH mutation carriers were excluded. Control subjects were population 
controls, matched by age (± 5 years), gender and area of residence within Scotland46.  
2.1.3.4  SCOTLAND PHASE 2 
Phase 2 comprised 2,057 CRC cases (1,249 males, 808 females; mean age at diagnosis 
65.8 years; SD ± 8.4) and 2,111 population controls (1,257 males, 854 females; mean age 
67.9 years; SD ± 9.0) ascertained in Scotland. Cases were taken from an independent, 
prospective, incident CRC case series and aged <80 years at diagnosis. Control subjects 
were population controls matched by age (± 5 years), gender and area of residence within 
Scotland46. 
2.1.3.5  WELLCOME TRUST CASE CONTROL CONSORTIUM 1958 BIRTH COHORT (58C) 
This cohort was from the collection of DNA from all births in England, Wales and 
Scotland during a single week in 1958, consisting of 1,438 population controls from the 
Wellcome Trust Case Control Consortium 1958 birth cohort (58C, also known as the 
National Child Development Study) 46,268. 
2.1.4  Finland 
Germline DNA from blood was available for 1055 patients with CRC, and 864 controls 
(randomly selected anonymous Finnish blood donors), all ascertained in south-eastern 
Finland, the Finnish Colorectal Cancer Predisposition Study (FCCPS). DNA was 
extracted using standard methods, and whole-genome amplified by KBioscience, 
Hoddesdon, UK. 5-year OS was mature in August 2003. Genotyping was performed by 
allele specific PCR. 
2.1.5  Denmark 
Germline DNA was available for 599 patients with CRC at the Department of Molecular 
Medicine, Aarhus University Hospital, collected between February 1999 and November 
2007. Informed consent was obtained from all patients according to local ethical 
regulations and the study was approved by the local ethical committee according to the 
Helsinki Declaration. All patients were of white Caucasian background. Genotyping was 
performed by allele specific PCR.  
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2.1.6  Quasar 1 
Limited germline DNA was available for 492 patients enrolled in the Quasar 1 trial of 
adjuvant 5-FU chemotherapy versus observation for stage 2 colon cancer137. DNA was 
extracted from paraffin embedded tissue. Median follow-up was 5.4 years and analysis 
was truncated at 8 years, beyond which there were no events. Genotyping was performed 
by allele specific PCR. 
Table 2­2  Summary of cohorts used 
        Stage 
Cohort  Number  CRC  CRC survival  1  2  3  4 
58BC  1436  Controls  n/a  -  -  -  - 
Australia  477  Cases  2-year DFS  43  73  243  118 
Corgi 2  1905  Both  none         
London Phase 2  5719  Both  none         
Danish  599  Cases  2-year OS  81  235  186  81 
Epicolon  539  Cases  4-year DFS  68  230  146  95 
Finland  1,045  Both  5-year OS  200  390  272  126 
PETACC  1,216  Cases  4-year DFS  -  375  841  - 
Quasar 1  492  Cases  5-year DFS  -  492  -  - 
Quasar 2  494  Cases  1-year DFS  -  163  331  - 
Scotland Phase 1  1982  Both           
Scotland Phase 2  4116  Both  n/a  -  -  -  - 
VICTOR  1,136  Cases  3-year DFS  -  575  561  - 
 
2.1.7  Quasar 2 
Germline DNA was available for 539 patients enrolled in the Quasar 2 trial of 
capecitabine with or without bevacizumab for stage 2 (163 patients) and 3 (331 patients) 
colon cancer. Toxicity data was available for each patient for the 10 categories specified 
in the trial protocol. The latest available follow-up was 29 January 2009. Genotyping was 
performed on HumanHap370 arrays. 
2.1.8  Australia 
Tumour DNA from FFPE was available for SNP rs6983267 analysis from 477 patients 
with colorectal cancer (367 colon, 110 rectum) of all stages treated at the Royal 
Melbourne Hospital, Western Hospital between July 1990 and July 2006. All patients 
were selected from a prospectively collected comprehensive colorectal cancer database, 
Biogrid Australia269. 20 patients were missing follow-up information and were excluded. 
Written informed consent was obtained from all study subjects. A minimum of two-year 
follow-up was available for all cases. Genotyping was performed by allele specific PCR.  
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2.1.9  Epicolon 
Germline DNA for 515 CRC cases (305 males, 210 females; mean age at diagnosis 70.6 
years; SD ± 11.3) and 515 controls (290 males, 225 females; mean age 69.8 years; SD ± 
11.7) was ascertained through the EPICOLON initiative, a prospective, multicenter, 
nationwide study aimed at compiling prominent epidemiological and clinical data with 
respect to hereditary non-polyposis colorectal cancer and other familial colorectal cancer 
forms in Spain. This cohort consists of an incident series collected in Barcelona42. 
Genotyping was performed by allele specific PCR. 
2.1.10  VQ58 
The VICTOR, Quasar 2 and 1958 Birth cohorts were combined as a single group for the 
analysis of the impact of rs6687758 on CRC risk in Chapter 7. It does not contain any 
patients not already mentioned above, and has been used in the discovery of other CRC 
risk loci42. 
2.2  Experimental methods 
2.2.1  High‐throughput genotyping: Illumina Infinium arrays 
High-throughput genotyping was performed on Illumina HumanHap300 or 
HumanHap370 (Hap300 and Hap370 for short) arrays (BeadChips), containing 318237 
tagSNPs (Hap300) or 318237 tagSNPs plus 52167 markers in copy-number variation 
(CNV) regions on the Hap370 arrays (370404 markers).  
All arrays were ‘Duo’, meaning that two samples could be processed on each array. 
Figure 2-1 gives the distribution of SNPs on the Hap300 arrays by chromosome. The 
decreasing number of SNPs with increasing chromosome number reflects that higher 
numbered chromosomes are smaller. The median density of SNPs per chromosome is 
108 SNPs per Mb, ranging from 89 SNP per Mb (chromosome 15) to 137 SNPs per Mb 
(chromosome18). Both types are based on the Infinium II chemistry, proprietary to 
Illumina (San Diego, CA). Several multimer sequences are attached to beads, each 
consisting of 50 bases for target sequence recognition, and 22 bases for determining 
positional information (the IllumiCode). Each bead carries tags for only one SNP, and 
each bead type is replicated approximately 15-17 times per Duo array. The beads are 
randomly distributed on the array, and the positional tag is used to determine the position 
of each bead, and with it the associated SNP, prior to use with sample DNA. This 
positional information is required when scanning the arrays, as otherwise there will be no 
correlation between dye intensity and SNP analysed.  
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Figure 2­1  Distribution of Hap300 SNPs by chromosome 
 
Percentage of total Hap300 content per chromosome. The decreasing percentage of content going right 
reflects the smaller size of these chromosomes. The X-chromosome is included in this figure for illustration 
purposes only, these SNPs were not analysed in this thesis. 
 
All alleles are coded A and B according to the Illumina convention (Table 2-3): the A 
allele of any SNP is always the adenosine (A) or thymine (T), the B allele always the 
cytosine (C) or guanine (G) . All SNPs on the array are either A or T substituted by either 
C or G, there are no A/T or C/G SNPs present (see also section 2.3.1). 
The genotyping is based on a single base extension assay, with one dye for the A allele, 
and another for the B allele. After annealing of the sample DNA to the template sequence 
tag on the bead, the single base extension step adds one hapten labelled base to the distal, 
3’ end of the bead sequence, complementary to the sample. This hapten signal recognised 
by a two-colour antibody-based staining and signal amplification step (red dinitrophenol 
for A, green biotin for B)270. 
Table 2­3  Illumina allele naming convention 
Actual Base  Illumina name 
Adenosine (A) or Thymine (T)  A 
Cytosine (C) or Guanine (G)  B 
The Illumina naming convention allocates the same name to a particular allele of a SNP, irrespective of 
whether the SNP is typed on the +strand or -strand, as A on the +strand would be paired with T on the -
strand. Likewise, C would be paired with G, and because no A/T or C/G SNPs are on the array, this 
convention allows all SNPs to be unambiguously represented by A and B.  
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2.2.1.1  METHOD 
All DNA was and freeze-dried and resuspended in 15µL dH2O at 50ng/µL (total 750ng). 
The genotyping was performed according to Illumina’s protocols. The workflow 
comprises of neutralisation and denaturing for whole-genome amplification of the sample 
DNA. The amplified DNA is fragmented using ‘end-point fragmentation’ to avoid over-
fragmentation. The fragmented DNA is collected by precipitation, resuspended and 
applied to the Illumina BeadChips followed by overnight incubation. 
The next day, excess or non-specifically hybridised DNA is washed off, followed by single 
base extension with incorporation of detectable labels that are stained with antibody. 
Finally, the arrays are coated with a proprietary polymer and scanned on the Illumina 
BeadStation (Figure 2-2). 
Figure 2­2  Illumina workflow for BeadChip analysis 
 
Per  sample  workflow  involves  three  day  protocol  with  overnight  amplification  of  the  DNA,  followed  by 
preparation of the DNA for incubation on the array, overnight from day 2. On the third day, the single-base 
extension step is followed by staining and scanning of the finished array. In manual mode, batches of 16 
samples are the most efficient way of processing. The single base-extension step occurs at the distal end of 
the multimer attached to the bead, after which the sample DNA is stripped off (figure courtesy of Illumina, Inc, 
CA, and modified with permission). 
 
2.2.1.2  INTERNAL QUALITY CONTROLS 
In addition to the beads on the arrays used for genotyping purposes, there are several 
Beadtypes for quality control purposes. These are sample independent controls to assess 
the performance of specific steps in the protocol (staining, single-base extension, target  
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removal, hybridisation), and sample dependent controls to assess the performance of the 
protocol across samples (stringency of hybridisation, non-specific binding, non-
polymorphic controls). The controls assess one or the other of the two colour channels 
(red and green), or both. For each control, there are a number of Beadtypes with 15-17 
replicates each. The internal controls allow exploration of reasons for failure or 
underperformance of samples and arrays271. 
2.2.1.2.1  Staining controls 
Twenty Beadtypes for each colour are labelled only with varying levels of the hapten of 
that colour, testing the efficiency of the signal amplification step. It s independent of 
sample and hybridisation. This tests both the red and green channel. 
2.2.1.2.2  Extension controls 
Ten Beadtypes for each of the four bases. Each bead has hairpin multimers attached, 
which allow single-base extension without sample at the end of the hairpin. These beads 
should stain in the normal fashion, and test both colours (A and T for red, C and G for 
green). 
2.2.1.2.3  Target removal controls 
Ten Beadtypes with multimers that do not allow extension at the distal, 3’ end. Target 
removal controls, short sequences of DNA complimentary to the target removal control 
bead sequences are added after the overnight hybridisation of sample, and after 
annealing, extend at the 3’ end of the target removal control DNA. After the stripping of 
sample DNA, the target removal DNA sequences should also be removed, and no colour 
signal detectable from the target removal control beads. All beads have a green extension 
step. 
2.2.1.2.4  Hybridisation controls 
Hybridisation is tested at three concentration levels of synthetic template (0.2pM, 1pM, 
5pM), with ten Beadtypes for each level. Synthetic template with perfect complimentarity 
is added after the overnight hybridisation of sample, and subjected to single-base 
extension. Colour intensity at each beads should be correlated to the concentration of the 
synthetic template. All beads have a green extension step. 
2.2.1.2.5  Stringency controls 
This is a sample dependent assessment of the stringency of hybridisation of non-
polymorphic template DNA. The 20 Beadtypes have varying levels of mismatch in the 
multimer sequence, from perfect match to 12bp mismatch. With increasing mismatch, the 
staining intensity will reduce. All beads have a red extension step.  
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2.2.1.2.6  Non-specific binding controls 
Forty Beadtypes with multimers complimentary to bacterial sequences, with a distal, 3’ 
end available for single-base extension if sample DNA has annealed. Human DNA should 
not hybridise to these sequences under normal stringency conditions (as used in the 
Illumina process). This is monitored for both red and green channels. 
2.2.1.2.7  Non-polymorphic controls 
This tests the overall performance of the process, by using non-polymorphic template 
DNA. 10 Beadtypes are included for each base, and the colour intensity at these loci 
permits comparison of assay performance across samples. 
2.2.1.3  GENOTYPING QUALITY CONTROL ALGORITHMS 
2.2.1.3.1  GenTrain score  
The GenTrain score is a SNP specific, statistical score, defining how well an individual 
SNP has assayed. It takes into account the shapes of the clusters and their relative distance 
to each other. The GenTrain scores can range from 0 to 1, with 0 representing poorly 
performing/failed genotyping, and scores close to 1 representing the best performing 
genotyping at that SNP. It is not a score routinely used by the Illumina BeadStudio 
software to assess the robustness of genotypes, although GenTrain score <0.3 is likely to 
reflect a poorly performing SNP. 
Figure 2­3  Sample genotype plot generated in BeadStudio (rs1955049) 
 
Plot  of  the  normalised  intensities  of  red  and  green  channels  for  rs1955049,  the  SNP  with  the  highest 
GenTrain score (left). The genotypes clearly fall into three clusters. The data points are converted into a plot 
of angle from the origin θ versus the log normalised intensity (θ=(2/π) x arctan(B/A) where B is the green 
channel (y-axis) and A the red channel (x-axis). This new plot (right) forms the basis of the genotype calling 
algorithm. 
 
2.2.1.3.2  GenCall score 
The GenCall score is a sample and SNP specific quality score that is based on cluster 
position and definition in the genotype cluster plot (Figure 2-3), and is a measure of the 
distance of the individual genotype position from the centre of the cluster in that plot. Its 
value is influenced by the signal intensity, dispersion of genotypes, overlap of clusters, and  
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angle θ of the cluster. GenCall scores are calculated for each genotype, and give an 
estimate of how reliable that genotype is (for a specific sample and SNP). It ranges from 0 
to 1, with a lower score indicating increasing distance from the centre of a cluster, 
implicating worse clustering. The sensitive range of the GenCall score is in the region of 
0.2-0.7 depending on the Illumina platform used272. Below that range, the SNP generally 
has failed, above that, and the SNP is generally robust. For Infinium arrays (all the arrays 
used in this thesis), the recommend GenCall cut-off is 0.15 due to the very tight clustering 
seen with this assay273, i.e. a SNP may be legitimately associated with a cluster, but 




The cluster separation between AB and BB is poor, and samples lying between the two clusters cannot be 
reliably allocated to either one or the other, and the SNP was excluded (left). A well performing SNP with 
good cluster separation, there is no ambiguity about the genotype calls (right). 
 
2.2.1.3.3  Call frequency 
Call frequency is a per SNP score giving the percentage of samples called for that SNP. It 
is the number of samples called divided by the total number of samples. It assesses how 
well a SNP has performed across samples, and is driven by GenTrain and GenCall score.  
2.2.1.3.4  Call rate 
The call rate is a per sample measure of the number of SNPs called. It is the number of 
SNPs successfully called divided by the total number of SNPs. It reflects the quality of the 
DNA, as well as the fidelity of the process. It is ultimately also driven by the quality and 
GenCall scores as these determine the number of SNPs called. 
2.2.1.4  GENOTYPE CALLING 
The Illumina genotype calling and visualisation software BeadStudio determines clusters 
of genotypes by the colour at each bead locus: red for A homozygote, green for B 
homozygote, and yellow for heterozygote loci. The colour intensity at each bead is  
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measured and converted into an angle θ versus log-normalised intensity. The signal at 
each SNP locus should cluster into positions corresponding to the three genotypes (Figure 
2-3). 
The first step is self-normalising of the array, taking into account normal variation in 
signal intensity, variation in background intensity between the two channels, and the 
possibility of 'cross-talk' between the channels. The normalising process aids the formation 
of clusters, which are recognised by Illumina proprietary algorithms. This generates the 
GenTrain score for each SNP. 
Using the intensity data from each array, based on the GenTrain score, individual 
samples are assigned to a cluster. During this process the GenCall score is generated. As 
the algorithm requires a minimum of 100 samples to function properly, all samples were 
analysed jointly at the end. Illumina also advises manual editing of SNPs with poorly 
performing automated clustering273, this was performed on SNPs with low call frequency 
(Figure 2-5 and section 2.2.1.5). 
Any SNP that had a GenCall score of 0 allocated by the calling software, or that on visual 
inspection of the cluster, had a poor cluster separation was deemed to have failed. These 
SNPs were not considered for the verification phase. 
2.2.1.5  MANUAL RECALLING OF GENOTYPES 
Poorly performing SNPs were inspected visually and, within the constraints of the calling 
software BeadStudio, reassigned genotypes based on the cluster distribution. The first step 
was to run the calling algorithm and then sort SNPs based on their call rates. The cluster 
plot for each SNP was then inspected starting with the least well performing SNPs, and if 
the automatic clustering was unsatisfactory, manual reclustering was attempted unless the 
SNP was poorly clustered (see Figure 2-4 left), when it was excluded.  
Manual clustering within the BeadStudio software can be performed in two separate 
ways: firstly, selecting a cluster and forcing the algorithm to recognise this as a particular 
genotype, and secondly, by moving the cluster boundaries to include or exclude samples 
that are deemed to be included or excluded, respectively, in the cluster based on 
automated calling. In both instances, the genotype allocation is constrained by the 
algorithm so that it is not possible to allocate a sample any genotype but rather the plot 
position of the sample in relation to the other samples analysed is still taken into 
consideration. In Figure 2-5, both techniques are demonstrated: the rightmost cluster is 
not recognised as the BB cluster as it lies where normally an AB cluster would be expected 
(top left). By forcing the rightmost cluster to be recognised as BB, the other two clusters 
are unambiguously allocated the appropriate genotypes, but this now includes an  
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ambiguous sample, and moving the BB cluster area (blue ellipse) slightly to the right, will 
exclude this sample. 
Figure 2­5  Impact of manual recalling 
 
This SNP (rs10904494) clearly forms three clusters, but the calling algorithm determines that it does not 
conform to the expected locations of the clusters (the BB cluster should be centred around Norm θ=1) and 
does not call the AB cluster correctly (top left). By selecting the samples of the rightmost cluster, and forcing 
the  calling  software  to  use  these  as  the  BB  cluster  (top  right,  shaded),  all  three  clusters  are  assigned 
appropriate genotypes at this locus (bottom left), even if the generated GenTrain score remains low (0.367). 
The sample indicated by the arrow does not clearly belong to either AB or BB cluster, and by shifting the 
cluster position, this can be excluded from the BB cluster (bottom right). 
 
2.2.2  Single‐marker genotyping 
This section describes the standard conditions for each technique. All variations and 
primer sequences are given in the relevant appendices. All reagents are CRUK in-house 
versions, where this differs, it is indicated in the text. The manufacturer is given for all 
proprietary reagents. Primers were typically designed using Primer3 (Whitehead Institute 
of Biomedical Research) and obtained from SigmaAldrich (Gillingham, UK). 
2.2.2.1  STANDARD PCR FOR GENESCAN AND SEQUENCING 
The PCR for GeneScan and sequencing reactions is made up to 25µl total volume, and 
typically contains 30-50ng of template DNA per reaction. The Mg2+ concentration was 
1.5mM, or adjusted during optimisation for each primer pair (usually 2.5mM), DMSO 
replaced Q-solution (Quiagen, Crawley, UK) for the amplification of GC rich regions 
(Table 2-4).   
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Table 2­4  Reagents for standard PCR (all volumes in µL) 
      GC rich regions 
Reagent  1.5mM Mg
2+  2.5mM Mg
2+  1.5mM Mg
2+  2.5mM Mg
2+ 
DNA  2.0  2.0  2.0  2.0 
Taq Polymerase  0.25  0.25  0.25  0.25 
Forward primer [20mM]  0.25  0.25  0.25  0.25 
Reverse primer [20mM]  0.25  0.25  0.25  0.25 
MgCl [25mM]  1.5  2.5  1.5  2.5 
Buffer  2.5  2.5  2.5  2.5 
Nucleotide  2.0  2.0  2.0  2.0 
Q solution  5.0  5.0  -  - 
DMSO  -  -  2.5  2.5 
dH2O  11.25  10.25  12.75  11.75 
 
Reagents were mixed for the total number of samples to be typed and plated onto 96-well 
plates (ABgene, Epsom, UK), followed by the addition of DNA to each well. Plates were 
sealed with Thermowell sealers (Corning) and immediately run on a Tetrad PCR 
machine (MJ Research, Waltham, MA). The cycling conditions are given in Table 2-5 
with a standard annealing temperature of 55°C. All primers underwent optimisation for 
magnesium content, the use of DMSO and annealing temperature prior to experimental 
use. 
PCR products were visualised by agarose gel electrophoresis and ethidium bromide 
staining (Section 2.2.2.1.1). 
Table 2­5  Conditions for standard PCR 
Temperature  Time   
95°C  4 minutes  Initial denaturing 
94°C  1 minute   
55°C  1 minute  For 35 cycles 
72°C  1 minute   
72°C  10 minutes  Final extension 
15°C  Until plates removed from machine   
 
2.2.2.1.1  Agarose gel electrophoresis 
Depending on the size of the PCR product, 1, 2 or 3% agarose gels were used to visualise 
PCR product. The required amount of agarose (Invitrogen) was dissolved in 1X TBE 
buffer (Cancer Research UK) and ethidium bromide was added to a final concentration 
of 0.25µg/ml. The gels were set, samples were loaded and the gel was run in an 
electrophoresis chamber typically at 120V for 20 minutes. The DNA was then visualised 
with a White/2UV Transilluminator (UV Products, Cambridge, UK).   
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2.2.2.1.2  GeneScan analysis 
Following primary PCR, products were visualised by agarose gel electrophoresis and 
ethidium bromide staining (Section 2.2.2.1.1). The PCR product was diluted with dH2O 
according to the intensity of the band run on an agarose gel (between 1:1 and 1:150) and 
3µL volume of final dilution plated onto barcoded optical plates (ABgene, Epsom, UK). 
The plates were analysed using an AB3100 genetic Analyzer (Applied Biosystems, 
Woolston, UK) with 7-10ms injection time. 
2.2.2.1.3  Sequencing 
Following primary PCR, 5µL of PCR product were incubated with 2µL ExoSAP-IT (GE 
Healthcare, Amersham, UK) to remove any excess reagents and incubated for 30 minutes 
(Table 2-6). 
Table 2­6  ExoSAP reaction conditions 
Temperature  Time 
37°C  15 minutes 
80°C  15 minutes 
15°C  Until plates removed from machine 
 
Product from this reaction was diluted according to the intensity of the band on an 
agarose gel (Section 2.2.2.1.1) from the primary PCR, and amplified in a 2nd PCR (Table 
2-7), yielding fragments of varying length with a base specific dye in the last base of the 
fragment.  
Table 2­7  Reagents for sequencing PCR  
Reagent  Amount [µL] 
PCR product  4.0 
Primer [20mM]  1.0 
BDT  8.0 
dH2O  7.0 
BDT - Big Dye Terminator (Applied Biosystems, Woolston, UK) 
 
Table 2­8  Conditions for sequencing PCR 
Temperature  Time   
95  5   
96  .5   
50  .75  35 
60  4   
4°C  Until plates removed from machine   
 
Following the 2nd PCR step, the total reaction volume was placed in a DyeEx spin column 
(or plate if 96 samples were processed simultaneously, Quiagen, Crawley, UK) to remove 
unincorporated dye terminators, and spun at 2400rpm for 3 minutes. The eluant was  
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placed into bar-coded optical plates (ABgene, Epsom, UK). The plates were analysed 
using an AB3730 DNA Analyzer (Applied Bioscience, Woolston, UK). The output was 
read visually in each case. 
2.2.2.2  KASPAR 
KASPar is an allele specific PCR based on allele specific dye incorporation. The dye 
intensity is measured and converted into a genotype call. The biochemistry is proprietary 
to KBioscience (Hoddesdon, UK). All forward primers are labelled and chosen using 
KBioscience PrimerPicker software. 
Table 2­9  Reagents for KASPar PCR  
Reagent  Amount [µL] 
DNA  1.0 
Common primer [100mM]  0.025 
Forward primer [100mM]  0.010 
Reverse primer [100mM]  0.010 
Taq Polymerase  0.039 
MgCl [50mM]  0.096 
4x Reaction Buffer  3.0 
dH2O  7.822 
 
2.2.2.2.1  Standard PCR 
The reagents are supplied by KBioscience as PCR buffer, Hot-start Taq and 50mM 
Mg2+. Primers are obtained separately (Sigma Aldrich, Gillingham, UK). The total 
reaction volume was 12µL, the final Mg2+ concentration 2.2mM as the 4x buffer contains 
1.8mM Mg2+ (Table 2-9) Reagents were mixed for the total number of samples to be 
typed and plated onto 96-well optical plates (Applied Biosystems, Woolston, UK), 
followed by the addition of DNA to each well. Plates were kept on ice when not handled. 
The plates were sealed with Optical seals and immediately run on a Tetrad PCR machine 
(MJ Research, Waltham, MA) with a thermal mat to avoid evaporation. 
Table 2­10  Conditions for KASPar genotyping 
Temperature  Time   
94°C  15 minutes  For Hot-start Taq activation 
94°C  10 seconds   
57°C  5 seconds  For 20 cycles 
72°C  10 seconds   
94°C  10 seconds   
57°C  20 seconds  For 18 cycles 
72°C  40 seconds   
15°C  Until plates removed from machine   
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The PCR cycling protocol commenced with a Taq activation step followed by a 2-cycling 
programme according to manufacturer’s instructions. If the incorporation of dye was not 
fully completed, the second cycling step could be expanded to get better genotyping 
results (Table 2-10). 
2.2.2.2.2  Genotype analysis 
Plates were read on an AB7900HT scanner (Applied Biosystems, Woolston, UK), using 
SDS software 2.2 with automatic genotype calling and 95% confidence intervals. All data 
were transferred into a single Excel file for cross-checking results between plates and 
assessing plate heterogeneity by χ2 test with the appropriate degree of freedom (df=1 for 
allelic tests, df=2 for genotypic tests). All wells that could not be reliable assigned to a 




Genotype clustering based on FAM and HEX dye intensity. Allele 1 is always the FAM dye, as determined by 
the PrimerPicker software. The plot shows the results for a 96-well plate, the three genotypes are shown in 
navy (FAM/FAM), maroon (FAM/HEX), and lavender (HEX/HEX). Blue is the negative control, and green 
excluded samples that could not reliably be allocated a genotype. 
 
2.2.2.3  LIGHTSCANNER 
The LightScanner technology determines genotypes by measuring dye release during 
DNA melting. The base substitution of a simple SNP subtly alters the melting 
temperature of the PCR product, which is measured for each well via release of LC  
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Green incorporated during the PCR. All primers are chosen by the LightScanner® 
software and are unlabelled. 
2.2.2.3.1  Standard PCR 
The standard PCR was made up to 12.5µl total volume, and typically contained 15-25ng 
of template DNA per reaction. The Mg2+ concentration was 2.5mM (Table 2-11). 
Reagents were mixed for the total number of samples to be typed and plated onto white 
96-well plates (ABgene, Epsom, UK), followed by the addition of DNA to each well. 20µL 
of mineral oil were added to each well to avoid evaporation. Plates were sealed with 
Thermowell sealers (Corning) and immediately run on a Tetrad PCR machine (MJ 
Research, Waltham, MA). The PCR conditions are given in Table 2-5. 
2.2.2.3.2  LightScanner analysis 
Following the PCR, plates were loaded into the LightScanner® (Idaho Technologies, Salt 
Lake City, UT) without seal. Empty wells and controls were marked, and the plate 




Bottom left are the controls for analysis. Top left shows distribution of samples in 96-well plate, colour coded 
by genotype: in this case, grey squares are homozygous wildtype, blue positive controls (mutant allele 
carriers), red carriers detected in samples. Purple squares are blanks, and green failed samples. The latter 
two categories are excluded from the curves shown in the right-hand side panels. Top is the temperature 
normalised fluorescence, the residual fluorescence per well at any given temperature, bottom is the release 
of fluorescence in each well in response to temperature changes during the LightScanner analysis. The 
colours are the same as in the left panel, and the difference between wildtype and carriers is evident.  
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Table 2­11  Reagents for LightScanner PCR 
Reagent  Amount [µL] 
DNA  1.0 
Taq Polymerase  0.125 
Forward primer [20mM]  0.125 
Reverse primer [20mM]  0.125 
MgCl [25mM]  1.25 
Buffer  1.25 
Nucleotide  1.0 
Q solution  2.5 
dH2O  3.875 
LC green  1.25 
 
2.3  Statistical methods 
All statistical analyses were performed in Stata 9.2 or 10.1 (StataCorp, College Station, 
TX), p-values were 2-sided and confidence intervals are 95%, χ2 tests for 2x2 tables were 
continuity corrected. Fishers exact test was used if expected values in any cell of the χ2 test 
were <5. For comparison of a distribution of two variables, the two independent samples 
t-test was used for normally distributed interval variables (Stata command: ttest), and the 
Wilcoxon-Mann-Whitney test for all others (Stata command: ranksum). Comparison of 
medians was performed using a nonparametric K-sample test on the equality of medians 
(Stata command: median). 
2.3.1  Allele naming beyond Illumina 
Alleles were represented by A and B according to the Illumina convention (Table 2-3). 
For A/T and C/G SNPs, the convention was extended that in these circumstances the A 
allele was A or C, respectively.  
2.3.2  Models tested 
In all association analyses, the major allele was coded M and the minor allele m, 
irrespective of whether the minor allele was A or B. Allele frequencies were determined by  
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M = 2MM + Mm ∧ m = 2mm+ Mm (1) 






















and significance was tested by χ2 test with df=1. 
The genotypic model (genotype frequencies) was tested using a χ2 test with df=2. In both 
cases, if the expected frequency in any cell was <5, Fisher’s exact test was used. In 
addition, recessive and dominant models were tested, both are named with respect to the  
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minor allele m compared to the major allele M, i.e. the recessive model groups MM and 
Mm (vs. mm), while the dominant model group Mm and mm (vs. MM). The analyses 
performed for the latter two models were the same as the genotypic model (Table 2-12). 
Genotypes were coded numerically for analysis purposes, MM=1, Mm=2, mm=3. In 
recessive and dominant models, the group containing the MM genotype was coded 0, the 
other 1. All effect sizes (ES) therefore give the impact of the m allele with respect to the 
MM genotype, and dominant and recessive models are with respect to m of this naming 
convention. 
2.3.3  Logistic regression 
For categorical analyses (case/control, relapse/no relapse), logistic regression was used as 
the test for trend (Stata command: logistic). Odds ratios generated through logistic 
regression give a trend estimate for the genotypic model with increasing numbers of m 
alleles (MM vs. Mm vs. mm), while for recessive and dominant models, it is approximated 
by eq. (2) with the allele counts replaced with group counts. The associated p-value was 





∧ p = 2×(1− normaldistribution z ) (3) 
2.3.4  Logrank test and Cox regression 
In cases where survival data was available, the genotypic, recessive, and dominant models 
were tested. Time to event analysis was performed using the logrank test for the equality 
of survivor function (Stata command: sts test). This test formed the basis of the selection of 
SNPs in Chapter 3 for verification in chapter 4. 
For the calculation of the HR for death by Cox regression (Stata command: stcox), alleles 
were coded in the same fashion as already described (section 2.3.2). All survival data was 
to first recorded relapse, or right censored for patients lost to follow-up. All follow-up data 
was left-truncated at the date of surgery. The ptrend was calculated using eq. (3) above. The 
survival data for section 3.4 were initially generated by David Mesher using Stata 10.1. 
Table 2­12  Tests of significance used 
Genetic model  Components  Comparison of groups  Trend test 
Allelic  M, m 
χ
2 test 





MM vs. Mm vs. mm 
(MM+Mm) vs. mm 






Categorical comparisons were tested using χ2 or Fisher’s exact test, trend testing was performed for the 
genotypic, recessive, and dominant models, using logistic regression. The Survival functions were tested 
using the logrank test and Cox regression.  
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2.3.5  Cochran‐Armitage trend test for the additive model 
The Cochran-Armitage trend test for the additive genotypic model generates the ϒ2 




N{(r 1 + 2r2)−φ(n1 + 2n2)}
2
φ(1−φ){N(n1 + 4n2)−(n1 + 2n2)
2}
(4) 
where N=total number of subjects, φ=proportion of cases, r1=number of Mm in cases, 
r2=number of mm in cases, n1=number of Mm in N, n2=number of mm in N. 
2.3.6  Power calculations 
Power calculations were performed using the Center for Statistical Genetics, University of 
Michigan's Power Calculator for Genetic Studies (CaTS). This is designed for power 
calculations for 2-stage genetic association studies based on the principles described by 
Skol et al.274, see Table 10-1 for the URL. 
2.3.7  Determination of Hardy‐Weinberg equilibrium (HWE) 
Deviation from HWE was tested for by genotypic χ2 test with df=1, calculating the 
expected frequencies from the observed allele frequencies, and based on 
€ 
a
2 + 2ab+ b
2 =1 (5) 
where a=allele frequency of A, and b=allele frequency of B. 
HWE was tested for the overall group, control group, and case group, with p<0.01 
deemed to be a significant deviation in the overall and control groups. Cases were allowed 
to deviate from HWE, as this could be manifestation of the association of the tested locus 
with the case group. 
2.3.8  Detection of population substructure 
Deviation from the expected versus the observed quantiles of the χ2distribution were 








with 0.456 the predicted median χ2 for df=1, and 1.386 for df=2, and the reference line 
adjusted accordingly275. 
The Eigensoft programme was used to test for ancestral variation between cases (relapsed 
patients) and controls (non-relapsed patients). Eigensoft is a software suite to correct for 
population stratification using a three-step algorithm: first, principal component analysis 
(PCA) is used to infer genetic variation along principal axes based on ancestral differences 
between cases and controls, and the output displayed graphically and in list format276. 
Secondly, if significant stratification is detected, then genotypes are adjusted to take  
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account of ancestral differences and thirdly, the new genotypes are used for future 
association studies277. 
The PCA step is very sensitive to known population stratifiers, e.g. HLA types. To avoid 
these known stratifiers obscuring the potential signal from non-random distribution within 
the VICTOR cohort, a random set of SNPs was chosen, spaced evenly across the 
genome. This method reduces the impact of the HLA types by using fewer SNPs residing 
in this area, without decreasing the power such that cryptic relatedness between subjects 
could not still be detected. This analysis was performed by Dr Jean-Baptiste Cazier. 
2.3.9  Linkage equilibrium testing  
Linkage disequilibrium relationships were determined using Haploview 4.1 (ref 278). LD 
blocks were determined using the algorithm described by Gabriel et al.279, as implemented 
in Haploview 4.1. For all risk and outcome loci, r2 was used as the determinant of the LD 
relationship. For the section on tagging insertion/deletion changes (Chapter 8), D’ was 
used to capture the LD relationship of rare alleles more accurately. 






D’ is calculated using allele frequencies at both loci and is a ratio of observed LD (denoted 
D) and maximal LD (denoted Dmax) between the two loci280. Assuming that the allele 
frequencies of the four alleles (A, a and B, b) are given by p1, p2, q1, and q2, then the 
gamete frequencies g11, g10, g01, and g00 are given as 
      Locus A 
  Alleles    A  a 
    Allele frequency  p1  q1 
B  p2  g11  g01 
Locus B  b  q2  g10  g00 
 
Then D is given by  
€ 
D= g11g00 − g10g01 (9) 








Dmax = min(p1q2,q1p2) for D≥ 0 ∧ Dmax = min(p1p2,q1q2) for D< 0 (11) 
As such, D’ is also high when the minor allele homozygote of one locus is (almost) always 
associated with the minor allele homozygote of the second locus even if the reverse was  
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not true. In these instances r2 would be lower, suggesting no LD. In practice, this requires 
inference of haplotype frequencies in a given dataset, a step inherent in the analysis 
performed by Haploview 4.1. 
2.3.10  Shrinkage of estimates and their standard errors 
The first step was to make assumptions about the true underlying associations between 
the SNPs and relapse from CRC: that at most hundreds of SNPs would have a true 
hazard ratio of greater than 1.15 (or less than 0.87, the reciprocal of 1.15 ), that at most 
50 would have a true hazards ratio of greater than 1.2 (or less than 0.83), and that most of 
the true HR would be close to 1.0. 
Formally, therefore, for the logHR, all but 3 per 10,000 would be normally distributed 
with mean zero and standard deviation 0.04. In addition, a small proportion (1.5 per 
10,000) was to have a moderate positive association and the same small proportion to 
have a moderate negative association. Formally, both would also be normally distributed 
with means +/- 0.2 and standard errors of 0.5. The prior distribution on the log hazard 
ratios was the mixture of these three normal distributions. With 309,200 SNPs, this prior 
probability gave 113 hazard ratios greater than 1.15, 36 greater than 1.2, 22 greater than 
1.5 and 9 greater than 2. By symmetry, the same numbers were less than the reciprocal of 
these hazard ratios. 
Figure 2­8  Graphical Representation of prior probability density function 
 
The prior probability function assumes that virtually all SNPs have no effect on prognosis (logHR≈0), and that 
only a tiny proportion have logHR≠0, representing SNPs with an effect on prognosis. 
 
The prior probability density function is illustrated in Figure 1. It looked like a spike at 
zero, but if zoomed in and ignoring the function between -0.175 and 0.175, it was 
apparent that the tails had “shoulders” at about +/- 0.2, corresponding to the possibility 
of containing a few clinical important associations (Figure 2-8).  
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The clinical data yielded estimated log hazard ratios and standard errors for each SNP. 
These were treated as representative of the means and standard errors of normally 
distributed likelihoods. 
These were combined with the prior distribution to obtain a posterior distribution for 
each SNP (Figure 2-9 for examples). Due to the unusual prior chosen - i.e. the 
combination of three normally distributed SNP populations rather than assuming that all 
SNPs lie within the same normal distribution - the posterior density function can be 
bimodal, with two spikes separated by a region with very little probability mass. Despite 
this, the posterior means and standard errors and used in the meta analysis were treated 
as if they came from normally distributed posteriors, and the main spike adjusted for the 
magnitude and probability of the second peak. 
The shrinkage was performed by David Mesher and Prof Peter Sasieni, and applied to 
the analyses in section 4.3. 
Figure 2­9  Examples of posterior probability density functions 
 
Examples of the posterior probability for the dominant model of four SNPs. Both examples on the left have an 
adjusted HR<1 (logHR<0), with logHR for rs1924597 being -0.466, and for rs9514816 being -0.095. The 
greater deviation from zero for rs1924597 is driven by the greater posterior probability of logHR=-1. The 
SNPs on the right show a logHR≈0 (0.038 for rs4715476 and -0.003 for rs1822917), with no evidence of a 
second peak. 
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2.3.11  Meta‐analysis 
All meta-analyses of OR or HR were performed using log transformed effect sizes in a 
fixed effects model with inverse variance weighting. Meta-analyses of counts (e.g. of 
alleles) were performed using a fixed effects model with Mantel-Haenszel weighting. 
Heterogeneity was assessed using the I2 statistic, namely the proportion of observed 




var logHRi ( )









where logHRi is the log transformed point estimate of the individual study, logHR the 
summary estimate, and var(logHRi) the variance of the point estimate for the individual 
study. 
Values of I2 ≥ 50% were considered moderate heterogeneity281), and the use of a random-
effects model was considered. Likewise if qualitative measures of study characteristics 
revealed inter-study heterogeneity. Heterogeneity was further assessed with Egger’s bias 
coefficient282 and by funnel plot283.  
When performed, sensitivity analysis to exclude a significant influence of other 
characteristics was performed by meta-regression (Empirical Bayes model)284. 
  






GWAS for prognostic markers: 
Discovery phase 
 
3 GWAS for prognostic markers: Discovery phase 
The patients of the VICTOR trial offered a unique opportunity to employ a GWAS 
approach to biomarker discovery: to date, there has been very limited study of the 
germline in the prognostication and prediction of response in CRC, and the VICTOR 
trial combines the availability of good quality DNA with robust clinical data. This GWAS 
was conceived in parallel with the successful GWAS for CRC risk loci performed in our 
laboratory, which has already demonstrated the successful application of high throughput, 
unbiased SNP screening for a given phenotype42-46. 
3.1  Study design 
The VICTOR GWAS for novel markers of outcome in CRC was designed as a 2-stage 
study: an initial phase (discovery phase or phase 1) during which all autosomal SNPs 
(309,200) on Illumina Hap300 arrays would be tested for an association with outcome, 
and a verification phase (phase 2), for the top 40 SNPs of interest. The results from both 
phases were planned to be combined to derive a 'final' estimate of prognostic information, 
and to confirm or exclude the selected SNPs as prognostic markers. The incorporation of 
the hypothesis generating set in the verification analysis improves power despite more 
stringent p-values for statistical significance274. At the beginning of the discovery phase, a 
further cohort of stage 2 and 3 patients from a clinical trial (PETACC 3) had already been 
identified, and further cohorts would be considered as they became available. 
The chosen strategy provides a trade-off between statistical power and cost274, and while it 
would be preferable to type all SNPs in all samples of the verification phase as this is the 
power limiting step, the cost associated with this approach is prohibitive. Assuming a 
second cohort of 1000 patients, an overall event rate of 25% (phase 1 and 2 combined), a  
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frequency of the allele associated with relapse of 33% in the overall population, this study 
would have 85% power to detect a relative risk of 1.5 at a cut-off of p≤1e-07 in the joint  
Figure 3­1  Power estimation for different genotyping scenarios 
 
Power estimation based on the cohort sizes, and various assumptions for relative risk and allele frequency. 
Both models assume an overall relapse rate in all patients of 25%. The cohort size is given in the central 
column, with 931 patients in phase 1, and between 1000 and 4000 additional patients in phase 2. The model 
on the left assumes a constant genotypic relative risk (GRR) of 1.5 and varying MAF. The model on the right 
assumes constant MAF of 0.25 and varying GRR. Power estimations are based on the Power Calculator for 
Genetic Studies274. 
 
analysis. With the same assumptions, but a second cohort of 2000 patients, the power 
increases only marginally, as is the case with a further 3000 and 4000 additional patients. 
With an allele frequency of 25%, only with relative risks above 1.5 does power approach 
80%, almost irrespective of the number of additional patients (Figure 3-1). Therefore, this 
study was powered to detect either quite marked effects (relative risk ≥1.5), or risk alleles 
with quite high frequencies (≥30%). 
3.2  Patient details 
At the cut-off point in November 2007, 934 samples of the VICTOR trial were available, 
with 156 relapses (cases) and 778 non-relapsed patients (controls). There was a slight 
preponderance of males; the median age of diagnosis was 64.4 years; these variables were 
well matched between stages. There was a slightly higher proportion of rectal carcinomas 
in the stage 3 group. Therapy was as expected for site and stage of disease, with 
significantly higher rates of adjuvant chemotherapy and relapse in stage 3 (Table 3-1).  
In three cases the last date known to be alive was not available in the database under this 
heading; these patients were allocated a censor data of the last known contact with the 
trials office, the date of discontinuation of the trial medication. Two patients were 
allocated to the 15th day of the months as relapse date, as this part of the date was missing. 
Fourteen patients died of other causes and were censored. One patient died on relapse; 
this was considered the relapse date.  
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Table 3­1  Patient characteristics of analysed patients 
  All  Stage 2  Stage 3  p-value 
Patients  931  475  459   
Gender [%male]  64.7  65.7  63.6  5.11e-01 
Median age at diagnosis (range)  64.4 (24.6-86.4)  64.9 (24.6-86.4)  64.2 (34.0-83.9)  1.47e-01 
Disease site        1.00e-02 
Colon [%]  64.8  68.2  61.2   
Rectosigmoid junction [%]  8.3  9.1  7.4   
Rectum [%]  27.0  22.7  31.4   
Adjuvant chemotherapy [%]  62.6  31.1  95.0  4.96e-90 
Radiotherapy [rectal patients %]  38.7  35.5  41.0  3.80e-01 
p-value is for the comparison between stage 2 and 3, for interval variables the two independent samples t-
test was used, and the Wilcoxon-Mann-Whitney test for all others 
 
3.3  Parameters and quality control of genotyping 
3.3.1  Genotype quality based on internal controls 
In total, 934 patients were analysed using the Illumina Infinium Duo arrays: 526 using 
Hap300 arrays, and 408 using Hap370 arrays. The parameters used to assess the quality 
of the data were GenTrain score for each individual SNP, call rates for each sample, and 
GenCall score for individual genotypes per patient and SNP (see section 2.2.1.2 for a 
detailed description). 
3.3.1.1  PER SAMPLE ANALYSIS 
Samples were only included in the analysis if the call rate was >95%, this was the case for 
931 samples. Three samples had call rates <95%: in one case, this was due to the sample 
quality, as a repeat of this sample had the same poor call rate (65%), and in two cases this 
was likely to be a failed SNP array, as both samples were analysed on the same array and 
had equally poor call rates (70%). There was insufficient DNA to repeat these samples. 
One patient was enrolled twice in the trial (as VIC0284 and VIC0890) and only the 
higher scoring array was included in the analysis. 
For the patients included, the median call rate was 99.93% (range 96.65-99.99%) and the 
mean call rate was 99.90%, with only six samples having a call rate <98.5%, and 19 
samples <99.5%; the majority of samples had a call rate>99.90% (Figure 3-2). The 
GenCall score was not assessed at a per genotype level at this stage, but was taken into 
account when the SNPs for further investigation were selected. 
The proportion of call-rates ≥99.9% was higher for Hap370 than Hap300 arrays, while 
the proportion of samples with a call-rate ≥99.95% was higher in the Hap300 arrays, 
56.6% vs. 43.4% (Table 3-2). From a practical point of view, however, call rates of 
≥99.90% for each array are good enough to accept the array as not failed and the 
genotypes generated as valid.  
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Figure 3­2  Distribution of patients by call rate 
 
The percentages below the bars are the lower bounds of 0.05% bins for the call rate, the exact value is 
included in that bin. The bottom two bins are for call-rates 95 to <98.5% and 98.5 to <99.5%. All values are 
absolute numbers for Hap300 (light blue) and Hap370 (navy) of the samples included in the analysis. 
 
3.3.1.2  PER SNP ANALYSIS 
Single nucleotide polymorphisms were only considered for further analysis if >95% of 
samples had a genotype allocated by the genotyping software (Illumina BeadStudio 3.0). 
If this was less, the SNP was deemed to have failed (98 SNPs). For the remaining SNPs, 
the median number of samples called per SNP was 931(range 885-931), and in 97.82% at 
least 926 samples were called. Genotyping per SNP was robust: the median GenTrain 
score for the VICTOR samples was 0.848 (range 0.367-0.972). In total, 159 SNPs, 
equivalent to 0.05% of all SNPs, were excluded and had their GenTrain score set to zero. 
Table 3­2  Call rate by array type 
  All  Hap300  Hap370  p-value 
Median call rate  99.95%  99.95%  99.95%  0.492 
Call rate ≥99.90%>  82.92%  81.71%  84.48%  2.01E-13 
Call rate ≥99.95%  50.81%  56.57%  43.35%  4.75E-12 
The call rate distribution differs significantly by array type (Hap300 vs. Hap 370) without having any known 
practical implications. 
 
While the GenCall score was not analysed for individual SNPs and samples at this stage, 
the summary GenCall score for each SNP (based on the distribution of the individual 
GenCall scores) suggested that the samples performed uniformly well and genotyping was 
very robust. When the median GenCall score (GC50) for each SNP was compared to the 
10th centile GenCall score (GC10) for the same SNP, the values were identical in all but  
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774 SNPs, suggesting that, at a minimum, the best performing 90% of samples for each 
SNP behave in a uniform fashion during genotype calling. 
3.3.2  Repeat samples and reproducibility 
Out of the 931 samples, 17 had call rates at initial genotyping of just below the 95% 
threshold required for inclusion in further analysis, they all repeated with call rates 
≥99.90% on 2nd genotyping. The reasons for failing to achieve the required threshold 
initially were mostly due to technical problems with the first batch of Hap300 arrays, 
when occasionally bubbles would be introduced while loading the DNA onto the array. 
Later Hap300 arrays and the Hap370 arrays did not suffer from this problem. 
To test the reported robustness of the Infinium chemistry employed in the Hap 300 and 
Hap370 arrays270, data for the one duplicate sample with excellent call-rates in both runs 
(VIC0890 and VIC0284), and one SNP (rs6983267), also typed by direct sequencing, 
were analysed. VIC0284 was typed once on the Hap300 and once on the Hap370 arrays 
(as VIC0890 in the latter). For 555 SNPs (0.17%), the genotypes were not concordant, the 
majority (475 SNPs, 85.6% of non-concordant SNPs) because the SNP was a ‘no-call’ in 
one of the samples. Of the remaining SNPs, all but one were AB calls for VIC0284 
(Hap300) and BB calls for VIC0871 (Hap370). The one exception was a the reverse, BB 
in VIC0284, AB in VIC0871, suggesting a slight difference in the calling of genotypes for 
SNPs where the AB and BB clusters are close together. Overall, however, for the Hap300 
content, the concordance was >99.97%, with only 80 SNPs allocated a different genotype 
in the two runs. None of the SNPs later taken into verification (Chapter 4) fell into this 
category. 
Table 3­3  Discrepancies between direct sequencing and Illumina genotyping 
Sample ID  Illumina  GenCall score  Sequencing 
VIC0152  TT  0.874  TG 
VIC0155  TG  0.874  GG 
VIC0871  TT  0.874  TG 
Genotypes for rs6983267 in samples where direct sequencing differed from the Illumina called genotypes. In 
all cases, the Illumina genotypes appeared robust on genotyping parameters (GenTrain score=0.842 and 
GenCall scores=0.874 for all three samples). 
 
rs6983267 was typed in 881 samples for which data was available from the Illumina 
arrays as part of the initial GWAS for CRC risk44. Manual genotyping of the same sample 
had been performed by Dr Oliver Sieber using direct sequencing. Genotypes were called 
blinded to the results from the other technology, and reproduced in 878 samples (99.7%). 
In three cases, the genotype was discrepant by one allele (Table 3-3). The genotypes for 
all three samples when called by BeadStudio are robust, they all have the same high 
GenCall score (0.874) and there is no ambiguity about the cluster membership (and thus  
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genotype) based on the 15 replicates per array (Figure 3-3). It is likely that the discrepancy 
arose on the side of direct sequencing, and Illumina genotypes were used in all cases. 
Figure 3­3  Genotype clusters for rs6983267 
 
Genotype  clusters  for  rs6983267  with  discordant  samples  highlighted  in  yellow.  Based  on  the  15-fold 
replication inherent in the Illumina arrays, there appears no doubt about the genotypes for these samples, 
making it likely that the discrepancy arose on the side of the sequencing. Sample VIC0926 was excluded 
from the survival analysis even though on visual inspection it looks most likely to be a BB genotype. 
 
3.3.3  Manual recalling of genotypes 
While the Illumina genotyping algorithms attempt to “ . . . mimic evaluations made by a human 
expert’s visual and cognitive systems.”272, Illumina recommend manual adjustment of SNP 
clusters where distinct clusters form but the algorithm has been unable to determine these 
with certainty. 
All SNPs with a call frequency with of <98.71% were inspected and adjusted manually 
where samples were not allocated a genotype despite clearly belonging to a particular 
cluster. The cut-off was driven by the Illumina standard of expecting a successful SNP to 
have a call frequency of >98.5%, and because the yield for successful increases in call 
frequency for SNPs with a call frequency between 98.5% and 98.71% had already been 
low. Therefore, the next step up in call frequency (98.82%) was not assessed. 
The aim of manual recalling was to maximise the call frequency, without calling any 
unreliable genotypes, i.e. clustering had to be unequivocal for the adjusted samples. This 
was performed for 1855 SNPs and improved the call frequency for the majority of SNPs 
inspected. In a small minority of SNPs, manual recalling decreased the call frequency as  
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the cluster separation had not been satisfactory on visual inspection and equivocal 




The genotypes for rs10904494 clearly fall into distinct clusters, but the calling software does not recognise 
the rightmost cluster as the BB cluster as it is not close enough to the expected position (Norm θ=1, left). 
Manual recalling assigns appropriate genotypes to all three clusters. This manoeuvre increases the call 
frequency from 52.5% to 99.8% for this SNP (right). 
 
The impact of manual recalling on global parameters of genotyping, however, was 
modest, as only 0.6% of SNPs were inspected in this fashion (1855 of 309,200 SNPs) , and 
for those edited, for many, the call frequency improved by only a few samples per SNP, 
although for some SNPs, the call frequency improved much more dramatically (Figure 
3-4). 
3.4  Disease-free survival analysis 
Only autosomal SNPs (309,200) were analysed for an association with survival, based on 
the 931 samples and the follow-up available at the data cut-off point on 17 November 
2008. All SNPs were analysed for the four models: genotypic, dominant, recessive, and 
allelic. They were analysed by logrank test for equality of the survival function and Cox 
regression with a time-to-event analysis for the genotypic, dominant and recessive models, 
and by allelic OR for the allelic model. 
Table 3­4  Survival and relapse 
  All  Stage 2  Stage 3  p-value 
3-year DFS [%]  86.5  90.4  82.8  2.07e-03 
All patients  931  472  459   
All relapsed patients in follow-up  156  51  105   
All relapsed patients in follow-up [%]  16.8  10.8  22.9  8.50e-05 
3-year DFS appears higher than would be expected from the relapse rate due to a further 34 relapses 
beyond 36 months follow-up. The p-value is for Cox regression comparing stage 2 and 3.  
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All survival data were to first recorded relapse, or right censored for patients lost to follow-
up. The median follow-up was 44.1 months, SD ± 12.8 months for the overall cohort, and 
46.1 months, SD ± 10.3 months if relapsed patients are excluded. 
Table 3-4 shows the number of relapsed patients during the whole follow-up period and 
gives the estimated 3-year DFS, by stage. 156 patients had relapsed (16.8%), and as 
expected, this was higher in stage 3 than stage 2 (22.9% and 10.8%, respectively; 
p=8.50e-05). The median survival was not reached at the data cut-off, with a 3-year 
disease-free survival of 86.5%. For stage 2, 3-year DFS was 90.4% and for stage 3, 
DFS=82.8%, with a HR=1.79 (95% CI 1.23-2.59, p=2.07e-03). The 3-year DFS does 
not take into account all recorded relapses in the VICTOR cohort, and there were a 
further 34 relapses beyond 36 months follow-up (Figure 3-5). 
Figure 3­5  Survival by stage in VICTOR cohort 
 
As  would  be  expected,  there  is  a  statistically  significant  difference  in  the  survival  between  the  stages 
(p=8.50e-05); stage 2 - navy; stage 3 - maroon. 
 
3.4.1  Genome wide p‐values 
The distribution across the genome of p-values for the SNPs analysed was assessed 
visually by plotting the negative logarithm of the p-value from the logrank test for the 
genotypic model against SNP position on each chromosome (Manhattan plot). Figure 3-6 
shows the plot for the whole chromosome.  
  70 
Figure 3­6  Genome wide Manhattan plot 
 
Plot of the negative log10 of pgen vs. the position on chromosomes 1 to 22, starting at the telomeric end of the 
p-arm of chromosome 1 and ending at the telomeric end of the q-arm of chromosome 22. There are small 
gaps to indicate the different chromosomes, where there are larger gaps, there are no SNPs in that region 
(the short arm of chromosomes 13, 14, 15, 21 and 22; the centromeric region of chromosomes 9, 16, and 
18). 
 
The Manhattan plot for each chromosome was scrutinised for regions of nominal 
significance (-log10 (pgen)>4.0). Areas where there were adjacent SNPs with a -log10 
(pgen)>3.0 were also noted, likely to represent areas of LD with a possible association with 
prognosis . This process was to ensure that the selection strategy based on numeric values 
(outlined in section 3.6) did not miss potentially significant regions. All Manhattan plots 
by chromosome are given in Appendix B. 
3.5  Population stratification 
Hidden population substructures are capable of artificially inflating the χ2 statistic for 
positive associations, causing spurious assertions about the link between a particular 
marker and outcome285,286. To test if the observed matched the expected χ2 distribution, 
the inflation factor λ was calculated and the distribution shown in a Q-Q-plot of observed 
versus expected quantiles of the χ2 distribution for the allelic model (Figure 3-7). On 
visual inspection, there was no evidence of systematic overestimation of the χ2 statistic.  
The inflation factor was λall=1.001, again suggesting no hidden substructure. There was 
no evidence in the other models (genotypic, recessive, dominant) for an inflation of the χ2 
statistic (λgen=0.989, λrec=1.010, λdom=0.999).  
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Figure 3­7  Q­Q plot for allelic model 
 
Q-Q plot of observed against the expected quantiles of the χ2 distribution. The green line represents the 
perfect fit of data and model, in other words, exact agreement between the two distributions. The deviation 
from the perfect fit line at the tail is expected, as there is a lower density of points in this part of the plot, and 
‘true’ associations would be expected to move the observed distribution above the expected. 
 
The genetic substructure was further analysed using principal components analysis (PCA) 
as part of the Eigenstrat software suite designed to detect population substructure. PCA 
aims to reduce a large number of measurements, e.g. genotypes, to a few principal 
components which can explain the majority of the variability, an approach largely applied 
to the detection of sub-populations in admixture mapping, but which can be equally 
applied to any population and trait276. “Thus, the first principal component is the mathematical 
combination of measurements that accounts for the largest amount of variability in the data.” 287. 
Table 3­5  p­values associated with the top 10 Eigenvectors 
Eigenvector  p-value  Eigenvector  p-value 
1  0.570  6  0.741 
2  0.127  7  0.362 
3  0.857  8  0.782 
4  0.297  9  0.356 
5  0.560  10  0.568 
The p-values for each Eigenvector are non-significant, meaning that there is no significant separation along 
the vector. 
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PCA was performed by Dr Jean Baptiste Cazier, and did not reveal any population 
stratification along the top ten Eigenvectors as assessed by numerical means (Table 3-5) 
and visual inspection (Figure 3-8). The p-values associated with individual SNPs (see 
section 3.4 for the survival analysis and p-value generation) were therefore not adjusted 
prior to selection of SNPs to be taken into the verification phase.  
Figure 3­8  Eigenvectors 1 and 2 for VICTOR cohort 
 
Plot generated by SmartPCA, the PCA component of the Eigenstrat software suite277. Eigenvectors are 
named 1, 2, 3, . . . N, in decreasing order of impact on variability, and vectors 1 and 2 are shown. There is an 
even distribution of the samples around the mean for both vectors, implying that there is no heterogeneity of 
the population. Lower order Eigenvectors should in this instance also have even distributions, and visual 
inspection confirmed this (see Appendix B).  
 
3.6  SNP selection for verification 
3.6.1  Selection strategy and rationale  
Forty SNPs were to be taken into the initial verification phase. These were selected from 
the autosomal content of the Hap300 arrays after excluding failed and non-informative 
SNPs, those not in HWE, and those not meeting the significance threshold for inclusion of 
p<1e-04.  
The logrank test was more sensitive than χ2 and Fisher’s exact test to small numbers in 
the minor homozygote group mm, with marked inflation of the observed logrank χ2 
values. Therefore, SNPs with low minor homozygotes frequencies were excluded, 
reducing the over-inflation of positive associations. The higher the cut-off value for the 
minor homozygote frequency, the lower the deviation of the observed tail on the Q-Q  
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plot, but this risks excluding true associations. The cut-off chosen was a minor 
homozygotes frequency less than 10, and while the appearance of the Q-Q plot was 
markedly improved (Figure 3-9), only in the genotypic model did it improve λ appreciably 
(new λgen=0.996).  
Figure 3­9  Omission of SNPs with low minor homozygote frequencies 
 
The χ2 distribution derived from the logrank test appeared to be more sensitive to small numbers in the minor 
homozygote  group  with  marked  inflation  of  the  observed  χ2  values  (left).  Therefore,  SNPs  with  minor 
homozygotes  less  than  10  in  the  control  group  were  not  considered  further,  producing  a  less  inflated 
distribution (right). Model shown is recessive. 
 
Twenty five SNPs would be chosen purely based on statistical significance; 15 SNPs 
would be chosen from the remainder of the eligible SNPs based on biological rationale.  
Biological rationale was assessed using the function of the gene nearest to the SNP as 
denoted by the UCSC Genome browser , e.g. involved in cell signalling, cycling, and 
motility, have a previous described role in or association with cancer, the distance of the 
gene to the SNP, level of conservation in region of the SNP, some evidence for other 
SNPs in the region being associated with prognosis based on Manhattan plots, and finally, 
if two SNPs appeared to have a similar biological rationale, statistical relevance (p-value). 
Further, in order to maximise the number of distinct loci to be evaluated in phase 2, if two 
SNPs were in the same gene, only the SNP with the lower p-value would be taken 
forward, provided they did not have markedly differing genotype distributions, in other 
words low linkage disequilibrium (LD) defined as r2<0.7. The reasons for choosing 
individual SNPs based on biological rationale are described in section 3.6.2. 
Thus, of the 318,237 SNPs on the arrays, 9037 were not included in the survival 
estimation as they were X or Y chromosome linked, leaving 309,200 autosomal SNPs 
with survival analysis data. 180 SNPs were excluded because they had a GenTrain score 
of 0, and a further 43 SNPs because they did not cluster well enough for any further 
analysis. These 223 SNPs constituted the failed SNPs. 56 SNPs were excluded because 
they were monomorphic in the VICTOR cohort. After applying the p-value cut-off, 565  
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SNPs remained, excluding 308,356 SNPs. 457 further SNPs were excluded because a 
minor homozygote frequency of <10, leaving 112 SNPs with a MAF of >0.12. Nine SNPs 
were not in HWE in the control group or overall cohort, leaving 103 SNPs. All performed 
well on genotyping parameters, with a median GenTrain score of 0.843 (range 0.708-




Starting with 318,237 SNPs, these were reduced in a succession of steps according to the pre-planned 
exclusion strategy, numbers excluded in brackets. The final 103 SNPs formed the basis of selection for the 
verification phase. 
 
The genotypes and quality parameters for the chosen SNPs are given in Table 3-6, and 
the distinction between SNPs chosen statistical significance and biological rationale is 
indicated. The impact on survival and a functional annotation is given in Table 3-7 (see 
also Table 10-2). 
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Table 3­6  Genotypes for SNPs selected for verification in phase 2 
    Control  Relapse      HWE   
Rank  SNP  AA  AB  BB  Total  AA  AB  BB  Total  GT  GC50  ptotal  pcontrol  Alleles 
1  rs472660  9  169  597  775  12  39  105  156  0.853  0.887  0.234  0.440  C/T 
2  rs7556894  38  291  445  774  24  55  77  156  0.861  0.898  0.649  0.274  A/G 
3  rs2589183  46  252  476  774  2  26  128  156  0.901  0.937  0.034  0.106  C/T 
4  rs764372  11  199  565  775  11  41  104  156  0.784  0.791  0.931  0.162  A/G 
5  rs672757  105  386  284  775  42  83  31  156  0.848  0.881  0.206  0.146  A/G 
6  rs7912136  386  329  59  774  77  49  30  156  0.853  0.888  0.356  0.332  A/G 
7  rs6972789  218  399  158  775  36  61  59  156  0.830  0.859  0.754  0.318  C/T 
8  rs7007146  217  391  167  775  31  65  60  156  0.866  0.903  0.544  0.712  C/T 
9  rs745888  44  320  411  775  25  60  71  156  0.838  0.870  0.618  0.072  A/G 
10  rs4978394  575  188  12  775  97  47  12  156  0.927  0.958  0.526  0.447  A/G 
11  rs3784780  14  223  537  774  11  23  122  156  0.760  0.751  0.723  0.093  C/T 
12  rs10510044  410  303  62  775  61  64  31  156  0.839  0.871  0.088  0.567  C/T 
13  rs712082  27  228  518  773  18  41  96  155  0.781  0.785  0.030  0.751  A/C 
14  rs11788150  78  329  367  774  35  61  60  156  0.804  0.821  0.104  0.735  A/C 
15  rs10842099  377  323  75  775  104  47  5  156  0.842  0.874  0.462  0.632  C/T 
16  rs4715476  527  228  19  774  85  59  12  156  0.823  0.849  0.708  0.330  A/G 
17  rs1526884  389  314  72  775  108  36  11  155  0.889  0.926  0.062  0.455  A/G 
18  rs4649314  81  370  322  773  35  60  59  154  0.791  0.801  0.754  0.093  A/C 
19  rs1350308  119  355  300  774  45  72  39  156  0.851  0.886  0.143  0.410  A/C 
20  rs9533457  413  318  44  775  78  54  24  156  0.853  0.887  0.830  0.088  A/G 
21  rs1571583  29  297  449  775  19  61  76  156  0.880  0.917  0.191  0.018  C/T 
22  rs567564  62  324  388  774  30  63  63  156  0.918  0.951  0.502  0.621  A/G 
23  rs7866165  30  291  454  775  18  51  87  156  0.856  0.891  0.522  0.046  G/T 
24  rs437171  18  240  517  775  15  48  93  156  0.832  0.862  0.890  0.107  A/G 
25  rs3752261  523  237  15  775  93  51  12  156  0.807  0.826  0.335  0.044  A/G  
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Table 3­6  Genotypes for SNPs selected for verification in phase 2 (cont’d) 
    Control  Relapse      HWE   
Rank  SNP  AA  AB  BB  Total  AA  AB  BB  Total  GT  GC50  ptotal  pcontrol  Alleles 
26  rs1924597  565  193  17  775  139  15  2  156  0.886  0.923  0.432  0.914  A/G 
27  rs1822917  447  292  36  775  90  44  21  155  0.936  0.964  0.647  0.178  C/T 
28  rs9514816  10  155  610  775  6  53  97  156  0.843  0.875  0.876  0.965  A/C 
29  rs6518956  284  345  144  773  44  100  12  156  0.810  0.831  0.808  0.032  A/G 
30  rs1878632  269  383  123  775  51  59  46  156  0.810  0.830  0.449  0.491  G/T 
31  rs7600624  590  171  14  775  96  50  10  156  0.932  0.961  0.226  0.694  A/G 
32  rs9315425  13  202  560  775  10  31  115  156  0.931  0.960  0.589  0.281  C/T 
33  rs10429965  599  166  10  775  119  28  9  156  0.868  0.905  0.172  0.693  T/C 
34  rs5997921  11  164  599  774  9  35  112  156  0.863  0.899  0.174  0.953  G/T 
35  rs1824476  70  336  369  775  5  51  100  156  0.852  0.886  0.697  0.602  C/T 
36  rs4776494  574  188  12  774  95  53  8  156  0.862  0.898  0.754  0.444  C/T 
37  rs1438620  259  361  154  774  27  85  44  156  0.833  0.862  0.326  0.167  A/G 
38  rs2514841  172  403  200  775  13  94  48  155  0.895  0.932  0.025  0.250  C/T 
39  rs1034116  14  168  592  774  8  51  97  156  0.807  0.826  0.358  0.605  C/T 
40  rs25689  26  266  483  775  14  67  75  156  0.816  0.839  0.271  0.145  A/G 
Genotypes and associated data for 40 SNP selected for phase 2. SNP chosen on statistical grounds only (see text) are highlighted in grey. The GenTrain score is for that SNP, the SNP50 score 
is the 50th centile of the GenCall scores for that SNP.  
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Table 3­7  Survival and associated genes for SNP selected for phase 2 
Rank   SNP  Chr  Position  Nearest gene  Distance  Logrank p  Model  ES (95% CI)  p-trend 
1  rs472660  7  99298043  CYP3A43 protein  intronic  1.62e-09  recessive  5.11 (2.83-9.22)  6.21e-08 
2  rs7556894  2  65365572  Actin-related protein 2 isoform b  15kb  9.19e-08  recessive  3.09 (2.00-4.77)  3.98e-07 
3  rs2589183  8  97591685  Syndecan 2 precursor  intronic  1.06e-07  allelic  0.37 (0.25-0.55)  1.00e-06 
4  rs764372  18  9817368  RAB31, member RAS family  intronic  5.09e-07  recessive  4.24 (2.30-7.84)  4.00e-06 
5  rs672757  1  112148779  K+- voltage-gated channel  intronic  1.08e-06  allelic  1.85 (1.45-2.38)  4.53e-07 
6  rs7912136  10  6790287  Protein kinase C, theta  128kb  1.27e-06  recessive  2.59 (1.74-3.85)  3.04e-06 
7  rs6972789  7  66757993  Stromal antigen 3-like 4  350kb  1.42e-06  recessive  2.18 (1.57-3.01)  2.57e-06 
8  rs7007146  8  103603973  E3 ubiquitin protein ligase  108kb  2.33e-06  recessive  2.14 (1.55-2.95)  4.01e-06 
9  rs745888  2  119626784  Complement component 1  4kb  2.48e-06  recessive  2.69 (1.75-4.12)  6.09e-06 
10  rs4978394  9  111306488  PTPN3 protein  6kb  2.48e-06  genotypic  1.72 (1.32-2.24)  5.08e-05 
11  rs3784780  15  89110479  Bloom’s helicase  intronic  2.94e-06  genotypic  0.88 (0.64-1.20)  4.17e-01 
12  rs10510044  10  120227066  Receptor for prolactin-releasing hormone  130kb  3.60e-06  recessive  2.46 (1.66-3.64)  7.45e-06 
13  rs712082  1  222792683  EST BU947851  intronic  3.89e-06  recessive  3.01 (1.84-4.92)  1.13e-05 
14  rs11788150  9  13815565  Nuclear factor I/B  250kb  6.77e-06  recessive  2.32 (1.59-3.38)  1.24e-05 
15  rs10842099  12  23080053  Homo sapiens cDNA FLJ37414 fis  intronic  7.26e-06  allelic  0.51 (0.37-0.69)  1.55e-05 
16  rs4715476  6  54730244  Tubulointerstitial nephritis antigen  370kb  8.12e-06  genotypic  1.73 (1.33-2.24)  3.81e-05 
17  rs1526884  19  22095491  near cluster of ZNF proteins  31 - 750kb  8.47e-06  dominant  0.47 (0.33-0.66)  1.38e-05 
18  rs4649314  1  231636367  Mixed lineage kinase 4  50kb  8.54e-06  recessive  2.30 (1.57-3.35)  1.52e-05 
19  rs1350308  8  4600956  CSMD1: CUB and Sushi multiple domains 1  intronic  9.39e-06  allelic  1.75 (1.37-2.22)  1.19e-05 
20  rs9533457  13  42806849  Ecto-NOX disulfide-thiol exchanger 1  intronic  9.62e-06  recessive  2.58 (1.67-3.99)  2.01e-05 
21  rs1571583  9  4257209  GLIS family zinc finger 3 isoform b  intronic  1.10e-05  recessive  2.80 (1.73-4.53)  2.58e-05 
22  rs567564  6  116263486  FRK tyrosine kinase  105kb  1.21e-05  recessive  2.37 (1.59-3.53)  2.20e-05 
23  rs7866165  9  13802685  Nuclear factor I/B  273kb  1.23e-05  recessive  2.85 (1.75-4.67)  2.94e-05 
24  rs437171  5  18165562  Cadherin 18, type 2 preproprotein  1.3Mb  1.28e-05  recessive  3.08 (1.81-5.25)  3.45e-05 
25  rs3752261  20  44553077  Zinc finger protein 334 isoform b  10kb  1.41e-05  recessive  3.41 (1.89-6.15)  4.48e-05  
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Table 3­7  Survival and associated genes for SNP selected for phase 2 (cont’d) 
Rank   SNP  Chr  Position  Nearest gene  Distance  Logrank p  Model  ES (95% CI)  p-trend 
26  rs1924597  13  96238572  Heparan sulfate 6-O-sulfotransferase 3  intronic  1.46e-05  allelic  0.38 (0.23-0.61)  5.81e-05 
27  rs1822917  8  72430567  Eyes absent 1 isoform c, protein tyrosine kinase  intronic  1.55e-05  recessive  2.65 (1.67-4.21)  3.26e-05 
28  rs9514816  13  107581123  DNA ligase IV  77kb  1.68e-05  allelic  2.08 (1.52-2.86)  4.69e-06 
29  rs6518956  22  34271966  RASD family, member 2  intronic  2.37e-05  genotypic  0.97 (0.78-1.21)  7.95e-01 
30  rs1878632  2  153031404  Formin-like 2  intronic  2.58e-05  recessive  2.06 (1.46-2.91)  3.84e-05 
31  rs7600624  2  152990621  Formin-like 2  intronic  2.91e-05  allelic  1.96 (1.45-2.66)  1.60e-05 
32  rs9315425  13  35980608  Cyclin A1  65kb  3.09e-05  recessive  3.58 (1.89-6.81)  9.74e-05 
33  rs10429965  1  209907121  NEK2 protein kinase  exonic  4.78e-05  recessive  3.68 (1.88-7.22)  1.50e-04 
34  rs5997921  22  29960896  LIM domain kinase 2 isoform 1  intronic  4.88e-05  recessive  3.68 (1.88-7.22)  1.52e-04 
35  rs1824476  18  27281399  Desmoglein 3 preproprotein  0.6kb  5.10e-05  allelic  0.55 (0.41-0.74)  6.47e-05 
36  rs4776494  15  62497880  Thyroid hormone receptor interactor 4  exonic  5.66e-05  genotypic  1.77 (1.35-2.32)  3.55e-05 
37  rs1438620  2  222746705  PAX3  26kb  8.25e-05  dominant  2.25 (1.49-3.41)  1.28e-04 
38  rs2514841  8  109129843  R-spondin family, member 2  intronic  9.83e-05  recessive  0.34 (0.19-0.60)  2.05e-04 
39  rs1034116  14  89024929  Checkpoint suppressor 1  intronic  1.14e-04  allelic  1.89 (1.39-2.56)  6.19e-05 
40  rs25689  9  73549916  Transmembrane protein 2  exonic  1.81e-04  allelic  1.69 (1.30-2.22)  9.40e-05 
Survival function of SNP selected for verification phase. The p-value is by logrank test on which the SNP was chosen or Fisher’s exact test for the allelic model, and the effect size (ES) and 95% 
CI are from Cox regression for the same genetic model (OR in the case of allelic model). For SNP chosen based on the allelic model, the significance of the trend test, ptrend from the Cochran-
Armitage test. The nearest gene is either the one in which the SNP is located (exonic or intronic), or the nearest gene in either direction on the chromosome. Unless the SNP is located within a 
hypothetical gene, the nearest gene is always a known gene (see also sections 3.6.2 and Table 10-2).  
  79 
3.6.2  Choosing on biological rationale 
Following the top 25 most significant SNPs, rs1822917 and rs9514816 were the next most 
significant, excluding rs6487867 because this was not in HWE in the control group in the 
initial calculation, although is in fact only borderline (pHWE=0.011), and rs1411684 
because it was in high LD with rs4978394 already included. Of the following next eight 
most significant SNPs, only one SNP (rs6518956) was included as it was located in a gene 
(RASD family, member 2, part of the family of RAS related proteins), while a further 




Two SNPs located in formin-like 2 were included in the verification phase (rs1878632 and rs7600624), they 
were most significant in different models: rs1878632 in the recessive model (top) and rs7600624 in the allelic 
model (bottom). The plots revealed that there was one other SNPs in formin-like 2 that was of borderline 
significance (rs4442949), and a further SNP excluded based on low homozygote frequency but with a p-
value <1e-05 is indicated in green. 
 
The next included SNPs are rs1878632 and rs7600624, both located in formin-like 2 on 
chromosome 2, whose overexpression has been linked to CRC metastasis288. The two 
SNPs were of similar significance even if the effect on survival was more marked for 
rs7600624 (HRgen=1.77, 95% CI 1.36-2.29, pgen=1.80e-05). They are only in weak LD 
(r2=0.22) and not in the same LD block, although located in the same intron. There was 
one other SNP (rs4442949) in formin-like 2 that was of borderline significance with 
pall=2.56e-04, and an excluded SNP based on low homozygote frequency (rs2345873) 
with a prec=3.12e-05 (Figure 3-11). 
rs9315425 was included because it is in the vicinity of cyclin A1, a known regulator of the 
cell cycle. A further four SNPs were chosen because they are located within or very close 
to genes: rs10429965 is a non-synonymous change in NEK2, a protein kinase that is 
abnormally expressed in many cancers and may have a role in mitotic regulation and 
chromosomal instability289; rs5997921 is intronic in LIM domain kinase 2, a gene 
implicated in tumour invasion and metastasis formation290; rs1824476 immediately  
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upstream of desmoglein 3 and further upstream, the desmoglein cluster, members of the 
cadherin superfamily of cell adhesion molecules, implicated as markers of progression291 
and worse prognosis in oral squamous cell cancer292; and rs4776494 in TRIP4, implicated 
as a transactivator of NF-κB293. Based on the regional Manhattan plots, three 
(rs10429965, rs5997921, rs1824476) of these five SNPs had some evidence of other SNPs 
in the vicinity with an association with prognosis as supporting evidence of possible 
biological relevance. 
rs1438620 is located in PAX3, a known transcription factor associated with the 
development of alveolar rhabdomyosarcoma294 and the development of borderline and 
malignant phyllodes tumours of the breast295. rs2514841 is located in RSPO2, an r-
spondin associated with WNT in the canonical signalling pathway296. Both these SNPs 




The Manhattan plot for rs472660 on chromosome 7 does not suggest any other SNPs associated with 
outcome in the region when the rare variant cut-off is set to minor homozygote frequency ≥9 (left). This is 
equivalent to setting the MAF=0.12 If the rare variant cut-off is set to MAF>0.05, several other SNPs suggest 
that this region is highly significantly associated with prognosis (right) and three further highly significant 
SNPs emerge (rs585071, rs678040, and rs667660). 
 
Four SNPs did not reach the required level of significance on logrank testing, but had a 
ptrend <1e-04. Two, rs1034116 and rs25689, were chosen as they were located within 
genes (checkpoint suppressor 1 and transmembrane protein 2, respectively). 
Lastly, rs472660, located intronic in CYP3A43, was one of the six SNPs with a minor 
homozygote count of 9, excluded on the basis of a low homozygote count, despite missing 
the cut-off by only one. It was included as it was the most significant association of these 
six SNPs (and any of the 40 chosen), and a cytochrome P450 detoxification gene would be 
an interesting candidate for a prognostic marker. While the Manhattan plot based on the 
SNPs as selected did not suggest other SNPs in the region to support an association of 
rs472660 with outcome, setting the cut-off for rare variants to MAF>0.05 would have  
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included many highly significant SNPs, supporting the inclusion of rs472660 in the 
verification set (Figure 3-12). Lastly, it lies within a strong LD block covering TRIM4 and 
GJE1 (gap junction protein epsilon 1), another candidate from the cell adhesion 
functional family, while CYP3A4 upstream of rs472660 is not covered by the same LD.  
3.6.3  Summary of SNPs taken forward into Phase 2 
The selected 40 SNPs represented a well performing subset of the 103 SNPs, based on 
genotyping parameters: the clustering was tight, with a median GenTrain score of 0.852 
(range 0.76-0.936). Consequently, the number of samples called per SNP was high, with 
at least 927 samples per SNP (median 931, SD ±0.871) called. This is equivalent to a call 
frequency per SNP ≥99.6%. 
The median GenCall score for all called genotypes of the 40 SNPs taken into phase 2 was 
0.886 (range 0.157-0.964), with only 50 genotypes out of 37,240 genotypes for 40 SNPs 
and 931 samples having a GenCall score of <0.7. 
As expected, all 40 SNPs were in HWE for the overall and control cohorts at the 0.01 
level. For the relapsed cohort, 12 SNPs (rs472660, rs7912136, rs3784780, rs712082, 
rs1526884, rs9533457, rs1822917, rs6518956, rs1878632, rs9315425, rs10429965, 




Three samples do not have a genotype call assigned by the calling software (left), but another seven are 
deemed unreliable on visual inspection and are excluded (right). 
 
All genotype plots were inspected visually for unreliable clustering. rs712082 was the only 
SNP where on visual inspection, cluster separation was not optimal between AB and BB 
clusters (Figure 3-13). As a consequence, rs712082 had the 2nd lowest GenTrain score of 
any of the selected SNPs. Three samples were excluded by the calling software, while 
seven were called but were deemed unreliable on inspection of the genotype plot. When 
the unreliable genotypes were excluded from the survival analysis, the resulting HR and  
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95% CI were essentially unchanged but slightly more significant (HRrec=3.03 (95% CI 
1.85-4.96, prec=9.87e-06) compared to HRrec=3.01 (95% CI 1.84-4.92, prec=1.13e-05) 
with all samples. Excluding the samples from the HWE calculations did not alter the 
outcome, with both overall and control cohort displaying no significant deviation from 
HWE. For further analysis, the unreliable samples remained excluded. 
There were no issues with the cluster definition in any of the other SNPs, including the 
SNP with the lowest GenTrain score (rs3784780). In that case, while the clusters were not 
as tight, there was no ambiguity about the cluster membership of individual samples. 
There were four SNPs for which the ptrend was greater than 1000-fold different to the p-
value derived from the logrank test (rs472660, rs4978394, rs3784780, rs6518956). For 
rs472660, the most significant model was recessive, and the heterozygote survival curves 
were close to one of the major homozygote curve, driving significance in this model in 
comparison to the minor homozygote. For rs4978394, the most significant logrank model  
Figure 3­14 Kaplan Meier curves for rs472660 and rs3784780 
 
Kaplan Meier curve for rs472660 (left) illustrating how the BB and AB genotypes have very similar survival 
functions, while AA has a markedly worse survival, making the recessive model most significant in logrank 
testing (p=1.62e-09), but the trend across the three genotypes less so (ptrend=6.21e-08). For rs3784780 
(right), the ‘order’ of the survival curves is not aligned with the coding for the trend test (AA=1, AB=2, BB=3), 
making the difference between the curves very significant (p=2.94e-06), but not the trend from AA to BB 
(ptrend=4.17e-01)  
 
was genotypic, but the survival curves are suggestive of a more marked effect in the 
recessive model, and if the significance of the recessive model is compared to that of the 
logrank test, the discrepancy diminishes. For two SNPs, the most significant model was 
genotypic, and the survival curves were ‘out of order’ compared to the coding: for 
rs3784780, the order of decreasing survival was AB, BB, AA, while for rs6518956, this 
order was BB, AA, AB, rendering the trend much less strong than the observed difference 
between the survival functions (Table 3-7 and Figure 3-14).In the absence of bias, the 
distribution across the genome should be roughly even, with an expectation that the 
larger the chromosome, the more ‘significant’ SNPs should be located there. The  
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distribution of SNPs by chromosome, given in Figure 3-15, shows that the 40 SNPs taken 
forward were spread across the genome, although some chromosomes did not carry any: 
five of the included SNPs each are located on chromosome 2, 8, and 9, whereas there are 
none on chromosomes 3, 4, 11, 16, 17, and 21. The difference to the expected 
distribution based on chromosome size (3.5 SNPs on chromosome 1 to 0.7 SNPs on 
chromosome 22), however, is not significant (p=0.115).  
Three SNPs were located in exons, 18 in introns, and 19 in intergenic regions. Two of the 
SNPs located in exons were non-synonymous base changes (rs10429965 and rs25689) 
while the third was synonymous base change (rs4776494). For the intergenic SNPs, the 




Histogram showing the frequency of significant association by individual chromosome. The distribution is not 
uniform, but not significantly different from the expected distribution if SNPs were purely picked at random. 
 
There were a number of interesting candidate genes associated with the top 25 SNPs 
based on p-value alone, and, perhaps more expected as additional SNPs were chosen 
based on function, the list of 40 SNPs. The most prominent category was genes broadly 
involved in cell adhesion and motility (10 SNPs), followed by genes involved in cell 
signalling (6 SNPs) and transcriptional regulation (6 SNPs). These categories were also the 
most prominent when only the 25 SNPs chosen on statistical grounds were considered, 
with 6 SNPs in or near genes broadly involved in cell adhesion and motility, followed by 
transcriptional regulation (5 SNPs) and genes involved in cell signalling (4 SNPs). The cell  
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adhesion and motility group contains 2 SNPs which are associated with the same gene 
(rs1878632 and rs7600624, formin-like 2), while the transmembrane group contains at 
least one SNP in a gene encoding a transmembrane protein with unknown function, but 
thought to be tumour suppressor (rs1350308, CSMD1297,298). See Figure 3-16 for the 
distribution across putative gene function, indicating those that were chosen based on 
statistical significance and those chosen on biological rationale. 
Figure 3­16 Distribution of functional categories across top 40 SNPs 
 
1 - Cell cycling, 2 - Cell motility and adhesion, 3 - Cell signalling, 4 - DNA processing, 5 - Detoxification, 6 - 
Immune  function,  7  -  Redox  system,  8  -  Transcriptional  regulator,  9  -  Transmembrane  protein,  10  – 
Unknown; lavender – SNPs chosen on statistical significance alone, navy – SNPs chosen on biological 
rationale. 
 
3.7  Discussion 
The data presented here show that using outcome in CRC as the complex trait in 
question, GWAS to determine novel markers of prognosis are feasible. Large patient 
series exist with good quality follow-up and sufficient germline DNA, high-density SNP 
typing platforms produce robust and reproducible genotypes, the statistical tools to 
analyse the data have been described, and the candidates selected for further validation 
largely fit with our current understanding of CRC biology. As was the case with GWAS 
successfully identifying CRC predisposition loci, SNPs described in phase 1 will require 
verification in further datasets, and two such series with 899 and 1338 patients have been 
identified: Scotland Phase 1, part of a GWAS for CRC risk299, and PETACC 3, a clinical 
trial142 and genotypes for selected SNPs are available from two population based cohorts.  
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The patients of the VICTOR trial had stage 2 and 3 CRC, perhaps the most interesting 
cohort to study for prognostic markers as the relapse rate in these stages is sufficiently high 
to warrant further intervention following surgery. In stage 1 CRC, the 5-year OS is in the 
region of 93%, making study difficult, and, unless the effect of a marker of poor prognosis 
carries a very large effect, intervention is unlikely to be acceptable to the patient. In stage 
4 CRC, treatment is often driven by the general fitness of the patient, and prognostic 
markers are likely to less helpful in making treatment decisions.  
The VICTOR trial design was that such that all patients had to have received standard 
surgery and (neo) adjuvant therapy as appropriate for the site and stage of disease. All 
patients receiving systemic therapy received 5-FU based chemotherapy, with only three 
patients also receiving a not otherwise specified novel agent. Subsequently, patients would 
be randomised to either rofecoxib for 2 or 5 years, or placebo for the same length of time. 
Due to the early closure of the trial following the worldwide withdrawal of rofecoxib due 
to excess cardiac events reported in the APPROVe study300, the duration of intervention 
with rofecoxib was short (median 8.4 months, interquartile range 3.4-15.1 months). At 
present, the data regarding a possible protective effect of a COX-2 inhibitor are not 
known, but the short duration of therapy with rofecoxib makes it likely that this was not a 
confounder in this study, making the VICTOR cohort a homogeneous patient set with 
reliable ascertainment of disease status. 
At the time of analysis, compared to reported rates, the event rate was lower than would 
be expected, 3-year DFS was 90.4% for stage 2, and DFS=82.8% for stage 3. The figures 
for stage 2 split into 93.0% for those who did not receive adjuvant therapy, and 89.2% for 
those who did. For stage 3, these figures are 69.6% and 83.2%, respectively. Reasons for 
this could be 1) the time from surgery to randomisation was substantial for some patients 
(median 7.7months, range 0.6 - 23.4months), although the majority of those delayed for 
more than 6months were patients with stage 3 disease who were randomised after the end 
of adjuvant chemotherapy; 2) sample collection was commenced 6 months after the trial 
closed, and while 66% of relapses were collected after the event, it is difficult to know how 
representative this set therefore is of the overall cohort as the final survival figures have 
not yet been published; 3) 11.8% of patients had not been followed for 3 years, and; and 
4) the precise ascertainment of DFS is difficult due to differing approaches of treating 
physicians to the timing of cross-sectional imaging and biopsy to prove relapsed disease. 
However, the differences of outcome in stage 3 patients based on the adjuvant therapy is 
reassuring, as the size of the benefit associated with adjuvant 5-FU based chemotherapy is 
in keeping with published data139. The main implication for this study is that lower event 
rates decrease power, but as outlined in section 3.1, depending on allele frequency and 
risk conferred, power was sufficient to detect meaningful markers of prognosis.  
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In line with other GWAS and the technology reports on the performance of the Illumina 
SNP typing platform270, genotyping was robust when applied to the samples of the 
VICTOR cohort. The vast majority of genotypes had good GenCall scores and, on a per 
SNP basis, good GenTrain scores. GenCall and GenTrain scores are measures validated 
internally by Illumina, and are not immediately amenable to cross checking, but visual 
inspection of cluster plots for individual SNPs confirmed the numerical assessment of 
genotyping, again with the overwhelming majority of randomly sampled plots showing 
good cluster separation (see Figure 3-3 for a representative plot). In addition, cluster plots 
for all SNPs with a call frequency of <98 .71% were inspected, and genotypes adjusted 
where necessary This cut off was set as the increase in call frequency following visual 
inspection had become negligible at this level. Lastly, internal (repeating the same analysis 
with the Illumina arrays) and external (generating genotypes by a different technology) 
reproducibility were high. 
Based on the available survival data and genotypes, it was possible to select SNPs at 
significance levels seen in other GWAS, and a number of SNPs reached the proposed 
levels of genome-wide significance of p<1e-07. The strategy for the selection of SNPs to 
be taken into verification (Figure 3-10) was designed to avoid missing positive associations 
(type 2 error), therefore inclusion criteria were relatively lax: four models were analysed 
for their association with outcome, and the threshold for selection set at p<1e-04. To 
compensate for a possible over-inflation of associations (type 1 error), exclusion criteria 
were much more stringent: the significance level for exclusion for deviation from HWE, 
as a measure of potential confounding by hidden genetic substructure, was set at p=0.01, 
much higher than the level of genome-wide significance assumed for outcome. Only cases 
were allowed to deviate from HWE at lower p-values as this could be representative of the 
underlying, true association, as the HWE assumption may not hold if samples are chosen 
based on relapse301.  
Further, SNPs with low minor homozygote frequencies were excluded, as ‘chance’ 
variation in small groups appeared to have a disproportionately large effect on the 
resulting effect size and p-value in the logrank model (Figure 3-9), although this did not 
affect λ to an extent that would have suggested a hidden population substructure. The net 
effect of the strategy employed here was to consider only SNPs with a MAF of >0.12, 
effectively excluding SNPs for which this study would not have had sufficient power. It 
did, however, exclude some SNPs that showed highly significant p-values, and in the case 
of the most significant SNP included for verification (rs472660), in a region spanning 
40Kb, two SNPs have much lower p-values (rs585071 and rs678040, in both cases 
p=4.35E-14) driven by minor homozygote counts of 0 in the control group and 5 in the 
relapsed group. A further SNP (rs667660, p=1.59e-08) had counts of 1 and 5,  
  87 
respectively. All three would have been included if the MAF cut-off had been set to 0.05 
(Figure 3-12).  
One concern was that the strategy of excluding low minor homozygote groups based on 
the control group might have biased against SNPs strongly associated with relapse. The 
level used is equivalent to 17-18 in the minor homozygote group for the overall cohort, 
and at that level, only four SNPs with a minor homozygote count of 9 in the control 
group would have been included in addition to the SNPs eligible for verification as 
described above. 
The predominant model associated with a significant effect was the recessive model; 
mostly because of the effect of small numbers on the logrank test for equality of the 
survivor function. This is known302, and due to the difficulty in estimating the asymptotic 
test value (one that would be derived if an infinite number of subjects were available) by 
only a small number of observations. This problem will complicate any GWAS for 
prognosis when compared to those GWAS for risk analysing any model other than the 
genotypic one. In the case of relatively small numbers of events, as was the case in the 
VICTOR cohort at the time of SNP selection, tests of proportion (χ2 or Fisher’s exact test) 
give very similar estimates of significance to a time-to-event test such as the logrank test303, 
but avoid the overestimation of χ2 values at the extremes, and a trend test such as Cox 
regression of all genotypes grouped separately also appear more robust in this respect and 
should be the analysis of choice if time-to-event data is to be included. 
The stipulation that SNPs had to be in HWE could have biased against SNPs that carry 
prognostic information, but are also strongly associated with CRC risk, thus distorting the 
HWE in the VICTOR cohort. This is unlikely to have been a factor, as most of the 
patients in the VICTOR cohort, on the grounds of being a population based cohort, are 
almost certain to have had sporadic CRC. Further, as the data in Chapter 6 
demonstrates, the SNPs with the strongest link to CRC risk were in HWE and did not 
show an association with prognosis. It is therefore unlikely that there are other SNPs that 
are associated with CRC sufficiently strongly to have a distorted HWE. 
Fifteen SNPs of the 103 SNPs making the significance cut-off were selected based on 
biological rationale, introducing an element of hypothesis driven research. It was hoped 
that by choosing SNPs that had a higher biological rationale, they might be more likely to 
replicate. Given the paucity of validated hypothesis driven markers of prognosis, discussed 
in section 0, only SNPs meeting the initial p-value cut-off were considered. These 15 
SNPs represent a compromise between the need to validate more markers than meet the 
most stringent significance thresholds to minimise the type 2 error and the cost associated  
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with validation of many hundreds of markers, both financially and in terms of DNA usage 
in patient series with good quality outcome data but limited amounts of DNA. 
Even without the 15 SNPs chosen in this fashion, the putative functional distribution of 
the nearest gene to the SNPs chosen based on p-value suggests that several SNPs in this 
group also present a plausible biological rationale: rs4649314 lies 50Kb downstream of 
mixed lineage kinase 4 (MLK4), a mitogen-activated protein kinase kinase kinase 
(MAP3K) on chromosome 1, and known activator of the JUN N-terminal kinase (JNK) 
and p38 mitogen activated protein kinase (MAPK) pathways304. The interplay of these 
pathways is involved in a plethora of cellular homeostatic functions (e.g. proliferation, 
apoptosis, migration305), and alterations in the MAPK pathway have been implicated in 
colorectal carcinogenesis306, although there is no evidence that MLK4 specifically is a 
factor in CRC. rs7556894 is located 15Kb downstream from Actin-related protein 2 
(ARP2), a member of the ARP2/3 complex involved in branching actin filaments and 
essential in cell shape and motility307, and actin filaments interact with LIM kinase during 
the metastatic process290. rs5997921, chosen on biological rationale, lies intronic in LIM2 
kinase and together, these two SNPs could implicate the metastatic pathway in the 
determination of prognosis. rs6972789 lies 350Kb downstream of stromal antigen 3-like 
4, which appears down-regulated in CRC. It is conceivable that rs6972789 could lie in a 
long range enhancer element influencing the expression of stromal antigen3-like 4 as at 
least 50% of such elements are more than 250Kb from ‘their’ gene308.  
One functional category not represented in the 40 SNPs was pharmacogenetic markers. 
This was to be expected as the analyses performed did not take into account treatment 
(given to just under two thirds of patients in the VICTOR trial), and therefore predictive 
markers were unlikely to be identified. Looking at SNPs in genes (and their neighbouring 
regions) involved in the metabolism of 5-FU did not reveal any associations with 
Bonferroni corrected p<0.05 (data not presented in this thesis). For a full functional 
annotation of the top 25 SNPs chosen on p-value alone see Table 10-2, even if at this 
stage, they are merely interesting candidates, without a proven association with outcome. 
The data presented in this chapter support the view that GWAS for outcome in CRC are 
feasible, that the data generated is robust at the genotyping level and plausible in the 
survival analysis. Despite the drawbacks discussed, the top 40 SNPs look interesting and 
their attempted verification is presented in Chapter 4.  
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4 GWAS for prognostic markers: Verification phase 
Replication of the findings in chapter 3 was attempted in two cohorts (PETACC and 
Scotland Phase 1), with genotypes available for selected SNPs in two further cohorts. All 
genotypes were analysed for the model for which the SNP in question had been most 
significant in Phase 1. Unlike phase 1 described in chapter 3, in this chapter, all p-values 
are trend as they pertain to the HR and CI to be meta-analysed. In the case of allelic OR, 
the p-value is derived using Fisher’s exact test. Genotypes are represented according to 




The verification was attempted in two phases: for significance using the raw ES and CI, then to derive an 
estimate of effect size, using adjusted data for the VICTOR cohort (see section 4.3). 
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The main aim of the verification phase is to derive an estimate of statistical significance 
(section 4.2) , although an estimate of the size of the effect can also be given (section 4-3), 
and the flowchart of the verification analysis is shown in Figure 4-1. 
4.1  Outcome in individual series 
In addition to the PETACC cohort identified at the outset of the discovery phase, a 
further cohort with genotype data for all but one SNP was identified (Scotland phase 1). 
Genotypes for a small proportion of SNPs were also available from a Danish cohort (10 
SNPs) and a Finnish cohort (1 SNP). 
Table 4­1  Summary of cohorts  
Cohort  Relapse  Non-relapse  Total  Number of SNPs 
VICTOR  184  763  947  40 
Scotland  289  610  899  39 
PETACC  386  865  1253  33 
Denmark  207  392  599  10 
Finland  322  638  960  1 
Total  1388  3268  4656   
Relapsed and non-relapsed patients for each cohort used in the verification phase, and number of SNPs 
typed in each cohort. 
 
4.1.1  PETACC  
Collaborators at the EORTC made available genotyping data for 33 of the 40 selected 
SNPs in 1338 patients with stage 2 and 3. Survival data were progression-free survival, 
with mature 4-year follow-up and 386 relapsed patients. Genotyping was performed in 
the laboratory of Dr Diether Lambrechts at the University in Leuven, Belgium; the 
survival analysis was performed by Dr Mauro Delorenzi at the Swiss Institute of 
Bioinformatics, Lausanne.  
Genotypes were generated using MassARRAY® iPLEX Gold single-base extension 
technology (Sequenom, CA) according to the manufacturer’s protocol. Of the 40 SNPs 
put forward from the discovery phase, seven SNPs did not perform sufficiently well during 
the initial primer design and were not included in the genotyping (rs10842099, 
rs1350308, rs1526884, rs4776494, rs5997921, rs672757, rs7912136). The SNPs were 
genotyped in two batches, of 18 and 17 SNPs; there was insufficient DNA to type the 
remaining SNPs with redesigned primers.  
Samples with >5 genotypes missing were deemed to have failed. Genotyping did not 
performed as well as the Illumina arrays, with 85 samples excluded from the first run, and 
44 from the second, leaving 1253 and 1294 samples, respectively. After exclusion of the 
failed samples, the median call frequency was 98.7% (range 90.1%-100.0%), showing the 
genotyping of the included samples was robust. Two SNPs from the first run were  
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repeated due to a low call frequency in one case (rs3752261, 80.2%) and poor clustering 
in the other (rs1924597). Both these SNPs performed well in the second run. After 
exclusion of the globally failed samples, the call rates between the two runs did not differ 
significantly (p=0.478).  
Table 4­2  Genotypes and hazard ratios for 33 SNPs in PETACC 3  
  Case  Control       
SNP  AA  AB  BB  AA  AB  BB  Model  ES (95% CI)  p-value 
rs472660  8  187  631  9  72  279  recessive  2.17 (1.12-4.21)  2.15e-02 
rs7556894  51  352  460  33  148  205  recessive  1.41 (0.98-2.01)  6.05e-02 
rs2589183  39  300  525  22  131  233  allelic  1.05 (0.85-1.28)  6.77e-01 
rs764372  17  220  628  10  99  277  recessive  1.28 (0.69-2.41)  4.34e-01 
rs6972789  258  410  169  108  191  77  recessive  0.99 (0.77-1.27)  9.17e-01 
rs7007146  213  387  164  91  168  65  recessive  0.91 (0.69-1.20)  5.03e-01 
rs745888  71  332  451  31  146  205  recessive  0.95 (0.66-1.37)  7.77e-01 
rs4978394  583  162  19  246  76  11  genotypic  1.10 (0.89-1.35)  3.67e-01 
rs3784780  25  227  550  11  103  250  genotypic  1.01 (0.83-1.22)  9.53e-01 
rs10510044  727  78  2  327  25  1  recessive  0.90 (0.13-6.38)  9.13e-01 
rs712082  28  255  582  14  105  267  recessive  1.09 (0.64-1.85)  7.58e-01 
rs11788150  121  376  338  53  168  151  recessive  0.95 (0.71-1.27)  7.34e-01 
rs4715476  563  238  26  244  113  10  genotypic  1.02 (0.85-1.23)  8.28e-01 
rs4649314  93  384  342  56  173  141  recessive  1.31 (0.98-1.74)  6.40e-02 
rs9533457  390  369  74  181  160  31  recessive  0.96 (0.66-1.39)  8.26e-01 
rs1571583  56  277  509  25  127  220  recessive  1.01 (0.67-1.51)  9.80e-01 
rs567564  72  382  370  35  148  185  recessive  1.05 (0.74-1.49)  7.86e-01 
rs7866165  85  355  420  44  145  196  recessive  1.11 (0.81-1.51)  5.33e-01 
rs437171  45  258  520  21  98  249  recessive  1.05 (0.68-1.63)  8.31e-01 
rs3752261  591  247  25  257  114  12  recessive  1.05 (0.59-1.86)  8.73e-01 
rs1924597  634  188  11  297  71  4  allelic  0.82 (0.63-1.08)  1.75e-01 
rs1822917  528  281  29  228  129  15  recessive  1.25 (0.74-2.09)  4.04e-01 
rs9514816  19  175  628  6  75  276  allelic  0.93 (0.71-1.22)  6.38e-01 
rs6518956  280  412  138  128  183  58  genotypic  0.96 (0.83-1.11)  5.92e-01 
rs1878632  262  423  149  110  177  85  recessive  1.26 (0.99-1.61)  6.10e-02 
rs7600624  609  237  20  264  105  16  allelic  1.14 (0.91-1.42)  2.68e-01 
rs9315425  16  181  639  7  79  286  recessive  0.99 (0.47-2.10)  9.87e-01 
rs10429965  627  193  14  278  85  6  recessive  0.97 (0.43-2.17)  9.35e-01 
rs1824476  82  362  391  39  163  168  allelic  1.05 (0.87-1.26)  6.02e-01 
rs1438620  288  371  160  117  163  84  dominant  1.14 (0.92-1.43)  2.32e-01 
rs2514841  180  369  222  82  158  102  recessive  1.05 (0.82-1.34)  7.09e-01 
rs1034116  11  205  650  7  92  286  allelic  1.06 (0.83-1.36)  6.56e-01 
rs25689  37  298  530  25  121  239  allelic  1.04 (0.85-1.28)  7.13e-01 
The genotypes for cases and control in PETACC 3. The effect size (ES) for the allelic model is OR, when the 
p-value is derived using Fisher’s exact test, for all other models, the ES is HR, and the p-value is the ptrend 
from Cox regression. The genetic model tested is the same as in the discovery phase in VICTOR. SNPs with 
an ES in the same direction as the VICTOR cohort are indicated in light grey, those not included in further 
analysis are indicated in dark grey. 
 
Three SNPs had a significantly different genotype distribution at the 0.01 level compared 
to the VICTOR cohort: rs2514841 (p=9.00e-03), rs7866165 (p=4.74e-07), and  
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rs10510044 (p=5.02E-100). The data from PETACC for the latter SNP was excluded 
from further analysis, as the analysis of the raw genotyping data (spectral frequencies of 
the Sequenom) showed this to be least reliable of the SNPs typed. In addition, two SNPs 
were not in HWE: rs1438620 (p=0.006) and rs437171 (p=0.004), these were also 
excluded, leaving genotypes for 30 SNPs for meta-analysis. For 45 samples, the survival 
analysis could not be reliably performed, and genotypes for these were excluded from 
logrank testing and Cox regression. The final distribution of the genotypes for all 33 SNPs 
is given in Table 4-2, and excluded SNPs are indicated. 
Only one SNP had p<0.05 in the PETACC cohort (rs472660), but 14 SNPs had an ES of 
greater than 1.05 (or less than 0.95) going in the same direction as that found in the 
VICTOR cohort (rs472660, rs7556894, rs764372, rs4978394, rs712082, rs4649314, 
rs567564, rs7866165, rs3752261, rs1924597, rs1822917, rs1878632, rs7600624, 
rs1034116).  
4.1.2  Scottish cohort 
Collaborators in Edinburgh made available clinical and genotyping data for 899 patients 
of all stages, this cohort is a subset of the 1,012 patients described under Scotland Phase 1 
in section 2.1.3.3, part of a GWAS for CRC risk299. Survival data were CRC specific 
survival. After a median follow-up of 69.3 months there were 289 CRC specific deaths. 
There were 561 patients with stage 2 and 3 CRC, and 130 CRC specific deaths. 
Genotypes were available for 39 SNPs, and all SNPs were typed on Illumina arrays 
according to the manufacturer’s protocol; rs1526884 failed genotyping. For the remaining 
SNPs, genotyping performed well, with all but four SNPs having been typed successfully 
for all patients. For these four SNPs, the call frequency was >99.1% with one or two 
genotypes missing for three SNPs, and eight for one SNP (rs672757). One SNP had a 
significantly different genotype distribution between the VICTOR cohort and Scotland 
Phase 1 (rs1571583, p=0.001), although the allele distribution was not significantly 
different once adjusted for multiple comparisons (pall=0.016). The genotype distribution 
for the other SNPs was not significantly different at the 0.01 level. All SNPs in Scotland 
Phase 1 were in HWE. The distribution of the genotypes is given in Table 4-3. 
Only one of the 39 SNPs had p≤0.05 in the Scottish cohort (rs1824476), and 15 SNPs 
had an ES of greater than 1.05 (or less than 0.95) going in the same direction as that 
found in the VICTOR cohort (rs764372, rs7007146, rs712082, rs11788150, rs4649314, 
rs1571583, rs567564, rs437171, rs1924597, rs1878632, rs7600624, rs5997921, 
rs1824476, rs1438620, rs2514841). 
For a comparison with the PETACC data, no SNP in the Scottish cohort reached p<0.05 
with an ES going in the same direction in both cohorts. There were seven SNPs with an  
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ES of greater than 1.05 (or less than 0.95) going in the same direction as that found in 
PETACC (rs764372, rs712082, rs4649314, rs567564, rs1924597, rs1878632, rs7600624). 
Table 4­3  Genotypes and hazard ratios for 39 SNPs in Scotland Phase 1  
  Case  Control       
SNP  AA  AB  BB  AA  AB  BB  Model  ES (95% CI)  p-value 
rs472660  16  130  464  6  57  226  recessive  0.80 (0.36-1.80)  5.95e-01 
rs7556894  44  225  341  19  110  160  recessive  0.90 (0.56-1.43)  6.54e-01 
rs2589183  33  192  385  15  91  183  allelic  0.99 (0.77-1.26)  9.51e-01 
rs764372  16  140  454  9  69  211  recessive  1.19 (0.61-2.31)  6.08e-01 
rs672757  121  291  192  51  141  95  allelic  0.93 (0.76-1.14)  5.06e-01 
rs7912136  308  245  57  141  124  24  recessive  0.89 (0.59-1.36)  5.95e-01 
rs6972789  181  292  137  86  142  61  recessive  0.95 (0.72-1.26)  7.15e-01 
rs7007146  170  306  134  64  155  70  recessive  1.06 (0.81-1.39)  6.56e-01 
rs745888  50  221  339  19  122  148  recessive  0.90 (0.56-1.43)  6.41e-01 
rs4978394  453  142  15  208  76  5  genotypic  1.04 (0.82-1.30)  7.61e-01 
rs3784780  14  176  420  8  82  199  genotypic  1.01 (0.81-1.26)  9.20e-01 
rs10510044  312  247  51  141  128  20  recessive  0.81 (0.51-1.27)  3.50e-01 
rs712082  25  177  408  16  76  197  recessive  1.22 (0.73-2.01)  4.48e-01 
rs11788150  76  275  259  40  136  112  recessive  1.11 (0.80-1.56)  5.24e-01 
rs10842099  339  225  46  154  119  16  allelic  1.01 (0.80-1.26)  9.54e-01 
rs4715476  383  200  26  182  96  10  genotypic  0.99 (0.81-1.22)  9.59e-01 
rs4649314  77  290  243  51  135  102  recessive  1.33 (0.98-1.80)  6.28e-02 
rs1350308  102  286  222  47  143  99  allelic  1.04 (0.85-1.27)  7.58e-01 
rs9533457  326  239  45  155  120  14  recessive  0.69 (0.40-1.18)  1.80e-01 
rs1571583  34  185  391  18  90  181  recessive  1.11 (0.69-1.78)  6.76e-01 
rs567564  52  255  303  27  102  160  recessive  1.11 (0.74-1.64)  6.18e-01 
rs7866165  47  240  323  23  115  151  recessive  1.02 (0.67-1.56)  9.31e-01 
rs437171  18  190  402  10  76  203  recessive  1.20 (0.64-2.26)  5.64e-01 
rs3752261  414  169  27  181  100  8  recessive  0.68 (0.34-1.37)  2.82e-01 
rs1924597  440  158  12  219  62  8  allelic  0.89 (0.67-1.18)  4.73e-01 
rs1822917  374  207  29  166  109  14  recessive  1.01 (0.59-1.73)  9.66e-01 
rs9514816  9  151  450  6  59  224  allelic  0.87 (0.65-1.17)  3.74e-01 
rs6518956  218  298  94  107  134  48  genotypic  0.97 (0.82-1.14)  6.94e-01 
rs1878632  214  296  100  96  140  53  recessive  1.11 (0.83-1.50)  4.79e-01 
rs7600624  442  158  10  200  84  5  allelic  1.14 (0.87-1.49)  3.60e-01 
rs9315425  13  155  442  3  74  212  recessive  0.52 (0.17-1.62)  2.58e-01 
rs10429965  468  133  9  216  69  4  recessive  0.84 (0.31-2.25)  7.29e-01 
rs5997921  13  158  439  7  51  231  recessive  1.07 (0.50-2.26)  8.64e-01 
rs1824476  60  246  304  19  109  161  allelic  0.80 (0.64-1.00)  5.00e-02 
rs4776494  441  153  16  206  79  4  genotypic  0.99 (0.79-1.24)  9.15e-01 
rs1438620  208  297  105  89  143  57  dominant  1.16 (0.90-1.49)  2.48e-01 
rs2514841  125  293  192  51  154  84  recessive  0.85 (0.63-1.15)  2.87e-01 
rs1034116  8  150  452  3  68  218  allelic  0.93 (0.69-1.25)  6.57e-01 
rs25689  20  231  359  14  83  192  allelic  0.83 (0.65-1.07)  1.56e-01 
The genotypes for cases and control in Scotland Phase 1. The effect size (ES) for the allelic model is OR, 
when the p-value is derived using Fisher’s exact test, for all other models, the ES is HR, and the p-value is 
the ptrend from Cox regression. The genetic model tested is the same as in the discovery phase in VICTOR. 
SNPs with an ES in the same direction as the VICTOR cohort are indicated in light grey. 
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4.1.3  VICTOR update 
Following the discovery phase, genotypes for a further 16 non-relapsed patients became 
available, as well as updated survival data. Follow-up lengthened by 261 days at the new  
Table 4­4  Genotypes and hazard ratios for 40 SNPs in VICTOR  
  Case  Control       
SNP  AA  AB  BB  AA  AB  BB  Model  ES (95% CI)  p-value 
rs472660  12  43  129  10  169  584  recessive  3.95 (2.20-7.09)  4.43e-06 
rs7556894  26  63  95  38  289  435  recessive  3.03 (2.00-4.59)  1.83e-07 
rs2589183  4  36  144  44  248  470  allelic  0.48 (0.34-0.67)  8.70e-06 
rs764372  11  50  123  11  195  557  recessive  3.79 (2.06-6.99)  1.91e-05 
rs672757  45  97  42  105  379  279  allelic  1.64 (1.31-2.07)  2.63e-05 
rs7912136  93  59  32  382  323  57  recessive  2.36 (1.61-3.45)  1.07e-05 
rs6972789  42  73  69  216  396  151  recessive  2.23 (1.65-3.01)  1.46e-07 
rs7007146  39  80  65  213  385  165  recessive  1.85 (1.37-2.51)  6.75e-05 
rs745888  25  71  88  44  316  403  recessive  2.35 (1.54-3.58)  7.44e-05 
rs4978394  118  54  12  568  182  13  genotypic  1.58 (1.24-2.03)  2.66e-04 
rs3784780  11  36  137  14  213  535  genotypic  0.99 (0.75-1.32)  9.51e-01 
rs10510044  76  75  33  401  300  62  recessive  2.26 (1.55-3.30)  2.18e-05 
rs712082  20  45  118  25  227  509  recessive  2.87 (1.80-4.57)  8.77e-06 
rs11788150  39  72  73  75  327  360  recessive  2.26 (1.59-3.23)  6.44e-06 
rs10842099  119  58  7  372  317  74  allelic  0.56 (0.42-0.73)  2.05e-05 
rs4715476  102  69  13  521  223  18  genotypic  1.67 (1.31-2.13)  3.11e-05 
rs1526884  121  49  13  381  311  71  dominant  0.53 (0.39-0.73)  6.05e-05 
rs4649314  37  72  73  80  367  314  recessive  2.05 (1.43-2.95)  9.51e-05 
rs1350308  50  86  48  119  344  299  allelic  1.65 (1.32-2.08)  1.96e-05 
rs9533457  88  70  26  413  307  43  recessive  2.24 (1.48-3.40)  1.38e-04 
rs1571583  21  72  91  27  294  442  recessive  2.71 (1.72-4.26)  1.79e-05 
rs567564  34  75  75  59  324  379  recessive  2.43 (1.67-3.53)  2.99e-06 
rs7866165  19  63  102  29  290  444  recessive  2.68 (1.67-4.31)  4.91e-05 
rs437171  16  58  110  18  234  511  recessive  2.99 (1.79-5.00)  2.85e-05 
rs3752261  109  63  12  516  231  16  recessive  2.90 (1.61-5.21)  3.66e-04 
rs1924597  165  16  3  550  196  17  allelic  0.36 (0.23-0.56)  8.88e-07 
rs1822917  109  52  22  437  291  35  recessive  2.39 (1.53-3.74)  1.27e-04 
rs9514816  7  59  118  9  153  601  allelic  1.96 (1.45-2.65)  2.73e-05 
rs6518956  53  114  17  279  341  141  genotypic  0.98 (0.80-1.20)  8.34e-01 
rs1878632  61  73  50  263  375  125  recessive  1.84 (1.33-2.55)  2.41e-04 
rs7600624  119  54  11  576  174  13  allelic  1.73 (1.29-2.31)  3.82e-04 
rs9315425  10  39  135  13  199  551  recessive  2.95 (1.56-5.59)  8.84e-04 
rs10429965  140  33  11  592  163  8  recessive  4.59 (2.49-8.46)  1.06e-06 
rs5997921  9  42  133  12  163  587  recessive  2.89 (1.48-5.65)  1.93e-03 
rs1824476  9  62  113  67  331  365  allelic  0.63 (0.48-0.83)  8.35e-04 
rs4776494  119  57  8  562  188  12  genotypic  1.55 (1.20-2.02)  8.93e-04 
rs1438620  36  99  49  256  353  153  dominant  2.00 (1.39-2.88)  2.00e-04 
rs2514841  20  110  53  166  396  201  recessive  0.46 (0.29-0.74)  1.14e-03 
rs1034116  9  58  117  13  162  587  allelic  1.85 (1.38-2.48)  7.46e-05 
rs25689  16  75  93  25  269  469  allelic  1.55 (1.20-2.00)  1.05e-03 
The genotypes for cases and controls in VICTOR after the addition of a further 16 samples. The effect size 
(ES) is the OR for the allelic model, when the p-value is derived using Fisher’s exact test, for all other 
models, the ES is HR, and the p-value is the ptrend from Cox regression.  
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cut-off date of 29 April 2009. The median follow-up was 51.2 months, SD ± 15.1 months 
for all patients, and 54.6 months ± 11.3 months for non-relapsed patients.  
The 16 additional samples performed well on genotyping, with a median call rate of 
99.84% (range 99.54%-99.95%). After the addition of the16 samples, all 40 SNPs 
remained in HWE. In most cases, the additional samples decreased statistical significance, 
although for ten SNPs, the association with outcome appeared more statistically 
significant after the update (rs7556894, rs6972789, rs712082, rs11788150, rs4715476, 
rs1571583, rs567564, rs437171, rs1924597, rs10429965). The resulting genotype 
distributions and HR are given in Table 4-4. 
4.1.4  Genotypes for 10 SNPs in the Danish cohort 
Genotypes were available for 10 SNPs (rs1034116, rs1350308, rs1571583, rs1822917, 
rs1924597, rs2589183, rs3784780, rs6518956, rs7556894, rs7600624) in a Danish cohort 
of 599 patients with all stages of CRC, of whom 401 had stage 2 and 3 CRC. The SNPs 
were typed using KASPar chemistry; the primers are given in Table 10-8, and the 
conditions used in Table 10-9, both in Appendix C. Except for one SNP (rs1571583), 
with a call frequency of 75.6%, genotyping performed well with a median call frequency 
of 98.0% (range 95.8%-98.3%). As the low call rate for rs1571583 was driven by the poor 
performance of two 96-well plates, these plates were excluded, after which the call 
frequency was 95.8%.  
Table 4­5  Genotypes and hazard ratios for 10 SNPs in Danish cohort 
  Case  Control       
SNP  AA  AB  BB  AA  AB  BB  Model  ES (95% CI)  p-value 
rs7556894  14  72  114  23  151  215  recessive  1.27 (0.74-2.20)  1.50E-01 
rs2589183  8  60  133  11  113  263  allelic  0.91 (0.66-1.24)  1.85E-01 
rs3784780  10  56  132  5  111  267  genotypic  1.16 (0.90-1.51)  2.56E-01 
rs1350308  33  102  65  55  191  141  allelic  0.88 (0.69-1.12)  3.02E-01 
rs1571583  10  65  75  16  107  180  recessive  1.31 (0.69-2.49)  3.82E-01 
rs1924597  150  47  5  295  88  4  allelic  0.86 (0.61-1.23)  4.09E-01 
rs1822917  128  56  14  217  137  23  recessive  1.12 (0.65-1.93)  4.11E-01 
rs6518956  61  106  26  96  224  61  genotypic  0.85 (0.68-1.06)  5.35E-01 
rs7600624  138  57  3  269  108  9  allelic  1.03 (0.74-1.43)  6.88E-01 
rs1034116  5  52  144  10  78  300  allelic  0.79 (0.56-1.12)  8.56E-01 
Genotypes and HR in the Danish cohort. The effect size (ES) for the allelic model is OR, when the p-value is 
from Fisher’s exact test, for all other models, the ES is HR, and the p-value is the ptrend from Cox regression. 
The genetic model tested is the same as in the discovery phase in VICTOR. SNPs with an ES in the same 
direction as the VICTOR cohort are indicated in light grey. rs6518956 was excluded from further analysis as 
it was not in HWE, and significantly differently distributed to the VICTOR cohort (shaded dark grey). 
 
All SNPs were in HWE at the 0.05 level except for one SNP (rs6518956, pHWE=3.28e-04). 
This SNP also had a significantly different genotype distribution compared with the 
VICTOR cohort and was therefore excluded, leaving nine SNPs for further analysis  
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(Table 4-4). Only one SNP reached statistical significance at the 0.05 level (rs3784780), 
and two (rs7556894, rs1571583) had an ES of greater than 1.05 (or less than 0.95) going 
in the same direction as that found in the VICTOR cohort. For rs7556894 this was also 
the case for the comparison with the PETACC cohort. 
4.1.5  rs4649314 in the Finnish cohort 
Genotypes for rs4649314 were available in a further verification cohort comprising 962 
Finnish patients of all stages, a subset of the cohort described in section 2.1.4. Overall 
survival was available for 959 patients with a median follow-up of 39.1 months; there 
were 638 deaths. There were 655 patients with stage 2 and 3 CRC. The genotypes were 
generated using KASPar allele specific PCR and the primers are given in Table 10-8, and 
the conditions used in Table 10-9, both in Appendix C. Genotyping performed well with 
a call rate of 97.1%, and the SNP was in HWE in this cohort. The HR was of a slightly 
smaller magnitude than in the other three cohorts where it had been typed, but consistent 
with an effect in the same direction (HR=1.08, 95% CI 0.89-1.31, p=4.59e-01). 
4.2  Meta-analysis for significance 
Meta-analysis was performed to determine the overall significance level for every SNP for 
which there was data from two or more cohorts. rs1526884 was excluded as this had only 
been typed successfully in the VICTOR cohort; data for SNPs that deviated from HWE 
(rs1438620 and rs437171 in PETACC; rs6518956 in the Danish cohort) or had a 
significantly different genotype distribution from VICTOR (rs10510044 in PETACC) 
were also not included. The meta-analyses were for the same genetic model as initially 
detected in the VICTOR cohort, using a fixed effects model. All effect sizes were based 
on the latest available survival data and are given in Table 4-2, Table 4-3, Table 4-4, 
Table 4-4, and section 4.1.5.  
4.2.1  Meta‐analysis for all stages 
This analysis included all patients for whom genotypes were available, i.e. stage 1 to 4 
patients from the Scottish, Danish, and Finnish cohorts. Overall, there were 10 SNPs 
typed in four cohorts, 24 SNPs in three cohorts, and 5 SNPs in two cohorts.  
The most significant SNP was rs472660, intronic to CYP3A43 protein on chromosome 7, 
with p=4.01e-05, but this did not reach genome-wide significance (p<1e-07). This SNP 
had data available from three cohorts; with PETACC showing a similar ES to VICTOR 
(HR=2.17, 95% CI 1.12-4.21, p=2.15e-02), but not the Scottish cohort (HR=0.80, 95% 
CI 0.36-1.80, p=5.95e-01). The summary ES for each SNP is given in Table 4-6.  
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Table 4­6  Summary ES and 95%CI for meta­analysis 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs472660  3  recessive  4.01e-05  2.24 (1.53-3.30)  79.5  7.55e-03 
rs7556894  4  recessive  7.38e-05  1.54 (1.25-1.92)  81.2  1.15e-03 
rs437171  2  recessive  3.05e-04  2.08 (1.40-3.10)  79.2  2.83e-02 
rs4649314  4  recessive  3.21e-04  1.27 (1.12-1.45)  69.2  2.10e-02 
rs1878632  3  recessive  4.97e-04  1.34 (1.13-1.57)  62.7  6.84e-02 
rs712082  3  recessive  7.70e-04  1.64 (1.23-2.19)  78.5  9.50e-03 
rs764372  3  recessive  9.84e-04  1.85 (1.28-2.66)  75.9  1.58e-02 
rs10429965  3  recessive  1.00e-03  2.08 (1.35-3.22)  84.8  1.41e-03 
rs1924597  4  allelic  1.27e-03  0.77 (0.65-0.90)  76.1  5.70e-03 
rs567564  3  recessive  1.81e-03  1.41 (1.14-1.74)  83.9  2.02e-03 
rs1438620  2  dominant  2.26e-03  1.38 (1.12-1.69)  82.9  1.57e-02 
rs7600624  4  allelic  3.65e-03  1.22 (1.07-1.40)  57.2  7.14e-02 
rs7912136  2  recessive  3.83e-03  1.52 (1.14-2.01)  91.2  7.73e-04 
rs1822917  4  recessive  5.27e-03  1.43 (1.11-1.85)  61.4  5.12e-02 
rs1571583  4  recessive  5.67e-03  1.40 (1.10-1.77)  74.1  8.91e-03 
rs10510044  2  recessive  7.63e-03  1.48 (1.11-1.98)  91.5  5.99e-04 
rs4978394  3  genotypic  7.82e-03  1.19 (1.05-1.36)  71.9  2.84e-02 
rs10842099  2  allelic  1.11e-02  0.80 (0.67-0.95)  90.5  1.14e-03 
rs6972789  3  recessive  1.17e-02  1.23 (1.05-1.44)  90.7  2.22e-05 
rs11788150  3  recessive  1.21e-02  1.27 (1.05-1.53)  86.3  6.85e-04 
rs5997921  2  recessive  1.53e-02  1.86 (1.13-3.06)  73.4  5.24e-02 
rs7866165  3  recessive  1.67e-02  1.31 (1.05-1.64)  82.1  3.79e-03 
rs1824476  3  allelic  2.06e-02  0.86 (0.76-0.98)  79.6  7.38e-03 
rs672757  2  allelic  2.31e-02  1.19 (1.02-1.39)  92.6  2.45e-04 
rs4715476  3  genotypic  2.96e-02  1.14 (1.01-1.29)  84.2  1.78e-03 
rs1350308  3  allelic  3.59e-02  1.15 (1.01-1.31)  87.0  4.69e-04 
rs4776494  2  genotypic  3.60e-02  1.20 (1.01-1.42)  85.0  9.89e-03 
rs7007146  3  recessive  4.57e-02  1.18 (1.00-1.39)  84.0  1.90e-03 
rs9315425  3  recessive  6.12e-02  1.53 (0.98-2.39)  77.4  1.21e-02 
rs745888  3  recessive  7.00e-02  1.25 (0.98-1.58)  84.3  1.74e-03 
rs3752261  3  recessive  8.69e-02  1.36 (0.96-1.94)  81.7  4.19e-03 
rs2589183  4  allelic  9.67e-02  0.90 (0.79-1.02)  81.2  1.14e-03 
rs2514841  3  recessive  1.10e-01  0.87 (0.72-1.03)  78.5  9.55e-03 
rs9514816  3  allelic  1.16e-01  1.14 (0.97-1.35)  88.8  1.37e-04 
rs9533457  3  recessive  1.36e-01  1.20 (0.94-1.54)  85.9  8.42e-04 
rs1034116  4  allelic  1.40e-01  1.12 (0.96-1.29)  82.0  8.18e-04 
rs25689  3  allelic  2.22e-01  1.09 (0.95-1.24)  83.4  2.45e-03 
rs6518956  4  genotypic  2.30e-01  0.95 (0.87-1.04)  0.0  7.74e-01 
rs3784780  4  genotypic  5.71e-01  1.03 (0.92-1.16)  0.0  8.05e-01 
Summary estimates for the 39 SNPs for which data was available in at least two cohorts. Meta-analysis was 
performed using a fixed effects model in all cases. ES, 95% CI , I2, and pQ are included for information only.  
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Table 4­7  Summary ES and 95%CI for meta­analysis in stage 2 and 3 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  1.33e-06  1.78 (1.41-2.24)  67.3  2.70e-02 
rs672757  2  allelic  1.69e-06  1.54 (1.29-1.84)  0.0  3.87e-01 
rs472660  3  recessive  7.92e-06  2.54 (1.69-3.83)  69.8  3.66e-02 
rs764372  3  recessive  3.96e-05  2.19 (1.51-3.18)  66.1  5.23e-02 
rs10429965  3  recessive  1.23e-04  2.60 (1.60-4.23)  78.0  1.06e-02 
rs7912136  2  recessive  2.28e-04  1.82 (1.32-2.50)  82.8  1.60e-02 
rs437171  2  recessive  2.80e-04  2.28 (1.46-3.56)  76.8  3.79e-02 
rs1878632  3  recessive  3.05e-04  1.39 (1.16-1.66)  53.0  1.19e-01 
rs1350308  3  allelic  8.96e-04  1.28 (1.11-1.47)  76.7  1.37e-02 
rs4649314  4  recessive  1.05e-03  1.29 (1.11-1.51)  67.2  2.76e-02 
rs712082  3  recessive  1.12e-03  1.71 (1.24-2.36)  78.8  8.97e-03 
rs7007146  3  recessive  1.20e-03  1.34 (1.12-1.60)  85.3  1.12e-03 
rs10510044  2  recessive  1.32e-03  1.73 (1.24-2.41)  89.0  2.59e-03 
rs1822917  4  recessive  1.75e-03  1.57 (1.18-2.09)  57.1  7.21e-02 
rs6972789  3  recessive  2.06e-03  1.32 (1.10-1.57)  89.0  1.12e-04 
rs7600624  4  allelic  2.17e-03  1.25 (1.08-1.45)  61.3  5.13e-02 
rs567564  3  recessive  2.90e-03  1.43 (1.13-1.82)  84.9  1.33e-03 
rs5997921  2  recessive  3.40e-03  2.37 (1.33-4.23)  22.4  2.56e-01 
rs1571583  4  recessive  3.71e-03  1.48 (1.14-1.94)  73.9  9.40e-03 
rs1438620  2  dominant  4.82e-03  1.45 (1.12-1.88)  83.2  1.47e-02 
rs4978394  3  genotypic  6.99e-03  1.22 (1.06-1.41)  70.8  3.26e-02 
rs11788150  3  recessive  7.53e-03  1.32 (1.08-1.62)  85.6  9.64e-04 
rs1034116  4  allelic  8.57e-03  1.23 (1.05-1.44)  76.6  5.10e-03 
rs10842099  2  allelic  8.88e-03  0.76 (0.62-0.93)  90.6  1.13e-03 
rs7866165  3  recessive  1.37e-02  1.36 (1.06-1.74)  81.6  4.33e-03 
rs4715476  3  genotypic  1.54e-02  1.18 (1.03-1.35)  82.6  3.15e-03 
rs4776494  2  genotypic  2.48e-02  1.27 (1.03-1.56)  84.5  1.12e-02 
rs9533457  3  recessive  2.90e-02  1.33 (1.03-1.72)  79.6  7.37e-03 
rs9315425  3  recessive  2.91e-02  1.69 (1.06-2.71)  73.3  2.36e-02 
rs9514816  3  allelic  3.18e-02  1.22 (1.02-1.45)  86.5  5.93e-04 
rs3752261  3  recessive  3.18e-02  1.53 (1.04-2.25)  77.7  1.13e-02 
rs25689  3  allelic  3.53e-02  1.17 (1.01-1.35)  71.4  3.04e-02 
rs1824476  3  allelic  6.00e-02  0.88 (0.76-1.01)  78.8  8.86e-03 
rs1924597  4  allelic  6.29e-02  0.85 (0.71-1.01)  84.5  2.34e-04 
rs745888  3  recessive  6.60e-02  1.28 (0.98-1.68)  87.0  4.64e-04 
rs2514841  3  recessive  1.84e-01  0.88 (0.72-1.07)  78.4  9.66e-03 
rs6518956  4  genotypic  2.12e-01  0.94 (0.85-1.04)  0.0  8.21e-01 
rs2589183  4  allelic  2.46e-01  0.92 (0.80-1.06)  82.8  5.85e-04 
rs3784780  4  genotypic  8.37e-01  0.99 (0.86-1.13)  0.0  7.08e-01 
Summary estimates for the 39 SNPs for which data was available in at least two cohorts, confined to stage 2 
and 3 patients only. Meta-analysis was performed using a fixed effects model in all cases. ES, 95% CI , I2, 
and pQ are included for information only. 
 
There was high statistical heterogeneity as measured both by I2 and pQ, for all but two 
SNPs. This was largely driven by the VICTOR cohort because the discovery phase had 
picked SNPs with particularly large ES (the ‘winner’s curse’), but as the ES in VICTOR  
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was likely to be an overestimation of the true ES, the heterogeneity measures were not 
taken into consideration here (see also section 4.3). 
4.2.2  Meta‐analysis confined to stage 2 and 3 CRC 
The SNPs chosen in the discovery phase came from the VICTOR cohort consisting of 
patients with stage 2 and 3 CRC only. This also was the case for the PETACC cohort, 
but the Scottish, Danish and Finnish cohorts consisted of patients with all stages of CRC. 
Therefore, further analysis was undertaken utilising the full data set from both VICTOR 
and PETACC , but only those Scottish, Danish and Finnish patients with stage 2 and 3 
disease to determine if any of the SNPs chosen had a particular effect in this setting. 
There were four SNPs (rs7556894, rs672757, rs472660, rs764372) with a p-value lower 
than the top SNP in the analysis including all stages. The top SNP from the analysis for 
all stages was no longer the most significant, but was still more significant in this stage 
restricted analysis (p=7.92e-06). No SNP reached genome-wide significance. 
4.2.3  Adjustment for stage 
Table 4­8  Meta­analysis for all stages, adjusted for stage 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  1.91e-05  1.60 (1.29-1.98)  75.8  6.14e-03 
rs472660  3  recessive  2.63e-05  2.29 (1.56-3.37)  68.4  4.23e-02 
rs7912136  2  recessive  3.47e-04  1.67 (1.26-2.22)  86.2  7.00e-03 
rs764372  3  recessive  4.97e-04  1.92 (1.33-2.76)  79.0  8.64e-03 
rs1878632  3  recessive  5.84e-04  1.33 (1.13-1.57)  66.8  4.91e-02 
rs672757  2  genotypic  1.41e-03  1.23 (1.08-1.39)  90.2  1.40e-03 
rs7600624  4  genotypic  1.89e-03  1.20 (1.07-1.34)  72.9  1.14e-02 
rs4649314  4  recessive  3.50e-03  1.22 (1.07-1.39)  70.2  1.80e-02 
rs567564  3  recessive  4.02e-03  1.37 (1.11-1.70)  81.2  4.95e-03 
rs1034116  4  genotypic  4.24e-03  1.19 (1.06-1.34)  73.7  9.75e-03 
rs10429965  3  recessive  4.45e-03  1.89 (1.22-2.92)  89.8  5.58e-05 
rs1571583  4  recessive  5.66e-03  1.40 (1.10-1.78)  70.5  1.72e-02 
rs6972789  3  recessive  6.95e-03  1.24 (1.06-1.46)  91.1  1.30e-05 
rs1438620  2  dominant  7.04e-03  1.23 (1.06-1.43)  76.8  1.33e-02 
Meta-analysis including stage in multivariate analysis, for patients of all stages. Only SNPs with p-value<0.01 
are shown. The full Table is given in Appendix A (Table 10-4). 
 
Stage is the strongest known prognostic indicator, and this was therefore included in a 
multi-variate analysis to test if there is additive prognostic information. Cox regression 
was performed including stage as a continuous interval variable. As it was not possible to 
adjust the allelic OR for stage, the stage adjusted genotypic model was used instead. The 
HR and 95% CI for each cohort are given in Table 4-8 for patients of all stages, and 
Table 4-9 for stage 2 and 3 disease, the tables are truncated at p≥1.00e-02, the full tables 
are given in Appendix A.  
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For the analysis including all stages, most SNPs changed in significance levels (p-value) by 
less than an order of magnitude, but for eight SNPs this was the case: rs7912136, 
rs672757, and rs1034116 became more significant; rs4649314, rs437171, rs712082, 
rs4978394, and rs1924597 became less significant. This change was particularly marked 
for rs1034116, with a p-value lower by an order of magnitude, and rs1924597 with a p-
value higher two orders of magnitude. 
For the analysis including only stage 2 and 3, there was very little change in significance 
and ranking for the SNPs analysed. Only two SNPs changed their p-value by an order of 
magnitude: rs1350308 and rs437171 both dropped in significance. The ‘biggest mover’ 
upwards was rs7600624, although the change in p-value was relatively modest. The 
significance levels were higher (lower p-values) for all but seven SNPs in the stage 2 and 3 
analysis compared to the stage adjusted analysis of all stages. 
Table 4­9  Meta­analysis for stage 2 and 3 CRC, adjusted for stage 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  8.96e-07  1.80 (1.42-2.27)  56.9  7.31e-02 
rs672757  2  genotypic  1.09e-06  1.47 (1.26-1.72)  38.4  2.02e-01 
rs764372  3  recessive  1.25e-05  2.30 (1.58-3.34)  66.4  5.09e-02 
rs472660  3  recessive  1.79e-05  2.45 (1.63-3.70)  63.9  6.25e-02 
rs10429965  3  recessive  8.52e-05  2.66 (1.63-4.33)  89.9  1.68e-03 
rs7912136  2  recessive  1.22e-04  1.87 (1.36-2.56)  80.7  2.28e-02 
rs1878632  3  recessive  3.78e-04  1.38 (1.16-1.65)  59.9  8.25e-02 
rs7600624  4  genotypic  6.79e-04  1.24 (1.10-1.41)  70.5  1.71e-02 
rs4649314  4  recessive  1.34e-03  1.29 (1.10-1.50)  64.4  3.78e-02 
rs712082  3  recessive  1.34e-03  1.70 (1.23-2.34)  79.5  7.58e-03 
rs6972789  3  recessive  1.59e-03  1.32 (1.11-1.58)  89.9  5.02e-05 
rs1571583  4  recessive  1.76e-03  1.53 (1.17-2.00)  67.5  2.65e-02 
rs7007146  3  recessive  2.22e-03  1.32 (1.10-1.57)  85.8  8.92e-04 
rs5997921  2  recessive  2.59e-03  2.43 (1.36-4.34)  0.0  3.38e-01 
rs10510044  2  recessive  4.52e-03  1.61 (1.16-2.24)  78.3  1.00e-02 
rs567564  3  recessive  5.37e-03  1.40 (1.10-1.78)  81.8  4.12e-03 
rs1822917  4  recessive  7.78e-03  1.47 (1.11-1.96)  54.6  8.53e-02 
rs11788150  3  recessive  8.63e-03  1.31 (1.07-1.61)  83.2  2.59e-03 
rs1438620  2  dominant  8.96e-03  1.25 (1.06-1.48)  76.6  1.38e-02 
rs1350308  3  genotypic  9.22e-03  1.20 (1.05-1.37)  75.8  1.62e-02 
Meta-analysis including stage in multivariate analysis, for patients with stage 2 and 3 CRC. Only SNPs with 
p-value<0.01 are shown. The full Table is given in Appendix A (Table 10-5). 
 
4.3  Meta-analysis for effect size 
The ES of the loci chosen based on statistical grounds are biased if the same data set is 
used for locus selection and ES estimation309. This is particularly true of GWAS, as the 
threshold for selection has to be very stringent, and at the same time, the statistical 
significance is correlated to the ES of the locus in question: for Cox-regression, it is given  
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by the ratio of the log-transformed ES and its standard error, but other tests of 
significance are equally affected (Figure 4-2). This effect makes the initial estimate of effect 
size, but not the p-value, of a particular SNP unreliable310. This can lead to the 
paradoxical phenomenon that a very large effect in the discovery phase reduces the 
significance levels following the verification phase, the ‘winner’s curse’. Additionally, 
empirical data also suggests that the true effect size is likely to be smaller than that first 
observed311. 
4.3.1  Regression to the mean for the HR and 95% CI of the VICTOR cohort 
To adjust for the phenomenon described above, and to derive a more reliable summary 
estimate of the effect size of the investigated SNPs, a Bayesian analysis of the VICTOR 
data was performed to derive a more reliable estimate of the true effect size of the SNPs 
analysed and avoid reporting false positive associations driven by the findings of the 
VICTOR cohort. 
Figure 4­2  Correlation between p­value and HR 
Plot of 100Kb either side rs672757 on chromosome 1. p-values are given as -log10 and plotted in navy, HR 
are given as log10 and plotted in maroon. To aid clarity, the position on chromosome is the number of SNPs 
typed in this region. 
 
In the absence of a body of evidence for germline determinants of outcome, the prior 
probability was estimated based on the genetics of CRC risk: there could be a similar 
number of high-penetrance loci influencing outcome as there are determining CRC risk, 
about 10 (the equivalent to APC, MMR genes (6 genes), PTEN, LKB1). In addition, 
there are 13 published SNPs conferring a lesser risk increase of CRC, plus one SNP  
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described in Chapter 7, and potentially further SNP based loci not yet described. The 
outside estimate was therefore that there would be no more than 36 loci influencing 
outcome with a HR=1.2 or greater, and there could be fewer (see also section 2.3.10). 
Table 4­10  Adjusted ES for the top 40 SNPs in the VICTOR cohort  
SNP  Model  Prior ES (95% CI) Posterior ES (95% CI)  Posterior p-value 
rs472660  recessive  3.95 (2.20-7.09)  1.36 (0.53-3.48)  5.21e-01 
rs7556894  recessive  3.03 (2.00-4.59)  2.38 (1.24-4.56)  9.02e-03 
rs2589183  allelic  0.48 (0.34-0.67)  0.86 (0.52-1.42)  5.50e-01 
rs764372  recessive  3.79 (2.06-6.99)  1.14 (0.61-2.12)  6.88e-01 
rs672757  allelic  1.64 (1.31-2.07)  1.11 (0.83-1.50)  4.82e-01 
rs7912136  recessive  2.36 (1.61-3.45)  1.26 (0.65-2.44)  4.93e-01 
rs6972789  recessive  2.23 (1.65-3.01)  2.00 (1.27-3.13)  2.54e-03 
rs7007146  recessive  1.85 (1.37-2.51)  1.08 (0.81-1.45)  6.02e-01 
rs745888  recessive  2.35 (1.54-3.58)  1.08 (0.74-1.58)  6.84e-01 
rs4978394  genotypic  1.58 (1.24-2.03)  1.05 (0.92-1.21)  4.74e-01 
rs3784780  genotypic  0.99 (0.75-1.32)  1.00 (0.93-1.08)  9.86e-01 
rs10510044  recessive  2.26 (1.55-3.30)  1.17 (0.68-2.00)  5.75e-01 
rs712082  recessive  2.87 (1.80-4.57)  1.31 (0.59-2.91)  5.00e-01 
rs11788150  recessive  2.26 (1.59-3.23)  1.34 (0.67-2.67)  4.07e-01 
rs10842099  allelic  0.56 (0.42-0.73)  0.91 (0.65-1.26)  5.60e-01 
rs4715476  genotypic  1.67 (1.31-2.13)  1.10 (0.83-1.46)  5.11e-01 
rs1526884  dominant  0.53 (0.39-0.73)  0.92 (0.68-1.26)  6.03e-01 
rs4649314  recessive  2.05 (1.43-2.95)  1.07 (0.79-1.46)  6.58e-01 
rs1350308  allelic  1.65 (1.32-2.08)  1.13 (0.82-1.55)  4.72e-01 
rs9533457  recessive  2.24 (1.48-3.40)  1.06 (0.79-1.42)  6.99e-01 
rs1571583  recessive  2.71 (1.72-4.26)  1.19 (0.63-2.25)  5.94e-01 
rs567564  recessive  2.43 (1.67-3.53)  1.53 (0.70-3.34)  2.86e-01 
rs7866165  recessive  2.68 (1.67-4.31)  1.10 (0.69-1.75)  6.87e-01 
rs437171  recessive  2.99 (1.79-5.00)  1.13 (0.64-1.99)  6.67e-01 
rs3752261  recessive  2.90 (1.61-5.21)  1.03 (0.83-1.29)  7.79e-01 
rs1924597  allelic  0.36 (0.23-0.56)  0.77 (0.36-1.66)  5.09e-01 
rs1822917  recessive  2.39 (1.53-3.74)  1.06 (0.77-1.46)  7.13e-01 
rs9514816  allelic  1.96 (1.45-2.65)  1.20 (0.72-2.02)  4.80e-01 
rs6518956  genotypic  0.98 (0.80-1.20)  1.00 (0.93-1.07)  9.41e-01 
rs1878632  recessive  1.84 (1.33-2.55)  1.05 (0.86-1.28)  6.25e-01 
rs7600624  allelic  1.73 (1.29-2.31)  1.05 (0.89-1.24)  5.75e-01 
rs9315425  recessive  2.95 (1.56-5.59)  1.02 (0.87-1.21)  7.90e-01 
rs10429965  recessive  4.59 (2.49-8.46)  1.75 (0.55-5.53)  3.40e-01 
rs5997921  recessive  2.89 (1.48-5.65)  1.02 (0.89-1.16)  7.92e-01 
rs1824476  allelic  0.63 (0.48-0.83)  0.96 (0.87-1.07)  4.73e-01 
rs4776494  genotypic  1.55 (1.20-2.02)  1.04 (0.94-1.15)  4.51e-01 
rs1438620  dominant  2.00 (1.39-2.88)  1.05 (0.83-1.33)  6.68e-01 
rs2514841  recessive  0.46 (0.29-0.74)  0.97 (0.84-1.12)  7.14e-01 
rs1034116  allelic  1.85 (1.38-2.48)  1.10 (0.79-1.53)  5.81e-01 
rs25689  allelic  1.55 (1.20-2.00)  1.04 (0.94-1.16)  4.47e-01 
Prior ES and 95% CI derived from latest available survival data (29 April 2009), and the resultant posterior 
ES and 95% CI after adjustment. The model was retained for each SNP, the p-values were derived using 
Wald’s test. The two SNPs with p<0.05 are highlighted in light grey.  
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Furthermore, a risk increase of 1.2 would be clinically meaningful, based on the only 
established prognostic factor, stage, where a risk differential in this order of magnitude is 
observed between stage 2A and 2B, with the latter generally considered for adjuvant 
chemotherapy. Based on these assumptions, the adjusted HR and 95% CI were 
determined for the most significant model for each SNP (see Methods, section 2.3.10).  
All SNPs had a lower ES, the SE are smaller for the shrunk estimates than the original 
estimate for 19 SNPs, while for 21 SNPs the SE of the shrunk estimate is larger, leading to 
smaller and larger 95% CI, respectively. 
The final posterior ES and 95% CI are given in Table 4-10. The adjustment does not 
allow for a new calculation of Fisher’s exact test, used for the allelic model, and the p-
value for the allelic model was derived using Wald’s test. Following the shrinkage, as 
expected, none of the SNPs retained their original levels of statistical significance. 
4.3.2  Meta‐analysis of all stages 
Meta-analysis was performed to determine the overall ES for every SNP for which there 
was data from two or more cohorts. As before, rs1526884 was excluded as this had only 
been typed successfully in the VICTOR cohort; data for SNPs that deviated from HWE 
(rs1438620 and rs437171 in PETACC; rs6518956 in the Danish cohort) or had a 
significantly different genotype distribution from VICTOR (rs10510044 in PETACC) 
were also not included. The meta-analyses were for the same genetic model as initially 
detected in the VICTOR cohort, using a fixed effects model. All effect sizes were based 
on the latest available survival data and are given in Table 4-2, Table 4-3, Table 4-4, 
Table 4-9, and section 4.1.5. 
Two SNPs reached statistical significance at the p<0.05 level, rs7556894 with HR=1.32 
(95% CI 1.04-1.67, p=2.11e-02) and rs4649314 with HR=1.24 (95%CI 1.04-1.47, 
p=1.53e-03). Both SNPs had data available from four cohorts, and there was no 
significant heterogeneity, either by I2 or pQ.. The summary ES for all SNPs are given in 
Table 4-10. 
There was limited heterogeneity between the adjusted VICTOR data and the verification 
cohorts, with I2>50% for only one SNP. Overall, the suggested effect sizes were relatively 
modest, with the most extreme effect observed for the SNP that had been the most 
significant in the initial screening in VICTOR, rs472660 (1.43, 95% CI % CI 0.92-2.25).  
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Table 4­11  Summary ES and 95%CI for meta­analysis using posterior estimates 
SNP  Cohorts  Model  ES (95% CI)  p-value  I
2  pQ 
rs7556894  4  recessive  1.32 (1.04-1.67)  2.02e-02  49.2  1.16e-01 
rs4649314  4  recessive  1.16 (1.02-1.32)  2.11e-02  0.0  5.09e-01 
rs1924597  4  allelic  0.85 (0.72-1.01)  6.29e-02  0.0  9.76e-01 
rs1878632  3  recessive  1.13 (0.98-1.29)  8.77e-02  0.0  5.13e-01 
rs472660  3  recessive  1.43 (0.92-2.25)  1.15e-01  42.9  1.73e-01 
rs7600624  4  allelic  1.08 (0.97-1.21)  1.64e-01  0.0  9.15e-01 
rs4978394  3  genotypic  1.06 (0.96-1.17)  2.65e-01  0.0  9.17e-01 
rs1438620  2  dominant  1.10 (0.93-1.30)  2.71e-01  0.0  5.80e-01 
rs1824476  3  allelic  0.95 (0.88-1.04)  2.72e-01  44.2  1.67e-01 
rs764372  3  recessive  1.20 (0.83-1.74)  3.27e-01  0.0  9.63e-01 
rs712082  3  recessive  1.18 (0.85-1.65)  3.29e-01  0.0  9.16e-01 
rs6972789  3  recessive  1.08 (0.91-1.28)  3.86e-01  76.5  1.42e-02 
rs567564  3  recessive  1.11 (0.87-1.43)  3.98e-01  0.0  6.88e-01 
rs1822917  4  recessive  1.09 (0.88-1.36)  4.28e-01  0.0  9.47e-01 
rs1571583  4  recessive  1.11 (0.86-1.43)  4.36e-01  0.0  9.13e-01 
rs437171  2  recessive  1.16 (0.76-1.77)  4.80e-01  0.0  8.86e-01 
rs7866165  3  recessive  1.08 (0.87-1.35)  4.97e-01  0.0  9.52e-01 
rs9514816  3  allelic  0.94 (0.78-1.13)  4.99e-01  0.0  5.64e-01 
rs4776494  2  genotypic  1.03 (0.94-1.13)  5.23e-01  0.0  6.81e-01 
rs2514841  3  recessive  0.97 (0.86-1.09)  6.00e-01  0.0  5.68e-01 
rs6518956  4  genotypic  0.99 (0.93-1.05)  6.70e-01  0.0  8.75e-01 
rs11788150  3  recessive  1.04 (0.85-1.29)  6.85e-01  0.0  5.93e-01 
rs4715476  3  genotypic  1.03 (0.91-1.16)  6.89e-01  0.0  8.52e-01 
rs9533457  3  recessive  0.96 (0.78-1.19)  7.05e-01  0.0  3.96e-01 
rs10510044  2  recessive  0.94 (0.66-1.33)  7.23e-01  6.0  3.02e-01 
rs3784780  4  genotypic  1.01 (0.95-1.08)  7.51e-01  0.0  7.53e-01 
rs1034116  4  allelic  0.98 (0.84-1.13)  7.67e-01  0.0  4.95e-01 
rs5997921  2  recessive  1.02 (0.90-1.16)  7.72e-01  0.0  9.03e-01 
rs25689  3  allelic  1.01 (0.93-1.11)  7.77e-01  27.8  2.50e-01 
rs10842099  2  allelic  0.97 (0.81-1.17)  7.83e-01  0.0  6.05e-01 
rs10429965  3  recessive  1.06 (0.61-1.83)  8.36e-01  0.0  6.09e-01 
rs672757  2  allelic  0.98 (0.83-1.16)  8.45e-01  0.0  3.27e-01 
rs2589183  4  allelic  0.99 (0.86-1.13)  8.46e-01  0.0  8.23e-01 
rs745888  3  recessive  0.98 (0.78-1.23)  8.74e-01  0.0  8.04e-01 
rs7007146  3  recessive  1.01 (0.86-1.19)  8.76e-01  0.0  6.40e-01 
rs9315425  3  recessive  1.01 (0.86-1.18)  9.24e-01  0.0  5.11e-01 
rs7912136  2  recessive  0.99 (0.69-1.40)  9.34e-01  0.0  3.87e-01 
rs1350308  3  allelic  1.00 (0.87-1.15)  9.69e-01  0.0  4.29e-01 
rs3752261  3  recessive  1.00 (0.82-1.22)  1.00E+00  0.0  5.32e-01 
ES and 95% CI for the 39 SNPs for which there were genotypes available for more than one cohort. Model is 
the genetic model tested. The rightmost two columns give the measures of heterogeneity, with pQ referring to 
the significance of the Q-statistic. Only the data for the VICTOR cohort was adjusted back to the mean.  
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Table 4­12  Summary ES and 95%CI for meta­analysis in stage 2 and 3 CRC 
SNP  Cohorts  Model  ES (95% CI)  p-value  I
2  pQ 
rs7556894  4  recessive  1.52 (1.17-1.96)  1.60e-03  0.0  5.30e-01 
rs672757  2  allelic  1.26 (1.03-1.54)  2.79e-02  18.3  2.68e-01 
rs472660  3  recessive  1.58 (0.97-2.58)  6.63e-02  21.3  2.81e-01 
rs4649314  4  recessive  1.14 (0.99-1.33)  7.65e-02  0.0  6.38e-01 
rs764372  3  recessive  1.40 (0.96-2.04)  7.99e-02  0.0  4.47e-01 
rs1878632  3  recessive  1.13 (0.98-1.30)  9.90e-02  0.0  5.14e-01 
rs7600624  4  allelic  1.09 (0.97-1.23)  1.51e-01  0.0  5.55e-01 
rs6972789  3  recessive  1.14 (0.94-1.38)  1.86e-01  73.1  2.44e-02 
rs7007146  3  recessive  1.11 (0.93-1.33)  2.27e-01  71.5  3.01e-02 
rs1350308  3  allelic  1.09 (0.93-1.28)  2.98e-01  0.0  7.80e-01 
rs4978394  3  genotypic  1.06 (0.95-1.18)  3.19e-01  0.0  8.41e-01 
rs1822917  4  recessive  1.11 (0.87-1.41)  3.90e-01  0.0  6.84e-01 
rs25689  3  allelic  1.04 (0.95-1.13)  4.32e-01  0.0  9.34e-01 
rs1034116  4  allelic  1.06 (0.91-1.25)  4.41e-01  0.0  4.37e-01 
rs6518956  4  genotypic  0.98 (0.92-1.04)  4.47e-01  0.0  6.01e-01 
rs1824476  3  allelic  0.97 (0.89-1.06)  4.67e-01  3.3  3.56e-01 
rs1571583  4  recessive  1.11 (0.83-1.48)  5.03e-01  0.0  7.20e-01 
rs7866165  3  recessive  1.08 (0.84-1.37)  5.57e-01  0.0  8.64e-01 
rs712082  3  recessive  1.11 (0.75-1.64)  5.96e-01  0.0  8.73e-01 
rs4776494  2  genotypic  1.03 (0.93-1.13)  5.97e-01  0.0  3.95e-01 
rs1438620  2  dominant  1.05 (0.86-1.28)  6.14e-01  0.0  9.94e-01 
rs10429965  3  recessive  1.18 (0.61-2.28)  6.31e-01  0.0  7.10e-01 
rs7912136  2  recessive  1.11 (0.72-1.71)  6.32e-01  0.0  6.22e-01 
rs4715476  3  genotypic  1.03 (0.90-1.19)  6.44e-01  0.0  8.75e-01 
rs2589183  4  allelic  1.03 (0.89-1.19)  6.59e-01  0.0  8.63e-01 
rs567564  3  recessive  1.06 (0.80-1.41)  6.87e-01  0.0  5.30e-01 
rs11788150  3  recessive  1.05 (0.83-1.32)  7.12e-01  0.0  5.41e-01 
rs437171  2  recessive  1.09 (0.68-1.76)  7.13e-01  0.0  8.23e-01 
rs745888  3  recessive  0.95 (0.74-1.23)  7.18e-01  34.8  2.16e-01 
rs1924597  4  allelic  0.97 (0.81-1.17)  7.49e-01  12.0  3.33e-01 
rs5997921  2  recessive  1.02 (0.90-1.16)  7.49e-01  0.0  6.40e-01 
rs2514841  3  recessive  0.98 (0.87-1.11)  7.80e-01  0.0  7.73e-01 
rs10510044  2  recessive  0.95 (0.61-1.45)  7.99e-01  37.9  2.04e-01 
rs9514816  3  allelic  0.98 (0.80-1.20)  8.19e-01  0.0  6.83e-01 
rs9315425  3  recessive  1.01 (0.86-1.19)  8.68e-01  0.0  5.37e-01 
rs3752261  3  recessive  1.02 (0.83-1.25)  8.82e-01  0.0  6.28e-01 
rs9533457  3  recessive  1.02 (0.82-1.26)  8.92e-01  0.0  9.13e-01 
rs3784780  4  genotypic  1.00 (0.93-1.07)  9.17e-01  0.0  7.02e-01 
rs10842099  2  allelic  1.01 (0.81-1.26)  9.37e-01  0.0  3.85e-01 
ES and 95% CI for the 39 SNPs for which there were genotypes available for more than one cohort. Model is 
the genetic model tested. The rightmost two columns give the measures of heterogeneity, with pQ referring to 
the significance of the Q-statistic. Only the data for the VICTOR cohort was adjusted back to the mean.  
  106 
4.3.3  Meta‐analysis of stage 2 and 3 disease 
As before, a further analysis was undertaken utilising the full data set from both VICTOR 
and PETACC , but only those Scottish, Danish and Finnish patients with stage 2 and 3 
disease. The summary estimates are given in Table 4-12. The significance levels were 
affected for every SNP, and for 22 SNPs, it decreased, and for 17 SNPs, it increased. 
Again, there was very little heterogeneity, with I2>50% for only two SNPs. 
Two SNPs, rs7556894 and rs672757, had p-values below the p<0.05 level, while 
rs4649314, with p<0.05 in the analysis of all stages, no longer was below that level. For 
rs7556894, the p-value almost reached p<0.05 if it was adjusted for 39 multiple tests using 
Bonferroni correction. 
A multi-variate analysis including stage was also performed in stage 2 and 3 patients for 
all 39 SNPs, and the HR and 95% CI for SNPs with p<0.1 are given in Table 4-13. 
Table 4­13  Meta­analysis for stage 2 and 3, adjusted for stage 
SNP  Cohorts  Model  ES (95% CI)  p-value  I
2  pQ 
rs7556894  4  recessive  1.56 (1.21-2.03)  7.25e-04  0.0  6.23e-01 
rs672757  2  allelic  1.22 (1.03-1.46)  2.52e-02  0.0  3.46e-01 
rs764372  3  recessive  1.44 (0.98-2.09)  6.02e-02  0.0  5.27e-01 
rs4649314  4  recessive  1.15 (0.99-1.33)  7.24e-02  0.0  5.08e-01 
rs472660  3  recessive  1.53 (0.94-2.49)  9.04e-02  0.0  5.39e-01 
Meta-analysis including stage in multivariate analysis, for patients with stage 2 and 3 CRC. Only SNPs with 
p-value<0.1 are shown. The full Table is given in Appendix A (Table 10-6). 
 
For rs7556894, the summary estimate using all four cohorts (VICTOR, Scotland, 
PETACC , Denmark) was HR=1.56, 95% CI 1.21-2.03, p=7.25e-04, with no evidence of 
statistical heterogeneity, I2=0% and pQ=0.623. This reaches statistical significance at the 
Bonferroni corrected p<0.05 level. 
4.4  Discussion 
The data presented in this chapter support the view that GWAS of germline markers for 
outcome in CRC are feasible, and that verification cohorts of sufficient quality exist for 
the verification phase, which, pending further verification, could find novel determinants 
of prognosis. Given that the VICTOR screening cohort consisted only of stage 2 and 3 
patients, the findings for rs7556894 are particularly encouraging, and an effect of other 
SNPs, e.g. rs672757, rs472660, rs4649314 also cannot be ruled out.  
The screening set was included in all meta-analyses as this improves power despite the 
need for more stringent significance thresholds274, this is particularly relevant for studies 
where large numbers of SNPs are taken into the verification phase. While this did not 
apply to the study design presented in this thesis due to cost restraints, the power of a joint  
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analysis converges with that of a pure replication analysis with decreasing numbers of 
SNPs taken into verification, but the former approach is the more powerful one during 
conversion274. 
For rs7556894, the potential functional implications are intriguing, with genes that may 
play a role in essential cellular functions for tumorigenesis and metastasis nearby. It is 
located on the short arm chromosome 2, 15Kb downstream from and in the same LD 
block as Actin-related protein 2 (ARP2), a member of the ARP2/3 complex essential for 
cell shape and motility307 and the process of invasion312. rs7556894 was more significant in 
the stage 2 ad 3 setting, and this is perhaps expected as the initial screen was in these 
stages. This could be in keeping with the putative functional consequence of any 
disruption in the tagged gene, i.e. making early metastasis more likely. Patients with stage 
2 and 3 CRC homozygous for the minor allele would have a higher chance of being 
understaged, and micrometastatic distant dissemination would already have taken place 
at the time of surgery.  
No attempt was made as part of this thesis to elucidate the postulated causative loci, nor 
to validate the functional consequences, and before such work can be undertaken, 
rs7556894, and other SNPs, will need to be validated further, as none of the p-values 
reached genome-wide significance levels, generally taken to be p<1e-07. This level 
worked well for the GWAS for CRC susceptibility based on joint analysis, and the SNPs 
identified at this level were replicated by other groups, most notably rs698326738,44,299,313.  
While not reaching the necessary significance levels, the fact that the top SNPs became 
more significant in the analysis restricted to stage 2 and 3 patients, as well as when stage is 
included in multivariate analysis, suggests that the findings could be real. No attempt was 
made as part of this thesis to elucidate the postulated causative loci, nor to validate 
functional consequences. 
All meta-analyses for significance were performed using a fixed-effects model, despite the 
statistical heterogeneity between the cohorts. A random-effects meta-analysis is 
recommended when the cohorts evaluated do not represent the statistical spectrum of 
outcomes, while a fixed effects model is appropriate if all cohorts measure the same 
(single) effect, and if the studies were infinitely large, they would yield the same result314. It 
is likely that the SNPs that are associated with prognosis give a similar effect in each 
cohort under these assumptions, and the heterogeneity is largely driven by the VICTOR 
cohort, which, in order to derive highly significant findings, selected very large effect sizes, 
the so-called winner’s curse. The heterogeneity between the verification cohorts was 
much more modest, in many cases I2=0%, and only for four SNPs was I2>50%  
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(rs1824476, rs4978394, rs1924597, rs9315425), none of which was in the top ten most 
significant SNPs.  
The heterogeneity in terms of effect size and confidence intervals between the original 
screening cohort and the verification cohorts does make the estimate of the effect size 
unreliable310, so that even when the effect was consistently in the same direction as that 
detected in the VICTOR cohort, but more modest in size, the summary estimate of effect 
size was likely to be dominated by the VICTOR cohort. The effect size and confidence 
intervals for the VICTOR cohort were therefore adjusted to derive a better estimate of 
the potential effect conferred by individual SNPs, likely to be smaller than that detected in 
VICTOR for statistical310 and empirical311 reasons without losing the information 
included in the VICTOR cohort (an estimate of effect size could have been derived 
simply by combining the verification cohorts). This particular problem was exacerbated in 
this GWAS, and likely to be encountered in other GWAS of prognosis using the logrank 
test in the recessive model, as this allowed for the introduction of very large effect sizes 
based on relatively few individuals. The estimate of effect size in this setting may be 
unreliable, and distort the meta-analysis even for those SNPs where there is a true 
association with prognosis. 
The net effect of adjusting the VICTOR effect sizes and confidence intervals was the 
same as if a further study with ES=1 and an appropriate confidence interval had been 
added to the meta-analysis, in essence making it a random effects analysis, based on 
significance levels. In other words, the significance levels of a fixed effects meta-analysis of 
all available cohorts using the shrunk VICTOR data are similar to those using a random 
effects meta-analysis with the same cohorts but the unshrunk, prior effects size and CI for 
VICTOR. In the former, the ES is slightly lower, with slightly smaller CI, making it 
perhaps a better estimate of the true effect size.  
The meta-analysis using shrunk data also gives a separate estimate of the significance 
levels, but as the effect sizes of the initial screen were adjusted for a possible 
overestimation, and thus the likelihood of a type 1 error, genome-wide significance at 
p<1e-07 is too conservative. The minimum p-value of the posterior estimates was 
p=2.54e-03, much more in keeping with what would be expected if only 40 SNPs had 
been analysed, and with what was seen in the Scottish cohort (rs7007146 in genotypic 
model, p=4.98e-03, not analysed here) and PETACC (rs472660 in recessive model, 
p=2.15e-02). A Bonferroni corrected p<0.05 for 39 SNPs would be more appropriate to 
test significance in the shrunk analysis, equivalent to p<1.28e-03 in the shrunk analysis, 
which rs7556894 reached only if also adjusted for stage.  
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The low rate of replication was to be expected as only 14 SNPs had an ES going in the 
same direction in all available cohorts, and in only seven of these (rs764372, rs712082, 
rs4649314, rs567564, rs1924597, rs1878632, rs7600624) was the ES not essentially 1 in 
one or the other of the verification cohorts. Only two SNPs had an ES of less than 0.85 
(or greater than 1.15) in all three cohorts: rs4649314 and rs764372. The latter did 
demonstrate that the shrinkage yielded reasonable estimates, as the posterior estimate for 
this SNP in the VICTOR cohort was HR=1.14 (95% CI 0.61-2.12, p=6.87e-01), very 
similar to the Scottish cohort HR=1.19 (95% CI 0.61-2.31, p=6.08e-01) and PETACC , 
HR=1.28 (95% CI 0.69-2.41, p=4.34e-01). 
In all but two SNPs, rs6518956 and rs3784780, the statistical heterogeneity introduced by 
using unshrunk priors from the VICTOR cohort yielded I2>50%. Both these SNPs were 
initially included based on the highly significant logrank test in the genotypic model, but 
with much higher p-values when analysed by Cox regression. This was due to the 
worsening survival from Mm to mm to MM genotypes, thus the coding was not ‘in order’ 
of the number of minor alleles. This effect was seen both in VICTOR and the Scottish 
cohort for rs3784780, but not in PETACC , while it was only seen in VICTOR for 
rs6518956. It suggests that the failure to replicate the association seen in VICTOR for 
both these SNPs was because of a false positive finding, rather than an interesting effect 
on tumour biology not capture by the coding of alleles and subsequent Cox regression. 
Some of the problems that arose from the initial selection strategy have been addressed by 
using shrunk posterior estimates for VICTOR, and it is likely that the final estimates of 
significance and effect size are reasonable, although further verification should be 
attempted for the top SNPs, rs7556894, at a minimum. However, it is likely that too 
many SNPs were being taken into the verification phase without sufficient evidence to 
support them, a result of allowing several models to be considered, and relatively low 
event rates. Therefore, an approach that restricts the initial SNP selection to Cox 
regression based on the genotypic model, includes stage in the initial discovery phase, and 
using larger cohorts with higher event rates might yield more germline SNPs that in the 
verification phase remain associated with prognosis. The discovery phase for such an 
approach is presented in Chapter 5. Based on the data presented in Chapter 3 and this 
chapter, an effect of the germline on prognosis in CRC remains possible, but is not 
proven.  






Alternative strategies for the discovery phase 
 
5 Alternative approaches to the discovery phase 
Different screening or discovery strategies can be derived, either to try to improve the 
discovery of true-positives in the search for prognostic determinants, or to try to discover 
predictive determinants. Based on the findings in Chapters 3 and 4, two such approaches 
are described in this chapter. 
5.1  Meta-analysis of two screening sets 
Given the limitations of the approach described in Chapters 3 and 4, a different screening 
approach was conceived to address some of the issues encountered and at the same time, 
increase the power for detection. Genotypes from the Scottish cohort utilised in Chapter 4 
were available for almost all SNPs analysed in the initial screen in the VICTOR cohort 
(see Chapter 3). Therefore, it was possible to meta-analyse the VICTOR and Scottish 
cohorts for all SNPs to increase sample size and event rate, and trying to address some of 
the limitations encountered so far. 
5.1.1  Analysis of individual cohorts  
Each autosomal SNP was analysed by Cox regression for the genotypic model only to 
avoid the over-representation of recessive model SNPs in the final analysis. The initial 
survival analysis for each cohort was adjusted for stage, age and sex to avoid detecting 
SNPs that might be associated with stage rather than prognosis per se.  
In CRC, the HR generated from 3-year DFS analysis compared to 5-year OS analysis are 
tightly correlated (r2=0.90)315, and, on the assumption of proportionality within the Cox 
model, should be at all time points. Increasing the event number should drive more 
precise estimates, and therefore DFS was used as outcome measure for VICTOR, while 
CRC specific survival was used for the Scottish cohort. 
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The survival analysis was conducted separately in each cohort, and the outcome measures 
meta-analysed using a fixed effects model. Significant SNPs at a level p<1e-04 displaying 
significant heterogeneity, defined as I2>50%, were further analysed using a random 
effects model. 
5.1.1.1  VICTOR 
The data cut-off for the Victor cohort was 29 April 2009, and 947 patients were included 
in the survival analysis. This cohort and outcome data are identical to that described in 
section 4.1.3. 
Table 5­1  Top SNPs in VICTOR cohort 
SNP  Chr  Position  HR (95% CI)  p-value  Function 
rs2144749  6  168.70  1.64 (1.34-2.02)  2.52e-06  SPARC related calcium binding 2 
rs5761880  21  25.69  2.08 (1.53-2.82)  3.04e-06  cDNA FLJ31418 (80kb) 
rs9514816  13  107.58  0.55 (0.42-0.71)  5.26e-06  DNA ligase IV 
rs672757  1  112.15  0.62 (0.50-0.76)  5.76e-06  K+- voltage-gated channel 
rs2827250  21  22.43  0.55 (0.42-0.71)  6.04e-06  clone qd65g07 PRED16 (17kb) 
rs17808334  18  66.02  0.36 (0.23-0.56)  6.54e-06  Rotatin 
rs4891821  18  66.00  2.72 (1.75-4.24)  9.70e-06  Rotatin 
rs1924597  13  96.24  0.39 (0.25-0.60)  1.78e-05  HS6ST3 
rs806711  19  5.57  0.51 (0.37-0.70)  2.30e-05  Scaffold attachment factor B2 
rs12275549  11  94.68  0.53 (0.40-0.71)  2.49e-05  AW966820 
rs2589183  8  97.59  1.93 (1.42-2.62)  2.86e-05  Syndecan 2 precursor 
rs3124028  9  7.66  1.56 (1.27-1.93)  3.34e-05  cDNA FLJ46908 (130kb) 
rs6491307  13  96.25  1.98 (1.43-2.73)  3.39e-05  HS6ST3 
rs7864533  9  29.58  0.60 (0.47-0.77)  4.18e-05  Nothing within 750kb 
rs806702  19  5.58  0.52 (0.38-0.71)  4.20e-05  Scaffold attachment factor B2 
rs4715476  6  54.73  1.65 (1.30-2.10)  4.67e-05  Tubulointerstitial nephritis antigen(370kb) 
rs3741355  11  3.08  0.55 (0.42-0.74)  4.72e-05  Oxysterol-binding protein like 5 
rs1041795  21  38.77  1.58 (1.27-1.97)  4.77e-05  Ets-related isoform 1 
rs6972789  7  66.76  1.55 (1.25-1.92)  5.67e-05  Stromal antigen 3-like 4 (350kb) 
rs11120735  1  214.35  0.57 (0.43-0.75)  5.79e-05  Usherin isoform B 
rs958882  5  123.03  1.56 (1.25-1.93)  5.83e-05  Casein kinase 1, γ3 isoform 4 (47kb) 
rs17677737  7  29.15  2.04 (1.44-2.90)  6.36e-05  Serine carboxypeptidase vitellogenic-like 
rs7798099  7  141.77  0.57 (0.44-0.75)  6.68e-05  mRNA for T cell receptor beta chain 
rs7600624  2  152.99  1.66 (1.29-2.14)  7.33e-05  Formin-like 2 
rs7229842  18  65.89  2.18 (1.48-3.20)  7.60e-05  Rotatin 
rs4239387  18  29.92  0.61 (0.47-0.78)  7.65e-05  Nucleolar protein 4 
rs10788500  10  88.15  0.59 (0.46-0.77)  7.75e-05  Wings apart-like homolog (40kb) 
rs10281994  7  125.27  1.74 (1.32-2.29)  8.17e-05  Glutamate receptor isoform c (550kb) 
rs6949266  7  125.18  1.76 (1.33-2.33)  8.69e-05  Glutamate receptor isoform c (550kb) 
rs10451282  17  41.14  0.43 (0.28-0.66)  9.59e-05  CRH receptor 1 (75kb) 
Thirty SNPs meeting significance threshold of p≤1e-04 by Cox regression in genotypic model, adjusted for 
stage, age and sex. The 30 SNPs represent 25 independent loci. The 7 SNPs selected in the initial screen 
are highlighted in light grey. Chr - chromosome. 
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Thirty SNPs had p<1e-04, they cover 25 independent loci. Thirteen loci are within genes, 
while 12 are in intergenic regions (Table 5.1). Only seven SNPs had been selected by the 
initial screen described in Chapter 3. 
While the most significant SNPs in this analysis were not being treated differently from 
any other SNP, there was again a number of candidate SNPs in interesting areas. In 
addition to the SNPs already described in Chapter 3, rs2144749, the most significant 
SNP in this analysis, is located in SPARC related modular calcium binding 2, a widely-
expressed matricellular protein which contributes to mitogenesis via activation of 
Integrin-Linked Kinase316. rs12275549 is located 75kb from sestrin 3, a TP53 responsive 
anti-oxidant that decreases the mutagenic effects of RAS induced intracellular reactive 
oxygen species317, while at the same time methylation of the CpG islands of sestrin 3 is 
strongly associated with MLH1 methylation318. 
5.1.1.2  SCOTTISH COHORT 
Forty-one SNPs had p<1e-04, they cover 34 independent loci. 10 loci are within genes, 
while 24 are in intergenic regions (Table 5.2). There was no overlap between the SNPs 
identified in this screen and either of the screens performed in the VICTOR cohort 
(section 5.1.1 and Chapter 3). 
Like for the VICTOR cohort, there were several interesting loci among the most 
significant SNPs. The most significant SNP, rs4074853, is located in PTPN5, a non-
receptor type protein tyrosine phosphatase, which inactivates MAPK319. rs3136551 lies 
just upstream of CD27, a member of the TNF-receptor superfamily, which upon binding 
of its ligand CD70 leads to the activation of NF-κB320. rs2413485 is located only 7kb from 
histone 1, family member 0 (H1F0), and tumour derived factors may inhibit dendritic cell 
differentiation by affecting H1F0 expression, thus decreasing the immune response to 
tumour related antigen321.  
Again, all SNPs from this analysis were treated the same and meta-analysed with the 
results of the VICTOR cohort. 
5.1.2  Meta‐analysis 
Data from both cohorts were available for 300,370 SNPs. 150,612 SNPs had an HR in 
the same direction in both cohorts, making these the likely candidates for significant 
findings. Of these, 564 SNPs had significant heterogeneity at the uncorrected phet<0.05, 
and a further 3760 SNPs had I2≥50%. 
Thirty-four SNPs met the significance threshold of p<1e-04, out of these, all but one SNP 
were in HWE in both cohorts. rs9810699 was not in HWE in the overall and control 
cohorts in VICTOR and was excluded. The 33 SNPs cover 30 independent loci. 17 loci   
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Table 5­2  Top SNPs in Scottish cohort 
SNP  Chr  Position  HR (95% CI)  p-value  Nearest gene 
rs4074853  11  18.749  0.44 (0.33-0.59)  3.04e-08  PTPN5, non-receptor type 
rs10027059  4  181.356  0.58 (0.46-0.73)  5.09e-06  Nothing within 750kb 
rs2280400  17  35.603  0.58 (0.46-0.74)  6.49e-06  Rap guanine nucleotide exchange factor 
rs10500624  11  4.905  1.53 (1.27-1.86)  1.07e-05  Olfactory receptor, F51, subfamily G (2kb) 
rs4861488  4  182.821  0.70 (0.59-0.82)  1.53e-05  cDNA FLJ31634 (204kb) 
rs4812851  20  42.754  1.44 (1.22-1.71)  2.27e-05  cDNA FLJ33523 
rs6906061  6  85.198  0.69 (0.58-0.82)  2.41e-05  KIAA1009 protein (104kb),  
rs895796  1  30.141  0.58 (0.45-0.74)  2.42e-05  cDNA clone IMAGE:4830073 (118kb)  
rs6803929  3  43.348  1.84 (1.38-2.45)  2.66e-05  SNF related kinase 
rs6788594  3  194.972  0.59 (0.46-0.76)  2.95e-05  optic atrophy 1 isoform 8 (73kb) 
rs4979603  9  117.778  2.11 (1.48-2.99)  3.20e-05  EST-YD1 mRNA (50kb) 
rs7741966  6  85.239  0.69 (0.58-0.83)  3.56e-05  KIAA1009 protein (104kb) 
rs1860339  17  58.205  0.72 (0.61-0.84)  3.80e-05  Ring finger protein 190 
rs2570583  11  4.921  1.51 (1.24-1.84)  3.93e-05  Olfactory receptor, F51, subfamily G (2kb) 
rs3136551  12  6.424  2.36 (1.56-3.55)  4.01e-05  TNF receptor superfamily (0.2kb) 
rs9449923  6  85.222  1.43 (1.20-1.70)  5.10e-05  KIAA1009 protein (104kb) 
rs6676127  1  33.805  1.42 (1.20-1.68)  5.16e-05  CUB and Sushi multiple domains 2 
rs2688492  3  196.982  1.44 (1.21-1.71)  5.25e-05  MUC4 
rs4812456  20  38.840  0.69 (0.58-0.83)  5.39e-05  EST DB112410 
rs1550790  16  58.442  0.69 (0.57-0.83)  5.63e-05  Nothing within 750kb 
rs1534995  6  41.069  0.68 (0.56-0.82)  6.26e-05  UNC5CL (33kb)  
rs9374571  6  116.207  0.70 (0.59-0.83)  6.26e-05  Fyn-related kinase (162kb) 
rs1445458  16  58.436  0.68 (0.56-0.82)  6.37e-05  Nothing within 750kb 
rs4394  22  47.055  0.62 (0.49-0.78)  6.51e-05  FAM19A5 (208kb) 
rs1572372  13  19.738  0.70 (0.59-0.84)  6.70e-05  Gap junction protein, beta 6 (44kb) 
rs2902374  2  82.703  0.65 (0.53-0.80)  7.13e-05  Nothing within 750kb 
rs2413485  22  36.524  1.41 (1.19-1.66)  7.56e-05  H1 histone family, member 0 (7kb) 
rs4381631  17  62.197  0.72 (0.61-0.84)  7.58e-05  Protein kinase C, alpha variant 
rs6818678  4  157.417  0.67 (0.55-0.82)  7.67e-05  PDGF C precursor (485kb) 
rs1046726  5  178.248  0.71 (0.60-0.84)  7.83e-05  Zinc finger protein 354B (29kb) 
rs3782181  12  87.478  1.44 (1.20-1.73)  7.98e-05  KIT ligand isoform b precursor 
rs6507839  18  44.091  0.67 (0.55-0.82)  8.09e-05  zinc finger and BTB domain containing 7C 
rs4694656  4  75.030  1.58 (1.26-1.99)  8.27e-05  platelet factor 4 (35kb) 
rs4438512  2  71.499  1.39 (1.18-1.64)  8.67e-05  zinc finger protein 638 
rs7562587  2  71.516  1.39 (1.18-1.64)  8.67e-05  zinc finger protein 638 
rs2825929  21  20.278  0.72 (0.61-0.85)  8.67e-05  nothing 
rs2407581  21  20.273  0.72 (0.61-0.85)  8.75e-05  nothing 
rs4946118  6  116.204  0.71 (0.59-0.84)  9.02e-05  Fyn-related kinase (162kb) 
rs2304218  19  44.651  0.45 (0.30-0.67)  9.22e-05  Transcription elongation factor SPT5 
rs6431734  2  15.792  0.69 (0.57-0.83)  9.37e-05  cDNA FLJ36206 (21kb) 
rs987189  17  14.492  0.58 (0.44-0.76)  9.95e-05  DNA FLJ45831 (119kb) 
Forty-one SNPs with p≤1e-04 by Cox regression in genotypic model, adjusted for stage, age and sex. The 
41 SNPs represent 34 independent loci. Chr - chromosome. The nearest gene is either the gene within which 
the SNP is located, or the nearest transcript to it. 
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Table 5­3  Top SNPs from the meta­analysis of VICTOR and Scottish cohort 
SNP  Chr  Position  HR (95% CI)  p-value  I
2 
HRScotland    
(95% CI)  pScotland 
HRVICTOR  
(95% CI)  pVICTOR  Function 
rs4074853  11  18.749  0.54 (0.43-0.68)  2.11e-07  80.7  0.44 (0.33-0.59)  3.04e-08  0.78 (0.53-1.17)  2.32e-01  Protein tyrosine phosphatase, non-
receptor type 
rs2280400  17  35.603  0.64 (0.54-0.77)  1.80e-06  42.5  0.58 (0.46-0.74)  6.49e-06  0.74 (0.56-0.99)  4.03e-02  Rap guanine nucleotide exchange factor 
rs10500624  11  4.905  1.46 (1.25-1.70)  2.44e-06  0.0  1.53 (1.27-1.86)  1.07e-05  1.31 (1.00-1.72)  5.40e-02  Olfactory receptor, 51G (2kb) 
rs2570583  11  4.921  1.45 (1.24-1.70)  4.33e-06  0.0  1.51 (1.24-1.84)  3.93e-05  1.35 (1.03-1.77)  3.12e-02  Olfactory receptor, 51G (2kb) 
rs240486  21  16.694  0.68 (0.57-0.80)  4.89e-06  0.0  0.65 (0.52-0.81)  1.27e-04  0.72 (0.55-0.92)  1.05e-02  LOC388815 isoform a 
rs2837132  21  40.026  1.51 (1.26-1.80)  5.55e-06  6.8  1.41 (1.13-1.75)  2.45e-03  1.71 (1.27-2.30)  4.00e-04  Immunoglobulin superfamily 5 like (13kb) 
rs729552  20  12.131  0.71 (0.61-0.83)  6.58e-06  0.0  0.75 (0.61-0.91)  3.67e-03  0.67 (0.54-0.84)  4.27e-04  BTB/POZ domain containing protein 3 
(312kb) 
rs10487167  7  103.163  1.77 (1.37-2.28)  1.36e-05  0.0  1.87 (1.34-2.62)  2.55e-04  1.63 (1.10-2.42)  1.59e-02  Reelin isoform a 
rs672740  1  170.404  0.76 (0.67-0.86)  1.63e-05  0.0  0.74 (0.63-0.87)  2.42e-04  0.79 (0.65-0.96)  2.02e-02  Dynamin 3 isoform a 
rs4381631  17  62.197  0.76 (0.66-0.86)  2.09e-05  2.1  0.72 (0.61-0.84)  7.58e-05  0.82 (0.67-1.01)  6.27e-02  Protein kinase C, alpha variant 
rs4861488  4  182.821  0.76 (0.66-0.86)  2.25e-05  59.8  0.70 (0.59-0.82)  1.53e-05  0.87 (0.70-1.07)  1.85e-01  cDNA FLJ31634 (204kb) 
rs895796  1  30.141  0.67 (0.55-0.80)  2.26e-05  62.1  0.58 (0.45-0.74)  2.42e-05  0.79 (0.60-1.04)  9.59e-02  cDNA clone IMAGE:4830073 (118kb) 
rs1004361  12  116.476  0.68 (0.57-0.81)  2.35e-05  0.0  0.70 (0.56-0.89)  3.00e-03  0.65 (0.49-0.86)  2.35e-03  Kinase suppressor of ras 2 
rs10027059  4  181.356  0.65 (0.53-0.80)  2.60e-05  71.8  0.58 (0.46-0.73)  5.09e-06  0.88 (0.61-1.28)  5.12e-01  Nothing within 750kb 
rs7600624  2  152.991  1.43 (1.21-1.70)  3.24e-05  59.4  1.27 (1.01-1.59)  4.52e-02  1.66 (1.29-2.14)  7.33e-05  Formin-like 2 
rs2640882  6  116.882  1.33 (1.16-1.52)  3.25e-05  0.0  1.35 (1.14-1.60)  5.17e-04  1.29 (1.04-1.61)  2.12e-02  Dermatan sulfate epimerase precursor 
rs4812456  20  38.840  0.74 (0.65-0.86)  3.33e-05  40.3  0.69 (0.58-0.83)  5.39e-05  0.83 (0.67-1.04)  1.08e-01  EST DB112410 
rs6853554  4  107.167  1.38 (1.18-1.61)  3.48e-05  57.4  1.25 (1.03-1.52)  2.25e-02  1.60 (1.25-2.04)  1.58e-04  TBC domain-containing kinase-like (19kb) 
rs1396087  17  49.668  1.38 (1.18-1.61)  3.97e-05  0.0  1.45 (1.19-1.77)  2.13e-04  1.27 (1.00-1.63)  5.01e-02  Kinesin family member 2B (411kb) 
rs2385168  7  103.866  0.74 (0.65-0.86)  3.97e-05  0.0  0.71 (0.59-0.85)  1.48e-04  0.81 (0.64-1.02)  6.76e-02  Lipoma HMGIC fusion partner-like 3 
rs3782176  12  87.463  0.68 (0.57-0.82)  4.29e-05  0.0  0.63 (0.50-0.80)  1.67e-04  0.76 (0.57-1.02)  6.36e-02  KIT ligand isoform b precursor 
rs1828096  17  49.668  0.73 (0.62-0.85)  4.52e-05  0.0  0.69 (0.56-0.84)  1.96e-04  0.79 (0.62-1.01)  5.98e-02  Kinesin family member 2B (411kb)  
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Table 5­3  Top SNPs from the meta­analysis of VICTOR and Scottish cohort (cont’d) 
SNP  Chr  Position  HR (95% CI)  p-value  I
2 
HRScotland  
(95% CI)  pScotland 
HRVICTOR  
(95% CI)  pVICTOR  Function 
rs6803929  3  43.348  1.61 (1.28-2.03)  5.13e-05  59.0  1.84 (1.38-2.45)  2.66e-05  1.25 (0.84-1.86)  2.75e-01  SNF related kinase 
rs1326450  13  104.330  0.76 (0.67-0.87)  5.91e-05  0.0  0.76 (0.64-0.90)  1.39e-03  0.77 (0.63-0.95)  1.49e-02  D-amino acid oxidase activator ()585kb 
rs4779800  15  27.199  1.47 (1.22-1.77)  6.18e-05  0.0  1.49 (1.16-1.91)  1.63e-03  1.43 (1.08-1.90)  1.31e-02  Amyloid β A4 precursor protein-binding 
(2kb) 
rs2296441  10  100.135  1.34 (1.16-1.55)  6.87e-05  0.0  1.34 (1.12-1.61)  1.38e-03  1.34 (1.05-1.71)  1.79e-02  Pyridine nucleotide-disulphide 
oxidoreductase domain 2 
rs966534  20  5.736  0.74 (0.63-0.86)  7.02e-05  0.0  0.75 (0.62-0.92)  5.05e-03  0.71 (0.56-0.90)  4.53e-03  Hypothetical protein LOC149840 
rs6849573  4  107.243  1.36 (1.17-1.58)  7.11e-05  39.4  1.25 (1.03-1.52)  2.24e-02  1.54 (1.21-1.96)  4.73e-04  TBC domain-containing protein kinase-like 
rs10883450  10  101.913  1.69 (1.30-2.18)  7.71e-05  31.5  1.46 (1.03-2.07)  3.56e-02  2.01 (1.37-2.94)  3.72e-04  ER lipid raft associated 1 
rs988421  1  72.322  0.77 (0.68-0.88)  8.25e-05  0.0  0.75 (0.64-0.89)  7.77e-04  0.80 (0.65-0.99)  3.58e-02  Neuronal growth regulator 1 
rs7424907  2  69.158  1.49 (1.22-1.82)  8.82e-05  0.0  1.61 (1.25-2.07)  2.34e-04  1.31 (0.95-1.81)  9.60e-02  Anthrax toxin receptor 1 isoform 3 
precursor 
rs7752055  6  106.067  1.49 (1.22-1.81)  9.02e-05  0.0  1.53 (1.18-1.99)  1.45e-03  1.43 (1.05-1.94)  2.13e-02  Prolyl endopeptidase (70kb) 
rs10459149  12  90.937  0.71 (0.60-0.85)  9.90e-05  0.0  0.68 (0.55-0.86)  1.07e-03  0.75 (0.58-0.97)  2.98e-02  Full length insert cDNA clone YW25A12 
Thirty-three SNPs meeting significance threshold of p≤1e-04 by fixed effects meta-analysis. These SNPs represent 30 independent loci. The 10 SNPs picked in the most significant SNPs from 
the Scottish cohort are highlighted in light grey, the single SNP from the VICTOR cohort in darker grey.  
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were within genes, while 13 were in intergenic regions. Out of the top 33 SNPs, one had 
been present in the top SNPs from the VICTOR screen (rs7600624), and 10 in the top 
SNPs from the Scottish cohort screen (rs4074853, rs2280400, rs10500624, rs2570583, 
rs4381631, rs4861488, rs895796, rs10027059, rs4812456, rs6803929); see Table 5-3. 
Seven SNPs had I2≥50% and were also analysed by a random effects model (rs4074853 
rs4861488 rs895796 rs10027059 rs7600624 rs6853554 rs6803929). In all cases, 
heterogeneity was driven by the HR from one cohort not being within the 95% CI of the 
other cohort. As expected, for all SNPs, in random effects meta-analysis, the 95% CI 
became wider and the significance levels decreased, with higher p-values, while the 
summary HR only change changed by a small degree (Table 5-4). 
Table 5­4  Random effects meta­analysis for SNPs with I2≥50% 
SNP  HR (95% CI)  p-value  I
2 
HRScotland    
(95% CI)  pScotland 
HRVICTOR   
(95% CI)  pVICTOR 
rs4074853  0.58 (0.33-1.01)  5.50e-02  80.7  0.44 (0.33-0.59)  3.04e-08  0.78 (0.53-1.17)  2.32e-01 
rs4861488  0.77 (0.62-0.95)  1.40e-02  59.8  0.70 (0.59-0.82)  1.53e-05  0.87 (0.70-1.07)  1.85e-01 
rs895796  0.67 (0.49-0.91)  1.10e-02  62.1  0.58 (0.45-0.74)  2.42e-05  0.79 (0.60-1.04)  9.59e-02 
rs10027059  0.70 (0.46-1.05)  8.50e-02  71.8  0.58 (0.46-0.73)  5.09e-06  0.88 (0.61-1.28)  5.12e-01 
rs7600624  1.44 (1.11-1.89)  7.15e-03  59.4  1.27 (1.01-1.59)  4.52e-02  1.66 (1.29-2.14)  7.33e-05 
rs6853554  1.40 (1.10-1.78)  5.44e-03  57.4  1.25 (1.03-1.52)  2.25e-02  1.60 (1.25-2.04)  1.58e-04 
rs6803929  1.56 (1.07-2.27)  2.20e-02  59.0  1.84 (1.38-2.45)  2.66e-05  1.25 (0.84-1.86)  2.75e-01 
The heterogeneity is largely driven by higher significance levels in the Scottish cohort, although for two 
SNPs, this is the case for VICTOR, including rs7600624, which had been selected in the initial discovery 
phase presented in Chapter 3. 
 
The top SNP in the meta analysis was the same as that from the Scottish cohort, 
rs4074853 located in PTPN5, but this also had the highest degree of statistical 
heterogeneity, making this SNP not significant a random effects analysis. Other SNPs are 
of biological interest, but given the low replication rate of those SNPs chosen on biological 
rationale in Chapters 3 and 4, this should not be a criterion for selection of SNPs for 
further verification. This verification has not yet been not performed, but further suitable 
cohorts are actively being identified; it is therefore not presented in this thesis. 
5.2  Screening for loci predictive of benefit from 5-FU chemotherapy 
As well as screening for prognostic markers, the samples of the VICTOR cohort also 
provided an opportunity for the discovery of predictive markers. Therefore, the subset of 
the VICTOR cohort that had received adjuvant chemotherapy was analysed separately 
for loci that might carry such predictive information.   
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5.2.1  GWAS for predictive markers 
Of the total VICTOR cohort, 595 patients received adjuvant 5-FU based chemotherapy, 
151 with stage 2 and 444 with stage 3 CRC. At the data cut-off point on 29 April 2009, 
there were 135 relapses after a median follow-up of 60.2 months (SD ±12.2 months).  
Table 5­5  Top predictive SNPs in VICTOR 
SNP  Chr  Position  HR (95% CI)  p-value  Nearest gene 
rs4715476  6  54730243  1.89 (1.61 - 2.17)  7.17e-06  Tubulointerstitial nephritis antigen (370kb) 
rs6117279  20  646986  1.72 (1.48 - 1.97)  1.04e-05  Sulfiredoxin 1 homolog (60kb) 
rs1408811  9  12565420  2.22 (1.86 - 2.58)  1.39e-05  Tyrosinase-related protein 1(120kb) 
rs917205  7  87555697  2.32 (1.94 - 2.71)  1.52e-05  ADAM metallopeptidase 
rs1516708  4  92721389  0.57 (0.31 - 0.83)  1.87e-05  FAM190A, transcript variant 1 
rs968757  4  120976901  1.69 (1.45 - 1.93)  2.02e-05  Phosphodiesterase 5A isoform 2 (209kb) 
rs7924634  11  132932946  1.91 (1.61 - 2.21)  2.27e-05  Opioid binding /cell adhesion (25kb) 
rs5743291  16  49314776  2.17 (1.81 - 2.52)  2.29e-05  Nucleotide-binding oligomeriszation 
rs7787525  7  99331595  2.42 (2.01 - 2.83)  2.33e-05  TRIM4 isoform 
rs510902  2  238992521  1.68 (1.44 - 1.92)  2.58e-05  Ankyrin repeat/SOCS box (8kb) 
rs746017  7  130955479  0.51 (0.19 - 0.82)  2.61e-05  Podocalyxin-like isoform precursor (64kb) 
rs3124238  9  89436136  1.66 (1.42 - 1.89)  3.05e-05  Death-associated protein kinase 1 
rs10281994  7  125272031  1.90 (1.60 - 2.21)  3.19e-05  Glutamate receptor, isoform c (590kb) 
rs2002059  10  101120844  2.32 (1.92 - 2.71)  3.53e-05  Cyclin M1 
rs2144749  6  168695539  1.67 (1.43 - 1.91)  3.61e-05  SPARC related modular calcium binding 2 
rs3784929  16  74234527  1.82 (1.54 - 2.11)  3.77e-05  Lysyl-tRNA synthetase isoform 3 
rs10102339  8  27023404  1.66 (1.42 - 1.91)  3.89e-05  Stathmin-like 4 (126kb) 
rs13253769  8  100102019  0.59 (0.34 - 0.84)  4.08e-05  Vacuolar protein sorting 13B isoform 4 
rs1041795  21  38774265  1.70 (1.44 - 1.95)  4.38e-05  Ets-related isoform 1 
rs8053257  16  74232188  2.03 (1.69 - 2.37)  4.94e-05  Lysyl-tRNA synthetase isoform 2 
rs883834  2  45310614  2.07 (1.72 - 2.43)  5.01e-05  Homo sapiens cDNA FLJ38231 
rs9514816  13  107581122  1.89 (1.58 - 2.20)  5.78e-05  DNA ligase IV (75kb) 
rs4923791  15  36476362  1.97 (1.64 - 2.31)  6.41e-05  Sprouty-related protein 1 (90kb) 
rs10913063  1  173942218  1.98 (1.64 - 2.31)  6.46e-05  Tenascin R 
rs237176  16  26567930  0.55 (0.26 - 0.84)  6.79e-05  Heparan sulfate D-glucosaminyl (510kb) 
rs7591253  2  34840709  1.67 (1.42 - 1.93)  7.06e-05  cDNA clone CS0DI009YL06 (39kb) 
rs2013746  2  7328172  1.79 (1.50 - 2.08)  7.35e-05  Ring finger protein 144 (227kb) 
rs337532  9  100490229  2.21 (1.82 - 2.61)  7.52e-05  G protein-coupled receptor 51 
rs1819887  18  50654310  1.67 (1.42 - 1.93)  7.90e-05  Member RAS oncogene family 27B 
rs6491307  13  96252810  0.47 (0.09 - 0.85)  8.10e-05  Heparan sulfate 6-O-sulfotransferase 3 
rs10934005  3  111185514  1.71 (1.44 - 1.97)  8.42e-05  Development pluripotency assoc’d (645kb) 
rs5764560  22  42876697  0.57 (0.29 - 0.85)  8.53e-05  Parvin, beta isoform a 
rs10161354  12  87869619  2.25 (1.84 - 2.65)  8.73e-05  Homo sapiens cDNA FLJ30500 (60kb) 
rs12419726  11  59495242  1.80 (1.50 - 2.09)  9.17e-05  mRNA for Hsa11-digit01-13-09-F 
rs17596719  6  26205172  1.93 (1.60 - 2.26)  9.49e-05  Haemochromatosis splice variant (0.1kb) 
rs1892431  1  90143395  1.81 (1.51 - 2.11)  9.61e-05  Leucine rich repeat containing 8 family 
rs1730265  18  49843033  1.88 (1.56 - 2.20)  9.66e-05  Methyl-CpG binding protein 2 (90kb) 
rs11709756  3  103334906  1.89 (1.57 - 2.21)  9.90e-05  Zona pellucida-like domain containing 1 
SNPs representing 38 independent loci. The nearest gene is either the gene within which the SNP is located, 
or the nearest transcript to it. The genetic model is genotypic for all SNPs. Chr - chromosome. 
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Unlike the analysis presented in section 5.1, there was no dataset available that had 
information on chemotherapy and genotypes for all SNPs on the Hap300 arrays. SNPs 
with a minor allele frequency of less than 5% were excluded to avoid the difficulties 
encountered in the discovery phase of the GWAS for prognosis presented in Chapter 3; 
again, only the genotypic model was analysed by Cox regression. As there are no 
established predictive markers for the efficacy of 5-FU, and no data on MSI status 
available, the survival analysis was not adjusted for further variables.  
Table 5­6  Predictive SNPs in PETACC 3 
SNP  Chr  Position  HR (95% CI)  p-value 
rs4715476  6  54730243  1.02 (0.85-1.23)  8.28e-01 
rs9514816  13  107581122  0.93 (0.75-1.16)  5.08e-01 
HR and 95% CI for the two SNPs that had been typed in the PETACC cohort. 
 
Forty-seven SNPs fell below the threshold of p<1e-04. Of these SNPs, two had minor 
allele frequencies of less than 5% (rs8076116, rs11155360), and one SNP (rs273674) was 
not in HWE with pHWE=1.11e-05 for the overall cohort. The remaining SNPs are 
presented in Table 5-5; five loci were tagged by two or more SNPs, and the redundant 
SNPs are not presented, leaving 38 SNPs. Two SNPs had been selected in the screen for 
prognostic markers presented in Chapter 3: rs4715476 on chromosome 6, 370kb from the 
tubulointerstitial nephritis antigen, and rs9514816 on chromosome 13, 77kb from DNA 
ligase 4. None of the SNPs were in or near genes known to be involved in the metabolism 
of 5-FU.  
5.2.2  Further verification of predictive SNPs 
All patients in PETACC 3 received 5-FU based chemotherapy, but data on survival were 
only available for the 30 SNPs included in the verification of prognostic SNPs, presented 
in section 4.1.1. Therefore only two of the 44 SNPs from section 5.2.1 above could be 
verified. The HR and 95% CI for the PETACC cohort are given in Table 5-6. 
Table 5­7  Meta­analysis of the VICTOR and PETACC cohorts 
SNP   HR (95% CI)  p-value  I
2  pQ 
rs4715476  1.24 (1.06-1.45)  7.15e-03  92.3  3.17e-04 
rs9514816  1.18 (0.98-1.41)  7.51e-02  92.6  2.46e-04 
A fixed-effects analysis was used for both SNPs. 
 
The estimates for these two SNPs were meta-analysed with those of the VICTOR cohort 
using a fixed-effects model (Table 5-7). Neither approached genome-wide significance, 
and the heterogeneity was highly significant and above 90% in both cases.  
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5.3  Discussion 
The data presented in this chapter represent one logical next step following the analyses 
performed in Chapters 3 and 4: the low replication rate and the high proportion of 
recessive model SNPs that were included on the basis of an imprecise significance 
estimate provided by the logrank test. In addition, by adjusting for other prognostic 
variables in the initial screen, the risk of rendering a significant association insignificant 
once these are included in the model is avoided.  
Perhaps the biggest advantage of the approach presented in this chapter is that by 
increasing probands, event rate and power, SNPs which in individual studies may only be 
borderline significant and would not have been taken into verification, are captured as 
well provided they are borderline significant in the other cohort as well. In fact, it is 
generally SNPs that have a similar HR and a significance level that is no more than two 
orders of magnitude apart that have met the overall threshold of p<1e-04, although the p-
value for the most significant SNP, rs4074853, was driven predominantly by significance 
in the Scottish cohort, and did therefore not appear significant in a random effects model 
(Figure 5-1).  
Figure 5­1  Plot of HR and ­log10(p­value) for VICTOR and Scottish cohort 
 
For most SNPs, the HR correlate well between VICTOR and the Scottish cohort (r2=0.72), including the most 
significant SNP, rs4074853 (yellow), although for HR<1, the Scottish cohort has lower HR while for HR>1, 
VICTOR has higher HR (left). The p-value distribution presented as the -log10(p-value) is more spread along 
a crescent, with the median sum of the -log10 from both cohorts being 5.1, showing that for most SNPs, the 
final  significance  level  is  driven  by  both  SNPs,  except  for  the  ends  of  the  crescent,  where  one  SNP 
dominates, and the heterogeneity increases (lavender) and rs4074853 lies in that region (yellow). 
 
This approach therefore largely selects SNPs after meta-analysis that may not have met 
the thresholds in the individual cohorts. Still, some of the top SNPs following meta-
analysis are interesting, for example, rs1004361, lying within Kinase suppressor of ras 2 
(KSR2), a scaffold protein required for KRAS-induced activation of the RAF-MEK-ERK 
phosphorylation cascade322. While the precise effect of KSR2 is not yet known, KSR1, a 
close homolog, is required for cell cycle re-initiation following various types of DNA  
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damage323. rs1004361 would not have been taken forward from either cohort as the p-
value in both was in the order of p=3e-03. A similar story emerges for rs2640882, within 
dermatan sulfate epimerase precursor, also known as SART2324, a tumour-rejection 
antigen recognised by HLA-A24-restricted and tumour-specific cytotoxic T 
lymphocytes325, where the individual p-values from VICTOR and Scottish cohorts would 
also not have met a p<1e-04 threshold. While the verification should not be based on 
selection by biological rationale, again based on the experience from Chapters 3 and 4, 
the existence of a strong biological rationale also does not make the SNPs less likely to 
replicate. 
Contrasting these positives is the problem of different outcome measures, forced by 
available data. DFS was not available in the Scottish cohort and the event rate was low 
for CRC specific survival in VICTOR. As outlined in the introduction to this chapter, 
DFS and CRC specific survival are tightly correlated in 18 clinical trials looking at the 
effect of different treatment strategies315. Outcome in these trials will have been affected 
by germline pharmacogenomic variation and the type of therapy given as much as by the 
type of prognostic SNP screened for in this thesis. These studies are not an exact model 
for the analyses performed here, but nonetheless suggest that, in order to drive a more 
precise estimate of the risk contribution of individual SNPs, the comparison of two 
different CRC specific outcome measures may be valid. 
The knowledge of prognosis is useful to plan the appropriate therapy, adjust existing 
treatment strategies, and help define subgroups for which new treatments are required. 
Knowledge of the likelihood of response to a given treatment, predictive information, will 
help to avoid giving ineffective systemic therapy, and therefore help improve the 
therapeutic ratio of currently available chemotherapy. An attempt was therefore made to 
perform a discovery phase for predictive marker using the patients of the VICTOR 
cohort who had received adjuvant chemotherapy, although no good verification cohort 
had been identified. No significant findings were made, and no SNP in or near genes of 
the metabolic pathway of 5-FU was in the top most significant SNPs. While the evidence 
for germline variation influencing outcome from 5-FU therapy is weak (section 1.6.2.1), it 
nonetheless exists. Consequently, either this evidence does not reflect the actual impact on 
5-FU efficacy and was therefore not replicated, or, equally likely, the power to detect 
predictive germline markers was too small in the discovery phase presented here. 
Compared to the screening cohorts used for CRC susceptibility loci, the cohorts used here 
remain small, between 30% and 40% of the susceptibility studies44,299. The relative event 
rates are smaller still, 19.43% in VICTOR and 32.15% in the Scottish cohort, compared 
to 49.20% and 48.48% CRC cases (‘events’) in the susceptibility screens, and an even  
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smaller cohort and event rate in the screen for predictive loci. Thus, despite the proven 
potential of GWAS to detect susceptibility loci for many diseases39-41,44,326, the power to 
detect germline prognostic or predictive SNPs or loci is more limited. It is likely that 
GWAS for predictive markers will represent the next challenge beyond prognostic 
markers, as the cohorts needed for this approach require information not only on disease 
status and time to relapse, but also treatments given, ruling out most population based 
cohorts. 
Ultimately, the success or otherwise of the approach taken in this chapter will depend on 
the ability to identify verification cohorts of sufficient size, with an appropriate ethnic and 
clinical background. Like for susceptibility GWAS, verification is key, and future efforts to 
define suitable cohorts for the verification of the SNPs identified in this chapter have 
already begun, and will ultimately be crucial for our understanding of the contribution of 
an individual’s genetic make-up to prognosis and response to (systemic) therapy, a key 
prerequisite in the supposed age of personalised medicine.  






rs6983267 is associated with micrometastasis 
 
6 rs6983267 is associated with micro-metastatic disease 
Genome wide association studies have identified common, low-penetrance susceptibility 
alleles in a variety of cancers38,39, and in CRC, 10 loci have now been described42-46,52. 
The high penetrance syndromes (FAP, HNPCC, JPS, PJS) are associated with an early 
age of onset, and early age of onset in turn has anecdotally been associated with worse 
prognosis in CRC327,328. Others have not found such an association329,330, but not all 
studies performed a stage for stage comparison, and none split the patients into more than 
two age bands. While not well established in CRC, this is contrary to breast cancer, where 
young age of onset is an independent prognostic variable, possibly reflecting a different 
tumour biology331. It is therefore conceivable that the recently described low-penetrance 
CRC risk loci could predispose to an earlier age of onset and be associated with prognosis 
(Table 6-1).  
Table 6­1  Known CRC low­penetrance risk loci 
SNP  Alleles  Chromosome  OR (95% CI)  p-value  Gene  Distance 
rs6983267
44  T/G  8q24  1.21 (1.15-1.27)  1.3E-14  MYC   337Kb 
rs16892766
42  A/C  8q24  1.25 (1.19-1.32)  3.3E-18  EIF3H  27Kb 
rs10795668
42  A/G  10p14  0.89 (0.86–0.91)  2.5E-13  none  within 500Kb 
rs3802842
52  A/C  11q23  1.17 (1.12-1.22)  1.08E-12  POU2AF1  51Kb 
rs4444235
46  T/C  14q22  1.11 (1.08–1.15)  8.1E-10  BMP4  9.4Kb 
rs4779584
43  T/C  15q13  1.26 (1.19-1.34)  4.4E-14  GREM1  15Kb 
rs9929218
46  A/G  16q22  0.90 (0.87–0.94)  1.2e-08  CDH1  intronic 
rs4939827
45  T/C  18q21  0.85 (0.81–0.89)  1.0E-12  SMAD7  intronic 
rs10411210
46  T/C  19q13  0.83 (0.78–0.88)  4.6e-09   RHPN2  intronic 
rs961253
46  A/C  20p12  1.12 (1.08–1.16)  2.0E-10  BMP2  342Kb 
OR  are  for  CRC  risk.  MYC  –  MYC  proto  oncogene;  EIF3H  -  eukaryotic  translation  initiation  factor  3; 
POU2AF1 - POU class 2 associating factor 1; BMP - bone morphogenic protein; Grem1 - gremlin-1; CDH1 - 
E-cadherin; RHPN2 - Rho GTPase binding protein 2. Where more than one SNP has been described per 
locus, only the most significant SNP is listed. 
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6.1  Screening risk SNPs for association with outcome in VICTOR 
All 10 SNPs were typed in the VICTOR cohort as part of the verification phase of the 
initial susceptibility GWAS. Four SNPs were typed by KASPar allele specific PCR 
(rs10758668, rs16892766, rs961253, rs10411210) with otherwise standard conditions for 
KASPar PCR (for primer sequences and conditions see Table 10-10 and Table 10-11). 
Genotypes for rs10411210 were generated by Kimberley Howarth. The remaining six 
SNPs were typed on the Illumina Hap300 arrays, and genotypes were generated for 947 
patients (Table 6-2).  
Not all samples had DNA available for KASPar genotyping, although overall, the call 
frequencies were high. Fidelity of the KASPar genotypes was assessed by direct 
sequencing within the laboratory. All SNPs were in HWE for the overall group as well as 
the relapsed and non-relapsed groups at the p>0.01 level. 
Table 6­2  Genotypes in VICTOR 
      Relapse  Non-relapse   
SNP  Total  Call rate  AA  AB  BB  AA  AB  BB  Method 
rs6983267  945  99.8%  30  96  54  164  382  219  Illumina 
rs16892766  809  100%  137  27  1  547  91  6  KASPar  
rs10795668  892  99.0%  20  76  77  53  300  366  KASPar  
rs3802842  947  100%  92  71  17  368  313  86  Illumina 
rs4444235  946  99.9%  54  80  46  208  389  169  Illumina 
rs4779584  947  100%  7  66  107  45  230  492  Illumina 
rs9929218  947  100%  17  71  92  55  308  404  Illumina 
rs4939827  946  99.9%  57  90  32  233  384  150  Illumina 
rs10411210  754  95.2%  1  26  118  5  86  518  KASPar  
rs961253  800  99.3%  18  73  56  83  320  250  KASPar  
 
To test the influence on survival, all SNPs were analysed for the genotypic, recessive and 
dominant models by Cox regression in the VICTOR cohort in a univariate model. The 
cut-off for survival data for this analysis was 29 September 2008. Of the 10 SNPs, only 
rs6983267 and rs10768558 reached significance at the p<0.05 level (Table 6-3).  
For rs6983267 in the recessive model, HR=0.66 (95% CI 0.44-0.99, p=4.57e-02), and for 
rs10768558 in the genotypic and recessive models, HRgen=1.30 (95% CI 1.03-1.64, 
p=2.43e-02) and HRrec=1.65 (95% CI 1.04-2.64, p=3.49e-02). 
The significant associations were tested in multivariate analysis with stage. rs10768558 
retained significance at the p<0.05 level for both models, while rs6983267 did not quite 
reach significance in the recessive model (p=9.10e-02, Table 6-4).  
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Table 6­3  HR for death for CRC risk SNPs 
SNP  Model  HR (95% CI)  p-value 
rs6983267  genotypic  0.84 (0.68-1.04)  1.18e-01 
rs16892766  genotypic  1.10 (0.76-1.60)  6.18e-01 
rs10795668  genotypic  1.30 (1.03-1.64)  2.43e-02 
rs3802842  genotypic  0.88 (0.70-1.10)  2.58e-01 
rs4444235  genotypic  0.99 (0.80-1.22)  9.17e-01 
rs4779584  genotypic  1.07 (0.84-1.36)  6.01e-01 
rs9929218  genotypic  1.09 (0.87-1.38)  4.53e-01 
rs4939827  genotypic  0.91 (0.73-1.12)  3.75e-01 
rs10411210  genotypic  1.16 (0.79-1.71)  4.56e-01 
rs961253  genotypic  1.01 (0.79-1.29)  9.28e-01 
rs10795668  recessive  1.65 (1.04-2.64)  3.49e-02 
rs6983267  recessive  0.66 (0.44-0.99)  4.57e-02 
HR  and  95%  confidence  intervals  determined  by  Cox  regression  in  univariate  analysis.  Significant 
associations at the p<0.05 level are shaded in grey; for those SNPs not showing an association at this level 
in any model, only the genotypic model is given. 
 
To test if the association of rs6983267 with DFS in univariate analysis was because of an 
association with stage, the genotypic and dominant models were analysed by logistic 
regression. For the recessive model, this was significant, ORrec=0.68 (95% CI 0.49-0.93, 
p=1.68e-02), and for the genotypic model of borderline significance (Table 6-5). None of 
the models tested revealed a significant association of rs10768558 with stage (data shown 
for genotypic model only in Table 6-5. 
Table 6­4  Multivariate Cox regression including stage  
SNP  Model  HR (95% CI)  p-value 
rs10795668  genotypic  1.27 (1.01-1.60)  3.84e-02 
rs10795668  recessive  1.61 (1.01-2.57)  4.55e-02 
rs6983267  recessive  0.70 (0.47-1.06)  9.10e-02 
 
While the association of rs6983267 with stage is interesting, it is also only of borderline 
significance, and in itself does not offer any new prognostic information. If it predisposed 
to micro-metastatic disease (the definition of stage 3 CRC if metastasis is confined to 
lymphnodes on pathological examination), it would offer new prognostic information: 
pathological stage 2 patients who had undetected micro-metastasis should be offered 
adjuvant chemotherapy analogous to stage 3 patients. 
Table 6­5  Association with stage 
SNP  Model  OR (95% CI)  p-value 
rs6983267  genotypic  0.83 (0.69-1.00)  5.11e-02 
rs6983267  recessive  0.68 (0.49-0.93)  1.68e-02 
rs10795668  genotypic  1.09 (0.89-1.34)  3.99e-01 
There was a significant association of rs6983267 with stage in the recessive model, this was borderline in the 
genotypic model; for rs10795668 no association was found, data only shown for genotypic model.  
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Therefore, a new group with (micro)-metastatic disease was defined: those with stage 3 
and hence confirmed metastatic disease on pathological examination, and relapsed stage 
2 disease, who, on the assumption of adequate surgery and negative resection margins, 
must have had micro-metastatic disease in order to relapse. This group was compared to 
stage 2 patients who did not relapse, and are patients who did not have micro-metastatic 
disease. 
The association of rs6983267 with the new category of (micro)-metastatic disease was 
significant in the genotypic and, in particular, in the recessive model, HRrec=0.65 (95% 
CI 0.47-0.89, p=7.58e-03). This association remained if chemotherapy was included in 
the model (HR=0.59, 95% CI 0.40-0.86, p=6.93e-03). There was no association between 
this clinical group and rs10768558 in any model (Table 6-6). 
Table 6­6 Association with micro­metastatic disease 
SNP  Model  OR (95% CI)  p-value 
rs6983267  genotypic  0.81 (0.67-0.97)  2.38e-02 
rs6983267  recessive  0.65(0.47-0.89)  7.58e-03 
rs10795668  genotypic  1.20 (0.97-1.48)  8.73e-02 
There  was  a  significant  association  of  rs6983267  with  micro-metastatic  disease  in  the  genotypic  and 
recessive models, for rs10795668 no association was found in any model, data only shown for genotypic 
model. 
 
6.2  Verification in further cohorts 
The intriguing hypothesis raised by this work warranted further investigation, especially 
due to the retrospective nature of the initial analyses. Therefore, rs6983267 and 
rs10768558 were typed in further cohorts to test the association of rs10758668 with 
prognosis, test the association of rs6983267 with metastatic disease and stage, and refute 
its association with prognosis. 
Table 6­7  Further genotyping for rs6983267 and rs10758668  
Cohort  rs6983267  rs10758668 
Australia  Collaborators  not typed 
Quasar 1  Collaborators  not typed 
Quasar 2  Illumina  not typed 
Denmark  KASPar   KASPar  
Epicolon  Collaborators  not typed 
Finland  Collaborators  Collaborators 
PETACC  Collaborators  Collaborators 
VICTOR  Collaborators  No further samples 
Genotyping work undertaken to further evaluate rs6983267 and rs10758668 in additional cohorts. Conditions 
for KASPar genotyping were as described above, all Quasar 2 samples were typed on Hap370 arrays. For 
the VICTOR cohort, there were an additional 185 samples with genotypes for rs6983267 available. 
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The required genotyping for rs10758668 and rs6983267 was undertaken by my 
collaborators, except for the Danish cohort, where both were typed by KASPar PCR (for 
primer sequences and conditions see Table 10-10 and Table 10-11), and rs6983267 in 
Quasar 2, typed on Illumina Hap370 arrays. This is summarised in Table 6-7. 
6.2.1  rs6983267 and micro‐metastatic disease 
Genotype data for rs6983267 was available in a further seven cohorts: Australia, 
Denmark, Epicolon, Finland, PETACC, Quasar 1 and Quasar 2, providing genotypes for 
4991 patients of all stages, including an additional 185 patients from the VICTOR trial 
who were genotyped from FFPE tissue by Dr Oliver Sieber. Follow-up was updated for 
the VICTOR cohort , the cut-off date was 29 January 2009. All cohorts were in HWE for 
the overall, non-relapsed and relapsed groups at the p>0.01 level. 
Figure 6­1  Forest plot of association with micro­metastasis 
 
In the recessive model, TT is compared with TG/GG combined; all but two studies are suggestive of a lower 
risk of micro-metastasis associated with the T allele. Studies are ordered by increasing inverse variance 
weight.  
 
The association of rs6983267with micro-metastatic disease in loco-regional CRC was 
tested in the eight cohorts available, and except in two cohorts (Denmark and PETACC), 
the direction of the effect was consistent with a decreased risk of micro-metastatic disease 
for minor allele homozygotes, although no other cohort reached statistical significance. 
The result from the VICTOR trial remained significant with longer follow-up. The 
combined OR of the risk of having micro-metastasis at surgery was statistically significant 
with ORrec=0.86 (95% CI 0.74-1.00, p=4.33e-02) in the recessive model (Figure 6-1) with  
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no evidence of significant inter-study heterogeneity (I2=36.8%, pQ=0.135). In the 
genotypic model, which had had the smaller effect in the discovery phase in the VICTOR 
samples, the association was also significant ORgen=0.92 (95% CI 0.85-1.00, p=4.10e-02). 
Figure 6­2  Funnel plot of association with micro­metastasis 
 
Funnel plot of the recessive model with pseudo 95% CI represented by the dotted lines. There is no evidence 
of significant bias in the studies analysed. 
 
Visual inspection of the funnel plot (Figure 6-2) did not reveal any significant 
heterogeneity, and Egger's test was non-significant (p=0.333). To assess the impact of 
individual studies on the overall effect size, a leave one out analysis was performed: no 
study dominated the summary estimate.  
The same analysis was performed, restricted to stage 1 and 2 patients who would be 
candidates for adjuvant chemotherapy if they had micro-metastasis (the equivalent to 
stage 3 if micro-metastases were detected on pathological examination of the 
lymphnodes). In the absence of adjuvant chemotherapy, this analysis is equivalent to 
predicting relapse in stage 1 and 2 patients. While the summary estimate did not reach 
formal statistical significance (ORrece=0.86, 95% CI 0.69-1.08, p=1.93e-01; I2=0%, 
pQ=0.898) the result was consistent with an effect of the same magnitude and direction as 
before (Table 6-8).  
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Table 6­8  Association of rs6983267 with micro­metastatic disease in stage 1 and 2 
Cohort  OR (95% CI)  prec  pQ 
Australia  0.90 (0.23-3.45)  8.75e-01   
Quasar 1  0.86 (0.50-1.47)  5.80e-01   
Quasar 2  1.27 (0.24-6.67)  7.87e-01   
Denmark  1.15 (0.64-2.08)  6.33e-01   
Epicolon  0.99 (0.55-1.75)  9.65e-01   
Finland  0.73 (0.49-1.10)  1.29e-01   
PETACC  1.01 (0.50-2.08)  9.78e-01   
VICTOR  0.66 (0.35-1.25)  1.87e-01   
Summary estimate  0.86 (0.69-1.08)  1.93e-01  0.898 
Data shown for the recessive model, restricted to 2,918 stage 1 and 2 patients. 
 
6.2.2  rs6983267, survival and stage 
None of the seven additional cohorts showed a significant association with survival, but in 
five, the results were compatible with a better prognosis for the TT genotype.  
Figure 6­3  Kaplan­Meier curve for all patients 
 
Kaplan-Meier curve for rs6983267 for all patients combined, recessive model: TT - navy, TG/GG - maroon. 
There is no statistical difference between the curves p=0.111. 
 
When these data were meta-analysed, the overall effect was not significant with 
HR=0.93, 95% CI % CI 0.87-1.01, p=7.67e-02. The association with stage was tested, 
and the same picture emerged: no study was individually significant, neither was the 
overall effect with OR=0.93, 95% CI % CI 0.85-1.01, p=8.10e-02. There was no 
association when either survival or stage was tested in the recessive model, initially the  
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strongest association (Table 6-9), although there was an impression from the Kaplan-
Meier curves that the two groups could be different (Figure 6-3). 
Table 6­9  rs6873267 is not associated with survival or stage 
Outcome  Model  HR (95% CI)  pgen  pQ 
Survival  Genotypic  0.93 (0.87-1.01)  7.67e-02  0.646 
Stage  Genotypic  0.93 (0.85-1.01)  8.10e-02  0.132 
HR for survival, OR for stage. 
 
However, when the event rate (either relapse or death) was analysed by stage, a 
relationship between stage and TT homozygosity emerged: the lower the stage, the lower 
the OR, 0.79 for stage 1 and 2.78 for stage 4. Within each stage group, the effect of 
rs6983267 was not significant (Table 6-10). 
Table 6­10  T allele is inversely associated with event rate in early stage CRC  
Stage  OR (95% CI)  prec  pQ 
1  0.79 (0.43-1.40)  4.27e-01  0.194 
2  0.84 (0.66-1.07)  1.56e-01  0.989 
3  0.91 (0.74-1.13)  3.92e-01  0.295 
4  2.78 (0.82-14.64)  1.63e-01  0.847 
The protective effect of the TT homozygote decreases with increasing stage. 
 
6.2.3  rs10795668 and prognosis 
rs10795668 was typed by allele specific PCR in three further cohorts: Denmark , Finland, 
and PETACC. All three cohorts were in HWE for the overall, non-relapsed and relapsed 
group at the p>0.01 level. No model reached statistical significance in any of the 
additional cohorts, although the data were consistent with an increased risk associated 
with the A allele. Updated data were used for the VICTOR cohort (data cut-off 28 
January 2009), which slightly diminished the effect size without losing significance.  
When meta-analysed, the summary estimate was not significant in the genotypic model 
with HRgen=1.08 (95% CI 0.99-1.17, p=8.80e-02) with only moderate heterogeneity 
(Table6-11). There was no significant association in any other model, nor when only stage 
2 and 3 patients were considered. 
Table 6­11  rs10795668 and outcome 
Cohort  HR (95% CI)  pgen  pQ 
Victor  1.28 (1.02-1.6)  3.30e-02   
Danish  1.19 (0.95-1.49)  1.24e-01   
Finnish  1.03 (0.9-1.18)  7.11e-01   
PETACC  1.01 (0.86-1.18)  8.99e-01   
Summary estimate  1.08 (0.99-1.17)  8.80e-02  0.246 
Data shown for the genotypic trend model, GG vs. GT vs. TT. 
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6.3  Discussion 
The data presented in this chapter suggest that the T allele of rs6983267 protects from 
early micro-metastatic disease in CRC, thus resulting in disease that would be cured by 
surgery alone, not warranting further systemic adjuvant therapy. In addition, the T allele 
was also the protective allele in the GWAS for CRC susceptibility, meaning that TT 
homozygotes have not only a lower risk of CRC44, but also are more likely to have a less 
aggressive form of the disease. Conversely, carriers of one or two G alleles appear more 
likely to develop CRC and have a more aggressive cancer. This association with tumour 
biology is not found with any of the other CRC susceptibility SNPs described so far, 
although there is some evidence that rs3802842 confers a higher risk of distal CRC52.  
The data appear real, as genotyping was robust and yielded similar results in six out of 
eight studies despite differences in genotyping method. The two studies with OR 
suggestive of a protective effect of the G allele (Denmark and PETACC) utilised KASPar 
genotyping and Sequenom technology, respectively, and the allele frequencies were 
similar in all cohorts, with T being the minor allele in line with previously published 
figures44. 
The distinction between metastasis and no metastasis points to a fundamental difference 
in cancer cell biology. Non-malignant cells do not leave the environment of like cells, and 
the ability to metastasise is one of the hallmarks of cancer. This ability in the early stages 
could have a significant impact on prognosis, but is less likely to be a major prognostic 
factor in the later stages, especially stage 4, when the ability to metastasise is less 
important than overall cancer burden - which of course does include metastasis, but at 
this point other factors presumably govern the number and size of metastasis and 
prognosis.  
Thus, the apparent disappearance of a protective effect against an event (relapse or death) 
of the TT genotype with increasing stage is supportive of this concept: the likelihood not 
to have metastasised in stage 1 and 2 CRC means that the pathological stage truly reflects 
the ‘biological’ stage, whereas in stage 3 disease most patients already receive 
chemotherapy and in stage 4 disease obvious and often widespread metastasis are present. 
It was not possible to link the propensity to early metastasis, or lack thereof, to a clinically 
useful outcome measure, and this finding remains one of scientific interest without at 
present impacting the management of patients with CRC. A separate marker for micro-
metastatic disease would be clinically most useful in situations where there is no evidence 
of metastasis, namely in stage 1 and 2 CRC: patients at high risk of micro-metastasis 
could be offered adjuvant chemotherapy, while those patients at low risk could be 
reassured and spared the toxicity of chemotherapy, perhaps even in the presence of  
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adverse features which at present might otherwise convince clinicians to offer adjuvant 
therapy. Unfortunately, the data did not allow a firm conclusion regarding the impact on 
relapse rates: both for the dichotomous (relapse yes/no) as well as the time-to-event 
analysis, the magnitude of the effect size and its direction was the same in stage 1 and 2 
patients as it had been when all patients are included, but did not reach statistical 
significance. It is not clear why this should have been, but variability of follow-up and 
associated clinical information may have played a part. Follow-up for the Danish and 
Finnish cohorts was ascertained through the national cancer registries, which only record 
death but not cause or relapse date. Furthermore, for these patients, no systemic 
treatment details were available, although it is likely that for both cohorts, stage 2 patients 
would not have received adjuvant therapy as they were ascertained prior to the general 
acceptance of adjuvant chemotherapy in high-risk stage 2 patients. Other potential 
confounders were the relatively low event rate in the VICTOR cohort, and the fact that 
only four cohorts were trial based. Furthermore, data on other prognostic features was 
not available, in particular no information regarding the resection margin, which, if 
positive, would indicate residual tumour predisposing to relapse without the ‘need’ for 
early occult metastasis from the primary tumour.  
Again, rs6983267 stands out from other susceptibility SNPs in any cancer: not only is it 
the only SNP for which evidence of an effect on tumour biology exists, it is also the only 
SNP that predisposes to more than one tumour type47, residing in the 8q24 region that 
more generally is associated with an increased risk of developing cancer49. The causal 
variants remain to be elucidated; the transcription factor POU5F1P1 located 15Kb from 
rs6983267 is of an as yet undetermined functional significance. However, the location of 
rs6983267 on 8q24, 337Kb centromeric to the proto-oncogene MYC, invites speculation 
that changes in MYC expression and function could be the effector of both susceptibility 
and early metastasis, possibly via long-range cis-acting enhancer elements that are 
>250Kb from their respective gene in 50% of cases308, a case now likely for CRC332. 
While MYC has not been specifically linked to the metastatic process, deregulation of 
MYC is one of the most common single gene abnormalities detected in human cancer333, 
leading to occurrence and perpetuation of genomic instability which in turn plays an 
important role in the evolution of cancer cells334, usually leading to the formation of 
distant metastasis. In B-lymphocytes, MYC expression decreases expression of LFA-1, 
involved in homotypic cell adhesion335, and MYC could therefore also play a role in the 
release of CRC cells from the primary site to form metastasis.  
MYC has been implicated in WNT signalling, being a downstream target of activated β-
catenin, which jointly with TCF4 enhances MYC expression via the TCF4 binding site in  
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the MYC promotor336, and deletion of MYC can rescue the abnormal intestinal phenotype 
associated with APC deletions50. It appears that the 8q24 region harbours a TCF4 binding 
site that may affect MYC expression337, and there may be several tissue specific long-range 
enhancers of MYC, defined by the five LD blocks in this region, including one associated 
with CRC49, possibly targeting only some of the many cellular processes (e.g. cell cycle338, 
proliferation339, apoptosis340, cell adhesion341) in which MYC is involved. While there is no 
evidence linking MYC to prognosis in CRC, there is evidence from haematological 
malignancies that 8q24.21 rearrangements correlate with a more aggressive phenotype, 
speculatively the equivalent of early metastatic potential in solid organ malignancy, and a 
worse prognosis342-344.  
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7 rs6687758 is a novel CRC risk locus 
rs6687758 is an A/G polymorphism on chromosome 1 at 220,231,571bp (1q41), with a 
MAF (G allele)=0.200 in HapMap samples of European ancestry.  
In the recent GWAS for CRC susceptibility, it had been borderline significant at the 
p<0.05 level in one of two screening data sets (Scottish Phase 1, OR=1.16, 95% CI 1.00-
1.35, p=0.049) but not the other (Corgi 2, OR=1.11, 95% CI 0.94-1.30, p=0.229) in the 
allelic model. The SNP was taken forward into two further screening sets for all SNPs at 
p<0.05 from Phase 1, where it was significant at the 0.05 level in both (Scottish Phase 2, 
OR=1.14, 95% CI 1.02-1.27, p=0.023; London Phase 2, OR=1.13, 95% CI 1.03 -1.24, 
p=0.009). Taken together, these cohorts suggested that rs6687758 is associated with CRC 
(p=3.39e-05), without reaching formal significance at the p=1e-07 level (Table 7-1). 
These analyses were performed by collaborators. 
Table 7­1  Allelic OR for rs6687758 in four screening cohorts 
Cohort  HR (95% CI)  Pall  pQ 
Corgi  1.11 (0.94-1.30)  2.29e-01   
Phase 2  1.13 (1.03-1.24)  8.54e-03   
Scotland Phase 1  1.16 (1.00-1.35)  4.90e-02   
Scotland Phase 2  1.14 (1.02-1.27)  2.30e-02   
Summary estimate  1.14 (1.07-1.21)  3.39e-05  0.975 
OR and significance levels for rs6687758 in the screening cohorts for the GWAS for CRC susceptibility. 
 
7.1  rs6687758 in VQ58 and Finnish samples 
To confirm the initial findings, genotypes for two further datasets were collected: VQ58, a 
combined dataset of the samples of the VICTOR and Quasar 2 trials as cases, and the 
samples of the 1958 Birth Cohort as controls. The Finnish sample collection contained 
both cases and controls.  
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7.1.1  VQ58 
This sample set consisted of 947 cases in the VICTOR trial, 494 cases in the Quasar 2 
trial, and 1420 controls from the 1958 Birth Cohort. rs6687758 is on the Illumina 
Infinium Hap300 and Hap 550 arrays; it was typed as part of the GWAS for outcome (see 
Chapter 3), and the genotypes for the 1958 Birth Cohort were typed on the Illumina 
Hap550 arrays by collaborators as part of a GWAS for risk. The SNP performed well, 
with good cluster separation (GenTrain score=0.806 in VICTOR) and a call frequency of 
99.7% in the VICTOR and Quasar 2 samples and 98.9% in the 1958 Birth Cohort 
(Table 7-2). The cohort was in HWE for all subgroups at the p<0.05 level. 
The combined dataset showed a significant association between rs6687758 and CRC risk, 
OR=1.27, 95% CI 1.12-1.45, p=2.95e-04. 
Table 7­2  rs6687758 genotypes in VQ58 
Cohort  Type  Total  AA  AG  GG 
Total cases  Cases  1436  875  493  68 
•  VICTOR    1.  944  2.  581  3.  314  4.  49 
•  Quasar 2    5.  492  6.  294  7.  179  8.  19 
1958 Birth Cohort  Controls  1420  962  404  54 




The Finnish sample set consisted of 988 cases and 864 controls. The genotypes were 
generated using KASPar genotyping (see Table 10-12 and Table 10-13 for primers and 
condition). Of the 1852 samples, 65 were excluded due to unreliable sensors in the 
scanner and 22 samples failed genotyping, giving a call frequency of 98.7%.  
Table 7­3  rs6687758 genotypes in Finnish cohort 
Cohort  Type  Total  AA  AG  GG 
Finland  Cases  928  476  385  67 
Finland  Controls  803  437  317  49 
 
Reproducibility was tested with repeat analysis of 192 cases with very good concordance 
(98.96%). The discrepancy arose from one well on each plate that had failed initially 
being called in the repeat run. Genotypes were confirmed by sequencing a subset of 
samples, using the primers in Table 10-14 with standard conditions. The concordance 
was 100% in 83 samples for which genotypes were available from both techniques. 
Additional genotypes available after direct sequencing are included in the final analysis. 
The final genotype count is given in Table 7-3; the genotypes were in HWE at p=0.479.  
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There was no significant association between rs6687758 and CRC risk, OR=1.11, 95% 
CI 0.96-1.30, p=1.61e-01. Of note is that the OR, although not formally significant, is 
consistent with an effect of the same magnitude and direction as the other cohorts. 
7.2  Meta-analysis of VQ58 and Finnish cohort 
In order to derive a summary estimate of the CRC risk conferred by rs6687758, OR were 
generated for each group using logistic regression and pooled using a fixed effects model 
(Figure 7-1). The overall OR=1.15 (95% CI 1.10-1.21, p=5.04e-08) with no evidence of 
statistical heterogeneity (I2=0%, pQ=0.727). Because the frequency of the G allele was 
significantly different in the Finnish cohort (MAFFinland=0.270) compared to all other 
cohorts (MAFmean=0.203, range 0.199-0.209, p=1.5E-15), a random effects model was 
also used. The result of fixed and random models were identical, and are shown for the 
genotypic model (Table 7-4). 
Figure 7­1  Forrest plot of association of rs6687758 with CRC risk 
 
OR and 95% CI conferred by rs6687758. Studies are ordered by increasing inverse variance weight. 
 
The overall effect size was also calculated using allelic, dominant and recessive models. All 
models retained significance for an association of the G allele with CRC risk, although the 
data are most consistent with a multiplicative model in which an increasing number of G 
alleles confers a constant increasing risk in a dose dependent manner: ORhet1=1.15 for the 
comparison of AA vs. AG and ORhet2=1.14 for the comparison of AG vs. GG. There was 
no evidence of a synergistic effect of two G alleles, ORhom for the comparison of AA vs.  
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GG being again virtually identical to the product of ORhet1 and ORhet2 (ORhet=1.32), 
ORhom=1.32 (95% CI 1.14-1.53, p=2.08e-04). 
Table 7­4  Meta­analysis with different models 
Model  OR (95% CI)  p-value  pQ 
Genotypic, fixed  1.15 (1.10-1.21)  5.04e-08  0.727 
Genotypic, random  1.15 (1.10-1.21)  5.04e-08  0.727 
Allelic  1.15 (1.09-1.21)  5.64e-08  0.678 
Dominant  1.17 (1.10-1.24)  2.38e-07  0.521 
Recessive  1.25 (1.08-1.45)  2.00e-03  0.386 
Homozygous  1.32 (1.14-1.53)  2.08e-04  0.501 
 
Statistical heterogeneity was further assessed using Egger’s test (p=0.889) and visual 
inspection of a funnel plot (Figure 7-2). Neither revealed any evidence of statistical 
heterogeneity. To assess the impact of individual studies on the overall effect size, a leave 
one out analysis was performed. As expected the resulting OR was smallest if VQ58 , the 
study with the largest OR, was left out, but the result remained significant (OR=1.13, 
95% CI 1.07-1.20, p=1.19e-05). 
Figure 7­2  Funnel plot of association of rs6687758 with CRC risk 
 
Funnel plot of the recessive model with pseudo 95% CI represented by the dotted lines. There is no evidence 
of significant bias in the studies analysed. 
 
7.3  Functional considerations of rs6687758 
There are no known genes in the immediate vicinity, rs6687758 lies 250kb upstream of 
and telomeric to dual-specificity phosphatase 10 (DUSP10), a known negative regulator of  
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the MAPK superfamily. Further telomeric lie TATA binding protein associated factor 1A 
(TAF1A, 566kb), melanoma inhibitory activity 3 (MIA3, 625kb), axin interactor (AIDA, 
680kb), dispatched A (DISP1, 937kb), toll-like receptor 5 (TLR5, 1Mb), and tumour 
protein p53 binding protein 2 (TP53BP2, 1.7Mb).  
Figure 7­3  LD blocks around rs6687758 defined by VICTOR genotypes 
Long-range  LD  relationships  between  rs6687758  and  DUSP10  (chromosome  1,  position  219.95Mb  to 
222.23Mb). There is evidence of a weak LD block extending towards DUSP10, there is no evidence of an LD 
block extending telomeric towards TAF1A. 
 
To assess the potential for rs6687758 to have an impact on these genes, the region 
extending from DUSP10 to TP53BP2 was assessed using the genotypes for the VICTOR 
samples (Figure 7-3), likely to be more informative due to the higher number of probands 
than had been typed in HapMap. There is only a weak LD relationship within the region 
flanked by rs6687758 and DUSP10, but not extending telomeric towards TAF1A, AIDA, 
TLR5, and TP53BP2.  
Further analysis of the immediate vicinity of rs6687758 revealed three ESTs within 60kb: 
BE568587 from a carcinoma cell line, AI732358 from colon tissue, and BX119652 from 
MSI+ve colon cancer. The linkage relationship of this area was plotted for HapMap 
SNPs (chromosome 1, position 219.5Mb to 222.1Mb). Due to the higher number of SNPs 
typed, this gives a higher resolution (Figure 7-4). The LD block in which rs6687758 lies 
covers both BE568587 and BX119652. There are no polyA tracts recorded in the UCSC 
genome browser for this region, although the NCBI UniGene site records a polyA signal 
for BX119652. The function of any these three ESTs remains unresolved.   
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Figure 7­4  LD blocks around rs6687758 defined by HapMap genotypes 
 
LD blocks defined by HapMap genotypes (chromosome 1, position 220.16Mb to 220.43Mb). rs6687758 lies 
in an LD block with BE568587 and BX119652, and to a lesser extend AI732358. 
 
There are no other described transcripts, e.g. miRNA or ORFs, or functional elements in 
the region, e.g. long-range enhancers or CpG islands. There is minimal conservation in 
vertebrates across the region.  
In an analogous analysis to that undertaken in Chapter 6 for published CRC risk loci, the 
impact of rs6687758 on DFS was assessed in the VICTOR data set. There was no 
evidence that rs6687758 influenced progression-free or overall survival in any of the 
genetic models (for DFS in genotypic model: HR=1.01, 95% CI 0.79-1.29, p=9.23e-01, 
see Figure 7-5), there was no association with stage (HR=0.98, 95% CI 0.79-1.22, 
p=8.79e-01) and micro-metastatic disease (HR=0.98, 95% CI 0.79-1.22, p=8.51e-01). 
7.4  Discussion 
The data presented here support rs6687758 as a further low-penetrance CRC 
susceptibility locus: the genotyping was robust, the effect size very similar in all cohorts 
with no statistical heterogeneity, and even when the study with the largest individual effect 
was omitted (VQ58), the resulting summary estimate remained very similar to the overall 
estimate (OR=1.13 vs. OR=1.15). The summary OR for all studies reached genome-wide 
significance with p=5.04e-08. 
The MAF was virtually identical in the cohorts of Western European descent 
(MAF=0.203), but significantly different in the Finnish cohort (MAF=0.270), but the  
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resulting OR was the same in the Finnish cohort as it was in all but one of the European 
cohorts. Leaving the Finnish cohort out of the summary estimate did not change the 
overall OR and 95% CI appreciably. Rather than weaken the evidence, the different 
MAF in the Finnish samples is therefore suggestive of a real effect of rs6687758 on CRC 
risk, as even with a different allele distribution, the resulting OR is the same as in the 
Western European cohorts. 
Figure 7­5  Kaplan­Meier curves for rs6687758 
 
Kaplan-Meier curves for the three genotypes: AA – blue long dash, AG – red solid line, GG – green short 
dash. There is no difference between the survival curves (p=0.923).  
 
rs6687758 had not been further evaluated in the initial meta-analysis of the four cohorts 
(Corgi, Phase 2, Scotland Phase 1 and Phase 2) of the GWAS for CRC susceptibility as 
the combined threshold did not reach the pre-specified level (p<1e-05)46. The power of 
that study to detect major common loci conferring quite large risks (1.2 or greater as was 
the case for rs6983267) was high and it is unlikely hat there are many additional CRC 
susceptibility SNPs with similar effects for alleles with frequencies >0.2 in populations of 
European ancestry. This underlines the efforts needed to detect low-penetrance variants 
that confer risks <1.2 and/or have MAF<0.2, as variants with these characteristics are 
likely to make up a large proportion of susceptibility loci for CRC, either because the 
effect sizes of the causal variant are truly that small, or the causal variant is being tagged 
inefficiently by the SNPs included in the arrays used for the initial screen. While the 
Illumina Hap550 arrays used in the London and Edinburgh Phase 1 are designed to 
capture the majority of common SNPs with MAF of >0.2 in European populations with  
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r2>0.80, only around 10% of SNPs with MAF=0.05-0.1 are tagged at r2>0.80, thus 
limiting the ability to detect this type of susceptibility SNP46. It is therefore plausible that 
there are many other loci with similar genetic characteristics to rs6687758 that remain to 
be discovered. 
It is likely that other classes of genetic variation exist that can confer an increased CRC 
risk, a view supported by the continued excess of associations observed over those 
expected, but for which current strategies for GWAS are not ideally suited46. For 
susceptibility loci with lower MAF but higher penetrance, e.g. MAF=0.01 and a 
genotypic relative risk of 5 giving a relevant population attributable risk, tagging SNPs on 
currently available arrays are not well paced to detect an association (see also Chapter 8). 
In addition, the content of earlier generations of SNP array did not capture CNV well, 
and these may also affect CRC risk, but more recent arrays have started to address this 
issue by including dedicated CNV content, SNPs, and other markers, that are located in 
regions of known CNV. Whether the data generated from such loci is of sufficient quality 
to analyse CNV in a manner analogous to SNPs remains to be determined345. 
Expanding the scale of GWAS by including more SNPs in the initial screen, analysing 
CNV content, increasing sample size and the number of SNPs taken into the replication 
phase, with all the costs that this would involve, will likely identify additional susceptibility 
loci for CRC. In parallel with further expansion of GWAS, however, functional studies of 
the identified loci are important, as many do not offer an immediate explanation for their 
association with CRC risk42, and even for rs6983267 located in a general cancer 
susceptibility region on chromosome 8q24, the functional correlate or causal variant has 
not been identified, despite the evidence pointing towards MYC (see section 6.3). Similar 
uncertainties remain for rs6687758, as no elements of any obvious functional relevance 
have been found in its vicinity, and while several ESTs are found relatively close by 
(60Kb), it is not clear whether they represent actual genes and what their function might 
be. DUSP10 would make a good candidate but does not lie within an LD block with 
rs6687758, and would therefore require rs6687758 to tag an interference with long-range 
enhancers or chromatin folding as mechanisms for altering gene expression.   
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8 Tagging SNPs tag potential cancer loci 
There are two approaches to selecting content for the current SNP typing platforms: one 
is to select SNPs in a quasi random fashion, with an emphasis on regions of interest (e.g. 
Affymetrix346), or to choose SNPs based on their relationship to each other, i.e. tagging 
SNPs (e.g. Illumina). The latter approach improves the number of SNPs in LD at r2>0.8 
for any given SNP typed on the array from 69% on the Affymetrix Mapping 500K Array 
Set346 to around 89% on the Illumina Hap500 arrays in Caucasian populations347. The 
LD relationships are based on the analysis of SNPs typed for the HapMap project, which 
aims to describe common variants (SNPs with MAF>0.05) throughout the genome, and 
estimates “to capture untyped common variation with an average maximum r2 of between 0.9 and 0.96 
depending on population.”348. 
Given that the SNP selection for Illumina arrays was performed using HapMap SNPs, 
genetic variation not captured by HapMap may be covered less well348. This includes 
non-HapMap SNPs, insertion/deletion changes and polymorphic repeats. To test 
whether such changes are tagged efficiently, loci with some prior rationale for being 
associated with CRC were typed in subsets of Corgi 2. The rationale for each is briefly 
described in the section on each marker.  
The markers in this chapter on the whole are not SNPs; they therefore do not conform to 
the Illumina naming convention and all loci are represented as major and minor allele. 
8.1  Screen for CRC risk in plausible candidates 
This section details the outcome of the risk screen performed prior to assessing the LD 
relationship between these loci and SNPs present on the Illumina Hap500 arrays, typed 
in the Corgi 2 cohort as part of the GWAS for CRC susceptibility.  
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8.1.1  TGFβR1*6A 
The TGF-β receptor 1 (TGFβR1) on chromosome 9 contains a polymorphic nine alanine 
stretch (*9A), and alleles containing 5, 6, 8, 10, 11, and 12 alanine residues (*5A, *6A, 
*8A, *10A, *11A, *12A) have also been described349. Of the variant alleles, *6A 
(rs11466445 ) is the most common, with up to 22.7% of probands carrying at least one 
allele350, with a MAF between 5.0%-11.7% in published series350,351. *6A has previously 
been described as a cancer susceptibility allele for CRC, based on a meta-analysis of four 
datasets352, although the statistical analysis was not prepared in accordance with generally 




GeneScan trace for the TGFβR1*9A and *6A alleles. Homozygote 9A/9A (top) with a product size of 237bp, 
heterozygote 9A/6A (middle), and homozygote 6A/6A with a product size of 231bp (bottom). 
 
In an updated analysis of the original report, the same group, adding another two datasets 
to a total of 1585 CRC patients, again found an association with CRC354 although these 
results have not been replicated by others355.  
In order to test the association of TGFβR1*6A with CRC, the samples of the Corgi cohort 
were genotyped for TGFβR1 alleles using GeneScan (Figure 8-1). The conditions for the 
PCR reaction and primers are given in Table 10-15.The genotypes were in HWE for 
overall, case and control cohorts, and are given in Table 8-1. There was no evidence for 
an association with CRC risk associated with carrying *6A (OR=1.04, 95% CI 0.83-1.31, 
p=7.06e-01). 
Table 8­1  Genotypes for potential cancer variants 
    Cases      Controls   
Marker  MM  Mm  mm  MM  Mm  mm 
TGFβR1  673  145  10  746  159  8 
APC E1317Q  816  14  0  905  16  0 
rs28931588  155  0  0  162  0  0 
rs28931589  155  0  0  162  0  0 
M is the major allele, m the minor allele; for TGFβR1 M=*9A, for APC E1317Q M=G.  
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8.1.2  APC E1317Q 
Germline mutations in APC on chromosome 5 play a major role in inherited CRC. APC 
E1317Q (rs1801166) is a non-truncating mutation near the mutational hotspot at 1307, 
resulting in a substitution of the normal glutamate for a glutamine residue. This germline 
mutation has been associated with an increased risk in white Caucasian populations of 
CRC356 and colorectal adenomata357, a finding not replicated by others358. To test the 
possible association of APC E1317Q with CRC, the samples of the Corgi cohort were 
typed using the LightScanner methodology (Figure 8-2). The conditions for the PCR 
reaction and primers are given in Table 10-15. 
Figure 8­2  LightScanner output for APC E1317Q alleles 
 
Left panel shows distribution of samples in 96-well plate. Grey squares are APC wildtype; blue squares, 
positive controls (APC E1317Q carriers); red squares, carriers detected in the Corgi 2 cohort. Purple squares 
are blanks, and green squares, failed samples. The latter two categories are excluded from the curves shown 
in  the  right  panel  plotting  changes  in  fluorescence  in  response  to  temperature  changes  during  the 
LightScanner analysis. Colours are the same as in the left panel, and the difference between wildtype and 
carriers is evident. 
 
The genotypes were in HWE for overall, case and control cohorts, and are given in Table 
8-1. There was no evidence for an association with CRC risk associated with carrying the 
minor allele (OR=0.97, 95% CI 0.47-2.00, p=9.35e-01). 
8.1.3  Insertion‐deletion polymorphisms 
The May 2004 assembly of the UCSC Genome browser was screened for non-
synonymous insertion-deletion polymorphisms of known genes. Thirty-eight 
polymorphisms were selected based on known MAF >0.05, putative gene involvement in 
a cancer relevant function, and location of the polymorphisms within the middle 80% of 
the gene in an attempt to enrich for functionally relevant polymorphisms. All were 
screened in 192 cases and 192 controls of the Corgi 2 cohort using GeneScan (Figure 8-3). 
This design allowed for >80% power if the allele frequency was 5% in controls and 14% 
in cases, or 10% in controls and 21% in cases. Furthermore, if three or less alleles were  
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detected, there would be a >95% chance that even the complete Corgi set would not 
have sufficient power to detect an association and the polymorphism in question could be 
discarded from any future investigation for association with CRC risk. 
The primers and conditions are given in Table 10-16.  
Figure 8­3  GeneScan for insertion­deletion alleles 
 
GeneScan trace for heterozygotes for rs17879749, rs11509437, and rs11283943 showing the difference of 
PCR product of 1bp, 3bp, and 14bp, respectively. The scale to the right of each lane is in arbitrary units 
determined by the analysis software. 
 
Two polymorphisms failed genotyping: rs11478027 in TRPC4-associated protein and 
rs10667315 in the CD40 antigen. The remaining polymorphisms performed well on 
genotyping, with a median call rate of 97.5% (range 93.8%-99.7%). All but one 
polymorphism (rs5790928) were in HWE in the overall and control groups. In only 14 
polymorphisms could the minor allele be detected, the remainder were monomorphic in 
both cases and controls. None of the 14 polymorphic variants was associated with an 
increased risk of CRC at the p<0.05 level, and only one polymorphism (rs11509437) 
located in glutathione-S-transferase omega 1 came close to statistical significance 
(OR=2.37, 95% CI 0.89-6.31, p=8.40e-02). The genotypes, associated genes and OR are 
given in Table 8-2. 
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Table 8­2  Genotypes, associated genes and statistical significance of insertion­deletion polymorphisms 
          Controls  Cases     
SNP  Chr  Position  Gene  Alleles  AA  AB  BB  AA  AB  BB  OR (95% CI)  p-value 
rs10697058  17  3753242  Purinergic receptor P2X1  -/TTTTTTTT  180  0  0  170  0  0     
rs11283943  5  112434687  Mutated in colorectal cancers  -/CGCGCTGT 
CTTCCT 
83  73  21  85  69  19  1.08 (0.78-1.48)  6.57e-01 
rs11350445  22  39883245  E1A binding protein p300  T/-  177  0  0  173  0  0     
rs11364237  2  112324604  Anaphase promoting complex subunit 1  T/-  177  0  0  172  0  0     
rs11376162  11  65129818  MAP kinase kinase kinase  -/G  179  0  0  165  0  0     
rs11424286  18  59477610  Serine proteinase inhibitor  -/T  175  1  0  173  0  0  2.96 (0.12-72.85)  5.07e-01 
rs11476163  20  31728743  E2F transcription factor 1  G/-  169  0  0  173  0  0     
rs11477710  20  18419125  Retinoblastoma binding protein 9  T/-  163  0  0  172  0  0     
rs11509437  10  106012825  Glutathione-S-transferase omega 1  AGG/-  148  13  0  166  6  0  2.37 (0.89-6.31)  8.40e-02 
rs11564598  19  53272844  Phospholipase A2, group IVC  C/-  169  10  0  159  5  0  1.86 (0.63-5.49)  2.63e-01 
rs11564619  19  53262887  Phospholipase A2, group IVC  G/-  178  0  0  165  0  0     
rs140596  15  46563377  Fibrillin 1  A/-  175  2  0  174  0  0  4.94 (0.24-103.3)  3.03e-01 
rs17001464  19  11549959  Acid phosphatase 5  G/-  162  0  0  172  0  0     
rs17879749  11  102172656  Matrix metalloproteinase 1  T/-  163  3  0  169  6  0  0.52 (0.13-2.11)  3.62e-01 
rs2066730  1  183647677  Phospholipase A2, group IVA  T/-  177  0  0  172  0  0     
rs3069752  7  99601783  Paired Ig-like type 2 receptor beta  GGA/-  108  51  10  122  47  5  1.36 (0.92-2.00)  1.21e-01 
rs3092768  20  39474243  Chromodomain helicase DNA binding 
protein 6 
C/-  174  0  1  171  3  0  0.66 (0.11-3.98)  6.51e-01 
rs3212987  19  50604348  CD3E antigen  TTC/-  93  68  14  86  78  9  0.98 (0.71-1.37)  9.25e-01 
rs3214276  5  140753085  Protocadherin gamma subfamily A, 8   C/-  181  0  0  171  0  0     
rs3217458  19  1776929  Transcription elongation factor B   CTC/-  121  51  7  102  52  11  0.77 (0.53-1.11)  1.64e-01 
rs4067742  2  112330488  Anaphase promoting complex subunit 1  -/TTA  175  1  0  175  0  0  2.99 (0.12-73.68)  5.03e-01 
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Table 8­2  Genotypes, associated genes and statistical significance of insertion­deletion polymorphisms (cont’d) 
          Controls  Cases     
SNP  Chr  Position  Gene  Alleles  AA  AB  BB  AA  AB  BB  OR (95% CI)  p-value 
rs4987226  11  59383178  Transcobalamin I precursor  A/-  178  0  0  174  0  0     
rs5030651  3  10158713  von Hippel-Lindau tumour suppressor  C/-  163  0  0  171  1  0  0.35 (0.01-8.64)  5.22e-01 
rs5773188  1  27360299  Synaptotagmin-like 1  C/-  178  0  0  172  0  0     
rs5790928  11  33326090  Homeodomain interacting kinase 3  G/-  165  2  0  172  1  1  0.69 (0.12-4.17)  6.89e-01 
rs5803440  13  47984938  Regulator of chromosome condensation  T/-  181  0  0  171  0  0     
rs5814559  15  91287210  Chromodomain helicase DNA binding 
protein 2 
T/-  181  0  0  169  0  0     
rs5820291  17  34818392  PPAR binding protein  GTC/-  177  0  0  175  0  0     
rs5844947  22  30065477  zinc finger protein 278  C/-  175  0  0  173  0  0     
rs5848002  3  37489931  Integrin, alpha 9 precursor  C/-  177  0  0  166  0  0     
rs5848302  3  38019751  Villin-like protein  G/-  176  0  0  172  0  0     
rs5883925  7  44914210  Cell cycle progression 2 isoform 1  -/C  173  0  0  175  0  0     
rs5888463  7  151287527  Mixed-lineage leukaemia 3  C/-  176  0  0  175  0  0     
rs9332131  10  96699028  Cytochrome P450, family 2, subfamily C  A/-  168  0  0  174  0  0     
rs9332736  6  32010046  Complement component 2 precursor  GTGGACAGGGTCAG
GAATCAGGAGTCTG/- 
172  2  0  176  2  0  1.02 (0.14-7.30)  9.82e-01 
rs9333357  9  21218001  Interferon alpha 17  T/-  181  0  0  171  0  0     
Genotypes and associated data for 36 insertion-deletion polymorphisms. Two polymorphisms failed genotyping (rs11478027 and rs10667315); these are not included in the table.  
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8.1.4  beta‐catenin: rs28931588 and rs28931589 
Several somatic mutations in the degradation targeting box of the β-catenin gene on 
chromosome 3 are associated with childhood hepatoblastoma (hepatocellular carcinoma, 
HCC)359. Two of these have been described as SNPs in the germline: Asp32Tyr 
(rs28931588) and Gly34Val (rs28931589). While to date there is no evidence in the 
literature associating these polymorphisms with CRC, they are plausible candidates due 
to the importance of WNT signalling in the development of CRC. These two variants 
were 192 cases and 192 controls. The power considerations were the same as those 
described in section 8.1.3. The genotypes were determined by direct sequencing (Figure 
8-4) using the conditions given in Table 10-15, and the sequencing reaction performed 
with the reverse primer. 
Figure 8­4  Sequencing trace for rs28931588/9 alleles 
 
The arrows show the location of the two SNPs, rs28931588 and rs28931589, both are homozygous for the 
major allele G, read on the reverse strand as C. 
 
There were no minor alleles detected, with all genotypes being major allele homozygotes 
(Table 8-1). rs28931588 and rs28931589 are not associated with CRC based on this 
samples set. 
8.2  LD between variants screened and tagSNPs on Illumina Hap550 
The samples of the Corgi 2 cohort had been typed on Illumina Hap550 arrays as part of 
the GWAS for CRC risk, and the LD relationships between the polymorphisms typed in 
section 8.1 and the tagSNPs of these arrays were evaluated. For each polymorphisms, 
tagSNPs 100Kb either side were extracted, and the maximal r2 and D’ were determined 
using Haploview 4.1. 
As expected, it was only possible to generate r2 or D’ values for the non-monomorphic 
variants, monomorphic variants (rs28931588/9 and 22 insertion-deletion polymorphisms) 
did not have r2 and D’ values for any of the tagSNPs and thus they are not tagged by  
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SNPs on the Hap550 arrays (see Figure 8-3 for an example of the LD relationship in such 
a case). The remaining 16 polymorphic variants (TGFβR1*6A, APC E1317Q, and 14 
insertion-deletion polymorphisms) were tagged efficiently (r2≥0.80) only if the variant in 
question had MAF≥0.05. For variants with MAF<0.05, the maximum r2=0.12, while 
D’=1 for all but two polymorphism, for APC E1317Q, D’=0.914 and for rs5790928, 
D’=0.625 (Table 8-3). For the five variants with MAF>0.05 (TGFβR1, rs11283943, 
rs3069752, rs3212987, rs3217458), r2 ranged from 0.82 to 0.99, and D’ from 0.980 to 1. 
Of the insertion-deletion polymorphisms that are likely to be most deleterious to the 
resulting protein, i.e. those that do not change the base pair sequence by multiples of 
three, only one polymorphism was common (rs11283943, MAF=0.317), and only one 
further had a MAF>0.01 (rs17879749, MAF=0.013). The remaining common 
polymorphisms all inserted or deleted whole codons.  
Figure 8­5  LD block surrounding rs10697058 
 
rs10697058 (SNP 19) is monomorphic and not tagged by any of the SNPs on the Illumina Hap550 arrays. 
This plot is representative of other monomorphic SNPs. 
 
For variants with MAF<0.05, in the cases where there was a high D’, this gave a 
misleading picture about the ability to tag the polymorphism as the minor allele was not 
tagged well: for APC E1317Q, the major allele of its tagSNP, rs10515449, is associated 
with the proposed CRC risk allele in 6.4% of cases, while the major allele is associated 
with the APC wildtype allele in 93.6%. For the minor allele of rs10515449, it is associated 
with proposed risk allele in 0.1% and the wildtype allele in 99.9%. Neither allele of 
rs10515449 therefore gives a good estimate of the chance of the proband carrying APC 
E1317Q when only the former is typed. Conversely, for TGFβR1*6A with MAF=0.098,  
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the major allele of its tagSNP, rs7850895, captures the wildtype allele of TGFβR1 in 
98.5%, and TGFβR1*6A is captured by the minor allele of rs7850895 in 98.8%. 
Table 8­3  Tagging of insertion­deletion polymorphisms  
SNP  Δ  M  m  MAF  r
2  D'  tagSNP  MAF  MM  Mm  mM  mm 
rs10697058  8  700  0  0  0  0             
rs11283943  14  478  222  0.317  0.993  1  rs2227950  0.315  68.1  0.1  0  31.7 
rs11350445  1  700  0  0  0  0             
rs11364237  1  698  0  0  0  0             
rs11376162  1  688  0  0  0  0             
rs11424286  1  697  1  0.001  0.014  1  rs3853683  0.090  91.0  8.9  0  0.1 
rs11476163  1  684  0  0  0  0             
rs11477710  1  670  0  0  0  0             
rs11509437  3  647  19  0.029  0.054  1  rs156697  0.355  64.9  32.3  0  2.9 
rs11564598  1  671  15  0.022  0.066  1  rs1019786  0.254  74.6  23.2  0  2.2 
rs11564619  1  686  0  0  0  0             
rs140596  1  700  2  0.003  0.001  1  rs9806163  0.234  76.1  23.6  0.3  0 
rs17001464  1  668  0  0  0  0             
rs17879749  1  673  9  0.013  0.012  1  rs1010698  0.476  51.5  47.2  1.3  0 
rs2066730  1  698  0  0  0  0             
rs3069752  3  558  128  0.187  0.990  1  rs6955367  0.192  81.1  0.1  0  18.7 
rs3092768  1  693  5  0.007  0.007  1  rs4142393  0.490  49.7  49.6  0.7  0.0 
rs3212987  3  504  192  0.276  0.874  1  rs3212986  0.298  69.7  2.6  0.1  27.5 
rs3214276  1  704  0  0  0  0             
rs3217458  3  549  139  0.202  0.982  1  rs3746037  0.202  79.5  0.3  0  20.2 
rs4067742  3  701  1  0.001  0.003  1  rs9653414  0.325  67.1  32.8  0  0.1 
rs4987226  1  704  0  0  0  0             
rs5030651  1  669  1  0.001  0.012  1  rs1642739  0.111  88.8  11.1  0  0.1 
rs5773188  1  700  0  0  0  0             
rs5790928  1  677  5  0.007  0.008  0.63  rs3847595  0.271  72.6  26.7  0.2  0.5 
rs5803440  1  704  0  0  0  0             
rs5814559  1  700  0  0  0  0             
rs5820291  3  704  0  0  0  0             
rs5844947  1  696  0  0  0  0             
rs5848002  1  686  0  0  0  0             
rs5848302  1  696  0  0  0  0             
rs5883925  1  696  0  0  0  0             
rs5888463  1  702  0  0  0  0             
rs9332131  1  684  0  0  0  0             
rs9332736  28  700  4  0.006  0.120  1  rs4151672  0.045  95.4  4.0  0  0.6 
rs9333357  1  704  0  0  0  0             
TGFβR1*6A  9  3142  340  0.098  0.823  0.98  rs7850895  0.085  90.1  0.1  1.4  8.3 
APC E1317Q  0  3472  30  0.009  0.051  0.914  rs10515449  0.12  87.5  11.7  0.1  0.8 
rs28931588  0  634  0  0  0  0             
rs28931589  0  634  0  0  0  0             
Alleles M and m are for the overall cohort (cases and controls), tagSNPs denotes the SNP on the Hap550 
arrays with the highest r2 with the tested variants. Δ represents the number of bases inserted or deleted. The 
last four columns denote the haplotype frequencies, with the first letter being the allele given in columns 3 
and 4, and the second letter being the major (M) or minor (m) allele of the tagSNP. 
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8.3  Discussion 
The data presented in this chapter again underline the problems faced by a hypothesis 
driven marker search: unless the prior hypothesis is very compelling, verification is 
difficult. None of the markers analysed showed an association with CRC risk despite what 
at first glance appears to be a reasonable biological rationale. In over half the markers in  
the insertion/deletion screen, the minor allele was so uncommon that genotyping is 
unlikely to be worthwhile due to the large number of samples which would need to be 
typed to reach sufficient levels of power. It is conceivable that rs11509437 is associated 
with CRC, and will be typed in the whole Corgi set, with power of 80% to detect an 
association based on the observed allele frequencies. For two SNPs with a suggestion of an 
association (rs3069752 and rs3217458), the sample size analysed was too small to 
definitively exclude an association, but as they are well tagged by SNPs on the Illumina 
Hap500 array, r2=0.99 and r2=0.98, respectively, it is unlikely that typing either in the 
whole Corgi cohort would add to the knowledge derived from the analysis of the tagging 
SNPs. 
The data in this chapter do show that tagSNPs can tag any locus that shows variability, 
but that the tagging is only efficient if the variant is sufficiently common. Taking the 
reverse approach to a GWAS, in this chapter putative CRC susceptibility loci were 
screened in the samples of the Corgi cohort and, as none of the variants were on the 
Illumina Hap550, the tagging efficiency determined retrospectively. The majority of the 
variants analysed were insertion-deletion changes, and the implication for GWAS in 
CRC, or any other disease, is that they will be able to detect non-SNP based variation in 
just the same manner as they can detect SNP based variation, thereby including an 
important pool of potential susceptibility loci. The flip-side is that rare insertion-deletion 
changes also behave like SNPs with low MAF and are thus not efficiently tagged. 
Therefore they are unlikely to be detected by GWAS with current SNP typing arrays. 
The variants tested in this chapter were not designed to find the lowest MAF for which 
tagging was efficient, but it appears that below about MAF=0.1, tagging as measured by 
r2 will become inefficient using current SNP arrays. It may be that if the cut-off MAF for 
SNPs included on the high-density arrays were less than the current MAF≥0.05 (for the 
Illumina arrays used here), those rare, non-monomorphic variants could achieve higher 
tagging efficiency. 
It is also clear that D’ is not the appropriate measure to determine tagging efficiency of 
rare variants, as the nature of the D’ measure yields a high value when the rare allele of a 
putative locus is almost invariably associated with one of the alleles of a nearby tagSNP, 
but that the reverse is not true, that the allele in question of the tagSNP does not reliably  
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inform about the status of the rare variant. If for the putative, rare variant the MAF is 
low, say MAF=0.01, and that for SNPs included on current arrays MAF≥0.05, even if the 
minor allele of the rare variant is always associated with the minor allele of the tagSNP, 
the reverse would be true in at most 20% of cases. Therefore, r2 should be used as the 
measure of tagging efficiency for rare variants, and as the interest is in determining 
exactly the genotype at untyped loci even if the MAF is higher, r2 should be the measure 
of choice for tagging efficiency for all loci. 
Consequently, in order to capture rare variants, some degree of fine-mapping will be 
required. This could be performed subsequent to screening using ‘conventional’ SNP 
arrays, but it appears unlikely that a region harbouring a relatively highly penetrant but 
rare variant would be detected in the first instance360. It is possible that lower level 
significance across a region harbouring a rare variant could be detected, but at a lower 
level of significance, the noise-to-signal ratio would be high due to multiple testing 
producing falsely positive associations, which could also span across a region with high 
LD between the common variants typed. On the assumption that algorithms could be 
devised that would allow to gain some higher degree of certainty, it would still be likely 
that many regions showing such a weak association would need to be taken into the 
verification phase. This would have considerable resource implications, financially, 
manpower, and availability of DNA. As part of the work presented in this chapter, no 
attempt was made to determine the level of significance that might be expected across a 
region harbouring a true causal, rare variant, nor to devise any algorithms that might 
distinguish true low-level significance from false-positive findings.  
Another approach would be to ‘fine-map’ using higher density SNP arrays, consisting not 
only of SNPs with MAF>0.05, as is the case for most of the non-CNV content of 
commercial arrays at present, but also SNPs with MAF≥0.01 or even less. Achieving 
sufficient density for such SNPs is likely to present considerable challenges, as 
determination of MAF in that order of magnitude requires the typing of hundreds to 
thousands of normal controls to reliably determine the allele frequencies, many more 
probands than have been typed as part of the HapMap project348, the current selection 
basis for SNP arrays. Recognising the gap in the knowledge of genetic variation, those 
that lie between the very rare but highly penetrant loci, captured by traditional linkage 
analysis of affected families, and the common variant with low penetrance, captured by 
current SNP arrays, the 1000 genomes project was launched in 2008. It aims to generate 
very dense maps of human variation across many genetic backgrounds361 to enable rare 
variants occupying the ‘middle ground’ to be examined for associations with disease. The 
implication is that the GWAS performed to date will have to be repeated, with new,  
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higher density arrays, more participants to generate the prerequisite power, and the 
attendant cost of performing such a study.  
Despite the challenges facing the unbiased search for susceptibility loci for CRC, or any 
other complex trait, it still holds the greater promise for discovery of novel loci, and the 
hypothesis generation necessary for furthering understanding of the molecular biology of 
the cell, than some strands of current hypothesis driven research. None of the loci 
investigated in this chapter, irrespective of the strength of the prior hypothesis were shown 
to be associated with CRC risk, despite leveraging a large cohort of cases with a strong 
familial CRC background and hypernormal controls, underlining again the importance of 
verification of an initial hypothesis, a premise true for both hypothesis driven and 
unbiased marker discovery.   









The initial premise of this thesis was that the germline might be the driving factor for 
CRC risk, even if not all predisposing loci are discovered, and subsequently prognosis, in 
an as yet unquantified measure. Prognosis could be driven by factors that alter the 
likelihood of metastasis at an early time point, rendering surgery a non-curative 
intervention and increasing the role of adjuvant therapy, which may not be given because 
of the otherwise good prognostic pathological stage; or those factors that confer a growth 
advantage in the setting of hypoxia, chemotherapy, or to the host response of surrounding 
tissue. In the absence of any validated hypothesis of how the germline might influence 
prognosis, an unbiased, high-throughput screen of germline markers was adopted to try to 
address this question. 
GWAS for prognosis are feasible, but the statistical analysis is crucial 
The data presented in this thesis show that there is no intrinsic reason why GWAS aimed 
at teasing apart a complex genetic trait cannot be applied to outcome. Many of the 
necessary components are available to perform such a GWAS: large patient series with 
good quality follow-up and germline DNA, reliable, high-density SNP typing platforms, 
the statistical tools to analyse the data, and roadmaps to execute this GWAS successfully. 
A large cohort of patients with stage 2 and 3 CRC with follow-up data to clinical trial 
standard was identified, good quality DNA had been extracted, and this was analysed 
with excellent results on Illumina Hap300 or Hap370 BeadChips. Following the statistical 
analysis, the top candidate SNPs were typed in further verification cohorts, and the 
cohorts meta-analysed for patients with all stages of CRC and restricted to stage 2 and 3 
patients. The most consistently significant SNP across these analyses was rs7556894, 
although it did not reach formal genome-wide statistical significance. For most SNPs 
analysed, restricting the analysis to patients with stage 2 and 3 disease, and for the top 
significant SNPs, adjusting for stage, increased the significance levels. Again, genome- 
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wide statistical significance was not reached. In an analysis to estimate the potential effect 
sizes of SNPs associated with prognosis, the estimates of the ES for the screening cohort 
were regressed to the mean, and it would appear that some SNPs could have HR≥1.5, an 
effect that, if proven, would have a major clinical impact. Based on that analysis, adjusted 
for stage, again rs7556894 was the most significant SNP, and on the assumption that ES 
and significance levels are already adjusted and correction is therefore only required for 
the multiple testing of the 39 SNPs included in verification, would have reached formal 
significance at a Bonferroni corrected p<0.05 (p=7.25e-04). 
To date, the statistical tools had been applied only to the detection of genetic risk of a 
wide variety of malignant disease, e.g. colorectal42,43, prostate38, breast39, ovarian362, skin 
cancer363, lymphoma364, childhood ALL365, melanoma366, glioma367; non-malignant 
disease, e.g. cardiovascular disease40,368, type 1 and 2 diabetes41,369, multiple sclerosis370; 
and also for normal physiological variation such as age at menarche and menopause263 or 
height264. In the larger studies, the risk replicated not only in the verification analyses by 
the same group, but also across different groups attempting to define novel risk loci at the 
same time. The most notable example of this regarding the susceptibility to CRC is 
rs6983267 on chromosome 8q24, which was published independently by two groups at 
the same time44,299. For some studies, one of the criticism is that the number of cases in the 
discovery phase was small, decreasing the power for detection364,365. For susceptibility, 
however, it is relatively easy to ascertain controls, and to a certain extent cases, as this is 
done on a snapshot-in-time basis, and power can thus be increased. For the GWAS 
presented here, and any GWAS for prognosis, this ascertainment is much more difficult, 
as all ‘controls’ still need to have the disease in question, but without relapse, and that 
both relapsed and non-relapsed patients need to have been followed up for at least three 
years, depending on the stage of disease investigated. This restricts the ability to conduct a 
GWAS for prognosis, and is generally cited, together with the relatively low event rate in 
the adjuvant setting, as the reason why none have yet entered the public domain.  
A further draw-back of GWAS for prognosis is that in order to capture all survival 
information, a time-to-event analysis should be performed, unless the event rate is low, 
when tests of proportion such as the χ2 or Fisher’s exact test give very similar estimates of 
significance to a time-to-event test303. In the discovery phase, the logrank test did not 
perform optimally in the recessive model due to its asymptotic nature and the poor 
estimate of the true effect in a small number of cases302, and an over-representation of this 
genetic model among the SNPs taken forward from the discovery phase. This problem is 
not encountered in the GWAS of disease susceptibility as, generally, allele based tests 
(allelic odds ratios or the Cochran-Armitage test) are used. These tests also have their 
critics because, compared to using patients and genotype categories, there will be a  
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doubling of the numbers in each category (of alleles)371, but appear to have been robust in 
the determination of many replicated susceptibility loci44,52,299,372. Ultimately, the 
approach is valid provided the locus in question is in HWE, and with allele counts, the 
more robust tests of proportionality can be used and the problem of small numbers in a 
category does not arise. 
Therefore, the choice of survival analysis is critical for the success of a GWAS for 
prognosis. One such approach is presented in Chapter 5, where the data were analysed 
by genotype - analysis by allele does not allow time-to-event data capture - without 
further genetic models to avoid the over-representation of recessive model SNPs in the 
final analysis. The survival analysis was adjusted for stage, age and sex to avoid detecting 
SNPs that might be associated with stage rather than prognosis per se, and because the 
most significant SNP in the previous analysis had become more significant in multivariate 
analysis including stage. In addition, the discovery phase was extended to two cohorts 
with subsequent meta-analysis of all SNPs to increase power.  
Many cohorts of sufficient size do not report DFS, but may have disease-specific overall 
survival, which is tightly correlated with DFS (r2=0.90) in clinical trials evaluating 
interventions315. It is therefore reasonable to meta-analyse the two cohorts using a fixed 
effects model, provided that the statistical heterogeneity is not I2>50%. In that case, it is 
likely that despite a marked effect in one cohort, the failure to replicate with a similar HR, 
i.e. without statistical heterogeneity, is suggestive of a spurious finding and these SNPs 
should not be taken forward into further verification. 
Prognostic GWAS identify loci that largely fall into plausible functional categories 
Despite the drawbacks of the GWAS outlined above, the top SNP identified appears 
promising. It almost reaches genome-wide statistical significance, is most significant in the 
analysis restricted to stage 2 and 3 CRC as would be expected having performed 
screening in that setting, and falls into a functional category that would be a plausible 
candidate for a prognostic marker. In trying to determine a realistic effect size conferred 
by this SNP, the Victor data was shrunk310, but this also decreased the statistical 
significance. Using the shrunk values in stage 2 and 3 CRC, the ES for rs7556894 was 
HR=1.52, 95% CI 1.17-1.96, p=1.60e-03, increasing in significance to HR=1.56, 95% 
CI 1.21-2.03, p=7.25e-04 if this analysis was stage adjusted in multivariate analysis. It is 
likely that the effect size, due to the drawback of the time-to-event analysis with small 
numbers in the minor homozygote group, is more in keeping with that derived from the 
meta-analysis using the VICTOR data in its stage adjusted, shrunk form. 
For the SNPs most consistently at the top of the list in terms of significance levels 
(rs7556894, rs672757, rs764372, rs4649314, rs472660), the function of the genes  
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associated with these loci appears largely plausible. rs7556894 is located on the short arm 
chromosome 2 at 2p14, 15Kb downstream from Actin-related protein 2 (ARP2), lying 
within an LD block covering the 3’ end of the gene. ARP2 is a 339 amino acid protein 
and a member of the ARP2/3 complex involved in branching actin filaments. These are 
essential for cell shape and motility307. The ARP2/3 complex is increasingly expressed in 
CRC progression, both by tumour and stromal cells, and may thus provide a suitable 
environment for tumour invasion and metastasis373. Further, cancer cells require ARP2/3 
to form actin-rich membrane protrusions (invadopodia) for the process of invasion312. 
Other elements required for the formation of invadopodia are cofilin and LIM kinase290. 
rs5997921 identified in the discovery phase, lies within LIM-kinase 2 on chromosome 22, 
and although this SNP did not replicate, it is attractive to speculate that germline 
variation affecting genes within the invadopodia pathway may be related to prognosis. 
rs4649314 is located on the long arm of chromosome 1 at 1q42.2, 50Kb downstream of 
mixed lineage kinase 4 (MLK4), a mitogen-activated protein kinase kinase kinase 
(MAP3K). MLK4 activates the JUN N-terminal kinase (JNK) and p38 mitogen activated 
protein kinase (MAPK) pathways304 and these pathways are involved in a wide variety of 
cellular functions (e.g. proliferation, apoptosis, migration305) and alterations in the MAPK 
pathway have been implicated in colorectal carcinogenesis306. There is no evidence 
linking MLK4 to CRC tumorigenesis, but further suggestive data for an involvement of 
the MAPK pathway in CRC prognosis comes from the gene 25kb telomeric of rs7556894, 
sprouty-related protein with EVH-1 domain 2 (SPRED2), which belongs to a family of 
proteins that regulate growth factor-induced activation of the MAP kinase cascade via 
their effect on the RAS/ERK pathway374. In addition, rs764372 lies in intron 5 of RAB31 
on chromosome 18p, a member of the Ras superfamily of small transforming GTPases 
what ultimately converge onto the MAPK pathway. Again, no evidence for a role of 
RAB31 in CRC exists, but over-expression of RAB31 has been associated with poorer 
prognosis in lymph node negative breast cancer375. 
rs472660 is located intronic in CYP3A43, a cytochrome P450 detoxification gene that 
would be an interesting candidate, although more plausible as a predictive marker. It did 
not reach p<1e-04 in the screen for predictive markers for 5-FU, likely because CYP genes 
do not play a major role in the metabolism of 5-FU. It could be that the SNP tags GJE1 
(gap junction protein epsilon 1), another candidate from the cell adhesion functional 
family, tying it into the same functional category as rs7556894. The SNP for which there 
is no obvious potential link to prognosis is rs672757 in intron 2 of KCND3, a K+- voltage-
gated channel on chromosome 1. While there has been no link to cancer, KCND3 is 
associated with small G-protein Rap signalling in response to angiotensin 1 (ref 376); like 
rs472660, it would be a better candidate as a predicative marker.  
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The concept of prognosis being linked to early metastatic potential, and thus the promise 
to be able to better predict who will have micrometastatic disease and offer adjuvant 
chemotherapy is attractive. It would also be relevant in stage 3 CRC, where patients have 
pathologically proven lymphnode metastasis, yet a large minority appear cured with 
surgery alone. In this setting, it would not be the offer of adjuvant chemotherapy that 
changed, but rather the type of regimen, length of treatment, and follow-up procedures to 
manage a potential relapse early, although in the absence of good prognostic markers 
beyond pathological stage, none of these avenues have been developed or shown to be 
more effective compared to the current standard of care.  
Another strand of suggestive evidence for the concept of a genetic locus being associated 
with early metastases that may not have been detected pathologically, comes from the 
findings presented in Chapter 6, where rs6983267 appears to be associated with micro-
metastasis and an at least borderline significant association with survival.  
A functional category not represented in the top 40 SNPs from the discovery phase was 
SNPs that reside in or are close to genes known to be involved in the metabolism of 5-FU, 
the most obvious functional area where germline variation might play a role, and the only 
area where there is at least a weak body of evidence suggesting an association with 
prognosis206,211,222. This is to be expected because the discovery phase did not take into 
account the administration of adjuvant chemotherapy, and this information was only 
available for one of the verification cohort, PETACC , in which all patients received 5-
FU, but genotype data, compared to VICTOR, was very restricted. Therefore, no formal 
verification of pharmacogenetic markers was undertaken, which might have yielded 
predictive, rather than prognostic, markers. The two SNPs for which there was data 
available from both cohorts did not reach genome-wide significance, and the restriction to 
patient who had received adjuvant chemotherapy also does not guarantee that the marker 
is predictive as such an analysis could also yield prognostic markers. Despite this, there is 
potential to perform such an analysis in patients who had received adjuvant 
chemotherapy. For example, the SNP from the discovery phase that is most plausible to 
carry predictive information, rs472660 in CYP3A43, also had a large effect going in the 
same direction in VICTOR and PETACC when restricted to patients who had received 
adjuvant chemotherapy, reaching significance at the p<0.05 level in the latter cohort 
(Table 4-2). The meta-analysis of just those two cohorts gave a p-value that almost 
reached genome-wide significance levels (p=6.04e-07, data not shown). This raises the 
possibility that the causative locus tagged by the minor allele of rs472660 may be a novel 
determinant of the usefulness of 5-FU in the adjuvant setting.  
  
  158 
Further risk markers are being discovered, with diminishing rates of return 
Following the initial successes in the detection of CRC susceptibility loci using unbiased, 
high-throughput GWAS, the discovery rate is diminishing, with larger and larger patient 
cohorts being required to detect an association. rs6687758, evaluated in Chapter 7, 
represents such a locus, reaching genome-wide significance at p=5.04e-08. In fact, 
rs6687758 had not been further evaluated in the initial meta-analysis of the four cohorts, 
which had been powered to detect common loci conferring quite large risks, generally 
larger that found for rs6687758 (OR=1.15). It is unlikely that there are many further 
CRC susceptibility SNPs with OR≥1.2 and minor alleles with frequencies >0.2 in 
populations of European ancestry. This underlines the efforts needed to detect low-
penetrance variants that have OR<1.2 and/or have MAF<0.2, as variants with these 
characteristics are likely to make up a further proportion of susceptibility loci for CRC. 
This implies expanding the scale of GWAS by including more SNPs in the initial screen, 
increasing sample size and the number of SNPs taken into the replication phase, with all 
the costs that this would involve. With the diminishing returns of the current strategy377, 
however, other sources of genomic variation will need to be considered, and in particular 
CNV378. There is now an increasing appreciation of the extent of CNV throughout the 
genome379-383, but the application of GWAS techniques to CNV has been limited so far. 
This has been driven by the poor coverage of CNV regions in earlier arrays384, and the 
signal-to-noise ratio for CNV inferred from intensity data at each analysed locus, which 
can be as low as 1.2 for some arrays385. Both are now being addressed by the major SNP 
array manufacturers345, as advances in SNP typing technology and CNV calling 
algorithms386 also improve the signal-to-noise ratio, and the first studies of genome-wide 
CNV analysis for cancer susceptibility have now been published387. 
The concern that GWAS might nonetheless ‘discover’ spurious associations remains, as 
not all described loci across the various diseases have an obvious functional consequence, 
or are even in or near a gene with a suggestive functional relevance. It is unlikely that all 
published susceptibility loci will have their functional consequences elucidated in the near 
future, but inroads are being made to address the lack of an immediate functional 
explanation of risk. rs6983267, located on chromosome 8q24, lies intergenic but nearest 
to POU5F1P1, a transcription factor of undetermined functional significance, and about 
337Kb from MYC, a target of WNT signalling. MYC acts downstream of activated β-
catenin in the WNT pathway, which jointly with TCF4 enhances MYC expression via the 
TCF4 binding site in the MYC promotor336. rs6983267 also lies in a T-cell factor (TCF) 
consensus binding sequence, and the two alleles show differential binding of TCF4337 and 
TCF7L2332, a further effector of WNT signalling388 and carrying itself a SNP associated 
with CRC risk389,390. This region physically interacts with the MYC promotor, although an  
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effect on MYC expression could not yet be established332,337. Fine mapping of the 8q24 
region did not reveal any further pathogenic variants, and it appears likely that rs6983267 
is indeed the causal variant391. 
SNP arrays can tag any genetic variation, but may not capture it well 
In the search for new determinants of complex traits, the concept of assessing the whole 
genome for genetic variation by only typing a relatively small number tagSNPs is very 
attractive as it reduces cost significantly. This approach has been proven useful by the 
many examples of GWAS mentioned above. The tagSNP itself can be the determining 
genetic alteration, as appears to be the case for rs6983267, but most tagSNPs are 
expected to be only markers for a causative variant. Therefore, it is important to 
understand the efficiency with which the tagSNP provides information about the 
variation within the tagged LD block. Every SNP typing platform contains SNPs that tag 
other loci, only the strategy for choosing the SNP content varies: for the first wave of SNP 
arrays, Illumina adopted an approach where the SNPs included in the array are those 
HapMap SNPs that performed best within a given LD block defined by D’, while other 
array providers focussed more on gene-centric SNPs.  
The premise of the Illumina BeadChips was that they were designed to capture the 
majority of common SNPs with MAF>0.2 in European populations with r2> 0.80. With 
the initial limitation of the number of SNPs included in the array, only around 10% of 
SNPs with MAF=0.05-0.1 are tagged at r2> 0.80, thus limiting the ability to tag this type 
of SNP360. Further, CNV was not tagged efficiently, because SNPs in CNV high regions 
do not perform well in the general measures of assay quality392, leading to bias against 
them in the selection of array content and subsequently poor coverage of CNV regions384. 
Lastly, it was not clear if insertion/deletion polymorphism would behave in the same 
fashion as ordinary SNPs, and what the tagging efficiency would be.  
Based on the data presented in Chapter 8, the insertion/deletion variants appear to 
behave like ordinary SNPs, but with minor allele frequencies well below the common 
variant ‘threshold’. Like other rare variants, they are insufficiently captured by current 
SNP arrays, but at least it appears that the question of tagging any particular locus is 
reduced to MAF frequency and copy-number, and the response to this the improved 
physical coverage of the genome, and its regions of interest, and the MAF of the tagSNP 
to efficiently tag CNV and rare variants, respectively. 
The biggest step forward has come from the inclusion of SNP or monomorphic probe 
content aimed specifically at CNV regions, and increasing the number included on the 
arrays to achieve greater physical coverage of the whole genome including CNV. With 
the data generated from these, CNV analyses become more robust, but still have the  
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caveat of an inferior signal-to-noise ratio compared to the genotyping performed at the 
same time. The higher density of SNPs, and inclusion of rarer SNPs begins to address the 
issues of rarer variants, but the knowledge of such rare variants remains limited due to the 
small number of individuals typed for the HapMap SNP database348, which at present 
forms the overwhelming basis for tagSNP selection. Inclusion of SNPs identified in the 
1000 Genomes project361 will help, but the tagging efficiency for SNP selection should not 
be based on D’ but rather on r2, as many rare variants already have D’=1, despite the 
inability to predict the minor allele reliably (see also section 8.3). 
It is therefore plausible that there are many other loci with similar genetic characteristics 
to rs6687758 that remain to be discovered, where the power of current GWAS is too 
small to detect other, similar loci. At the same time, the population attributable risk of 
such loci is likely to be small393. The future may therefore be the search for variants that 
are rare enough not to be captured by the common-variant GWAS, nor penetrant 
enough to cause familial clustering and be detected by traditional linkage analysis394. The 
number of loci to be discovered that way, however, could be small, and , for example in 
type 2 diabetes, on the assumption of MAF≤0.01 and OR=3, the remaining inherited risk 
could be accounted for by 30 loci393. Increasing SNP array density and improving our 
knowledge of rare variants will help this cause, but to have the power to detect such 
effects given the low MAF will drive up size, cost and effort. How such arrays would deal 
with rare CNV is not clear, and the possible effect of epigenetic risk factors would only be 
captured imperfectly as epigenetic changes can depend on underlying DNA sequence395, 
but may not always do so396. It is possible that next-generation sequencing (NGS), i.e. 
highly parallel, high-throughput sequencing397, may hold the key to these questions, 
although the statistical tools to take full advantage of the vast amount of data generated by 
NGS are still being developed398. 
The germline as the overarching paradigm? Yes and No 
The germline clearly carries the blueprint for many diseases, and regarding susceptibility 
to CRC, it clearly contributes to a large proportion of cases; loci driving this process have 
been and are being identified and evaluated. The common variant-common disease 
hypothesis has advanced our knowledge of CRC risk, without fully explaining the 
inherited proportion. Future GWAS will add to this knowledge, and if the lessons from 
earlier GWAS are learnt, particularly regarding rare variants, then a large part of familial 
CRC risk is likely to be explained. 
For prognosis, the jury remains out, and the data presented here do not preclude an effect 
without having been able to prove an association. Several of the promising candidates will 
be typed in further cohorts to derive a final assessment of these. Improving power and  
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statistical analysis will help, should the former approach ultimately fail, but again, like 
with GWAS for disease susceptibility, further verification to drive precision and power of 
the final estimate will be imperative. At present, the only genetic data for an effect on 
prognosis in CRC remains the association of resistance to anti-EGFR strategies with 
KRAS mutations. It is likely that somatic changes hold the majority of prognostic and 
predictive information, but it is conceivable that the somatic changes may be driven by 
germline variation. An example of the germline driving somatic changes would be 
HNPCC, but there is no clear data to suggest that HNPCC patients have the same, better 
prognosis that is conferred by sporadic MSI+ CRC188. It is also conceivable that the 
germline does not carry prognostic information with any clinical utility: several GWAS 
for disease susceptibility in haematological malignancies had a similar size and case-
control ratio to the work in this thesis, which covered 700 cases and 2146 controls with 
stage 2 and 3 CRC, yet these studies did identify novel disease susceptibility loci364,365,399. 
The work in this thesis is therefore likely to have excluded a very strong (HR≥2) effect of 
germline SNPs on prognosis. 
Further work is required before any germline locus can be thought of as being associated 
with prognosis or the response to therapy in CRC, and be incorporated into clinical 
decision-making algorithms. In addition to the work presented in Chapters 3, 4, and 5, an 
increasing understanding of tumour biology will lead to evaluation of more hypothesis 
driven markers, just as unbiased screening will generate more hypotheses to be tested. 
However, even for better validated markers, there is often little consensus about their 
value: the prognostic impact of the molecular phenotype has been known about for many 
years without driving prospective studies or influencing clinical decisions. It is clear that a 
much greater degree of cooperation is required between basic and clinical scientists to 
bring about trials with enough statistical power to provide results that will compel clinical 
engagement.  
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Table 10­1  URLs to resources used in this thesis 
Utility  Source 
CaTS  http://www.sph.umich.edu/csg/abecasis/cats/reference.html 
dbSNP  http://www.ncbi.nlm.nih.gov/SNP/ 
Eigensoft  http://genepath.med.harvard.edu/~reich/Software.htm 
Haploview  http://broad.mit.edu/mpg/haploview 
NCBI UniGene  http://www.ncbi.nlm.nih.gov/UniGene/ 
Primer3  http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
UCSC Genome Browser  http://genome.ucsc.edu/ 
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Chapter 3 
Table 10­2  Functional annotation of SNPs chosen only on p­value 
SNP  Description 
rs7556894  15Kb downstream from Actin-related protein 2 (ARP2), a member of the ARP2/3 
complex involved in branching actin filaments and essential in cell shape and 
motility
307. It lies within the LD block covering the gene based on D’, but not r
2. A 
little further away lie sprouty-related protein with EVH-1 domain 2, member of a 
family of proteins that regulate growth factor-induced activation of the MAP kinase 
cascade (25kb), and Ras-related protein Rab-1A (155kb). 
rs2589183  In intron 1 of syndecan-2 precursor, a transmembrane heparan sulfate proteoglycan, 
and may influence tumour behaviour through regulation of adhesion or proliferation 
in CRC
400. rs2589183 lies between the LD blocks of the exons either side, and there 
are no further suggestive SNPs in the region on Manhattan plot. 
rs764372  In intron 5 of RAB31 on chromosome 18p, a member of the Ras superfamily of small 
transforming GTPases. It lies at the heart of a weak LD block in intron 5. The over-
expression of RAB31 has been associated with poorer prognosis in lymph node 
negative breast cancer
375. 
rs672757  In intron 2 of KCND3, a K
+- voltage-gated channel on chromosome 1. While there 
has been no link to cancer, KCND3 is associated with small G-protein Rap signalling 
in response to angiotensin 1 (ref 
376). Other SNPs which are part of the same LD 
block were also weakly associated with prognosis in the discovery phase. 
rs7912136  128Kb upstream of protein kinase C, isoform θ on chromosome 10. Protein kinases 
have been implicated in many cellular processes, there is no specific evidence linking 
PKC, isoform θ to cancer. Of note, however, is that there are several SNPs with 
somewhat lower levels of significance located within protein kinase C, isoform θ, 
which are in long-range LD with rs7912136. 
rs6972789  350Kb downstream of stromal antigen 3-like 4 on chromosome 7 as part of an LD 
block extending towards but not reaching stromal antigen 3-like 4. The annotation of 
the UCSC genome browser suggests that stromal antigen 3-like 4 is down-regulated 
in CRC. Other SNPs within that LD block also show weak evidence for an 
association with outcome on the Manhattan plot. 
rs7007146  108Kb upstream of E3 ubiquitin protein ligase (also known as EDD) on chromosome 
8q22, a region gained in many breast cancer, where this has been linked to poorer 
prognosis. However, it appears that metadherin may be the causative gene
401, 
located 5Mb from rs7007146. Over-expression of EDD has been associated with 
worse-prognosis and resistance to cisplatin therapy in ovarian cancer
402. 
rs745888  Located just downstream of complement component 1-like (C1QL2) on 
chromosome 2. It is part of an LD block extending to the 5’ end of C1QL2, and part 
f a weak LD block extending to dudulin 2 (STEAP3). Dudulin 2 is differentially 
expressed in response to TP53 (ref 
403) and could be a regulator of apoptosis
404. 
Further, there is a SNP with weak evidence located downstream of dudulin 2. 
rs4978394  Located just upstream of protein tyrosine phosphatase N3 (PTPN3) on 
chromosome 9, part of a weak 200Kb LD block upstream of PTPN3. rs4978394, 
together with rs10816807 - itself associated with outcome at the 1e-04 level and 
included in the list of 109 SNPs under consideration for verification - flanks PTPN3 
either side. PTPN3 has been shown to be mutated in a subset of CRC
405. 
rs3784780  In intron 9 of Bloom’s helicase on chromosome 15. Bloom’s helicase is a DNA 
helicase with a probable role in DNA replication and double-strand break repair, 
and the gene underlying Bloom’s syndrome, an autosomal recessive disorder 
characterised by frequent chromosome breaks and a predisposition to many cancers. 
The SNP lies within the LD block covering most of the 5’ half of the gene, although 
there are no other suggestive SNPs in the region. Of note is that the strongest 
association with survival is in the genotypic model and it appears that the 
heterozygote carriers have the best prognosis, while homozygote AA carriers have 
the worst. The resulting p-trendgen=0.417.  
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Table 10­2  Functional annotation of SNPs chosen only on p­value (cont’d) 
SNP  Description 
rs10510044  130Kb downstream of the receptor for prolactin releasing hormone (PRLHR), a G-
coupled receptor largely found in the anterior pituitary. It is located in a large LD 
block, extending away from PRLHR, which also contains further SNPs with weak 
evidence for an association with survival. There is no evidence linking PRLHR to 
cancer. 
rs712082  In expressed sequence tag (EST BU947851) on chromosome 1, in a 35Kb block of 
high LD which includes two further SNPs associated with prognosis (rs698277 and 
rs712068) with virtually identical genotype distribution (and therefore not included in 
phase 2). rs712082 lies 80Kb upstream of cornichon homolog 3, a family of proteins 
involved in the transport, processing and secretion of TGFα, a known ligand of the 
epidermal growth factor receptor
406. 
rs11788150  250Kb downstream of nuclear factor I/B (NFIB) on chromosome 9, in a weak LD 
block extending almost to the 5’ end of NFIB. Nuclear factor IB has been described 
as a translocation partner in colonic lipomas
407, but while it has not been linked to 
adenocarcinoma, NFIB is down-regulated in colon cancer cells 
(http://symatlas.gnf.org/SymAtlas/). There is a further SNP in this LD block which 
reached the cut-off of 1e-04 and was included in the selection in section 3.6.2 as they 
are Only in moderate LD (r
2=0.52) even if D’ is higher (D’=0.92). 
rs10842099  Located within Homo sapiens cDNA FLJ37414 as a solitary ‘hit’, with no other genes 
in the vicinity. 
rs4715476  370Kb downstream of the tubulointerstitial nephritis antigen (TINAG), a novel 
basement membrane protein interacting with laminin and type IV collagen promoting 
cell adhesion
408. There is a weak LD block extending to the 5’ end of TINAG. There 
is a hypothetical gene 80Kb centromeric to rs4715476 (LOC222584), with a strong 
LD covering this locus and rs4715476. There is no evidence for any other SNPs in 
the region. 
rs1526884  Located on chromosome 19.12, among a cluster of zinc-finger proteins (ZNF). It lies 
between ZNF257 and ZNF676, downstream of both. There is high LD in this region, 
with the LD block in which rs1526884 lies extending towards and beyond ZNF257 
with D’=1.0. r
2 is much lower, and only with a cluster of SNPs immediately upstream 
of ZNF257 (rs431346 to rs408312) is it relatively high at r
2=0.51. A further LD block, 
of which rs1526884 is not part, extends towards ZNF676, but rs1526884 has high r
2 
with a SNP immediately downstream of ZNF676 (r
2=0.87), and high D’ with the 
whole gene. 
rs4649314  50Kb downstream of mixed lineage kinase 4 (MLK4), a mitogen-activated protein 
kinase kinase kinase (MAP3K) on chromosome 1, and known activator of the JUN 
N-terminal kinase (JNK) and p38 mitogen activated protein kinase (MAPK) 
pathways
304. The interplay of these pathways is involved in a plethora of cellular 
homeostatic functions (e.g. proliferation, apoptosis, migration
305, and alterations in 
the MAPK pathway have been implicated in colorectal carcinogenesis
306, although 
there is no evidence that MLK4 specifically is a factor in CRC. There is an LD block 
extending towards MLK4, with the region from exon 7 to 10 having a high D’ with 
rs4649317 (D’=0.69-1.0), but low r
2 with r
2=0.06-0.42. Of the SNPs on the arrays 
covering this region, no other was significantly associated with prognosis. 
rs1350308  In intron 1 of CUB and Sushi multiple domains 1 (CSMD1) on chromosome 8q23. 
CSMD1 is a huge gene with 3565 amino acid protein spanning over 2Mb and is of 
unknown function. CSMD1 covers a minimal region of deletion associated with 
higher stage in prostate cancer, and it has been linked to higher stage in CRC
297. The 
LD structure of the region displays weak LD blocks, and there is no evidence of 
long-range LD covering the exons flanking rs1350308. This is supported by the 
Manhattan plot, which shows that in the immediate vicinity, there is some weak 
evidence for an association with outcome. 
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Table 10­2  Functional annotation of SNPs chosen only on p­value (cont’d) 
SNP  Description 
rs9533457  In intron 9 of ecto-NOX disulfide-thiol exchanger 1 (ENOX1) on chromosome 13. 
ENOX1 is a plasma membrane bound electron exchange protein
409, as part of the 
plasma membrane redox system, implicated in control of cell growth and 
proliferation, among others
410. rs9533457 lies within an LD block covering exons 9 
and 10. 
rs1571583  In GLIS family zinc finger 3 isoform b, a Krüppel like zinc finger transcription factor 
that has been linked to neonatal diabetes. It has not been linked to CRC, but acts 
synergistically with BMP2 on osteoclast differentiation
411, and in turn BMP2 has been 
linked to CRC risk
46. 
rs567564  Located 105Kb from FRK tyrosine kinase, also known as RAK, interacts with the 
retinoblastoma protein, with growth suppressing properties
412. It may also have anti-
proliferative properties in its own right
413, but has not been linked to CRC. 
rs7866165  273b from Nuclear factor I/B, see entry for rs11788150. 
rs437171  Not located near any gene, the nearest gene is Cadherin 18, type 2 1.3Mb away. 
rs3752261  10Kb from Zinc finger protein 334 isoform b (ZNF334) belonging to the Krüppel 
C2H2 family of transcription factor without a known function. Members of this 
family have been found to interact with MYC
414. 
rs1924597  HS6ST3 modifies heparan sulfate so it can interact with a variety of proteins which in 
turn have been implicated in proliferation, differentiation, adhesion, and migration
415. 
Among the initial 25 SNPs chosen on p-value alone, it would be expected that not all would present a 
plausible  biological  rationale  for  an  association  with  prognosis.  There  were  nonetheless  a  number  of 
interesting candidate genes. The functional annotation of the 40 SNPs taken forward are listed in Table 3-7, 
are described in section 3.6.2 for SNPs chosen on biological rationale, and in more detail for those SNPs 
chosen on statistical significance below. For a distribution across functional categories, see Figure 3-16, 
Manhattan plots for all SNPs are given in Appendix B. 
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Table 10­3  List of 103 SNPs meeting all inclusion criteria 
SNP  Chr Base  Model  ES (95% CI)  p-value  Nearest gene 
rs7556894  2  65.37  recessive  3.09 (2.00-4.77)  9.19e-08  Actin-related protein 2 (15kb) 
rs2589183  8  97.59  allelic  0.37 (0.25-0.55)  1.06e-07  Syndecan 2 precursor 
rs764372  18  9.82  recessive  4.24 (2.29-7.84)  5.09e-07  RAB31 
rs672757  1  112.15  allelic  1.84 (1.44-2.36)  1.08e-06  KCND3 potassium channel 
rs7912136  10  6.79  recessive  2.58 (1.73-3.85)  1.27e-06  Protein kinase C, theta (128kb) 
rs6972789  7  66.76  recessive  2.17 (1.57-3.00)  1.42e-06  Stromal antigen 3-like 4 (350kb) 
rs7007146  8  103.60  recessive  2.14 (1.55-2.95)  2.33e-06  E3 ubiquitin protein ligase (108kb) 
rs745888  2  119.63  recessive  2.68 (1.75-4.12)  2.48e-06  Complement component 1 (4kb) 
rs4978394  9  111.31  genotypic  1.72 (1.32-2.24)  2.48e-06  PTPN3 (6kb) 
rs3784780  15  89.11  genotypic  0.88 (0.64-1.21)  2.94e-06  Bloom syndrome protein 
rs10510044  10  120.23  recessive  2.46 (1.66-3.64)  3.60e-06  PRLHR (130kb) 
rs712082  1  222.79  recessive  3.01 (1.84-4.92)  3.89e-06  EST BU947851  
rs11788150  9  13.82  recessive  2.32 (1.59-3.37)  6.77e-06  Nuclear factor I/B (250kb) 
rs10842099  12  23.08  allelic  0.51 (0.37-0.69)  7.26e-06  cDNA FLJ37414 
rs4715476  6  54.73  genotypic  1.73 (1.33-2.24)  8.12e-06  TINAG (370kb) 
rs1526884  19  22.10  dominant  0.47 (0.33-0.66)  8.47e-06  near cluster of ZNF (31 - 750kb) 
rs4649314  1  231.64  recessive  2.30 (1.58-3.35)  8.54e-06  Mixed lineage kinase 4 (50kb) 
rs1350308  8  4.60  allelic  1.74 (1.36-2.22)  9.39e-06  CSMD1 
rs9533457  13  42.81  recessive  2.58 (1.67-3.98)  9.62e-06  NOX disulfide-thiol exchanger  
rs1571583  9  4.26  recessive  2.80 (1.73-4.53)  1.10e-05  GLIS family zinc finger 3 isoform b 
rs567564  6  116.26  recessive  2.37 (1.59-3.53)  1.21e-05  FRK 
rs7866165  9  13.80  recessive  2.85 (1.74-4.66)  1.23e-05  Nuclear factor I/B (273kb) 
rs437171  5  18.17  recessive  3.08 (1.81-5.25)  1.28e-05  Cadherin 18, type 2 (1.3MB) 
rs3752261  20  44.55  recessive  3.41 (1.89-6.15)  1.41e-05  Zinc finger protein 334 (10kb) 
rs1924597  13  96.24  allelic  0.38 (0.23-0.61)  1.46e-05  HS6ST3 
rs6487867  12  30.01  recessive  2.30 (1.56-3.39)  1.54e-05  Transmembrane / 
tetratricopeptide repeat (220kb) 
rs1822917  8  72.43  recessive  2.65 (1.67-4.20)  1.55e-05  Eyes absent 1 isoform c 
rs1411684  9  111.36  genotypic  1.69 (1.30-2.19)  1.56e-05  PTPN3 (100kb) 
rs9514816  13  107.58  allelic  2.07 (1.51-2.83)  1.68e-05  DNA ligase IV (77kb) 
rs6764062  3  152.85  recessive  3.37 (1.87-6.08)  1.76e-05  Arylacetamide deacetylase (90kb) 
rs698277  1  222.79  recessive  2.86 (1.73-4.73)  1.91e-05  Cornichon homolog 3 (80kb) 
rs1665853  4  181.29  recessive  3.00 (1.76-5.11)  2.09e-05  nothing 
rs4411217  10  120.21  allelic  1.72 (1.35-2.21)  2.14e-05  PRLHR (130kb) 
rs4771704  13  110.09  allelic  1.99 (1.47-2.72)  2.18e-05  Cysteinyl-tRNA synthetase 2 
rs6518956  22  34.27  genotypic  0.97 (0.78-1.21)  2.37e-05  RASD family, member 2 
rs6853554  4  107.17  allelic  0.53 (0.39-0.72)  2.42e-05  Nephronectin (54kb) 
rs663472  12  3.97  recessive  3.18 (1.80-5.61)  2.46e-05  ADP-ribose polymerase (116kb) 
rs1878632  2  153.03  recessive  2.06 (1.46-2.91)  2.58e-05  Formin-like 2 
rs7221974  17  1.58  recessive  2.47 (1.60-3.81)  2.62e-05  Alpha-2-plasmin inhibitor 
rs1465365  3  188.56  genotypic  0.94 (0.70-1.27)  2.80e-05  INF responsive protein (13kb) 
rs7600624  2  152.99  allelic  1.96 (1.45-2.66)  2.91e-05  Formin-like 2 
rs935361  2  119.65  recessive  2.94 (1.73-5.01)  3.05e-05  Complement component 1 (20kb) 
rs9315425  13  35.98  recessive  3.58 (1.89-6.80)  3.09e-05  Cyclin A1 (65kb) 
rs958882  5  123.03  recessive  2.45 (1.58-3.78)  3.15e-05  Casein kinase 1(50kb) 
rs2827250  21  22.43  dominant  1.97 (1.42-2.73)  3.72e-05  Neural cell adhesion (604kb) 
Chr - chromosome, base - position on chromosome in Mb.  
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Table 10­3    List of 103 SNPs meeting all inclusion criteria (cont’d) 
SNP  Chr  Base  Model  ES (95% CI)  p-value  Nearest gene 
rs968757  4  120.98  recessive  1.99 (1.42-2.77)  3.79e-05  Phosphodiesterase 5A (210kb) 
rs4741450  9  15.07  recessive  1.96 (1.41-2.72)  3.87e-05  cDNA FLJ46077  
rs4813685  20  4.24  recessive  3.00 (1.73-5.19)  3.92e-05  Alpha-1D-adrenergic receptor 
rs3124028  9  7.66  allelic  0.59 (0.46-0.76)  4.05e-05  PTP (645kb) 
rs11682848  2  234.58  recessive  3.35 (1.81-6.19)  4.18e-05  Transient receptor potential 
channel 
rs1526643  2  76.34  genotypic  1.68 (1.26-2.22)  4.38e-05  GFHL3075 (480kb) 
rs2288742  16  25.03  allelic  0.59 (0.46-0.76)  4.57e-05  Leucine-carboxyl 
methyltransferase 1 (5kb) 
rs712068  1  222.78  recessive  2.73 (1.65-4.52)  4.58e-05  Cornichon homolog 3 (80kb) 
rs12587148  14  33.06  genotypic  1.10 (0.89-1.38)  4.75e-05  Neuronal PAS domain protein 3 
rs10429965  1  209.91  recessive  3.68 (1.88-7.22)  4.78e-05  NEK2 
rs5997921  22  29.96  recessive  3.68 (1.87-7.21)  4.88e-05  LIM domain kinase 2 
rs10513640  3  22.21  recessive  3.67 (1.87-7.20)  4.96e-05  Zinc finger protein 659 (240kb) 
rs6057021  20  9.85  recessive  2.36 (1.54-3.62)  4.99e-05  p21-activated kinase 7 (80kb) 
rs1824476  18  27.28  allelic  0.55 (0.41-0.74)  5.10e-05  Desmoglein 3 (0.6kb) 
rs4463351  7  99.92  recessive  3.04 (1.72-5.37)  5.28e-05  TSC22D4 (1.5kb) 
rs2291270  5  169.08  dominant  0.53 (0.39-0.72)  5.28e-05  DOCK2 
rs7974465  12  75.65  genotypic  1.14 (0.91-1.43)  5.46e-05  Oxysterol-binding protein (168kb) 
rs4776494  15  62.50  genotypic  1.77 (1.35-2.32)  5.66e-05  Thyroxine receptor interactor  
rs6782375  3  105.16  dominant  0.53 (0.39-0.73)  5.81e-05  cDNA clone 6614812 
rs4856091  3  105.12  dominant  0.53 (0.39-0.73)  6.01e-05  cDNA clone 6614812 (5kb) 
rs221259  7  157.03  recessive  3.43 (1.81-6.51)  6.04e-05  PTP receptor type, N 
rs2217375  8  112.63  recessive  3.43 (1.81-6.51)  6.04e-05  CSMD3 (900kb) 
rs1075737  7  102.86  recessive  3.43 (1.81-6.52)  6.06e-05  SLC26A5 
rs657224  1  76.94  dominant  1.89 (1.38-2.60)  6.13e-05  ST6GALNAC3 (115kb);  
rs1366978  1  198.05  recessive  1.99 (1.41-2.80)  6.14e-05  Orphan nuclear receptor NR5A2 
rs10800652  1  198.05  recessive  1.99 (1.41-2.80)  6.14e-05  Orphan nuclear receptor NR5A2 
rs10876477  12  52.34  dominant  1.89 (1.38-2.59)  6.15e-05  ATP synthase (6kb) 
rs1038923  12  65.14  allelic  0.57 (0.43-0.75)  6.20e-05  Glutamate receptor interacting 1 
rs305002  15  67.93  dominant  0.53 (0.39-0.73)  6.25e-05  Transducin-like enhancer (211kb) 
rs1928661  9  29.30  allelic  0.59 (0.45-0.77)  6.31e-05  Leucine rich repeat neuronal 
(599kb) 
rs2280117  22  18.69  dominant  0.53 (0.38-0.73)  6.63e-05  DGCR6L 
rs4553248  1  105.98  recessive  3.41 (1.79-6.47)  6.77e-05  cDNA clone 5297905 (17kb) 
rs4242025  5  51.15  recessive  2.39 (1.53-3.72)  7.09e-05  ISL1 (425kb) 
rs10192011  2  53.66  recessive  2.81 (1.65-4.79)  7.17e-05  Ankyrin repeat/SOCS box-
containing 3 (90kb) 
rs215410  4  23.03  recessive  2.15 (1.46-3.18)  7.46e-05  PPARGC1A (370kb);  
rs457918  20  44.55  recessive  3.23 (1.75-5.96)  7.50e-05  Zinc finger protein 334 (20kb) 
rs10916777  1  20.58  dominant  1.87 (1.36-2.55)  7.53e-05  cDNA clone IMAGE:5269505 
rs10740509  10  54.14  recessive  2.28 (1.50-3.48)  7.73e-05  MBL2 (50kb) 
rs10816807  9  111.21  recessive  2.65 (1.60-4.39)  7.97e-05  PTPN3 
rs10414779  19  57.49  recessive  2.25 (1.49-3.42)  8.06e-05  Zinc finger protein 766 
Chr - chromosome, base - position on chromosome in Mb. 
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Table 10­3    List of 103 SNPs meeting all inclusion criteria (cont’d) 
SNP  Chr  Base  Model  ES (95% CI)  p-value  Nearest gene 
rs2327672  6  136.27  allelic  0.43 (0.28-0.68)  8.17e-05  Phosphodiesterase 7B 
rs4812682  20  41.22  recessive  2.23 (1.48-3.36)  8.20e-05  Protein tyrosine phosphatase 
rs1438620  2  222.75  dominant  2.25 (1.49-3.41)  8.25e-05  PAX3 (26kb) 
rs1094039  9  6.69  genotypic  0.96 (0.77-1.21)  8.30e-05  Glycine dehydrogenase (50kb) 
rs1565741  8  16.80  genotypic  1.75 (1.35-2.27)  8.38e-05  Fibroblast growth factor 20 (95kb) 
rs7974869  12  106.55  recessive  2.53 (1.56-4.08)  8.74e-05  BTB (POZ) domain containing  
rs2807602  9  125.93  genotypic  1.67 (1.30-2.14)  8.77e-05  LIM homeobox protein 2 (93kb)  
rs2760555  20  16.07  genotypic  1.64 (1.25-2.15)  9.35e-05  Kinesin-like motor protein (130kb) 
rs7616534  3  198.78  recessive  3.51 (1.79-6.89)  9.46e-05  3-hydroxybutyrate dehydrogenase  
rs2430893  18  52.58  genotypic  1.27 (1.02-1.59)  9.73e-05  WDR7 
rs2514841  8  109.13  recessive  0.34 (0.19-0.60)  9.83e-05  RSPO2 
rs10273192  7  149.57  recessive  2.31 (1.50-3.58)  9.90e-05  Actin-related protein 3-beta (7kb) 
rs838308  12  113.43  allelic  0.51 (0.36-0.73)  9.96e-05  T-box 5 isoform 1 (100kb) 
rs12330780  3  187.22  recessive  1.89 (1.37-2.63)  9.96e-05  Ets variant gene 5 (22kb) 
rs1034116  14  89.02  allelic  1.89 (1.38-2.57)  1.14e-04  Checkpoint suppressor 1 
rs25689  9  73.55  allelic  1.70 (1.29-2.22)  1.81e-04  Transmembrane protein 2 
rs12583114  13  97.56  genotypic  1.58 (1.26-1.98)  2.15e-04  FERM, RhoGEF, pleckstrin protein  
rs304998  15  67.93  allelic  1.61 (1.26-2.07)  2.43e-04  Transducin-like enhancer 3 
(200kb) 
Chr - chromosome, base - position on chromosome in Mb.  
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Table 10­4  Meta­analysis for all stages, adjusted for stage 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  1.91e-05  1.60 (1.29-1.98)  75.8  6.14e-03 
rs472660  3  recessive  2.63e-05  2.29 (1.56-3.37)  68.4  4.23e-02 
rs7912136  2  recessive  3.47e-04  1.67 (1.26-2.22)  86.2  7.00e-03 
rs764372  3  recessive  4.97e-04  1.92 (1.33-2.76)  79.0  8.64e-03 
rs1878632  3  recessive  5.84e-04  1.33 (1.13-1.57)  66.8  4.91e-02 
rs672757  2  genotypic  1.41e-03  1.23 (1.08-1.39)  90.2  1.40e-03 
rs7600624  4  genotypic  1.89e-03  1.20 (1.07-1.34)  72.9  1.14e-02 
rs4649314  4  recessive  3.50e-03  1.22 (1.07-1.39)  70.2  1.80e-02 
rs567564  3  recessive  4.02e-03  1.37 (1.11-1.70)  81.2  4.95e-03 
rs1034116  4  genotypic  4.24e-03  1.19 (1.06-1.34)  73.7  9.75e-03 
rs10429965  3  recessive  4.45e-03  1.89 (1.22-2.92)  89.8  5.58e-05 
rs1571583  4  recessive  5.66e-03  1.40 (1.10-1.78)  70.5  1.72e-02 
rs6972789  3  recessive  6.95e-03  1.24 (1.06-1.46)  91.1  1.30e-05 
rs1438620  2  dominant  7.04e-03  1.23 (1.06-1.43)  76.8  1.33e-02 
rs437171  2  recessive  1.16e-02  1.46 (1.09-1.97)  76.6  1.39e-02 
rs1822917  4  recessive  1.20e-02  1.39 (1.07-1.79)  59.2  6.13e-02 
rs4715476  3  genotypic  1.37e-02  1.16 (1.03-1.31)  81.5  4.46e-03 
rs712082  3  recessive  1.48e-02  1.43 (1.07-1.91)  86.6  5.75e-04 
rs1350308  3  genotypic  1.61e-02  1.14 (1.02-1.27)  79.3  7.90e-03 
rs10510044  2  recessive  1.66e-02  1.42 (1.07-1.89)  81.5  4.54e-03 
rs7007146  3  recessive  3.00e-02  1.20 (1.02-1.41)  84.0  1.94e-03 
rs5997921  2  recessive  3.14e-02  1.73 (1.05-2.86)  79.7  2.64e-02 
rs9315425  3  recessive  3.25e-02  1.63 (1.04-2.55)  73.8  2.21e-02 
rs7866165  3  recessive  4.30e-02  1.26 (1.01-1.57)  83.6  2.28e-03 
rs11788150  3  recessive  4.46e-02  1.21 (1.00-1.46)  85.6  9.87e-04 
rs6518956  4  genotypic  5.59e-02  0.92 (0.84-1.00)  0.0  6.00e-01 
rs1824476  3  genotypic  6.93e-02  0.91 (0.81-1.01)  86.0  7.77e-04 
rs3752261  3  recessive  7.24e-02  1.38 (0.97-1.97)  76.0  1.55e-02 
rs10842099  2  genotypic  8.80e-02  0.88 (0.75-1.02)  90.6  1.13e-03 
rs2514841  3  recessive  9.15e-02  0.86 (0.72-1.02)  80.8  5.50e-03 
rs9514816  3  genotypic  1.10e-01  1.12 (0.97-1.29)  89.8  5.76e-05 
rs4978394  3  genotypic  1.47e-01  1.10 (0.97-1.26)  85.1  1.21e-03 
rs745888  3  recessive  1.69e-01  1.18 (0.93-1.50)  80.5  5.99e-03 
rs4776494  2  genotypic  1.80e-01  1.12 (0.95-1.34)  88.2  3.60e-03 
rs9533457  3  recessive  1.92e-01  1.18 (0.92-1.50)  86.7  5.58e-04 
rs1924597  4  genotypic  2.48e-01  0.92 (0.81-1.06)  87.1  3.57e-05 
rs25689  3  genotypic  3.82e-01  1.05 (0.94-1.18)  82.4  3.40e-03 
rs2589183  4  genotypic  4.19e-01  0.96 (0.86-1.07)  83.4  4.35e-04 
rs3784780  4  genotypic  9.11e-01  1.01 (0.90-1.13)  0.0  9.07e-01 
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Table 10­5  Meta­analysis for stage 2 and 3 CRC, adjusted for stage 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  8.96E-07  1.80 (1.42-2.27)  56.9  7.31E-02 
rs672757  2  allelic  1.09E-06  1.47 (1.26-1.72)  38.4  2.02E-01 
rs764372  3  recessive  1.25E-05  2.30 (1.58-3.34)  66.4  5.09E-02 
rs472660  3  recessive  1.79E-05  2.45 (1.63-3.70)  63.9  6.25E-02 
rs10429965  3  recessive  8.52E-05  2.66 (1.63-4.33)  89.9  1.68E-03 
rs7912136  2  recessive  1.22E-04  1.87 (1.36-2.56)  80.7  2.28E-02 
rs1878632  3  recessive  3.78E-04  1.38 (1.16-1.65)  59.9  8.25E-02 
rs7600624  4  allelic  6.79E-04  1.24 (1.10-1.41)  70.5  1.71E-02 
rs437171  2  recessive  8.63E-04  2.13 (1.37-3.33)  72.8  5.53E-02 
rs4649314  4  recessive  1.34E-03  1.29 (1.10-1.50)  64.4  3.78E-02 
rs712082  3  recessive  1.34E-03  1.70 (1.23-2.34)  79.5  7.58E-03 
rs6972789  3  recessive  1.59E-03  1.32 (1.11-1.58)  89.9  5.02E-05 
rs1571583  4  recessive  1.76E-03  1.53 (1.17-2.00)  67.5  2.65E-02 
rs7007146  3  recessive  2.22E-03  1.32 (1.10-1.57)  85.8  8.92E-04 
rs5997921  2  recessive  2.59E-03  2.43 (1.36-4.34)  0.0  3.38E-01 
rs10510044  2  recessive  3.77E-03  1.64 (1.17-2.29)  88.7  2.90E-03 
rs1438620  2  dominant  4.10E-03  1.46 (1.13-1.89)  83.8  1.29E-02 
rs567564  3  recessive  5.37E-03  1.40 (1.10-1.78)  81.8  4.12E-03 
rs1822917  4  recessive  7.78E-03  1.47 (1.11-1.96)  54.6  8.53E-02 
rs11788150  3  recessive  8.63E-03  1.31 (1.07-1.61)  83.2  2.59E-03 
rs1350308  3  allelic  9.22E-03  1.20 (1.05-1.37)  75.8  1.62E-02 
rs4978394  3  genotypic  1.15E-02  1.20 (1.04-1.39)  71.6  2.97E-02 
rs9315425  3  recessive  1.19E-02  1.83 (1.14-2.94)  63.8  6.29E-02 
rs7866165  3  recessive  1.35E-02  1.36 (1.07-1.74)  79.9  6.91E-03 
rs1924597  4  allelic  2.13E-02  0.83 (0.71-0.97)  82.1  7.93E-04 
rs10842099  2  allelic  2.64E-02  0.81 (0.67-0.98)  88.4  3.31E-03 
rs4715476  3  genotypic  2.75E-02  1.16 (1.02-1.33)  82.8  2.95E-03 
rs1034116  4  allelic  3.00E-02  1.16 (1.01-1.33)  76.3  5.40E-03 
rs9514816  3  allelic  4.30E-02  1.17 (1.00-1.36)  88.6  1.51E-04 
rs3752261  3  recessive  5.03E-02  1.47 (1.00-2.16)  75.4  1.72E-02 
rs9533457  3  recessive  5.71E-02  1.28 (0.99-1.66)  82.2  3.68E-03 
rs4776494  2  genotypic  5.89E-02  1.22 (0.99-1.50)  85.1  9.70E-03 
rs25689  3  allelic  1.14E-01  1.11 (0.98-1.25)  75.4  1.71E-02 
rs745888  3  recessive  1.57E-01  1.21 (0.93-1.59)  83.6  2.21E-03 
rs2514841  3  recessive  1.69E-01  0.87 (0.72-1.06)  80.7  5.64E-03 
rs1824476  3  allelic  2.71E-01  0.94 (0.83-1.05)  84.3  1.69E-03 
rs6518956  3  genotypic  3.07E-01  0.94 (0.85-1.05)  0.0  6.28E-01 
rs2589183  4  allelic  3.14E-01  0.94 (0.83-1.06)  82.4  6.97E-04 
rs3784780  4  genotypic  6.30E-01  0.97 (0.85-1.11)  0.0  7.91E-01 
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Table 10­6  Meta­analysis for stage 2 and 3, adjusted for stage, using shrunk data 
SNP  Cohorts  Model  p-value  ES (95% CI)  I
2  pQ 
rs7556894  4  recessive  7.19e-04  1.56 (1.21-2.03)  0.0  6.23e-01 
rs672757  2  allelic  2.52e-02  1.22 (1.03-1.46)  0.0  3.46e-01 
rs764372  3  recessive  6.02e-02  1.44 (0.98-2.09)  0.0  5.27e-01 
rs4649314  4  recessive  7.24e-02  1.15 (0.99-1.33)  0.0  5.08e-01 
rs472660  3  recessive  9.04e-02  1.53 (0.94-2.49)  0.0  5.39e-01 
rs7600624  4  allelic  1.15e-01  1.09 (0.98-1.20)  21.1  2.84e-01 
rs1878632  3  recessive  1.18e-01  1.12 (0.97-1.30)  0.0  5.84e-01 
rs6972789  3  recessive  1.83e-01  1.14 (0.94-1.38)  75.2  1.76e-02 
rs7007146  3  recessive  2.98e-01  1.10 (0.92-1.31)  70.9  3.20e-02 
rs1438620  2  dominant  2.98e-01  1.08 (0.93-1.25)  0.0  9.25e-01 
rs1571583  4  recessive  3.18e-01  1.16 (0.87-1.56)  0.0  7.93e-01 
rs4978394  3  genotypic  3.74e-01  1.05 (0.94-1.17)  0.0  9.67e-01 
rs1924597  4  allelic  3.88e-01  0.93 (0.79-1.10)  0.0  4.40e-01 
rs6518956  4  genotypic  4.31e-01  0.98 (0.92-1.04)  0.0  5.18e-01 
rs7866165  3  recessive  5.25e-01  1.08 (0.85-1.38)  0.0  9.63e-01 
rs7912136  2  recessive  5.27e-01  1.15 (0.75-1.77)  0.0  7.10e-01 
rs1822917  4  recessive  5.27e-01  1.08 (0.85-1.37)  0.0  7.26e-01 
rs25689  3  allelic  6.14e-01  1.02 (0.94-1.11)  0.0  8.15e-01 
rs2589183  4  allelic  6.15e-01  1.03 (0.91-1.17)  0.0  8.24e-01 
rs11788150  3  recessive  6.21e-01  1.06 (0.84-1.34)  0.0  5.02e-01 
rs712082  3  recessive  6.29e-01  1.10 (0.75-1.63)  0.0  7.71e-01 
rs745888  3  recessive  6.41e-01  0.94 (0.73-1.21)  18.7  2.92e-01 
rs10429965  3  recessive  6.46e-01  1.17 (0.60-2.26)  0.0  3.80e-01 
rs9514816  3  allelic  6.48e-01  0.96 (0.81-1.14)  0.0  6.07e-01 
rs437171  2  recessive  6.56e-01  1.08 (0.78-1.49)  0.0  9.77e-01 
rs567564  3  recessive  6.75e-01  1.06 (0.80-1.41)  0.0  6.29e-01 
rs4776494  2  genotypic  6.90e-01  1.02 (0.92-1.13)  14.4  2.80e-01 
rs10510044  2  recessive  7.13e-01  0.92 (0.61-1.41)  0.0  4.10e-01 
rs5997921  2  recessive  7.34e-01  1.02 (0.90-1.17)  0.0  5.10e-01 
rs1350308  3  allelic  7.37e-01  1.03 (0.88-1.20)  0.0  8.52e-01 
rs9315425  3  recessive  7.61e-01  1.03 (0.87-1.20)  0.0  4.16e-01 
rs1824476  3  allelic  7.71e-01  0.99 (0.91-1.07)  52.2  1.23e-01 
rs1034116  4  allelic  7.71e-01  1.02 (0.89-1.17)  0.0  5.19e-01 
rs4715476  3  genotypic  7.75e-01  1.02 (0.89-1.17)  0.0  8.26e-01 
rs2514841  3  recessive  7.79e-01  0.98 (0.87-1.11)  0.0  7.36e-01 
rs3784780  4  genotypic  8.04e-01  0.99 (0.93-1.06)  0.0  7.76e-01 
rs3752261  3  recessive  9.17e-01  1.01 (0.82-1.24)  0.0  7.10e-01 
rs9533457  3  recessive  9.20e-01  0.99 (0.79-1.23)  0.0  7.81e-01 
rs10842099  2  allelic  9.20e-01  1.01 (0.83-1.23)  0.0  4.39e-01 
Meta-analysis including stage in multivariate analysis, for patients with stage 2 and 3 CRC, the data for 
VICTOR has been regressed to the mean.  
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Table 10­7  Predictive analysis of top 40 SNPs 
SNP  Position  HR (95% CI)  p-value  Gene 
rs4715476  54.73  1.89 (1.61-2.17)  7.17e-06  Tubulointerstitial nephritis antigen (370kb) 
rs6117279  0.65  1.72 (1.48-1.97)  1.04e-05  Sulfiredoxin 1 homolog (60kb) 
rs1408811  12.57  2.22 (1.86-2.58)  1.39e-05  Tyrosinase-related protein 1(120kb) 
rs917205  87.56  2.32 (1.94-2.71)  1.52e-05  ADAM metallopeptidase domain 22  
rs1516708  92.72  0.57 (0.31-0.83)  1.87e-05  FAM190A transcript variant 1, mRNA 
rs968757  120.98  1.69 (1.45-1.93)  2.02e-05  Phosphodiesterase 5A isoform (209kb) 
rs7924634  132.93  1.91 (1.61-2.21)  2.27e-05  Opioid binding protein (25kb) 
rs5743291  49.31  2.17 (1.81-2.52)  2.29e-05  Nucleotide-binding oligomerization 
rs7787525  99.33  2.42 (2.01-2.83)  2.33e-05  Tripartite motif protein TRIM4 isoform  
rs510902  238.99  1.68 (1.44-1.92)  2.58e-05  Ankyrin repeat/SOCS box-containing (8kb) 
rs746017  130.96  0.51 (0.19-0.82)  2.61e-05  Podocalyxin-like isoform 1 (64kb) 
rs3124238  89.44  1.66 (1.42-1.89)  3.05e-05  Death-associated protein kinase 1 
rs10281994  125.27  1.90 (1.60-2.21)  3.19e-05  Glutamate receptor, isoform c (590kb) 
rs2002059  101.12  2.32 (1.92-2.71)  3.53e-05  Cyclin M1 
rs2144749  168.70  1.67 (1.43-1.91)  3.61e-05  SPARC related modular calcium binding  
rs3784929  74.23  1.82 (1.54-2.11)  3.77e-05  Lysyl-tRNA synthetase isoform 3 
rs10102339  27.02  1.66 (1.42-1.91)  3.89e-05  Stathmin-like 4 (126kb) 
rs13253769  100.10  0.59 (0.34-0.84)  4.08e-05  Vacuolar protein sorting 13B isoform 4 
rs1041795  38.77  1.70 (1.44-1.95)  4.38e-05  ETS-related isoform 1 
rs8053257  74.23  2.03 (1.69-2.37)  4.94e-05  Lysyl-tRNA synthetase isoform 2 
rs883834  45.31  2.07 (1.72-2.43)  5.01e-05  Homo sapiens cDNA FLJ38231  
rs9514816  107.58  1.89 (1.58-2.20)  5.78e-05  DNA ligase IV (75kb) 
rs4923791  36.48  1.97 (1.64-2.31)  6.41e-05  Sprouty-related protein 1 (90kb) 
rs10913063  173.94  1.98 (1.64-2.31)  6.46e-05  Tenascin R 
rs237176  26.57  0.55 (0.26-0.84)  6.79e-05  Heparan sulfate D-glucosaminyl (510kb) 
rs7591253  34.84  1.67 (1.42-1.93)  7.06e-05  Full-length cDNA clone CS0DI009YL06 (39kb) 
rs2013746  7.33  1.79 (1.50-2.08)  7.35e-05  Ring finger protein 144 (227kb) 
rs337532  100.49  2.21 (1.82-2.61)  7.52e-05  G protein-coupled receptor 52 
rs1819887  50.65  1.67 (1.42-1.93)  7.90e-05  RAB27B, member RAS oncogene family 
rs6491307  96.25  0.47 (0.09-0.85)  8.10e-05  Heparan sulfate 6-O-sulfotransferase 3 
rs10934005  111.19  1.71 (1.44-1.97)  8.42e-05  Developmental pluripotency associated (645kb) 
rs5764560  42.88  0.57 (0.29-0.85)  8.53e-05  Parvin, beta isoform a 
rs10161354  87.87  2.25 (1.84-2.65)  8.73e-05  cDNA FLJ30500 (60kb) 
rs12419726  59.50  1.80 (1.50-2.09)  9.17e-05  mRNA for hypothetical protein (0.5kb) 
rs17596719  26.21  1.93 (1.60-2.26)  9.49e-05  Splice variant delE3-7 (HFE) (0.1kb) 
rs1892431  90.14  1.81 (1.51-2.11)  9.61e-05  Leucine rich repeat containing 8 family 
rs1730265  49.84  1.88 (1.56-2.20)  9.66e-05  Methyl-CpG binding domain protein 2 (90kb) 
rs11709756  103.33  1.89 (1.57-2.21)  9.90e-05  Zona pellucida-like domain containing 1  
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Appendix C: Primers, conditions and reagents used 
Chapter 4 
Table 10­8  Primers for KASPar genotyping 
Locus  Type  Primer 
rs1034116   Allele 1  GAAGGTGACCAAGTTCATGCTCAGGGGCTGTCGAGGCA 
  Allele 2  GAAGGTCGGAGTCAACGGATTCAGGGGCTGTCGAGGCG 
  Common  GCCATTCTGCAAAGGGGCAAAATGTT 
rs1350308   Allele 1  GAAGGTGACCAAGTTCATGCTGTGTGAGTATTAAGTCATTTGCTAATTGTT` 
  Allele 2  GAAGGTCGGAGTCAACGGATTGTGAGTATTAAGTCATTTGCTAATTGTG 
  Common  GGTTGGAGATTTAGCATTTGTATTTGTGAA 
rs1571583   Allele 1  GAAGGTGACCAAGTTCATGCTAAACCGTCACATCTCCCATCTTCTA 
  Allele 2  GAAGGTCGGAGTCAACGGATTCCGTCACATCTCCCATCTTCTG 
  Common  TAGAATAGTCTAGTAAAAACACTCCCACTT 
rs1822917   Allele 1  GAAGGTGACCAAGTTCATGCTGTTCTTAGACTCTGCAGTTACTTATTCT 
  Allele 2  GAAGGTCGGAGTCAACGGATTCTTAGACTCTGCAGTTACTTATTCC 
  Common  GAACATGAGTAGTGGCTTTTGTACCTTTT 
rs1924597   Allele 1  GAAGGTGACCAAGTTCATGCTTTTGATTGGTATTTCACTAAATTCATAGATCA 
  Allele 2  GAAGGTCGGAGTCAACGGATTGATTGGTATTTCACTAAATTCATAGATCG 
  Common  ATATAGTGAATATACCAATTCTCCCCAAGT 
rs2589183   Allele 1  GAAGGTGACCAAGTTCATGCTTGAACCAGGTCCAAATTGCTGAAT 
  Allele 2  GAAGGTCGGAGTCAACGGATTGAACCAGGTCCAAATTGCTGAAC 
  Common  GGTCTTCTTACCGTACCTGCACTTA 
rs3784780   Allele 1  GAAGGTGACCAAGTTCATGCTGTTTTAAAGATTAATGACAATGAAGGGGT 
  Allele 2  GAAGGTCGGAGTCAACGGATTGTTTTAAAGATTAATGACAATGAAGGGGC 
  Common  GGTAGCCATTGTTCAACCATTTGTCATAT 
rs4649314  Allele 1  GAAGGTGACCAAGTTCATGCTCTATCTGGGCAGTTACGTCT 
  Allele 2  GAAGGTCGGAGTCAACGGATTCTCTATCTGGGCAGTTACGTCG 
  Common  GTGGAGAGTCAGAGAAGTTACTGCTA 
rs6518956   Allele 1  GAAGGTGACCAAGTTCATGCTGAGGCTCCCATAGAAAGCTCTGA 
  Allele 2  GAAGGTCGGAGTCAACGGATTAGGCTCCCATAGAAAGCTCTGG 
  Common  CAAGGGTTATGGTTCTGGGGCAAA 
rs7556894   Allele 1  GAAGGTGACCAAGTTCATGCTACAGCTTGCTTATGAATTGCAAGGAT 
  Allele 2  GAAGGTCGGAGTCAACGGATTCAGCTTGCTTATGAATTGCAAGGAC 
  Common  CGTTTCTTCATTGCCGAGTTACCATATTT 
rs7600624  Allele 1  GAAGGTGACCAAGTTCATGCTGAAGTGCTCATACCAGAGAGAT 
  Allele 2  GAAGGTCGGAGTCAACGGATTGAAGTGCTCATACCAGAGAGAC 
  Common  GTTCTTGGCGGTTTCCAAACGACTT 
Primers for ten SNPs typed in the Danish cohort, and one SNP typed in the Finnish cohort (rs4649314). 
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Table 10­9  PCR conditions  
SNP  [Mg
2=]  Programme 
rs1034116  2.6mM  Standard 
rs1350308  3.4mM  Standard 
rs1571583  2.6mM  Standard 
rs1822917  2.6mM  Standard 
rs1924597  2.6mM  Standard 
rs2589183  2.2mM  Standard 
rs3784780  2.2mM  Standard 
rs4649314  2.2mM  Standard 
rs6518956  2.6mM  Standard 
rs7556894  2.6mM  Standard 
rs7600624  2.6mM  Standard 
Conditions used for ten SNPs typed in Danish cohort, and one SNP typed in Finnish cohort (rs4649314). 
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Chapter 6 
Table 10­10 Primer sequences for KASPar PCR 
Locus  Type  Primer 
rs10411210  Allele 1  GAAGGTGACCAAGTTCATGCTAACAAGCACCAACGGTTTCCCG 
  Allele 2  GAAGGTCGGAGTCAACGGATTCAACAAGCACCAACGGTTTCCCA 
  Common  GCCAGAGCGGAGCTTGGCAAAA 
rs10758669  Allele 1  GAAGGTGACCAAGTTCATGCTTGGTGGGAAATATAAAATCATGGAATT 
  Allele 2  GAAGGTCGGAGTCAACGGATTCTTGGTGGGAAATATAAAATCATGGAATC 
  Common  GCAGCAGCAGAAAGAGAAAAAGTTAGATT 
rs16892766  Allele 1  GAAGGTGACCAAGTTCATGCTGACATAAGGCATAACCTTTAACAGCT 
  Allele 2  GAAGGTCGGAGTCAACGGATTGACATAAGGCATAACCTTTAACAGCG 
  Common  CAGAACGGTCAGACGCAAACAGTTT 
rs6983267  Allele 1  GAAGGTGACCAAGTTCATGCTCATAAAAATTCTTTGTACTTTTCTCAGTGC 
  Allele 2  GAAGGTCGGAGTCAACGGATTCACATAAAAATTCTTTGTACTTTTCTCAGTGA 
  Common  CGTCCTTTGAGCTCAGCAGATGAAA  
rs961253  Allele 1  GAAGGTGACCAAGTTCATGCTCAGCAACTTCAATTAATCTTTCTGAATT 
  Allele 2  GAAGGTCGGAGTCAACGGATTCAGCAACTTCAATTAATCTTTCTGAATG 





2=]  Programme 
rs10411210  2.2mM 
  Standard 
rs10758669  3.6mM   Standard 
rs16892766  4.0mM   Standard 
rs6983267  2.2mM   Standard 
rs961253  2.2mM   Standard  
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Chapter 7 
Table 10­12 rs6687758 primers for KASPar assay 
Allele  Primer 
A  GAAGGTGACCAAGTTCATGCTAAAGAATGTGCATCTCTAGATTCCATATTT 
B  GAAGGTCGGAGTCAACGGATTGAATGTGCATCTCTAGATTCCATATTC 





2=]  Programme 
rs6687758  2.2mM Mg2




Direction  Primer 
Forward  GGGTGCTTCTGAGGACAGAG 
Reverse  CCCAGCAGGAATGCTTAAAA 
  




2+  Temp  Additive  Type  Primer 
TGFβR1   1.5  55  DMSO  Forward  9.  6GAGGTTTGCTGGGGTGAG 
        Reverse  10. AGCAGGAGCGAGCCAGAG 
APC E1317Q  2.5  55  Q-solution  Forward  11. AGAAAAGATTGGAACTAGGTCAGC 
        Reverse  12. TGCAGTCTGCTGGATTTGGT 
rs28931588/9  1.5  55  DMSO  Forward  13. TTTGATGGAGTTGGACATGG 




2+  Temp  Additive  Type  Primer 
rs10667315  2.5  55  Q-solution  Forward  AGGGGAGACCACCTGTTTCT 
        Reverse  TTTACTGCCCCATAGGCAAC 
rs10697058  1.5  55  Q-solution  Forward  ATGACAAGGTCTGCCCACAT 
        Reverse  GCTACGTGGTGCAAGAGTCA 
rs11283943  1.5  55  Q-solution  Forward  TGGATGCACTTCTACCCTGA 
        Reverse  CTAATCTGACAGGCCCACATC 
rs11350445  1.5  55  Q-solution  Forward  CATTGTGTCCCTTTTCTCTCC 
        Reverse  ACTGACTATTCAAGGGGATCG 
rs11364237  1.5  55  Q-solution  Forward  ACCTCGTCCAATGATCCAAG 
        Reverse  GACGATGTCCAACACAATGC 
rs11376162  1.5  55  Q-solution  Forward  CTATTGTGGCCTCCCCAAG 
        Reverse  CCCTTAGGATCTCCTTCCACA 
rs11424286  1.5  55  Q-solution  Forward  GACACAGACATCAGGATGCAA 
        Reverse  AGATCGCCAACAAGCTCTTC 
rs11476163  1.5  55  Q-solution  Forward  ATCCCACCTACGGTCTCCTC 
        Reverse  CTCAGTTTACCCTGCCTGCT 
rs11477710  1.5  55  Q-solution  Forward  ACTTACCACTTGCACGCTCA 
        Reverse  GCTGACATCATTTTTGTTTCTCC 
rs11478027  1.5  55  Q-solution  Forward  AGGCCATTCTCCTCAGAAGC 
        Reverse  GAAACGTGTTTCCTCACAAGC 
rs11509437  2.5  55  Q-solution  Forward  GAGGGGGCCGATACAGTTAG 
        Reverse  AAGTGACTTGGAAAGTGGGAAT 
rs11564598  1.5  55  Q-solution  Forward  TGAGGCTGCAAGAAAGTTCA 
        Reverse  TTAGGACAATGGCTGGCTTC 
rs11564619  2.5  55  Q-solution  Forward  TTGTGAAGAAAACAGGCATTTG 
        Reverse  GGGTCTTCTCACCGTGTTTG 
rs140596  1.5  55  Q-solution  Forward  GCAGACATCGATGAGTGTGAA 
        Reverse  TCTTCAGATGCCATGAATCC 
rs17001464  1.5  55  Q-solution  Forward  GAGAACACAGGCGTGCATC 
        Reverse  TCGGCTCTGTACCTGATGGT 
rs17879749  1.5  55  Q-solution  Forward  TGCTCATGCTTTTCAACCAG 
        Reverse  AGGGGTGGGAGAATTGAGAG 
rs2066730  1.5  55  Q-solution  Forward  TTATTTTAGGTGTCTGGGGCAGT 
        Reverse  GCCTCTGCTTTGTGAACCA 
rs3069752  1.5  55  Q-solution  Forward  CGTTCTGGGCACTTACCTTT 
        Reverse  CAGCAGCACAACCACCATAG  
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Locus  Mg
2+  Temp  Additive  Type  Primer 
rs3092768  2.5  55  Q-solution  Forward  TGGCAGGAACTCTCTCTTCC 
        Reverse  CAGACAAACCAAAGCAGAGGA 
rs3212987  1.5  55  Q-solution  Forward  ATCTCCTCTTGGGGCACTGT 
        Reverse  AGCCAGAGACAGAGGTGGTG 
rs3214276  1.5  55  Q-solution  Forward  AACTCCCTCCAGAGCTACCA 
        Reverse  TGGGTTTATGGCTCCATTGT 
rs3217458  1.5  55  Q-solution  Forward  CTCTGCGGACCTTACCTCCT 
        Reverse  ACTGTTCCATTCCCCACTTG 
rs4067742  1.5  55  Q-solution  Forward  AGGCAGCCTGAAGTCCTACT 
        Reverse  CATACCAGCAAAGGATGCAG 
rs4987226  2.5  55  Q-solution  Forward  TCACTGGTAGAAAAGATTCTGTCTG 
        Reverse  TTACCTGCATGGCTTCTCCT 
rs5030651  1.5  55  Q-solution  Forward  GAGTACGGCCCTGAAGAAGA 
        Reverse  GCGATTGCAGAAGATGACCT 
rs5773188  1.5  55  Q-solution  Forward  AGGGGTGGGGAAAGAAGG 
        Reverse  AGCATGCGGTCGAGAGAG 
rs5790928  1.5  55  Q-solution  Forward  GGGATTGCACATGTTGTCTG 
        Reverse  TGCAGAGGAAAGCTAAAGCA 
rs5803440  1.5  55  Q-solution  Forward  TCCATCAGATGTTAGCACCAA 
        Reverse  TGGGCAATGGGACAACTAAT 
rs5814559  1.5  55  Q-solution  Forward  GGTGAAATCCAGTACCTCATCA 
        Reverse  GCCCTTCACTTTCTGTTGCT 
rs5820291  1.5  55  Q-solution  Forward  AACAGGCTTCATTGGAGAGG 
        Reverse  GGGGTCTTCTGGATCTAGCC 
rs5844947  1.5  55  Q-solution  Forward  GTCCACCCCAGGTAACACAG 
        Reverse  AGCATGCAGCCAGAGGAG 
rs5848002  2.5  55  Q-solution  Forward  AAAGACCTGCCGGGAAGA 
        Reverse  CCAGGAGGGACTTACCAACA 
rs5848302  1.5  55  Q-solution  Forward  AGAATGAGGAAACGGTGCTG 
        Reverse  CTCTCCTCCCAACCCTGTTA 
rs5883925  1.5  55  Q-solution  Forward  ACAAAGCGACCCAGCAAGT 
        Reverse  AAGCATGTCAGCCACCTCTT 
rs5888463  1.5  55  Q-solution  Forward  TCAGCCGGTAAGAGCTCACT 
        Reverse  GGGTTTGGTCAGTAGCCACA 
rs9332131  2.5  55  Q-solution  Forward  TGCTTCCTGATGAAAATGGA 
        Reverse  CAACAAATCACAAATTCACAAGC 
rs9332736  1.5  55  Q-solution  Forward  ACTGTTCGCAGAGTGTGTCG 
        Reverse  TCAGCCTTTCCATCTTTGCT 
rs9333357  1.5  55  Q-solution  Forward  CTCCTGCCTGAAGGACAGAC 
        Reverse  TCTGCTGGATCATCTCATGG 
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